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Abstract 
In the last decade peptides filled the gap between small molecule drugs and biologics as 
therapeutics. A rich source of such peptides represents the venom of different animals 
evolved over millions of years. Conotoxins are small, disulfide-rich neuropeptides isolated 
from cone snails of the genus Conus, which act on different biological targets like ion 
channels or receptors. These toxins contain a complex cocktail of bioactive substances and 
are utilized for self-defence or hunting prey. With over 700 species known, these marine 
invertebrates reveal a large potential of novel pharmacologically active molecules, e.g. for 
the treatment of severe and chronic pain. Although peptide synthesis is established 
nowadays, preparation and characterization of disulfide-rich peptides is still a challenge. The 
formation of different disulfide isomers is one main issue facilitating the elucidation of such 
disulfide-rich peptides and proteins. 
The aim of this work was to investigate the folding of small multiple disulfide-bridged peptides 
under different conditions and perform structure-activity relationship studies of the resulting 
products. Within the scope of this project different conotoxins were synthesized by solid-
phase peptide synthesis. Disulfide formation was achieved by different methods i.e. oxidative 
self-folding, oxidation in Ionic Liquids and successive oxidation in combination with an 
orthogonal protecting group strategy. The oxidized conotoxins were systematically 
investigated and characterized with different analytical methods. Elucidation of the final 
three-dimensional structure was performed by NMR spectroscopy. Furthermore, 
determination of the disulfide connectivity was investigated by different methods of mass 
spectrometric analysis (LC-ESI and MALDI) after partial reduction and derivatization. The 
results of all applied analytical methods revealed their advantages and limitations for the 
discrimination of different disulfide isomers within conotoxins depending on primary amino 
acid sequence. Biological testing of the synthesized peptides on ion channels was performed 
in parallel with computational studies to enlighten the structure-activity relationships. The 
work presented in this thesis significantly extends the knowledge about conotoxins and 
disulfide formation, their impact with respect to biological activity, and the challenging 
characterization and structure elucidation procedures. 
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Zusammenfassung 
In den letzten Jahrzehnten haben Peptidtherapeutika begonnen, die Lücke zwischen nieder-
molekularen Arzneimitteln und Biopharmazeutika zu schließen. Eine reiche Quelle für solche 
Peptide stellen die Giftstoffe verschiedener Tiere dar, die sich über Millionen von Jahren 
entwickeln konnten. Conotoxine sind kleine, disulfidverbrückte, neuroaktive Peptide, die 
verschiedene biologische Ziele wie Ionenkanäle und Rezeptoren beeinflussen und aus dem 
Gift der Kegelschnecke der Gattung Conus isoliert werden. Dieses Gift besteht aus einem 
komplexen Cocktail aus bioaktiven Substanzen und wird von der Schnecke zur 
Selbstverteidigung oder zur Jagd eingesetzt. Mit über 700 bekannten Spezies bergen diese 
wirbellosen Meerestiere ein großes Potential für neuartige, pharmakologisch wirksame 
Moleküle, z.B. zur Behandlung von akuten und chronischen Schmerzen. Obwohl die 
Peptidsynthese heutzutage etabliert ist, stellt die Herstellung und Charakterisierung von 
disulfidverbrückten Peptiden immer noch eine Herausforderung dar. Hierbei ist die Bildung 
von unterschiedlichen disulfidverbrückten Peptidisomeren ein Hauptproblem, welches die 
Aufklärung disulfidverbrückter Peptide und Proteine erschwert. 
Das Ziel dieser Arbeit war es, die Faltung von kleinen, mehrfach disulfidverbrückten Peptide 
unter verschiedenen Bedingungen zu analysieren und Struktur-Aktivitätsuntersuchungen der 
erhaltenen Produkte durchzuführen. Im Rahmen dieses Projektes wurden unterschiedliche 
Conotoxine mittels Festphasenpeptidsynthese hergestellt. Zur Ausbildung der 
Disulfidbrücken wurden verschiedene Methoden eingesetzt:  oxidative Selbstfaltung, 
Oxidation in ionischen Flüssigkeiten und stufenweise Oxidation in Verbindung mit einer 
orthogonalen Schutzgruppenstrategie. Die oxidierten Conotoxine wurden anschließend 
funktionell untersucht und durch verschiedene analytische Methoden charakterisiert. Mittels 
NMR-Spektroskopie wurden die dreidimensionalen Strukturen der erhaltenen Peptide 
aufgeklärt. Weiterhin konnte nach partieller Reduktion und Derivatisierung die 
Disulfidverbrückung durch verschiedene massenspektrometrische Verfahren (LC-ESI und 
MALDI) bestimmt werden. Die Ergebnisse zeigen die jeweiligen Vorteile und Limitierungen 
der verwendeten analytischen Methoden hinsichtlich der Unterscheidung verschiedener 
disulfidverbrückter Conotoxinisomere in Abhängigkeit von ihrer primären 
Aminosäuresequenz. Parallel zu den biologischen Testungen der hergestellten Peptide 
wurden computerbasierte Untersuchungen durchgeführt um ihre Struktur-
Aktivitätsbeziehungen zu analysieren. Die vorgestellte Dissertation erweitert das Wissen 
über Conotoxine und die Bildung von Disulfidbrücken mit ihren Auswirkungen auf die 
biologische Aktivität und demonstriert darüber hinaus die schwierige Strukturaufklärung und 
Charakterisierung.
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1. Introduction 
 
Over the last decades peptides were established in the  drug market and filled the gap 
between small-molecules and larger biopharmaceuticals.1–3 A rich source of therapeutically 
useful peptides is the venom of different animals, for example snakes, scorpions, spiders, 
and cone snails, which has been evolved over millions of years.4 One group of toxins of 
particular interest are conotoxins, which are small, disulfide-rich peptides acting on different 
biological targets such as ion channels or receptors, isolated from cone snails of the genus 
Conus.5 The venom contains a complex cocktail of bioactive substances which is used for 
self-defence or hunting prey.6 With over 700 species known, these marine invertebrates 
possess large potential for identifying novel pharmacologically active molecules, especially 
for the treatment of pain.5 One conotoxin, Ziconotide (Prialt®), that is acting on calcium-
channels, is already available to treat severe chronic pain.7 Conotoxins are classified 
according to their pharmacological target, for instance -conotoxins block voltage-gated 
sodium channels with high selectivity and affinity.5 Therefore, several conotoxins represent a 
promising tool for drug development.1,8 Since the snail produces only small amounts of the 
venom, there is a big need for chemical synthesis of larger amounts after identification of the 
interesting components.5,9 Although standard solid phase peptide synthesis is established, 
preparation and characterization of cysteine-containing peptides forming disulfide bonds is 
still challenging.1,5 In particular the selective formation of disulfide isomers and possible 
rearrangement of disulfide bridges during peptide preparation is difficult essentially 
complicating synthesis and elucidation of cysteine-rich peptides and proteins.1,5 In addition, 
disulfide bonds are the most common posttranslational modifications in peptides and proteins 
stabilizing and conserving the bioactive conformation of the molecules.10 
In this work, formation of disulfide bonds during the preparation of selected conotoxins is 
analyzed using a set of methods for structure elucidation. The synthesized peptides are 
tested for their biological activity on voltage-gated sodium channels. In addition, in silico 
studies contribute to structure-activity relationship studies.  
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2. Theoretical background 
2.1 Drug lead substances 
2.1.1 Venom for drugs  
 
The father of toxicology Paracelsus (Theophrastus Bombastus von Hohenheim) established 
the phrase: ”The dose makes the poison” centuries ago.11 This statement still holds true 
today, especially if considering the most efficient and selective compounds in the process of 
drug discovery.12 Natural products remain  an inexhaustible source for the discovery of novel 
therapeutics.13 The venom of different animals, which has evolved over millions of years, 
represents a rich source of natural compounds and contains a complex mixture of bioactive 
substances.14 Besides non-peptidic toxins such as tetrodotoxin (TTX), saxitoxin or 
batrachotoxin typically developed for self-defence, peptide toxins are usually found in 
species with potential of envenomation. Animals like snakes, scorpions, fish or cone snails 
produce a species-specific venom mixture containing compounds with convergent recruited 
scaffolds like cystatins, cysteine-rich secretory proteins (CRISPs) or defensins.15,16 The 
advantages of using venom-derived peptides are discussed in detail in chapter 2.1.2. Today, 
numerous of these peptides are commercially available on the market or are in various 
stages of clinical or preclinical development.17 Several companies have optimized 
technologies for venom screening assays, venom libraries, hit-to-lead identification (e.g. de 
novo sequencing) and lead optimization.18,19 These “venomics” approaches have meanwhile 
been established as an important part of modern drug discovery with large potential of 
identifying novel pharmacologically active molecules.4 For the characterization of low-
molecular weight organic compounds of a venom cocktail, proper application and sustained 
progress of analytical methods is pivotal (chapter 2.4). The most frequently addressed 
biological targets of toxins comprise different isoforms of ion channels, G-protein-coupled 
receptors (GPCRs) and other receptors such as nicotinic acetylcholine receptors (nAChRs).4 
The development of the angiotensin-converting enzyme (ACE) inhibitor Captopril for the 
treatment of hypertension is mentioned as an example for drug development from venom. 
Initially, the nonapeptide Teprotide derived from the Brazilian pit viper Bothrops jararaca was 
chosen as lead structure.16,20 The minimal substrate-binding site was identified to be the 
tripeptide Phe-Ala-Pro using the crystal structure of carboxypeptidase A139, although later 
the ACE-Lisinopril complex crystal structure revealed low similarity between both enzymes. 
Several other examples for the successful application of venomics support this method as a 
new paradigm for drug discovery as is described in more detail in the following chapter.4,14  
2. Theoretical background  
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2.1.2 Peptides as drugs  
 
Meanwhile, significant improvements in peptide synthesis protocols and analytical 
characterization processes (chapters 2.3 and 2.4) led to the introduction of peptides in the 
pharmaceutical market. Various biomedical applications, such as tissue engineering for 
regenerative medicine, vaccine production, medical imaging technologies, and drug delivery, 
nowadays employ peptides.1 However, peptides are often of limited use due to a rather low 
oral bioavailabilty, which is usually circumvented by alternative administration strategies, e.g. 
by injection (subcutaneous, intravenous or intrathecal).21 In addition, peptides lack stability 
against enzymatic degradation. Approaches such as backbone cyclization, introduction of D-
amino acids or replacing cysteine by selenocysteine can increase the peptide stability and 
therefore lead to an improvement of the delivery methods (e.g. inhalation, transdermal, 
intranasal).21 Formation of multiple disulfide bonds represents another modification and result 
in a distinct topology and conformation. Such constrained peptides combine the unique 
properties of small molecules and biologics and consequently fill the gap between both 
(Figure 1).1   
 
 
Disulfide-bridged peptides do not only appear in the venomous animals mentioned above, 
but also in plants, as can be exemplified with the cyclotide kalata B1 which endures high 
temperatures and enzymatic degradation in its oxidized form.22 This peptide, derived from the 
plant Oldenlandia affinis, remains its active conformation and tolerates harsh conditions 
during tea preparation and oral application because of multiple disulfide bonds. Therefore, a 
Figure 1. Advantage of constrained peptides as therapeutics, filling the gap between small molecules and 
biologics by combining the properties of each type of drugs. Modified from 1 
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further application of such a disulfide-bond framework represents the molecular grafting 
combining sequence and conformation characteristics from different bioactive peptides.22,23  
Several advantages of constrained peptides are higher stability against enzymatic 
degradation, improved bioavailability, lower costs for large-scale production compared to 
biologics, together with higher potency, affinity, selectivity and fewer side effects compared to 
small molecules.1 Therefore, peptides were introduced in the market with high global sales in 
2007 as can be exemplified with Copaxone® ($ 3.33 billions), Lupron® ($ 1.88 billions), 
Byetta® ($ 967 millions), and Forteo® ($ 709 millions). Three years later, over 50 peptide 
therapeutics have been approved for the market.2,24 A large number of venom-derived 
peptides occur within these peptides. For instance, Exenatide (Byetta®), a 39 amino acids 
peptide, derived from the saliva of the venomous Gila monster Heloderma suspectum, was 
approved for the treatment of type 2 diabetes mellitus as the first glucagon-like peptide-1 
(GLP-1) receptor agonist.25  
Peptide production is performed by a variety of methods including chemical and biological 
synthesis. Beginning with solution-phase synthesis (SPS) introduced in 1953 by du Vigneaud 
peptide drugs became accessible for commercial usage. However, the method is less 
efficient considering time, labour and cost economics.2,26 A milestone in peptide synthesis 
overcoming the previous limitations was achieved by Merrifield in 1963 by the introduction of 
solid-phase peptide synthesis (SPPS).27 In this approach, an insoluble polymer resin is 
utilized for immobilization of primarily tert-butyloxycarbonyl (Boc)- or 9-
fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids, depending on the -amino acid 
protecting group (PG) strategy applied. Alternating steps of acid- (in case of Boc) or base-
labile (in case of Fmoc) deprotection and coupling of the following amino acid with coupling 
reagents, e.g. 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU) is performed together with extensive washing steps. Various protecting groups have 
been introduced for peptide preparation using different strategies.28 In recent years, however, 
the development of alternative approaches which facilitate complex peptide synthesis, such 
as the combination of SPS and SPPS (hybride synthesis)29 or chemoselective ligation 
strategies like native chemical ligation (NCL),30 have been promoted. The latter was 
established already in 1953 by Wieland et al. by combining two peptides via a thioester and a 
cysteine residue in a rearrangement reaction.31 After several decades and respective 
progress in SPPS, Dawson and Kent extended this principle in 1994 for cysteine-containing 
peptides.32 With this simple technique they were able to synthesize human interleukin 8 (72 
AA) by ligation of 33mer and 39mer peptide fragments. Since then even longer peptides and 
small proteins were prepared using one or more ligation steps.33 Furthermore, the limitations 
of cysteine containing sequences have been overcome with different ligation methods such 
2. Theoretical background  
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as methionine, histidine or glycine ligation.34 Among the proteinogenic amino acids cysteine 
is unique since it is able to introduce rigid structures in peptides through disulfide bond 
formation by connecting two cysteine residues in an intra- or intermolecular way.1,35 This 
special feature of cysteine will be discussed in more detail in chapter 2.3.1. 
Besides the chemical approach processes like enzymatic synthesis, native isolation as well 
as fermentation and recombinant expression have been established for bioactive peptide 
production. Although these methods are sometimes of limited use due to elaborate 
purification procedures or the incorporation of non-natural amino acids, several systems 
were established employing these approaches, e.g. the previously mentioned Forteo® was 
expressed in Escherichia coli.1,2,29 
2.2 Cysteine-rich peptides 
2.2.1 Conotoxins 
 
60 years ago A.J. Kohn described the marine cone snail of the genus Conus for the first time. 
The cone snail actively hunts fish using a harpoon and secreting a powerful neurotoxin.36 As 
a consequence of this observation the ecological niche of cone snails was changed from 
carrion eaters to active predators producing toxic venom.36 The lethal potential of the toxin 
mixture was discovered when the venom was accidentally injected into humans by a cone 
snail for self-defence. These people were collecting the beautiful shell which fascinated 
human cultures from ancient times up to now (Figure 2).37,38 The aforementioned toxin 
consists of neuroactive peptides, also called conopeptides, which are derived from marine 
cone snails.39 Cone snails comprise marine invertebrates of hunting gastropods with more 
than 700 species known so far.39,40 Because of the large diversity Puillandre et al. proposed a 
new classification in 2015 according to molecular phylogenetic analysis dividing the family 
(Conidae) into four genera, which is in contrast to the former system established by Cruz et 
al. in 1985.41,42 
 Figure 2. Shells from different fish-hunting cone snails: Conus ermineus (left), Conus purpurascens
(middle) and Conus striatus (right). Modified from 68,69  
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Nevertheless, the venom of each species is reported to contain 50 to 200 different 
components representing a highly complex cocktail of various peptides and proteins 
potentially binding to different biological targets.38 Today, due to the efforts made in the field 
of analytics, especially mass spectrometry, up to >2500 masses can be detected in a single 
conus species venom depending on factors which are described below.43 Thus, more than 
>70.000 pharmacologically relevant compounds are potential drug leads derived from cone 
snails, whereof only ~ 2000 toxins have been identified so far.44 
The diversity of cone snail venom and its composition depends on several factors. First of all, 
different cone snail species produce miscellaneous variations of venom for hunting prey, self-
defence or to deter competitors.45 Besides, the toxin is adapted to the respective dietary, i.e. 
worms (vermivorous), molluscs (molluscivorous) or fish (piscivorous).39 Furthermore, the 
components differ depending on the geographical regions and also individual variations can 
be found within a species.46,47 These aspects indicate that each individual specimen may 
adjust and brew its own specific toxin cocktail.48 
 
Figure 3. (Left) Schematic view of a cone snail venomous apparatus. (Right) Harpoon-like radular teeth 
enlarged by scanning electron micrograph from Conus purpurascens. Modified from 45 
The toxin envenomation system consists of a complex venom apparatus shown in Figure 3.45 
The complete mechanism of venom production is still unclear and further research is needed 
to enlighten the complex procedure. One difficulty arises from the observation that the venom 
composition highly differs from different levels (e.g. injected venom, venom duct) obtained. In 
general the toxin cocktail is produced in the venom duct and transferred for injection through 
contraction of the muscular venom bulb. The toxin is finally injected with a radular tooth 
acting as a hollow harpoon that is produced and stored in the radular sheath. From there the 
harpoon is transferred through the pharynx to the proboscis, where a single tooth is prepared 
for injection of the venom. Upon toxin application, the snail needs regeneration time  to 
recover full toxin potential.45,49,50 
First analysis of the venom mixture was made in 1977 by Spence et al. separating the crude 
poison of Conus geographus into several fractions. The following application into different 
2. Theoretical background  
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tissues revealed the specific action.51 Further detailed isolation and characterization of the 
toxin mixture of C. geographus and C. magus was performed in the laboratories of B. M. 
Olivera and L. J. Cruz later on.52,53 These piscivorous species were chosen because their 
venom contains more active components against vertebrates compared to species hunting 
invertebrates. Starting from this point, the analytical methods evolved rapidly. Improved 
purification and identification of the bioactive compounds of the toxin cocktail facilitate 
characterization nowadays. Therefore, it is now possible to describe the individual fractions 
and their respective biological activity more precisely (Figure 4). Distinct toxin fractions were 
thus identified as small, disulfide-rich peptides (10-30 AS). The peptides are characterized by 
high structural conservation, numerous post-translational modifications and, in general, were 
found to be smaller than most other toxins derived from animals like snakes, scorpions or 
spiders.6,49,53       
 
Figure 4. Crude venom of Conus geographus purified with HPLC and fractions labelled with respective 
biological activity. This was observed by intracranially injection of ~0.5 – 2 nmol of each fraction into mice. 
The fractions with † caused death at in least one injected animal. Modified from 49 
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Originally, the so-called conopeptides derived from cone snails were divided into two groups. 
The first group is composed of the disulfide rich peptides (conotoxins), defined for peptides 
with more than two cysteine residues. In contrast, the second group consists of the non-
disulfide rich peptides with several subclasses such as e.g. contulakin, conopressin or 
contryphan with two or less cysteines.38 However, this discrimination became redundant 
because phylogenetic analysis indicated similar signal sequences within the conopeptides 
previously classified according to the cysteine content.54 Classification of conotoxins has 
come a long way starting from a strict ordered concept that is nowadays inappropriate due to 
several novel insights. For example subtypes of classification were established based on the 
genetic superfamily, the cysteine framework, the biological target and the conotoxin family.38 
In the respective publication by Terlau and Olivera from 2004 only seven superfamilies have 
been reported.38 However, nowadays more than 30 superfamilies were described and 
several new superfamilies are permanently reported in current publications.44 Some of these 
families have not been fully described yet, leaving some subtypes of classification like 
biological target open, which are necessary for complete characterization.44 Today, new 
conotoxins are usually identified using cDNA sequencing and resulting in gene superfamilies 
as classification method established by Woodward et al. in 1990.55 The complex relationship 
between the genetic superfamily, the pharmacological family, the cysteine framework, and 
the number of cysteine residues is described in Figure 5 with the respective connections 
within the subgroups.38,44,56–58 Conotoxin classifications important for this work are highlighted 
in bold.  
The first isolated and described conotoxin was -GI containing two disulfide bridges and 
belonging to the A-superfamily.6,59 Greek symbol indicates the respective pharmacological 
family and the biological target, here nicotinic acetylcholine receptors (nAChRs), and the “G” 
refers to peptides isolated from the genus Conus geographus. The roman number “I” 
represents the cysteine framework with the corresponding connectivity, here CC-C-C 
containing bridges Cys1-Cys3 and Cys2-Cys4.59,60 The last Arabic letter in the conotoxin 
name (e.g. -GIIIA, -GIIIB,-GIIIC) represents the first, second or third peptide discovered 
with the same disulfide framework and the species origin.45,61 Although conotoxins with a 
distinct cysteine-framework share an identical cysteine scaffold, the residues within the loops 
can highly differ in their sequence. This indicates a large variation for each residue with the 
exception for those conserved amino acids essential for bioactivity.62 For instance, all -
conotoxins possess the same cysteine-framework (Cys1-Cys4, Cys2-Cys5, Cys3-Cys6), but 
the resulting structures, target affinity and selectivity vary highly from each other.63 Therefore, 
elucidation the relationship of the primary amino acid sequence and the biological effect of -
conotoxins is an interesting research target. In case of the -conotoxins the respective
  
 
 
Figure 5. Conotoxin classification displaying the relationship between genetic superfamily (red), pharmacological family (blue), cysteine framework (black) and 
cysteines included with respective connectivity if known (green). Modified from 56–58 
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biological target are the TTX-sensitive/resistant voltage-gated sodium channels (VGSCs) 
(see chapter 2.2.2.).63,64  
The M-superfamily, for example, is divided into five subfamilies based on the amino acid 
residues in the third loop region. Members possess primarily six cysteine residues with the 
disulfide framework III and two adjacent cysteine pairs (CC-C-C-CC).65,66 These 
superfamilies contain -conotoxins (target VGSCs), M-conotoxins (target voltage-gated K+ 
channels) and -conotoxins (target nAChRs). Most of the -conotoxins belong to the M4/5-
subfamily, e.g. -PIIIA from C. purpurascens, -SIIIA from C. striatus or -GIIIA from C. 
geographus, always the first members discovered.56,66 Another example is -EVIA, which 
was identified from C. ermineus, bearing cysteine framework VI (C-C-CC-C-C) and that 
blocks the inactivation of VGSCs. EVIA is part of the O-superfamily, which is divided into 
three subfamilies.56,67 Formation and also elucidation of the respective disulfide connectivity 
will be discussed in more detail in the following (chapter 2.3.1). Since 2008 Q. Kaas 
developed and perpetually updated an internet database, conoserver, with all relevant 
information about each conotoxin, their respective origin, biological activity and 
references.68,69  
The venom of each cone snail species can have different physiological effects depending on 
the tissue and therefore results in a huge therapeutic potential as previously mentioned.70,71 
Since 2004, the conotoxin Ziconotide (Prialt®) is commercially available on the market for 
pain treatment. Ziconotide or -MVIIA is a 25mer peptide which was derived from Conus 
magus as was first described in 1985 by Olivera et al..6,72 It selectively inhibits voltage-
dependent N-type calcium channel (CaV2.2), therefore exhibits a therapeutic potential for the 
treatment of chronic pain, and also for opiate-resistant patients.7,55 Although Ziconotide is at 
least 10-times more potent compared to a common analgesic like morphine, its application is 
limited due to several side effects likefor example ataxia, abnormal gait, dizziness, 
nystagmus and somnolence.55,77 For this reason widespread use is problematic. The 
application form, i.e. intrathecal infusion via a permanent implanted pump is restricted due to 
the necessity of a surgery. Nevertheless, Ziconotide was shown to help people suffering 
especially from cancer- or AIDS-related chronic pain enabling higher quality of life.7,52,73 
Further conotoxins are tested in clinical trials, with the challenge transferring the beneficial 
use from animal models to human application and finally a profitable drug. However, several 
reasons led to a failure of the respective studies. The -conotoxin CVID (Leconotide, AM336 
or CNSB0047) from Conus catus effects CaV2.2 channel like Ziconotide with the advantage 
of a higher selectivity and less side effects by intrathecal and intravenous application to 
rats.74 Clinical trials were stopped due to the liquidation of the developing company.17 A 
further example is the -conotoxin Vc1.1 (ACV 1) from Conus victoriae that decreases 
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calcium ion currents in nociceptive neurons. Surprisingly, the effect appears to be mediated 
by an altered mechanism, the conotoxin inhibits the CaV2.2 channel indirectly and voltage-
independently by acting on G protein-coupled -Aminobutyric acid (GABAB) receptor causing 
unwanted side effects. Furthermore, oral availability of this compound was reached after 
head-to-tail cyclization including a six residues linker sequence increasing the stability 
towards degradation in vivo. Nevertheless, further biological testing is required to clarify the  
mechanism and detailed mode of action and to avoid unexpected side effects, lack of 
efficacy or dose dependent effects.17,75–77  
Focussing on the therapeutic potential of - and -conotoxins there are several advantages 
and limitations for possible drug targets acting on VGSC.78 In general -conotoxins affect 
tetrodotoxin (TTX)-sensitive VGSC with the highest affinity against skeletal muscle isoform 
NaV1.4 and/or NaV1.2.7980 A more detailed description about specificity of selected peptides 
is included in chapter 2.2.2. However, medication-dependent properties reveal potent 
analgesic activity by intrathecal application in animal model, whereas intravenous injection 
generally causes paralysis and death, restricting the drug potential.79 On the other hand -
conotoxins were considered to have a lower therapeutic potential because they block the 
inactivation of VGSCs. Furthermore, the required elucidation of structure-activity 
relationships are rare because of challenging handling of the toxins during synthesis, folding 
and purification of these highly hydrophobic peptides.79  
Another import aspect of conotoxins is their target specificity within subtypes of ion channels. 
The toxin selectively blocks distinct ion channel isoforms and simultaneously remains others 
untouched (chapter 2.2.2). Therefore, they are applied tools for discrimination between 
different ion channels and there subtypes.  Although conotoxins are available on the market 
from several companies (e.g. Bachem®, Smartox®, Iris Biotech GmbH®), their synthesis as 
well as their structural determination and elucidation of the formed disulfide bridging is still 
challenging.1,2 
2.2.2 Voltage-gated ion channels  
 
Contiguous to nAChRs, voltage gated ion channels are one main target of conotoxins and 
other animal toxins. These channels are membrane proteins that transfer inorganic ions like 
Na+, K+ or Ca2+ depending on their state (open or closed). These channels exist in most 
vertebrates and invertebrates.81 Ion channels are essential in propagation of action potential 
in excitable cells like neurons or muscle cells.82 Starting in 1952 Hodgkin and Huxley 
established the so-called voltage clamp method that allows to quantify the membrane current 
in such cells.83 Although several species possess various ion channels in different tissues, 
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evolution developed nine human isoforms of voltage gated sodium channels, which were 
characterized so far (Table 1). The channels can be expressed in different tissues such as 
peripheral and central nervous system, skeletal muscle or heart and have different 
resistances against TTX, a toxin isolated from pufferfish, that is utilized as a pharmacological 
standard for differentiating the channel subtypes.81 In addition other selectively acting 
components of the toxins (e.g. snake-, scorpion- or conotoxins) can be utilized to 
characterise the structure and function of ion channels.84 VGSC consists of a - and one or 
more -subunits depending on the specific channel subtype. An active channel is usually 
established by the pivotal -subunit. This consists of four homologous domains with each 
domain build by six transmembrane segments (S1-6) (Figure 6). Segments S1-4 built the 
voltage sensor domain and S5-6 form the channel pore.85 Although the complete mechanism 
of action of the channel is still unknown, some details have been identified. The voltage 
sensor domain S4 induces a conformational change upon depolarization that leads to 
opening of the channel pore. This process is usually followed by intracellular fast inactivation, 
milliseconds after activation. Here, the loop connection between domain 3 and 4 (D3,4) 
blocks the pore from intracellular space with the residues IFM (Figure 6).86  
 
Figure 6. Voltage gated sodium channel -subunit consisting of 4 homologous domains (D1-4) with each 
consisting of 6 transmembrane segments (S1-6). The voltage sensor S4 is marked in red and the channel 
forming units S5/6 are shown in green. The loop responsible for fast inactivation between D3 and D4 is 
labelled with the relevant residues IFM relevant for fast inactivation. Modified from 86   
 Targeting this transfer of action potential for distinct pain-mediating subtypes of VGSCs 
specifically, results in powerful analgesics. Compared to small molecules like morphine or 
lidocaine, conotoxins have a higher selectivity for the different VGSC subtypes.87 This 
specificity is summarized for some -conotoxins and the respective channel in Table 1. 
Indeed, distinct subtypes play a pivotal role in pain treatment such as e.g. NaV1.7, 1.8 or 1.9. 
These represent interesting drug leads for toxins that block these channels selectively.88  
  
 
channel TTX 
resistance87 
Distribution 
(human)81,87 
-KIIIA -GIIIA -PIIIA -SIIIA -SmIIIA 
NaV1.1 Sensitive CNS, PNS 290 nM +/-11089# 260 nM +/-9090# 120 nM +/-1390 11 M +/-1.291 3.8 nM +/-1.390#  
NaV1.2 Sensitive CNS 61 nM +/-5,92  
5 nM93 
17.8 M +/-1.7,90 
2.7 M94 
620 nM +/-70,90 
690 nM94 
790 nM95 1.3 nM +/-0.790# 
NaV1.3 Sensitive CNS, Foetal 
DRG 
3.6 M +/-0.3,92 
8 M +/-189 
>10 M90 3.2 M +/-0.890 11 M +/-1.4,91  
5.3 M95 
35 nM +/-1490# 
NaV1.4 Sensitive Skeletal muscle 48 nM +/-6,92 
54 nM,93 
90 nM +/-1789 
19 nM+/-2,90 
19nM94 
36 nM +/-8,90 
41 nM,94 
47-204 nM  
+/-7-25*96 
130 nM +/-15,91 
330 nM,95 
560 nM +/-29097 
0.22 nM +/-0.190# 
NaV1.5 Resistant Heart muscle 287 M +/-40,89 
>10 M92  
H. sapiens 
>10 M90 >10 M90 251 M +/-3891 1.3 M +/-0.2590 
NaV1.6** Sensitive PNS, CNS 183 nM +/-31,92 
240 nM +/- 3090 
680 nM+/-6090 100 nM+/-2090 760 nM +/-6091 160 nM +/-4090 
R. norvegicus 
NaV1.7 Sensitive PNS, schwann 
cells 
147 nM93 >10 M,90 6 M94 >10 M,90 
6.2 M,94  
H. sapiens 
3.1 M94 
65 M +/-691 1.3 M +/-0.2390 
NaV1.8 Resistant DRG >10 M92 
 H. sapiens 
>10 M90 >10 M90 >10 M90 >10 M90 
NaV1.9 Resistant PNS - - - - - 
Table 1. Subtype specificity of different -conotoxins on VGSCs relating to their IC50 values. # Only KD available. CNS = central nervous system, DRG = dorsal root ganglia, 
PNS = peripheral nervous system; VGSC from R. norvegicus was used in general unless otherwise mentioned; * indicates bioactivity for respective isomer isolated; **1.6 from M. 
musculus.
   1
3
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Mutations of VGSC can cause several symptoms or diseases, e.g. selective deficiencies in 
pain pathways initiated by NaV1.8 channel knockouts or in the NaV1.9 channel.87,98 Exact 
channel binding sites of a toxin are identified by applying a highly specific blocking toxin to 
different subtype chimeras of two VGSCs. From these, one channel is blocked while the 
other is unaffected by the toxin. The chimeras are mutated versions with single domains or 
segments of the respective channels replaced, indicating the relevance for binding and 
blocking of the toxin. In addition, single point mutants reveal more detailed information about 
the interacting positions.97  
Nowadays, drug design is also performed in silico by predicting the interaction between 
channel and channel modifier and therefore giving a hint on the respective bioactivity of the 
applied substance.99 Essential for these studies are structural data from both sides: the 
VGSC, where only little data is available from x-ray structures, and the modulator. Structural 
data of the modulator can be derived from spectroscopic methods such as NMR (chapter 
2.4.3). If there is no structural data existing from a distinct subtype, a homology model can be 
created from a similar subtype with available structural data.99 To simplify these models parts 
of the channel (unimportant for the simulated interaction) are often excluded or exchanged 
with the residues present in the desired isoform.100 These results, together with the 
electrophysiology measurements, can be utilized to understand the interaction of the channel 
and the channel modulator.99 In the last two years several computational studies prove the 
rising interest in binding and blocking of -conotoxins to VGSC.100–102 
2.3. Synthesis of cysteine-rich peptides 
 
Within the field of peptide synthesis preparation of cysteine-rich peptides is a challenging 
task especially the oxidation and selective formation of disulfide bridges.1 Nevertheless, 
enormous research interest and therapeutic potential of cysteine-rich peptides make large 
scale synthesis of these peptides essential. In the past decades the knowledge of synthesis 
and oxidation of cysteine containing peptides has expanded due to the work of G. Barany, L. 
Moroder and F. Albericio.1,35,103–105 In general, three different approaches were established 
for synthesis of disulfide containing peptides.106 First of all, folding of the disulfide bridging on 
solid support is possible but requires low resin loading for preferred intramolecular oxidation 
and appropriate orthogonal protecting groups. During the second strategy the first disulfide 
bond is formed on solid phase. This restricts the conformational freedom for the formation of 
further disulfide bridges in solution after cleavage of the partially oxidized peptide. Finally, the 
formation of disulfide bridges can be performed completely in solution with different 
approaches e.g. oxidative folding forming all bridges with one step or successive oxidation 
applying suitable PG strategy (chapters 2.3.1 to 2.3.3).106 During oxidation of the cysteines to 
2. Theoretical background  
15 
 
respective disulfide connectivity, formation of different isomers by rearrangement is a big 
issue.35   
In 1973 Anfinsen established the dogma that polypeptide chains or proteins fold into a 
thermodynamically preferred “native” isomer based on the example of ribonuclease A. 
Furthermore, he stated that all other isomeric forms which appeared during preparation had 
lower biological activity.107,108 Extensive research elucidating the folding mechanism of 
disulfide containing peptides found in several molecule classes such as hormones, growth 
factors, enzyme inhibitors, neurotransmitters, toxins, and antimicrobial peptides to particular 
cysteine knot motives was necessary to support Anfinsen’s postulate.35,109–111 The 
characterization of the specific folding pathway of individual peptides like e.g. insulin, bovine 
pancreatic trypsin inhibitor (BPTI) and hirudin revealed different transition states for the 
respective peptide.109 However, non-native isomer formation during various folding 
procedures is highly sequence and parameter dependent and behaviour of undescribed and 
uncharacterized bioactive peptides is difficult to predict.108,109,112 This problem is described in 
the context of conotoxins in more detail in the following chapter with respective examples.  
Today for the -conotoxins with only two disulfide bridges resulting in three possible isomers 
synthesis, structure elucidation and biological activity is established and in focus of recent 
research progress.77,113,114 The three isolated isomers were synthesized, separated and 
characterized as globular (Cys1-Cys3, Cys2-Cys4), ribbon (Cys1-Cys4, Cys2-Cys3) and 
bead (Cys1-Cys2, Cys3-Cys4) isomer for several -conotoxins, e.g. -GI, -AuIB and -
Vc1.1 with distinct pharmacological activities.113–115 Furthermore, in 2002 Dutton et al. 
reported for the first time a non-native isomer of -AuIB that exhibits ten times higher 
biological activity compared to the native connectivity, representing a novel method for 
optimization of pharmacological properties.115 However, for conotoxins with six cysteines 15 
isomers are possible indicating the higher complexity for conopeptides bearing three disulfide 
linkages such as - and -conotoxins. The whole problem gets more complicated for an 
increasing number of cysteines, e.g. for four disulfide bonds 105 isomers are possible.108 
Because of this difficult intricacy and similar properties of the different disulfide isomers 
information about -conotoxins are rare or not existing in the case for -conotoxins.96,116 In 
general, different isomers were isolated after oxidative folding and identified via NMR 
structure elucidation. Determination of the disulfide linkage was performed applying mass 
spectrometry and MS-sequencing after different approached of sample preparation. 
However, only two or three isomers could be identified from the two -conotoxins -KIIIA and 
-PIIIA (Figure 7) and have been described to this day.96,116  
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These time consuming and exhausting researches show that not only synthesis but also 
following structure elucidation is difficult (chapter 2.4). Approaches performed so far only 
revealed the disulfide linkages observed during in vitro studies leaving the question open for 
in vivo conditions in the end.  
 In addition, the exchange of cysteine with selenocysteine is a further possibility for selective 
oxidation because of the different redox potential. Extensive research with partially replaced 
disulfide crosslinks, i.e. with a diselenide bridge, was performed for several peptides such as 
BPTI, -SIIIA and various -conotoxins indicating the large potential for substituting distinct 
linkages.113,117–119 Beside the previous mentioned chemical synthesis methods for conotoxins 
also biological methods such as peptide expression in E. coli, which was reported for the two 
conotoxins -LvIA and LtXVIA from the M-superfamily, show future potential. Nevertheless, 
both peptides lack of difficult posttranslational modifications hampering conotoxin expression 
in general.120,121   
  
Figure 7. Topology of the three isolated -PIIIA isomers from oxidative folding and structures derived 
from NMR elucidation (A) with the respective disulfide connectivity (B). The individual blocking of VGSC 
NaV1.4 is described below (C) with the highest bioactivity for a non-native isoform. Modified from 96 
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2.3.1. Protecting group strategies 
 
Protocols for different PG strategies developed and established in the last decades enable 
regioselective oxidation of highly disulfide linked peptides.1,5,28,106 The advantage of this 
method compared to the following ones is the selective formation of a disulfide bond from 
two selectively protected cysteine residues after their deprotection and an oxidation 
procedure. This allows stepwise formation of disulfide connectivity to the intended isomer. 
However, reaction conditions have to be chosen carefully to avoid breaking or scrambling of 
the already formed bridging.1,5 Furthermore, some PGs can be removed by oxidative 
cleavage conditions resulting in the disulfide rather than the thiol compound. Some 
approaches can be performed on-resin but most common procedures are off-resin 
approaches after cleaving the peptide with partially or fully protected cysteine residues.106 
According to their stability and lability for Fmoc-peptide synthesis the cysteine PG trityl (Trt), 
acetamidomethyl (Acm), 4-methylbenzyl (Meb)/4-methoxybenzyl (Mob), tert-butyl (tBu), and 
tert-butylthio (StBu) are favored.5,106 Additionally PGs with special cleavage conditions enable 
the combination with the common cysteine PG such as enzyme-cleavable 
(phenylacetamidomethyl, Phacm), photocleavable (coumarin- or nitrobenzyl-derivatives) or 
safety-catch (4,4-bis(dimethylsulfinyl)benzhydryl, Msbh) PGs.106 However, their application is 
also limited for several reasons like side effects or cleavage conditions.1,5,28,106 
Research on various -conotoxins indicates sequence dependencies as well as reaction 
conditions can affect the yield of the intended isomer.114,122,123 This shows the intricacy of 
disulfide rearrangement even with only two disulfide connectivity. While Akaji et al. reported 
no disulfide shuffling during preparation of -MI the same PG strategy (Acm and tBu) 
resulted in ambiguous isomers for the preparation of -GI performed by Szabo et al. 
revealing the coherence of several parameters like PG order of cysteine residues, reaction 
time or temperature.122,123 Similar to the previous mentioned -conotoxins, various 
approaches of selective folding were developed and applied to peptides with six or more 
cysteine residues like the conotoxins -SIIIA,124 -CnVID,125 -SI dimer126 or other disulfide-
rich molecules such as hepcidin.124,127 Again, in some cases the folding resulted into another 
isomer, although the reasons for this disulfide rearrangement are still not fully understood 
and seem to be highly depending on peptide sequence (especially for adjacent cysteine), PG 
strategy and reaction conditions.123,127,128 Finally, elucidation of the disulfide linkage is still a 
challenging and demanding mission and will be discussed in more detail in chapter 2.4.  
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2.3.2. Oxidative folding 
 
The so-called oxidative folding approach was established by Creighton to elucidate the 
folding pathway of BPTI.129,130 This approach differs from the conformational folding that is 
based on unfolding of the native species followed by refolding of the peptide to the native 
structure. The process is monitored with infrared spectroscopy, NMR, fluorescence 
spectroscopy or circular dichroism.10,109,131,132 On the other hand oxidative folding of proteins 
allows more detailed information about the folding intermediates, kinetics and folding 
pathway. This is achieved by folding of reduced, unfolded peptide in buffer solution 
containing oxidizing agents resulting in the native, restricted structure by formation of the 
respective disulfide bonds. Hereby the folding intermediates can be isolated and subjected to 
analytical by HPLC and other methods for characterization and structure determination 
(chapter 2.4).109 Different folding pathways are discussed nowadays, whereof three different 
types incorporate most folding processes from reduced to native state, namely the two 
extremes BPTI- and hirudin-like folding model or a mixture of both (BPTI/hirudin-like 
model).109 Whereas the BPTI folding pathway proceeds exclusively via distinct intermediates 
bearing the native connectivity, the hirudin folding progresses via various intermediates not 
only exhibiting the native linkage but non-native isomers depending on the oxidation 
condition. For this peculiar folding behaviour three condensation models exist depending on 
the native-like structured parts that form secondary structured elements prior to folding. 
These elements are anchored in the primary amino acid sequence and determine the 
accessibility of the thiol groups for the respective native structure. Therefore the framework 
model represents the BPTI folding with high amount of secondary structure elements, 
hydrophobic collapse for hirudin-like folding without structural information and nucleation-
condensation for the BPTI/hirudin-like folding with structural information.109 Protein folding 
with or without cysteine containing peptides and proteins is an important issue because 
peptide/protein misfolding can result in several severe diseases.133,134 Computational in silico 
studies help to  understand the folding mechanism in detail using funnel-shaped energy 
landscapes with different levels from the non-folded structure on top, intermediates in 
between and the native folded structure at the bottom of the funnel.135–138 
However, conotoxins appear to fold in a hirudin-like pathway whereas isolation and 
characterization of non-native isomers was possible upon oxidative folding as described 
previously (Figure 7).96,109 However, such isomers have also been reported during oxidative 
folding of several other cysteine-rich peptides such as hirudin,109,139 amaranthus -amylase 
inhibitor,140 cardiotoxin III,141 and tridegin.142 Concluding, these in vitro findings are not always 
consistent with Anfinsen’s dogma whereby only one native isomer possessed the bioactive 
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conformation.107,108 Still, in vivo conditions can differ because organisms developed several 
tools to assist folding, e.g. small molecule oxidants or protein disulfide isomerases (PDI).1,143 
These PDIs constitute a large part of proteins in the venom duct of cone snails indicating the 
high impact on the folding procedure of conotoxins.143 
Nevertheless, this common method is often weapon of choice for solution oxidation and 
conditions were optimized for several conotoxins with three disulfide connectivity including -
MVIIA,144 -SIIIA,145-PIIIA63 and -PVIA.67 Although there are miscellaneous oxidation 
methods existing, the most common technique is applying redox agent mixtures of reduced 
and oxidized glutathione (GSH/GSSG) or other oxidizing agents like cystine or cystamin in 
slightly basic (pH 7.5 - 8.5) buffer solutions and low peptide concentrations to prefer intra- 
rather than intermolecular reactions.1,5 Alternatively, dimethylsulfoxide (DMSO) can be used 
for oxidation due to the possible application in a pH range of 1 – 8 and it’s capability to 
improve solubility properties especially in the case of hydrophobic peptides. However, side 
reactions can occur at methionine, tryptophan and tyrosine residues and removal of large 
amounts of DMSO can complicate purification.5,145  
 
2.3.3. Room temperature Ionic Liquids for peptide oxidation 
 
Ionic liquids (IL) are so called molten salts and room-temperature Ionic liquids (RT-IL) are 
liquid below 100°C.146 They generally consist of a cation poorly coordinated by an anion, 
hindering the formation of ordered crystal lattice and resulting in unique physicochemical 
properties and liquid behaviour.146 One of the ions is generally a bulky, organic molecule with 
delocalized charge that is neutralized with a counter-ion.146 Therefore, a lower melting point 
compared to common crystalline structures is obtained.146 As a result RT-ILs are liquid at 
ambient temperatures. They can be divided in four groups based on the cation namely 
alkylammonium-, dialkylimidazolium-, phosphonium- and N-alkylpyridinium-based ILs.147 In 
the last decade RT-ILs were established for a wide range of applications because of 
exclusive properties tailored from the containing ions such as negligible vapour pressure, low 
volatility, high thermal conductivity, large electrochemical window, solvating potential, non-
flammable, recyclable and lower toxicity (compared to conventional organic solvents).146–148 
Therefore, they possess huge potential as environmental friendly reaction media, so called 
“green solvents” but due to their designable characteristics not all ILs have the quality of 
green solvents.147,149,150 Nevertheless, RT-ILs have been established in chemical 
synthesis,149 catalysis,148 biotransformation,146 biocatalysis151,152 biomass conversion152,153 
and further applications.154,155 The field of peptide synthesis and chemistry as well as protein 
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interactions (e.g. enzymes) has obtained special interest in this context and RT-ILs are used 
for different reasons.156 Protein activity and structure stabilization of enzymes mediated by 
RT-ILs can be explained with specific ion effects which evolved from the Hofmeister series 
founded in 1888.157–160 Since then chaotropic (weakly hydrated, low charged) and 
kosmotropic (strongly hydrated, highly charged) ions used for preparation of RT-ILs are 
described and have stabilising or destabilising effects on enzymes in neat or aqueous RT-
ILs, resulting in a change of bioactivity.157,161,162  
Another application of RT-ILs as an alternative reaction media is the coupling of amino acids 
to produce dipeptides in higher purities compared to conventional organic synthesis.163 
Furthermore, RT-ILs are utilized as resin during SPPS for immobilization of amino acids and 
coupling procedures to synthesize peptides such as the pentapeptide sansalvamide A or 
even longer ones with 15 residues.164,165 In addition, RT-ILs are used for oxidative folding of 
disulfide rich peptides without oxidizing agents. In 2009 Miloslavina et al. reported the first 
conotoxin oxidation performed in RT-ILs with the advantage of solving higher concentrations 
of hydrophilic (-SIIIA, -PIIIA) and hydrophobic (-EVIA, -SVIE) peptides in the respective 
RT-IL (1-ethyl-3-methylimidazolium acetate, [C2mim][OAc]) and higher yields compared to 
buffer solutions.166 
RT-ILs are used for several analytical purposes such as NMR, mass spectrometry (MS, 
especially as matrices), electrochemistry or chromatography.156,167–169 For instance, tandem 
mass spectrometry from peptides out of RT-ILs for Electrospray ionization (ESI)-MS and 
Matrix-assisted laser desorption ionization (MALDI)-MS was developed.170,171 For the latter 
case the RT-IL was prepared with an alkyne moiety which was able to open and modify the 
disulfide cysteine by a light induced reaction after dissolving the sample in the RT-IL.171 
Afterwards in-source decay (ISD) was directly applied performing fragmentation of the 
derivatized peptide out of the RT-IL matrix mixture and fostering the formation of fragment-
ions compared to classical matrices like 1,5-diaminonaphthalene, 2,5-dihydroxybenzoic acid 
and -cyanohydroxycinnamic acid,.171,172       
2.4 Analytical methods for multiple disulfide-bridged 
peptides 
 
Besides milestones in peptide and protein synthesis evolved in the past decades analytical 
methods co-evolved for peptide characterization correspondingly. Therefore, the Nobel prize 
in chemistry 2002 was awarded to Kurt Wüthrich, John B. Fenn and Koichi Tanaka for their 
pioneered research in the field of nuclear magnetic resonance (NMR) and mass 
spectrometry (MS) applied to biological macromolecules.173 Recent progress and high 
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importance of these techniques are related to structure- and disulfide elucidation of disulfide-
rich peptides (chapter 2.4.1-3). In general, analytical methods for elucidation of disulfide 
arrangement can be divided into destructive and non-destructive methods depending on the 
sample treatment and therefore the possible sample recovery. (Figure 8).1  
 
Figure 8. Analytical methods for the elucidation of disulfide bond connectivity of small, disulfide-rich 
peptides and respective characterization opportunities. Samples subjected to X-ray crystallography or 
NMR can be characterized by destructive methods afterwards because recovering is possible, which is 
not possible vice versa. Modified from 1        
Both non-destructive approaches (X-ray crystallography, NMR spectroscopy) result in 
complete 3D-structure models crucial for SAR studies.1 For X-ray crystallography a mayor 
issue is the preparation of suitable crystals from a peptidic or protein solution.174 Another 
aspect that has to be considered is that during these measurements the sample is solid and 
not in solution which can lead to misleading results compared to solution NMR.175 Solid-state 
NMR is rarely used for the elucidation of disulfide bridges for the same reasons as 
mentioned for crystallography. Therefore, solution NMR is the method of choice for small 
peptides (< 5 kDa) indicated by the structures available, since ~80% of the respective PDB 
entries are based on this technique. However, determination of the disulfide connectivity is 
not always possible for each structure and therefore, the final disulfide pattern is unclear or 
ambiguous isomers are possible for a distinct structure derived from NMR.176 The sample 
amount needed for non-destructive methods is typically much higher compared to the 
destructive techniques. This issue was solved by advances in peptide synthesis to generate 
sufficient sample amounts that allow  sequence identification and structure determination.177 
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On the other hand minimal sample amounts especially obtained from native material are 
analyzed with MS-based techniques nowadays which evolved in the progressive 
development of different combined “omics” approaches (e.g. venomics, proteomics) 
representative for the destructive methods.14,173,178 In the venomics approach the isolated 
samples can also be subjected to Edman degradation for identification of the primary 
sequence and disulfide elucidation.179–181 Nowadays, the preferred LC-MS based tandem 
mass spectrometry combines the chromatographic separation of the crude venom with the 
benefit of peptide sequencing via tandem mass spectrometry (e.g. LC-ESI-MS/MS).1,182 
Compared to NMR structure elucidation identification of a single peptide toxin sequence is 
achieved much faster exploiting the unique advantages of two established ionization 
methods: ESI- and MALDI-MS or MS/MS (chapters 2.4.1 and 2.4.2). Although both methods 
are MS-based, the spectra obtained from each method are often unique for each peptide or 
protein. Interestingly, some can be analyzed with both methods but others are peculiar for 
the respective method applied using their characteristic advantages and limitations.48,178,183,184 
In addition, both methods are able to quantify compounds, as was described for anthrax, up 
to attomol/mL range.185 Data obtained from MS/MS experiments are tremendously high and 
can be difficult to evaluate, especially after enzymatic digest and fragmentation.186 
Identification of peptides or proteins is usually performed using programs or databases with 
respective information available from measured or calculated experiments. Expertise in 
evaluation of these data is necessary to prevent false data interpretation, which includes 
time-intense manual data evaluation if required.178,186,187 Nevertheless, algorithms are also 
existing for the prediction of disulfide patterns of peptides and proteins.188   
For the final elucidation of the disulfide linkage in peptides or proteins by destructive 
methods, sample preparation is highly essential.178,189 Identification of the former disulfide 
bridge is typically determined after enzymatic digest of the peptide according to enzyme-
specific fragments.178,189 Comparing reductive and non-reductive conditions can clarify the 
bridged fragments of the whole peptide with a particular bridge opened or closed.142,189 
Especially larger peptides and proteins were subjected to this method whereas a trypsin-
based digest has the advantage of cleaving behind a positively charged residue which is 
ideal for detection via ESI-MS which might be hampered otherwise.189,190 When suitable 
enzyme cleavage positions are missing in the peptide sequence, partial reduction together 
with derivatization of the free thiol function is applied for disulfide elucidation.191 Several 
protocols have been developed based on different reagents like iodacetamide (IAA), N-
ethylmaleimide (NEM) and 4-vinylpyridine that react with the free thiol group of cysteines 
after reduction with a reducing agent like TCEP or DTT. 190–193 The elucidation of the 
derivatized cysteines can be performed by Edman degradation or MS.190–192 However, 
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disulfide scrambling during sample preparation can be challenging and parameters have to 
be optimized to avoid this, for example by using acidic reaction conditions.192   
The following chapters will focus on LC-ESI-MS, MALDI-MS and NMR especially for disulfide 
elucidation including advantages and limitations of the corresponding method.   
2.4.1 LC-ESI mass spectrometry 
 
Electrospray ionization (ESI) is one of the two destructive methods established for analytics 
of biomolecules.194,195 The major challenge is the soft ionization of the large biomolecules 
and the transfer to the gaseous phase.178,194 This was realized for solved biomolecules by an 
effect during evaporation of small droplets bearing a high positive charge. This leads to a 
disruption into smaller charged droplets and in the end to charged molecules only without 
solvent.178,194  Proteins and large peptides are usually detected as highly charged ions.173,194 
The great benefit of this technique is the direct combination of liquid chromatographic sample 
purification and MS for identification of each single fraction.196 Sequencing of the respective 
peptide, protein is typically performed with collision-induced decay (CID) in which a collision 
cell is used for fragmentation and isolation of the peptide ions.197 Two types of CID can be 
differentiate depending on the energy applied namely low energy CID and high energy CID 
(typically in ion trap MS) with a shorter activation time compared to conventional.198 Today, 
several devices utilizing ESI were used with different instrumental configurations e.g. 
quadrupole time-of-flight (Q-TOF), ion trap and Fourier transform ion cyclotron resonance 
mass spectrometer (FT-MS) each providing unique advantages and limitations.178  
In general, the use trypsin digest represents another advantage because of the cleavage site 
resulting in positively charged fragments that are easier to detect compared to other 
fragments observed by alternative enzymes.195 Although the disulfide linkage of -KIIIA was 
elucidated with tryptic digest in combination with CID-MS/MS for many other conotoxins this 
approach fails because they lack of suitable cleavage sites or ambiguous fragments 
obtained.5,116 More often a partial reduction and derivatization protocol is required prior to 
MS/MS sequencing as mentioned previously. The elucidation of -Si by Yen et al. was 
performed by partial reduction with TCEP in combination with alkylation using NEM and 
afterwards complete reduction and derivatization with IAA.192 The distinct alkylation of the 
thiol-groups revealed the disulfide connectivity of the examined fraction. It has to be 
mentioned that a previous approach using maleimide-biotin instead of NEM for derivatization 
failed because separation of the products was not possible.192 Nevertheless, the disulfide 
crosslinking of several conotoxins could be determined with this method after various 
preparation protocols (Table 2). But careful considerations are required because it is 
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reported that during preparation disulfide scrambling can occur resulting in unexpected 
fragments and a false determination of the disulfide bridging in the end.192,199 Therefore, 
different approaches are often used together for validation and reproducibility of the obtained 
fragments.184,199  
2.4.2 MALDI mass spectrometry 
 
Matrix-assisted laser desorption ionization (MALDI) represents the second MS method 
established for soft ionization of biomolecules.200 In this case the macromolecule is co-
crystallized with a distinct matrix.204 Ionization is performed afterwards with a laser suitable 
for the applied matrix, which evaporates it together with the intact biomolecule. With this 
approach higher masses can be investigated compared to ESI-MS and in addition the 
ionization method is softer compared to ESI- MS.204 One advantage of this approach is the 
robustness against contamination or sample impurities.173,200  Obtained MALDI-spectra are 
often less complex compared to ESI-spectra because they typically contain singly and doubly 
charged species, facilitating the evaluation.190 In general, two techniques for tandem mass 
spectrometry can be applied during MALDI namely in-source-decay (ISD) or the LIFT-
TOF/TOF-MS.201,202 The latter has the advantage of preselection of a precursor mass prior to 
fragmentation, whereas ISD reveals unique fragmentation pathways able to break disulfide 
bonds during fragmentation.201,202 Changing the matrix is a further possibility to increase the 
information obtained from a complex sample like crude venom.203 Application of 1,5-
diaminonaphthalene (1,5-DAN) together with -cyano-4-hydroxycinnamic acid (HCCA) as 
matrices reveals the amount of cysteine bridges of single samples in the venom mixture by 
comparison of  reduced and oxidized species because of the reducing properties of 1,5-DAN 
in contrast to conventional matrices.203 But usually previously mentioned sample preparation 
is also necessary to digest or reduce and alkylate the peptide for disulfide elucidation. It 
should be mentioned that during the laser ionization process gas-phase scrambling of 
disulfide bridges can occur.204 Nevertheless, MALDI-MS/MS raised during the last decades 
because of new approaches established including technical improvements as ISD and Lift.  
Combination of MALDI- and ESI-MS/MS was used for characterization of the 
bromotryptophan-containing conotoxin Mo1274 revealing the disulfide connectivity Cys1-
Cys3 and Cys2-Cys4.205 Comparison of the results obtained from MALDI- and ESI-MS for 
native material from C. purpurascens a higher number of masses was detected in the ESI-
approach.48 This was explained by poor ionization of the peptides examined.48 MALDI-
MS/MS holds also great perspectives besides disulfide elucidation. For instance, one special 
application for MALDI-MS/MS is imaging of tissue layers.206 With this method complex 
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molecular structures on surfaces can reveal detailed information of one distinct or several 
indicative masses on a certain area after covering with matrix.206  
Conotoxin Disulfide bridges Sample preparation Analysis method 
-SI192 2 partial reduction and  differential alkylation ESI-MS/MS 
-CnIa, -GI199 2 
partial reduction and 
differential alkylation or  
oxidation to cysteic acid 
ion mobility MS/MS CID 
Mo1274205 2 partial reduction and  differential alkylation 
ESI-FT-ICR MS and 
MS/MS 
-GI114 2 intact peptide NMR 
Ar1232, Ar1248, 
Ar1311, Vi1360, 
Vi1358, Ar1446, 
Ar1430207 
2-3 intact peptide and tryptic digest ESI-MS/MS, CID for disulfide bond cleavage 
-GIIIA, -GIIIB, 
-GIIIC208 3 
partial reduction, carbamido-
methylation and different digests Edman degradation 
-KIIIA116 3 tryptic digest, intact peptide LC-ion trap MS/MS CID, NMR 
-SIIIA91,95 3 intact peptide NMR 
-PIIIA209 3 partial reduction and differential alkylation Edman degradation 
-PIIIA96 3 tryptic digest, intact peptide MALDI-MS/MS, NMR 
-PIIIA64 3 intact peptide NMR 
-EVIA210 3 partial reduction and differential alkylation, intact peptide 
Edman degradation, 
NMR 
-GmVIA211 3 partial reduction and differential alkylation Edman degradation 
BtIIIA212 3 partial reduction and differential alkylation, intact peptide 
Edman degradation, 
NMR 
MrIIIA, TxIIIC65 3 partial reduction and differential alkylation Edman degradation 
Mo3964213 3 partial reduction and cyanylation, 
alkaline cleavage, intact peptide MALDI-MS, NMR 
Table 2. Comparison of disulfide elucidation methods and sample preparation techniques applied to respective 
conotoxins. 
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2.4.3 Two-dimensional NMR spectroscopy 
 
Nearly 60 years ago Saunders et al. reported the first NMR experiments with a biological 
macromolecule, Ribonuclease.214 Since then technical progress in superconducting magnets 
and progressive computational power for instrumental control and processing of spectra led 
from simple 1D to 3D NMR techniques.215 This includes different homonuclear (1H, protons) 
and heteronuclear (e.g. 13C, 15N) couplings with distinct structural information. Therefore 
isotope-labelling is often extended to proteins especially for structural or kinetic investigation 
of intra- and intermolecular interactions.215 Furthermore, NMR elucidation became extremely 
important for structure-based drug design not only for small molecules but also for larger 
peptides.175,216 Compared to common through-bound approaches such as correlation 
spectroscopy (COSY) or Total correlation spectroscopy (TOCSY) that give limited 
information about protons in close proximity (spin-spin coupling), the development of Nuclear 
Overhauser Enhancement Spectroscopy (NOESY) facilitates conformational observations 
also for protons correlating through-space (dipole-dipole coupling).175,216 Besides the already 
mentioned experiments several other correlation methods were established like rotating 
frame Overhauser effect spectroscopy (ROESY) that enhances limitations and enables high-
resolution NMR measurements.217 However, evaluation of the recorded spectra is still time 
consuming and demanding because combination of different experiments is taken into 
consideration, because each provides peculiar information for structure analysis. The known 
peptide sequence resonance assignment is performed together with a sequential assignment 
strategy based on the unique chemical shift of the included amino acids and their 
characteristic cross peaks in the spectra. The complete assignment provides information 
about distance constraints and dihedral angles between residues eventually resulting in a 
distinct structure.175,218 
Nowadays, for the elucidation and calculation of structures derived from NMR spectra 
various software programs are established and facilitate procedures such as CCPN or 
YASARA.219–221 Special interests within the field of structure elucidation is the visualization of 
complex macromolecular structures.222,223 This gives the possibility of representing a plethora 
of information to a broader community of life scientists.222 Furthermore, NMR gives the 
opportunity to observe peptide or protein folding with atomic resolution to elucidate the 
folding mechanism.112 
Within NMR structure determination the elucidation of disulfide connectivity is even more 
sophisticated but essential because at least one disulfide bond is present at 23% of the 
~62000 protein structures in PBD.224,225 For conopeptides, increasing numbers of several 
thousands of toxin primary sequences observed from high-throughput-screenings have been 
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described, whereas only a fractional amount of NMR-structures (164 from conoserver, 
20.12.2016) are available.68 This indicates the limitations in structure determination because 
of high expenditure of time and labour for generating such structures. Obviously the 
structures are also crucial for SAR-studies.4  
Structure elucidation of several conotoxins elucidated different structures for the respective 
peptides. Different isomers could be clearly separated and characterized via NMR by 
Gehrmann et al. for -GI and by Carstens et al. for various other -conotoxin.114 For more 
complex -conotoxins structure elucidation is also available for several peptides (Table 2). 
Although they prefer a distinct disulfide connectivity with two adjacent cysteines, for other M-
conotoxins also other disulfide crosslinking could be identified as well, e.g. BtIIIA, MrIIIA or 
TxIIIA within.212,226,227 All venomous animals produce a large variety of peptidic 
macromolecules from which ~70% bear two or more disulfide bridges representing a 
common feature in nature.228,229 Due to the high structural diversity depending on the primary 
sequence, including adjacent cysteines, the number of cysteines together with the formation 
of isomers and the absence of a sulphur isotope with beneficial NMR properties the 
unequivocal structure elucidation is hampered. The two major issues for elucidation are 
overlapping chemical shifts during NOESY of bridged cysteines and, on the other hand, 
adjacent cysteines, i.e. the connected cysteine is in close proximity to another not linked 
cysteine residue.228 Trusting only one technique can result in misleading structures as was 
reported for the NMR structure of hepcidin derived from NOESY.127,228 Therefore, several in 
silico methods developed for the prediction of the disulfide connectivity based on the existing 
data should be applied to overcome the previous mentioned problems. However, these 
computational programs focus their prediction algorithm on available structures, which might 
be revisited like mentioned for hepcidin, -KIIIA and neopetrosiamides.116,127,228,230 
Nevertheless, especially for peptides with three or more disulfide bridges different isomers 
still lack standards, including all possible isomers for a preserved sequence.176,231 One 
possibility of structure determination regarding the disulfide arrangement is isotope labelling 
with 15N/13C cysteine residues and 2D versions of standard triple resonance (1H,13C,15N) 
NMR experiments and 2D [13C,1H] HSQC, which might also be sophisticated in the case of 
two or more adjacent cysteines.232  
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3. Thesis outline  
 
Conotoxins may represent an interesting research target for the treatment of pain due to their 
impact on ion channels and/or receptors. This work aimed at the investigation of the folding 
behaviour of disulfide-bridged conotoxins under various oxidation conditions, a 
comprehensive analytical characterization of the resulting products and on their structure-
activity relationship. In order to pursue this goal, several approaches should be examined for 
the preparation of these target molecules, namely oxidation in conventional buffer systems, 
oxidation in Ionic Liquids, and selective cysteine bond formation by successive oxidation 
using an orthogonal protecting group strategy. The individual products should then be 
characterized by various analytical techniques such as HPLC, NMR, LC-ESI-MS/MS and/or 
MALDI-MS/MS. Furthermore, the impact of the disulfide-connectivity of the respective 
conotoxin on the biological activity at VGSCs should be considered as well. In addition, 
several computational methods should be applied to elucidate the folding behaviour of the 
peptides as well as the interaction of a respective conotoxin and selected VGSCs. 
As a starting point, peptide oxidation in room-temperature Ionic Liquids and the analytical 
characterization of the resulting products are to be investigated.166 Therefore, the influence of 
different IL compositions as well as educt concentration, temperature, and water content on 
product formation of different conotoxins should be analyzed. Validation and limitations of 
distinct methods (e.g. MS/MS) suitable for peptide chemical and structural analysis are in the 
scope of the second main topic of this thesis aiming at a direct comparison of these 
techniques. Here, -PIIIA containing three disulfide bonds should be utilized as model 
peptide for the selective synthesis of the 15 possible disulfide isomers, which are to be 
compared to the three isomers earlier isolated from a self-folding approach.96 Thus, selective 
formation of disulfide bridges should be performed using an orthogonal protecting group 
strategy and successive disulfide bond formation. In addition, the impact of the disulfide 
connectivity on conformation and, in turn, binding to and inhibition of the skeletal ion channel 
NaV1.4 should be examined. The obtained information should be combined and evaluated to 
derive structure-activity-relationships. In the end, the question whether one method alone 
can distinguish between all isomers or not should be answered. This is crucial to verify the 
results from the characterization of peptides containing multiple disulfide bonds in order to 
finally be able to establish standardization for the analysis of such disulfide isomers. This 
work demonstrates the essential need for the generation and application of standards and 
standard methods to provide unequivocal evidence of such complex molecules. 
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The present thesis is subdivided in six parts according to the publications included herein. 
Part I (chapter 4.1) explains several aspects of the application of ILs in peptide chemistry. In 
this review the advantages and disadvantages of ILs as novel reaction media are explained 
considering reports of the last decades with respect to synthesis, purification and analytical 
characterization. Current developments and perspectives are discussed in detail within this 
topic. 
Part II (chapter 4.2) presents the results of the two reactions namely oxidative folding and 
native chemical ligation of cysteine-containing peptides in ILs. Furthermore, the impact of 
reaction conditions such as temperature and water content on product formation are 
reported. 
Part III (chapter 4.3) encompasses the results of the application of various ILs on the 
oxidation of distinct model conotoxins containing two or three disulfide bonds. In addition, 
different IL mixtures and reaction conditions are analyzed using -SIIIA as model peptide. In 
this case, disulfide bonds were elucidated via LC-ESI-MS/MS after partial reduction and 
alkylation to confirm the native disulfide connectivity comparing the buffer- and IL-oxidized 
peptide. The impact of IL ions adhering to the peptide was demonstrated by differences 
regarding the biological activity of µ-SIIIA at VGSC NaV1.4 and yet, as a substrate for 
proteolytic degradation by the enzyme trypsin. 
Part IV (chapter 4.4) contains the characterization of the essential binding site of -EVIA at 
VGSCs and different chimeras of NaV1.4 and NaV1.7. Prior to the experimentally performed 
bioactivity tests and the molecular modelling studies, the structure of -EVIA was confirmed 
with solution NMR and LC-ESI-MS/MS. 
Part V (chapter 4.5) presents the results of the folding behaviour of a set of -conotoxins 
examined using molecular dynamics simulation of the NMR structures and also by computer 
visualistics studies with the aim to elucidate the influence of individual amino acids in the 
sequence to the folding process. Especially, the influence of individual disulfide bonds on the 
structural stability of the peptides after stepwise exclusion of the respective bridge was in the 
focus. The partially unfolded species with one disulfide bond removed show similar stability 
to the folded conotoxin which might indicate a possible retention of the biological activity. 
Although the different disulfide bridges increase the conformational stability of all structures, 
their positions within the molecule frequently change keeping the basic residues responsible 
for blocking of VGSC in a particular orientation on the surface of the peptide structure.  
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Part VI (chapter 4.6) comprises the results from selective synthesis, structure elucidation and 
biological characterization of the 15 possible isomers of -PIIIA. Comparison of the results 
obtained with the analytical techniques HPLC, NMR and MALDI-MS/MS should reveal if one 
method alone is sufficient to distinguish between all isomers. For the first time, structure-
activity relationship studies of these isomers are described regarding their inhibitory effect on 
the ion channel NaV1.4. 
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Preface 
Ionic Liquids represent alternative solvents for chemical and biological applications because 
of their unique properties.151,152,233 Ionic Liquids were established in peptide chemistry as 
novel solvents with improved solubility.156,163 Furthermore, purification and analytical 
procedures represent further applications for ILs with respect to peptides.156 This article 
contains an overview about current research and progress in the field of ILs and their broad 
application with respect to peptide synthesis, purification and analytics. 
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Abstract: This review aims to provide a comprehensive overview of the recent advances 
made in the field of ionic liquids in peptide chemistry and peptide analytics. 
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Abbreviations: 
[BF4]
− = tetrafluoroborate [C1C1IM]+ = 1,3-dimethylimidazolium 
[C1mim]
+ = 1-methyl-3-methylimidazolium  [C2mim]
+ = 1-ethyl-3-methylimidazolium 
[C4C1pyrr]
+ = 1-butyl-1-methylpyrrolidinium [C4mim]
+ = 1-butyl-3-methylimidazolium 
[C6mim]
+ = 1-hexyl-3-methylimidazolium [C8mim]
+ = 1-octyl-3-methylimidazolium 
[Ci,j,k,lN]
+ = tetraalkylammonium [DEP]− = diethyl phosphate 
ESI = electrospray ionization [Et3NH]
+ = triethylammonium 
[EtOSO3]
− = ethylsulfate [guan]+ = guanidinium 
[Me2PO4]
− = dimethylphosphate [MeOSO3]− = methylsulfate 
[MOEMIm]+ = 3-(2-methoxyethyl)-1-methyl-imidazolium 
[N(CN)2]
− = dicyanamide [OAc]− = acetate 
[OTf]− = triflate [OTs]− = tosylate 
[PF6]
− = hexafluorophoshate [SbF6]− = hexafluoroantimonate 
[SCN]− = thiocyanate [NTf2]− = bis(trifluoromethanesulfonyl)imide 
BOP = benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate 
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CCA = α-cyano-4-hydroxycinnamic acid DCC = N,N'-dicyclohexylcarbodiimide 
DHB = 2,5-dihydroxybenzoic acid DIEA = N,N-diisopropylethylamine, or Hünig’s 
base 
DMAP = 4-dimethylaminopyridine DMED = N,N-dimethyl-ethylenediamine 
GSH = glutathione  
GTHAP = [1,1,3,3,-tetramethylguanidinium-2,4,6,-trihydroxyacetophenone] 
H2O2 = hydrogen peroxide H3PO4 = phosphoric acid 
HATU = O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 
HPLC = high-performance liquid chromatography (high-pressure liquid chromatography) 
IL = ionic liquid ILM = ionic liquid matrices 
kDa = kilodalton LSER = linear solvation free energy 
relationship 
MPG = 2-methyl-2-(p-tolyl)-glycine MALDI = matrix-assisted laser desorption/ 
ionization 
MS = mass spectrometry MOPS = 3-[N-morpholino]propanesulfonic acid 
NCL = native chemical ligation NMR = nuclear magnetic resonance 
OGp = chymotrypsin and trypsin RP = reversed phase 
PyBOP = (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) 
SCIL = surface-confined ionic liquids SCm = V8 protease 
SPPS = solid phase peptide synthesis TFA = trifluoroacetic acid 
THF = tetrahydofurane TLC = thin layer chromatography 
TOF = time-of-flight TRH = thyroliberin (thyrotropin-releasing 
hormone) 
1. Introduction 
During the last decade the interest in establishing alternative solvents for organic synthesis to 
provide safe and environmentally clean processes has increased dramatically. Alternative solvent 
media that can provide suitable or even better reaction conditions for organic synthesis and which are 
less hazardous than conventional organic solvents are “molten salts” or so-called ionic liquids (ILs). 
Numerous reports have been published describing the unique properties of ILs such as negligible vapor 
pressure, low melting point, special phase behavior, electric conductivity, low flammability, and high 
thermal stability. The applications range from transition metal-mediated catalysis, e.g., hydrogenation, 
oxidation, or hydroformylation, to organic reactions such as the Diels-Alder reaction, the Friedel-Crafts 
reaction, cycloaddition, and esterification [1–3]. In addition, ILs became very attractive in a number of 
fields involving biological macromolecules, e.g., enzymes and proteins, where they lead to structure 
stabilization [4] and are applied to biotransformations by enzymatic catalysis [5], protein 
crystallization [6], and fluorescence quenching immunoassays [7]. In other applications, ILs show 
advantages due to their favorable solvation properties for polar substrates, including carbohydrates [8,9], 
proteins [10], and reduced emissions, but also as solvents in analytical chemistry and in chemosensing 
strategies [11]. 
In comparison to conventional solvents an IL consists of an anion and a cation, i.e., it possesses a 
dual character. For this reason, ILs are salts that can provide a suitable medium for biomolecules. 
Depending on the ionic liquid composition, the solvation environment, they can be adjusted to fit a 
specific solute and process requirements, such as solubility or phase separation from an organic or an 
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aqueous phase [12]. By manipulating the ionic solvent properties it is possible to design ILs for special 
reaction conditions, which in case of enzymatic reactions affect, for example, reaction rate, enzyme 
selectivity, and substrate solubility [5]. Lately, several reports about the interactions between an ionic 
liquid and various biomolecules were published. However, the nature and the forces of IL-solute 
interactions are still too little understood, to answer the questions why ILs stabilize the active form of 
enzymes/proteins [8,13], or why they provide an ideal platform for the folding of cysteine-rich 
peptides [14]. In the coming years, these will become more and more attractive in the field of 
biochemical research. 
In 2008 [15], Plaquevent et al. presented an excellent overview of IL applications in amino acid 
and, in part, peptide chemistry, as well as of the use of IL components to produce novel amino  
acid-based ILs [16,17]. Their intention was to answer the following quite comprehensive questions:  
Is it possible that ILs can provide a better reaction medium than traditional organic solvents and in 
which fields of chemistry and biochemistry can they be applied? However, there are still no satisfying 
answers and many more questions are open due to the large variety of applications offered in this field 
of research. During the last three years, interest in the use of ILs in peptide and protein research 
increased immensely. Finding new ways to improve coupling reactions, solubility of peptides and 
proteins in aqueous/buffer solutions, and their chemical characterization occupied the mind of peptide, 
protein and analytical chemists. Hence, detailed studies were carried out, including investigations on 
the influence of peptide/protein concentration on the outcome of a biochemical reaction, the effect of 
the ionic liquid on the peptide/protein structure, the effect on the function of a peptide/protein of 
interest, and more generally, on how to increase the stability and reactivity of such biomolecules in ILs.  
The main challenge is to select the best IL for a particular process and/or application. This review 
intends to support advances made in the field of IL applications in peptide chemistry by summarizing 
the current state in the field and condense the information available in the literature. Indeed, one may 
ask the question, why we are focusing our attention on peptides? Polypeptides and proteins are present 
in all living cells in a rather large number and variety. Model peptides are usually used to understand 
functions of large proteins [18]. However, it is also generally accepted that the effects and behavior of 
peptides in various reaction media differ from those of proteins. Proteins usually fold to form 
particular three-dimensional shapes, which determine their actions, while polypeptides are structurally 
less constrained, i.e., they can adopt many conformations in solution. Thus, proteins possess a rather 
well-defined tertiary structure that is in many cases missing in the case of peptides. Therefore, we 
intend to give an overview of the new fields of investigations that appeared during the last years with a 
focus on the use of ionic liquids in peptide chemistry, including purification, and analysis. Also,  
this survey represents new trends, which have appeared in the literature following the review of 
Plaquevent et al. [15] four years ago, to help to choose a suitable IL for the desired reactions and 
characterization techniques. 
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2. Ionic Liquids in Peptide Chemistry 
In this part, we describe the applications of ILs in peptide chemistry: peptide synthesis and 
modifications of special peptides. We included different synthetic strategies of conventional methods, 
where organic solvents are used primarily, but focused our attention on ILs as reaction media and the 
advantages and disadvantages of their use in peptide synthesis. Our report highlights the achievements 
made in peptide synthesis since the publication of the review mentioned earlier [15]. 
The choice of the ionic liquid in a peptide-chemical reaction depends on various factors, but most 
importantly is dependent on: (a) the solubility of the peptide/protein and/or its precursors and (b) the 
melting point of the ionic liquid. The latter aspect is important if the reaction is to be conducted in the 
absence of any co-solvent such as water, which would reduce the viscosity of the reaction mixture, but 
also affect the peptide-ionic liquid interactions. In analogy to other biopolymers, such as cellulose or 
silk, ionic liquids with rather nucleophilic anions dissolve proteins due to their ability to break the 
inter- and intramolecular hydrogen bonding network. Similarly, ionic liquids reduce the ability to form 
peptide-peptide hydrogen bonds, thus lowering the risk of protein denaturation through misfolding and 
aggregation. However, due to this property, protein-dissolving ionic liquids often feature melting 
points well above room temperature, which reduces their potential for applications with thermolabile 
peptides and proteins. While the anion is involved directly in the dissolution process, the cation choice 
can be used to modulate the properties of the ionic liquid with regards to viscosity, melting point and 
therefore mass transfer limitations somewhat. Dialkylimidazolium-based ionic liquids belong to the 
best investigated group of ionic liquids. However, it needs to be noted that questions of toxicity of ILs 
arise, especially if the peptide is to be used as pharmaceutical. For example, it can be expected that 
thiocyanide-, methylsulfate or biscyanamide-based ionic liquids will be toxic, while chlorides, sulfates 
and acetates should be less or non-toxic. In fact, [C2mim][OAc] is non-toxic and has been proven to be 
the IL of choice for the dissolution and conversion of the linear, rather hydrophobic peptides [14]. 
2.1. Peptide Assembly 
Nowadays, a large variety of methods is available to produce or obtain peptides, including isolation 
from natural sources (e.g., extraction from plants, animals and other organisms), recombinant 
synthesis, and production by chemical or enzymatic synthesis [19–23]. Only a few manuscripts have 
reported that ILs can be applied in this field of peptide assembly as pure solvents, as co-solvents in 
aqueous systems or as biphasic systems [8,24], in both, solid and solution phase synthesis as well as in 
enzyme-catalyzed peptide synthesis (Figure 1).  
In general, the choice of the synthetic method is usually determined by the length and the quantity 
of the peptide of interest. For example, enzymatic peptide synthesis is applied for the production of 
small peptides, e.g., di- or tripeptides [25], to obtain large quantities in industrial production scale. This 
method benefits from the high specificity of the reaction, the avoidance of side chain protection of the 
substrates and the racemate-free formation of the products. Chemical synthetic protocols have focused 
firstly, on the synthesis of longer peptides by Merrifield solid phase peptide synthesis (SPPS) [26], 
which is limited to a length of approximately 50 amino acids (though longer peptides can be prepared 
depending on the primary amino acid sequence), primarily because of the steric hindrance and 
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accumulation of undesired and truncated sequences during chain prolongation. Secondly, for the 
synthesis of polypeptides (>50 amino acids) or small proteins the method of segment ligation has been 
introduced as an alternative for recombinant production (see Section 2.2.3). The combination of 
chemical and enzymatic synthesis has been described by Guzman et al. representing a method that 
might be quite suitable for selected peptides [23]. In other procedures, the use of a soluble polymer 
support, which is called “liquid-phase” peptide synthesis, has been demonstrated [27]. This method 
was successfully applied for the synthesis of several oligopeptides, but the limiting factor here usually 
is the solubility during peptide assembly and work-up, in particular in solvents such as water or 
diethylether. In addition, “fluorous-phase” synthesis was established, where fluorous supports (i.e., 
trialkoxybenzhydryl-type, Wang-type and tert-butyl-type support) and fluorous chemistry were used 
for peptide synthesis exemplified for bioactive peptides, e.g., TRH [28,29]. However, the most 
common procedure of peptide synthesis still remains SPPS. 
Figure 1. Schematic representation of ionic liquid-applications in peptide synthesis. 
 
However, the methodologies applied nowadays clearly suffer from limitations covering solubility, 
low selectivity and yield, reactivity and steric issues as well as rather high costs of reagents. Thus, 
there is a high demand for new and/or optimized methods in this field. Indeed, ionic liquids have found 
their applications in the field of peptide chemistry in the last decade (Table 1). Since it was noticed that 
ILs improve the solubility of different reactants, separation of the products and the recovery of the ILs 
was possible [8–15]. ILs became more and more popular in peptide chemistry as summarized in the 
following sections.  
Table 1. Summary of the ionic liquids used in peptide chemistry. 
Ionic liquid Abbreviation Application Ref. 
1-methoxyethyl-3-methyl-
imidazolium hexafluoro-
phosphate or tetrafluoroborate 
[MOEMIM][PF6] 
[MOEMIM][BF4] 
Enzymatic peptide synthesis [30] 
1-butyl-3-methylimidazolium 
hexafluorophosphate 
[C4mim][PF6] Chemical peptide synthesis 
[15, 
31–34] 
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Table 1. Cont. 
Ionic liquid Abbreviation Application Ref. 
1-hydroxyethyl-1-methyl-
imidazolium tetrafluoroborate 
3-(2-hydroxyethyl)-1-methyl-
imidazolium tetrafluoroborate 
- IL supported peptide synthesis [35,36] 
1-butyl-3-methylimidazolium X 
[C4mim][X] (X = BF4, 
PF6, SbF6, OTf, NTf2) 
Radiolabeling of peptides [37,38] 
1-ethyl-3-methylimidazolium X 
1-butyl-3-methylimidazolium 
acetate 
[C2mim][X],(X = OAc, 
DEP, OTs, N(CN2)2) 
[C4mim][OAc] 
 
Oxidative folding and native 
chemical ligation of cysteine-
containing peptides 
[14,39] 
2.1.1. Enzymatic Peptide Synthesis 
Some reports describe ILs as suitable media to increase the solubility, stability and activity of 
enzymes.[10,13,40–43] For example, Constantinescu et al. [41] studied the denaturation of enzymes in 
ILs including the cations [C2mim]
+, [C4mim]
+, [C6mim]
+, [C4C1pyrr]
+, [Ci,j,k,lN]
+, [guan]+ and the 
anions [SCN]−, [MeOSO3]−, [EtOSO3]−, [OTf]−, [NTf2]−, [N(CN)2]−. It was found that the stability at 
higher temperature (70 °C) was increased compared to aqueous buffer solution, with [Ci,j,k,lN]
+ and 
[NTf2]
− showing the best results. These studies were later extended by others, for example to the use of 
[C2mim][FSI] (FSI = bis(fluorosulfonyl)imide) for the α-chymotrypsin-catalyzed reaction of Ac-Trp-OEt 
with Gly-Gly-NH2 to yield Ac-Trp-Gly-Gly-NH2 (see also below) [42]. Here, a 16-fold increase in the 
initial rates for peptide synthesis was observed compared to the reaction carried out in acetonitrile.  
In addition to these findings, they also found a 17-fold higher activity for α-chymotrypsin in ILs 
compared to organic solvents.  
Besides, other applications of ILs have been reported with respect to proteins, e.g., Summers and 
Flowers have described the renaturation of proteins in the IL ethylammonium nitrate as a one-step 
process [44]. This IL prevented aggregation and caused the refolding of proteins, e.g., lysozyme, 
resulting in its active state with up to 90% of active protein [44]. ILs as suppressors of protein 
aggregation and useful supports for refolding processes of denatured proteins were also described by 
Buchfink et al. in 2010 [45]. A series of [C2mim]
+ salts was used with a focus on the impact of the 
anions as refolding enhancers as well as different model proteins, among them recombinant 
plasminogen activator rPA. It was found that IL co-solvent systems with an intermediate capacity to 
solubilize proteins are effective as refolding additives, i.e., were found to permit effective renaturation 
of rPA. The most promising refolding enhancer in this respect was [C2mim][Cl]. By means of 
fluorescence correlation spectroscopy Sasmal et al. found that the presence of 6 M guanidine hydrochloride 
helps a protein, e.g., human serum albumin, to refold after addition of 1.5 M [pmim][Br] [46].  
An interesting contribution quantifying the biomolecular interactions of the functional groups in 
proteins with biocompatible ILs, e.g., diethylammonium and triethylammonium acetate, has been 
reported recently [47]. Herein, transfer free energies (G’tr) of compounds such as Gly, Gly-Gly and 
cyclo(Gly-Gly) from water to aqueous ionic liquid solutions were determined depending on the IL 
concentration. The solubility in aqueous solutions decreased with increasing IL concentration (salting-out 
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effect). This was attributed to the non-favorable interactions between IL and individual amino acid 
residue(s). However, overall all ILs could stabilize the structure of the model compounds—with 
triethylammonium acetate being the strongest stabilizer among the ILs used. On the other hand,  
a negative contribution (G’tr) of the peptide backbone from water to higher concentration of e.g., 
TMAA (50–70%) indicated that the interactions between the solvent and backbone unit are favorable.  
The first attempts in peptide bond formation by enzymes, however, were already reported by 
Erbeldinger et al. in 2000 [31]. Here, the synthesis of Z-aspartame in a thermolysin-catalyzed reaction 
in [C4mim][PF6] was demonstrated. Upon addition of 5% of water a biphasic reaction mixture was 
formed, and water exhibited a stabilizing effect on thermolysin. Also, the activity of the enzyme was 
dependent on the water content. In addition, an increased solubility was observed for the substrate and 
product upon addition of water. The reaction was monitored by HPLC after mixing of the reaction 
mixtures with 60% acetonitrile/water containing 10 mM orthophoshoric acid prior to injection. For the 
final procedure, however, a step allowing for the recycling of the IL was suggested after the reaction 
occured. The yield of the product was 95%, i.e., the same as found for organic solvents, e.g., ethyl 
acetate/water mixtures. 
In 2007, Xing et al. reported the use of an α-chymotrypsin-catalyzed synthesis of protected 
tripeptides, e.g., the fragment Z-Tyr-Gly-Gly-OEt of Leu-enkephalin, in six different 1-alkyl-3-
methylimidazolium hexafluorophosphates and tetrafluoroborates [30]. Again, it was found that the 
water content has a great influence on the two main factors, enzyme activity and coupling yield.  
At higher water content, the product is hydrolyzed, thus reducing the reaction yield. However, a small 
amount of water was essential for the reaction to succeed, i.e., for hydrophobic [MOEMIM][PF6] the 
minimum content was 3%, while for the more hydrophilic [MOEMIM][BF4] 8% turned out to be 
favorable. The authors also reported that [MOEMIM][PF6] was the most suitable IL among the ILs 
tested, and peptides were prepared in 68–75% yield. Further enzyme-supported reactions in ILs have 
been reported by Wehofsky et al. [48] and are in detail in section 2.2.3, because larger peptide 
molecules prepared by ligation reactions are in the focus of that study. However, enzymatic acylation 
of smaller peptides has also been described by other groups, as can be exemplified by the lipase-catalyzed 
acylation of Lys-Ser x HCl with oleic acid carried out in either organic media (2-methyl-2-butanol) or 
an ionic liquid ([C4mim][PF6]) [49]. Substrate conversion in this case was found to depend on peptide 
solubility which was improved in the IL. Primarily chemoselective acylation occurred at the N-amino 
group of lysine, while the side chain acylated serine derivative was not detected at all. Another 
example came from Malhotra et al., who reported on the immobilized protease-catalyzed synthesis of 
peptides, e.g., Boc-Leu-Trp-OEt, in the ionic liquids [C4mim][PF6], [C4mim][BF4], and [C2pyr][BF4] [50]. 
Here, product yields were comparable to those obtained in organic solvents, i.e., a maximum yield of 
49% for Boc-Leu-Trp-OEt was obtained. 
In summary, 1,3-disubstituted imidazolium-based ionic liquids were successfully applied as 
additives to enzymatic syntheses. They were described to have a positive effect on enzyme-catalyzed 
coupling reactions, to increase the enzyme’s activity, the coupling yields, the solubility of reagents as 
well as the product. Interestingly, the necessity of water for optimal coupling yields has been 
demonstrated regularly. Obviously a minimum amount of water (3–8%) is favorable for the activation 
respective enzyme. 
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2.1.2. Chemical Synthesis of Peptides 
2.1.2.1. Condensation of Free Amino Acids in Solution 
In a symposium report, Smith et al. demonstrated for the first time the peptide bond formation, e.g., 
for the generation of cyclopeptides, in ionic liquids at high temperatures (>100 °C). The thermally 
stable 1-butyl-3-methylimidazolium hexafluorophospate was used, while water was absent in the 
reaction mixture. Surprisingly, at temperatures below 100 °C no reaction occurred [32]. Subsequent 
works also reported the condensation of amino acids in ILs, in particular in 1-butyl-3-methylimidazolium 
hexafluorophosphate [15,33,34,51]. Here, high coupling yields were achieved for quaternary α-amino 
acids that are much more difficult to couple than tertiary amino acids [15]. The reaction is thought to 
proceed through the stabilization of a charged species in the ionic solvent. Interestingly, tetra-, octa- 
and cyclooctapeptides were obtained in high yields (80–90%), which was comparable to organic 
solvents (e.g., THF). However, the crude peptides had much higher purities compared to classical 
organic synthetic protocols. A stabilization effect of the coupling reagents HATU and BOP in the ionic 
liquid was suggested to be the cause of this observation [34]. Still, finding a suitable extraction 
protocol for separating the product from the reaction mixture provides rather difficult, but in another 
publication good isolated yields (66–87%) were obtained by extracting of a protected dipeptide  
(Z-Gly-MPGOMe) [33,51]. In addition to these reports, Petiot et al. described the use of a new 
ammonium-based poly(ethyleneglycol)-based ionic liquid (PEG-IL) and its use for the synthesis of 
various dipeptides containing Phe, Gly, Ala, Leu and Glu under microwave activation [52]. As an 
example, the formation of Boc-Phe-Phe-OMe by using HATU as coupling reagent (3.3 equiv.) in a 
bis-PEG350-IL carried out at 65 °C for 2 h yielded 64% of the product. It was discussed that the polar 
nature of bis-PEG350-ILs may have a beneficial effect on the solubilization of the starting material, 
i.e., amino acids and coupling agents. In addition, higher purities of the dipeptides obtained after work 
up, and reduced reaction times compared to previously reported peptide syntheses in ionic liquids were 
observed in this study. 
As demonstrated, first attempts have been undertaken to synthesize small peptides in ionic liquids 
as reaction media. In addition, the idea of a direct coupling of an amino acid to form a peptide bond by 
simply dissolving it in an ionic liquid and thus avoiding protection/deprotection steps seems promising 
for future applications of ILs in peptide synthesis [15]. 
2.1.2.2. Ionic Liquid-Supported Amino Acid Condensation 
Solid phase peptide synthesis (SPPS) may have several limitations, e.g., solvation of reagents, slow 
coupling rates, difficult access of the reagents to the reaction sites, and nonlinear reaction kinetics.  
As a consequence, “liquid phase” methods were developed and applied recently (section 2.1). One of 
these methods represents the IL-supported peptide synthesis introduced by Miao and Chan in 2005 [36]. 
Here, substrates were directly attached to the respective IL, i.e., 3-hydroxyethyl-1-methylimidazolium 
tetrafluoroborate, and by-products and excess reagents were removed from the desired product and 
intermediates by using simple washing steps (Figure 2). This synthetic procedure was used to produce 
Leu5-enkephalin of the sequence Tyr-Gly-Gly-Phe-Leu-OH. There were several advantages of this 
method, including (i) only a low excess of the coupling reagent (two equivalents PyBOP or DCC) was 
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required for the coupling steps instead of commonly used four to five equivalents, (ii) intermediates 
were easily purified by washing steps (liquid/liquid phase separation), and (iii) purity determination 
and structure identification were possible through spectroscopic methods (MS, NMR).  
Figure 2. Scheme of ionic liquid-supported peptide synthesis (modified from [36]). 
 
Furthermore, quantitative condensation of the first amino acid with DCC/DMAP and the second 
residue by using PyBOP/DIEA was achieved [36]. Additionally, IL-imidazolium attached oligomers 
were used as a soluble/solid support for the synthesis of hexapeptide building blocks. As an 
example/model the natural peptide Mucin4 containing a high number of serine and threonine residues 
was chosen. In contrast to previous studies, a mixture of HOBt/HBTU was used as coupling reagents, 
because of the difficulties to remove tripiperidinophosphine oxide from PyBOP during purification 
steps. Purification of the peptides was carried out by simple washing steps using water, because 
peptides were insoluble in water, while the soluble ionic supports could be washed out easily [53]. 
Shortly after this report, the same research group outlined the use of IL-attached oligomers for the 
large scale production of oligopeptides, oligosaccharides and oligonucleotides in a patent [35]. Other 
groups functionalized the ILs, namely cations 1-methylimidazolium and pyridinium and anions 
bromide, chloride, iodide and tetrafluoroborate, with amino, alcoholic or carboxylic groups. Rather 
high loadings (2.5–5.0 mmol/g) of the substrates of the ILs were obtained in these studies [54,55]. 
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Additionally, in the review mentioned earlier [15,56], the use of ILs based on histidinium salts for the 
synthesis of dipeptides was emphasized. They described coupling efficiencies of 78–83%, while no 
racemization occurred and the required product, the histidinium-coupled alanine derivative, was 
successfully obtained. The first total synthesis of a bioactive peptide, sansalvamide A (Figure 3),  
by ionic liquid-supported peptide synthesis was demonstrated by Chen et al. [57] Here, final ring 
closure was achieved by using PyBOP as coupling reagent. 
Figure 3. Molecular structure of cyclic depsipeptide sansalvamide A (modified from [57]). 
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An interesting approach, which combines advantages of SPPS and liquid phase reactions, represents 
the use of [58] onium salt soluble supports containing a trimethylammonium cation for peptide 
synthesis of small peptides (e.g., tripeptides). The onium salts-based soluble supports were easily 
prepared by classical synthetic routes in high yields (74–99%) with a final loading capacity between 
1.6 and 3.8 mmol/g, i.e., only 26–50 g per liter solvent was required in order to achieve the 
traditionally used 0.1 M concentrations during synthesis. Tripeptides were obtained in good yields 
(98% over two steps). In addition, several positive effects were observed, such as less than 5% 
diketopiperazine formation, less than 1% racemization for model peptide Val-Leu-Ala, compatibility 
with conventional reagents, e.g., coupling reagent HBTU or cleaving agent HPF6 in methanol, 
purification of peptides by extraction with water, and recycling of the support. The purification step, 
for example, could easily be achieved, since the peptide was soluble in water, while onium salts 
derivatives were soluble in dichloromethane. In addition, reactions could be monitored by NMR and/or 
HPLC without cleavage from the support rendering this method suitable for high throughput and large 
scale preparation of peptide libraries [58]. 
Finally, Cho et al. reported the preparation of ionic liquid resins with an ionic liquid environment 
on solid support by immobilizing ionic liquid spacers on a polystyrene (PS) resin [59]. The properties 
of IL resins were dramatically changed as the anions of IL were exchanged. The performance of IL 
resins for solid-phase peptide synthesis (SPPS) was evaluated by measuring coupling kinetics of the 
first amino acid, and synthesizing several peptides on IL resins. 
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In our opinion, the coupling of amino acids in ILs can obviously be carried out at a high rate 
without the use of a large excess of coupling reagents, and this, in turn, is one big advantage of the use 
of ILs in peptide chemistry. 
2.2. Peptide Modifications 
In this part we describe the progress made with respect to reactions other than the general peptide 
assembly methods, e.g., the synthesis of radiolabeled peptides, the formation of disulfide bridged 
polypeptides by oxidative folding and different ligation procedures used to obtain oligopeptides and 
small proteins. This novel and, at the current state, sparsely investigated research field hints to the 
successful use of ILs for such processes and opens exciting new ways for the optimization of protocols 
that are hampered by many drawbacks of conventional methods applied thus far. 
2.2.1. Radiolabeling of Peptides 
Radiolabeling is an established technique with many applications in biological research, such as the 
investigation of the distribution of labeled markers in vivo (e.g., in humans and in animals) by positron 
emission tomography [60]. The synthesis of the radiolabeled bioactive compounds, in particular 
peptides, is usually time consuming and requires complicated procedures and special equipment to 
purify the product from unwanted non-radioactive and radioactive byproducts. Strictly anhydrous 
conditions are highly recommended, for example, for fluoride ion displacement reactions in the 
conventional protocols. 
A new approach in this respect has been proposed by Kim et al. in 2003 (Figure 4) [37]. Herein, 
fluorine-18 labeling of alkyl mesylate or alkyl halides, e.g., 2-(3-methanesulfonyloxypropoxy)-
naphthalene, in ILs containing a hydrophobic cation ([C4mim][X], where X = [BF4]
−, [PF6]−, [SbF6]−, 
[OTf]−, [NTf2]−) was described for the first time. This method was successful despite the addition of a 
small amount of water, which is in contrast to the conventional method used. The ILs enhanced the 
reactivity of fluorides and also, a reduction of by-product formation (alkenes, alcohols) was observed. 
This approach led to further developments in this field as reported by Schirrmacher et al. [38]. The IL 
[C4mim][OTf] was useful for the labeling of short model peptides, e.g., GSH [38]. Thus, radiolabeling 
performed in IL (1,3-dialkylimidazolium salts) obviously occurs without the need for complicated 
procedures and strictly anhydrous conditions, but by direct addition of the IL to the reaction mixture 
and further simple purification steps. 
Figure 4. Radio-fluorine-18-labeling performed in an ionic liquid (modified from [37]). 
 
2.2.2. Disulfide Bond Formation and Peptide Folding 
Establishing efficient strategies for the synthesis of cysteine-rich peptides has always been a 
challenging task in the past. Generally, the incorporation of cysteine residues in peptide sequences is 
difficult as it requires the protection of the highly reactive thiol group [18,61–63]. Cysteine, however, 
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is very important since many naturally occurring peptides contain intramolecular disulfide bonds that 
stabilize the biologically active conformation [18,64,65]. Thus, one application of cysteine-residues in 
peptide chemistry represents disulfide bridge formation that may be achieved at various stages of the 
synthesis, on-resin as well as in solution [62,66–68]. Protecting group strategies differ according to the 
number of cysteine residues and disulfide bonds to be formed. While peptides containing one disulfide 
bridge are mainly prepared by oxidation (e.g., air, H2O2, iodine) in solution at low concentrations  
(10−3 to 10−4 M), for peptides with two or more disulfide bridges the situation is more complicated 
since intramolecular mispairing (scrambling) and/or intermolecular dimerization or oligomerization 
may occur [61–63]. 
The major disadvantages of these conventional methods are: (i) the requirement for a high dilution 
of the reaction mixture, (ii) very long reaction times, (iii) inadequate solubility of hydrophobic 
peptides in buffer solutions (including the need for organic solvents: isopropanol, methanol, 
acetonitrile), and (iv) the difficulty to control oxidation that requires the reaction to be carried out at 
low temperatures (usually 4 °C). Consequently, there are huge problems for producing such peptides in 
large amounts and sufficient purity. Over the years, many scientists were searching for a method that 
can overcome these problems. In our own work [14], we recently described for the first time the use of 
1-ethyl-3-methylimidazolium-based ILs with different anions including small hydrogen-bond 
acceptors (acetate [OAc]−, diethyl phosphate [DEP]−) as well as larger, less-coordinating anions 
(tosylate [OTs]−, dicyanamide [N(CN)2]−) for the oxidative folding of neuropeptides (Figure 5).  
Figure 5. Oxidative folding of cysteine-rich peptides performed in ILs. 
 
A very good solubility of hydrophobic peptides, e.g., -EVIA and -SVIE, containing six cysteine 
residues was observed in these ILs. The reaction was performed in ILs of low water content (between 
0.5–3%), in a very small volume and a rather high concentration of the peptides (10–15 mM) [14]. 
Thus, this seems to be a promising method for up-scaling the production of cysteine-rich peptides, also 
because the formation of by-products and misfolded species was minimized in comparison to 
conventional methods (oxidation in buffer solution [69,70]). In contrast to the latter, there is no need 
for additional redox reagents, thus the reaction can be performed in the pure IL. A stabilization of  
pre-formed secondary structures of the peptides investigated by the ILs was suggested to be the cause 
of these observations. 
Later, different naturally occurring cysteine-rich peptides were studied to understand the nature  
of interaction between ILs and peptides. Various model peptides—short (10 amino acids) and  
medium-sized (20–40 amino acids) native peptides with varying numbers of cysteine residues in their 
structure (from two to six) were subjected to these investigations. Depending on the net charge, amino 
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acid content and hydrophobicity of the peptide, the efficiency in the ILs used differed strongly. In 
contrast to conotoxins µ-SIIIA, µ-PIIIA, -EVIA, and -SVIE that showed best results when using 
[C2mim][OAc] as reaction medium [14], optimum conversion of linear CCAP-vil [39] was observed in 
[C2mim][OTs] (yield >90% according to HPLC analysis) and to a lesser extent in [C2mim][DEP] 
(yield >80% according to HPLC analysis). Interestingly, the target peptide did not form the oxidized 
version in [C2mim][OAc] in acceptable yields (57%), and the yield was even lower in case of 
[C2mim][N(CN)2] (approximately 44%). When increasing the lipophilicity of the ionic liquids  
(by increasing the alkyl substituent from [C2mim][OAc] to [C4mim][OAc]), the yield of the oxidized 
product decreased to approximately 47% [39]. 
It is clear from these studies that oxidative folding depends on the proper choice of the ionic liquid. 
Also, peptides with a high net charge are apparently more efficiently oxidized in ILs containing more 
basic anions, such as [C2mim][OAc], compared to small uncharged peptides such as CCAP-vil, where 
the most suitable ionic liquid contains a less basic anion, i.e., [C2mim][OTs]. Unpublished data related 
to our former work showed interesting dependencies of the reaction outcome and product purities on 
water content and reaction temperature (Figure 6). This can be exemplified for the conopeptide  
µ-SIIIA, where already an increase of the water content from 3-10% was disadvantageous for product 
formation. In contrast, an increase in temperature up to 80 °C was favorable for the oxidation reaction. 
Figure 6. RP-HPLC elution profiles of µ-SIIIA (crude mixtures) after oxidative folding in 
[C2mim][OAc] depending on (a) water content (cyan with 3% water, blue—5%, green—7.5%, 
red—10%) and (b) temperature (blue curve—80 °C, green—60 °C, red—40 °C).  
* Peak from ionic liquid.  
 
The role of ILs in oxidative folding of peptides is still sparsely investigated, since further candidates 
are necessary to derive a scientific explanation for these observations, yet the application of ILs for this 
reaction clearly has the potential to be developed as a key technology in peptide chemistry in the 
future. However, an interesting aspect with respect to the folding behavior of peptides was recently 
presented by Huang et al., who reported on the investigation of the folding of model peptides in neat 
ionic liquids by CD spectroscopy [71]. This study was motivated by the fact that previous IL studies 
have almost exclusively focused on large functional proteins, such as lysozyme, ribonuclease A and 
human serum albumin. Indeed, the authors were correct in stating that the interpretation of the results 
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obtained for proteins are complicated by their size and the different degrees of freedom available to 
either a peptide or a protein. Thus, they focused on small peptides, e.g., α-helical AKA2, miniprotein 
Trp-cage (contains e.g., α-helical part and 310 helix), and Trpzip4 (-hairpin), in order to understand 
the effect of ILs, in this case [C4C1pyrr][NTf2], on well-designed secondary structures. The model 
sequences used represent optimized native folds in an aqueous environment. Huang et al. characterized 
the thermal transitions of these peptides using circular dichroism (CD) spectroscopy and found that, in 
contrast to the aqueous data, the far-UV CD spectra of AKA2 and Trp-cage in [C4C1pyrr][NTf2] 
indicated only minimal helical structure at low temperatures. However, in both cases, this data and the 
temperature-dependent far-UV CD spectra suggested apparent heat-induced structure formation with 
structure persisting to the highest temperatures recorded (92 °C). In contrast to the results of the helical 
peptides, the CD data for Trpzip4 indicated huge destabilization by the IL medium with increasing 
temperature [71]. In addition to this report, Debeljuh et al. studied the impact of triethylammoniummesylate 
(TeaMS) on the structure of the Abeta(1–40) peptide for Alzheimer’s disease [72]. They found that the 
IL was able to induce a conformational change and also that this structural change influences the  
self-assembly of the peptide into amyloid fibrils. In our opinion, these studies are an important starting 
point for further investigations on peptide conformations and peptide folding observed in ionic liquids. 
2.2.3. Ligation Reactions in Peptide Synthesis 
Chemical ligation reactions are useful tools for the assembly of small to medium-sized proteins and 
protein domains starting from synthetic peptide fragments [73–75]. This type of chemical protein 
synthesis allows the modification of the molecular structure offering new insights into protein 
functions. Though 50 to 100-mer peptides can be assembled on a solid support, synthesis of longer 
peptides and proteins by the Merrifield method is often limited (see sections 2.1 and 2.1.2). Methods of 
segments ligation have been developed primarily in order to circumvent limitations in chain length. 
These segment condensation reactions, on the other hand, may be hampered by the low solubility of 
peptide fragments for the condensation reaction carried out in water or aqueous/organic solvent 
mixtures, and the stability of biomolecules. Both aspects are very important for the ligation reaction 
itself, and have an impact on later purification steps. One of the most widely used methods in this 
respect is the so-called “Native Chemical Ligation” (NCL) introduced by Kent and coworkers [73–75]. 
Here, an unprotected peptide with a thioester at the C-terminal and an unprotected peptide with an  
N-terminal cysteine react to yield a peptide bond. The mechanism of this reaction is shown in Figure 7. 
Related methods are the Staudinger ligation, which occurs between a peptide azide and a 
phosphinothioester, and protease-catalyzed ligations, where specific peptide esters (e.g., substrate 
mimetics) react regioselectively and stereospecifically with nucleophilic peptide species [73,76,77]. 
In section 2.1.1, we described examples of thermolysin- and α-chymotrypsin-catalyzed couplings of 
amino acids to generate short peptides. Bordusa and co-workers, however, highlighted the  
protease-catalyzed ligation using ILs for the first time in 2008 [48]. The reaction was performed in a 
mixture of buffer and 1,3-dimethylimidazolium dimethylphosphate [C1C1IM][Me2PO4] (40:60)  
(Figure 8). Several positive effects were observed for this reaction in the IL mixture in comparison to 
conventional methods, e.g., (i) the complete suppression of proteolytic side reactions (proteolytic 
hydrolysis and decreases competing hydrolysis activity of proteases toward the acyl donor esters to 
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some extent), (ii) high turnover rates, (iii) protease stability, and (iv) good solubility of the reactants 
and also of the reaction products. 
Figure 7. Native chemical ligation occurs between two unprotected peptide segments:  
(i) transthioesterification; (ii) S to N acyl transfer [73,74]. 
 
Figure 8. Protease-catalyzed ligation of parvulin (residues 46–92) employing peptidyl 
prolyl cis/trans isomerase (modified from [48]). 
 
Recently, we reported on the application of native chemical ligation to produce a 66-mer 
anticoagulant cysteine-rich peptide (Tridegin) that has been shown to act as an inhibitor of factor XIIIa 
(Figure 9) [78]. Generally, NCL may be carried out with and without additives, i.e., thiols (e.g., 
thiophenol, benzyl mercaptan) as catalysts [79–82]. Therefore, the comparison of segment ligation in 
buffer and ILs in the presence or absence of additives was performed as well. The results showed that 
NCL indeed yields the ligated product. The linear Tridegin was identified in [C2mim][OAc] even in 
the absence of thiophenol and benzyl mercaptan. In addition, by using additives the ligated product 
was also formed in [C2mim][DEP] that correlates well with the results published by Bordusa and  
co-workers mentioned above [48]. 
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Figure 9. Native chemical ligation performed in ILs (modified from [78]). 
 
In summary, the results of our and other groups demonstrate that medium-sized and large  
disulfide-bridged peptides are correctly formed in biocompatible ionic liquids. Moreover, the selection 
of peptide candidates examined thus far suggests that the correct intramolecular hydrogen bond 
interactions are not significantly perturbed by the presence of ILs, instead ILs seem to have a favorable 
effect on stabilizing pre-formed secondary structures of peptides. 
3. Ionic Liquids for Peptide Purification and Characterization 
Peptide purification and chemical characterization are the most important steps after a peptide has 
been synthesized. Usually peptides are purified using reversed-phase high performance liquid 
chromatography (RP HPLC) and characterized by different methods such as mass spectrometry  
(ESI or MALDI MS), thin-layer chromatography (TLC), and capillary electrophoresis. The structure of 
peptides can be determined by NMR spectroscopy. In this section, we give an overview of the 
applications of ILs in those methods, in which ILs have been applied so far. 
3.1. Peptide Separation by Liquid Chromatography Methods 
The use of ILs for chromatography reveals promising perspectives for the establishment of new 
separation methods and protocols. Examples for the application of ILs in separation techniques are 
well summarized in the review of Han et al. [83], but only few reports are found for the application in 
peptide chemistry. This field of investigation is rather new, however, the academic interest has 
increased enormously. Here, we explicitly highlight new applications of ILs for peptide separation and 
characterization, which were established in the last few years. 
3.1.1. Reversed-Phase HPLC 
HPLC is a widely used method for separation and purification of biomolecules. Especially for 
peptide analysis RP HPLC is the most common method applied. Some reports have been published 
about the application of ILs in RP HPLC for separation of nucleotides, geometric isomers, ephedrines or 
carboxylic acids [84–87]. These reports are based on the use of ILs as additives for the mobile phase [84] 
or as a stationary phase [87]. The commonly used ILs for these processes contained 1,3-dialkylimidazolium 
or N-alkylpyridinium cations and chloride, tetrafluoroborate, hexafluorophosphate, or trifluoroacetate 
as the anion depending on the analyte [86]. Nevertheless, none of the reports represents an example of 
an IL-supported optimal separation of peptides. Marszall et al. suggested that it is not possible to find a 
suitable IL for separation and purification processes [88] according to the principle, which can be 
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expressed by the basic chemical aphorism “similis similibus solvuntur” or “similar dissolves in 
similar”. Therefore, when the sample, i.e., the peptide, is polar, the use of a polar IL with chaotropic 
anions, such as hexafluorophosphate or perchlorate was proposed, while a less polar IL with a 
cosmotropic anion (e.g., chloride) was recommended for a nonpolar analyte [86]. That is exactly why 
an individual protocol for different analytes is required. 
3.1.1.1. ILs as Additives for RP HPLC Mobile Phase 
Ionic liquids have been used as additives to mobile phases in RP HPLC [86], because the relatively 
high viscosity of some ILs prevents their usage as pure eluent, in contrast to standard organic solvents 
(MeOH, ACN) commonly used for peptide purification. However, in the work of Polyakova et al.,  
IL concentrations of 2–50 mM resulted in an improvement in the peak shape and decreased peak 
tailing or band broadening [84]. They use the separation of o-, m- and p-amino benzoic acid involving 
[C2mim][BF4], [C4mim][BF4], [C2mim][MeOSO3] and [C8mim][MeOSO3] as additives. The best 
separation was found with the methylsulfate systems and a concentration of 1.0~8.0 mM/L. The 
kinetics of the solute-stationary phase is responsible for this feature. Later, this group also reported on 
changes in the retention time of analyte elution, which decreased or increased depending on the type of 
IL used, i.e., on the solute-stationary phase interactions [85], When the IL ions coat the silanol groups 
of the silica stationary phase the interactions of the analytes with the hydroxyl groups of the silica 
phase are minimized. Thus, the analyte eluted earlier [86]. Different models were proposed to explain 
this behavior: (1) ion-pairing, (2) adsorption of an IL layer on the C18 surface, or (3) linear solvation 
free energy relationship (LSER) [89,90]. The latter model was developed to describe the retention 
behavior in RP chromatography and included the calculation of intermolecular interactions [89,90]. 
3.1.1.2. ILs as Material for RP HPLC Stationary Phase 
Similar to the use of ILs as mobile phase for RP HPLC, researchers tried to use ILs as stationary 
phase. For example, the ionic liquid cation was covalently attached to the silica substrates by means  
of a linker, e.g., 3-mercaptopropylsilane or propyl [86,91]. Such stationary phases were named  
“surface-confined ionic liquids (SCIL)” (Figure 10) [91,92].  
Figure 10. Procedure for the preparation of a N-methylimidazolium-functionalized silica 
gel stationary phase (modified from [92]). 
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The commonly used ILs for this purpose are based on 1,3-dialkylimidazolium or N-alkylpyridinium 
cations with variably associated anions [91,93]. In 2010, the first example of SCIL applied to the 
separation of small peptides was reported by Chitta et al. [87]. They used a dipeptide (GY), a 
tripeptide (VYV), two pentapeptides (neuropeptides Leu-enkephalin, YGGPL, and Met-enkephalin, 
YGGPM), and an octapeptide (angiotensin II, DRVYIHPF) as subjects of investigation. The silica 
surface was modified with n-butylimidazolium bromide, and the effect of trifluoroacetic acid as  
ion-pairing agent was evaluated. In RP-HPLC of peptides, ion-pairing agents are commonly used as 
mobile phase additives. Such agents are primarily selected depending on the charge of the peptide(s) to 
be separated. Several volatile perfluorinated acids, such as TFA and pentafluoropropionic acid, are 
generally applied in this respect. They affect the retention behavior of a peptide through interactions of 
the ions with charged functional groups of the peptide’s side chains, e.g., of basic residues Lys, Arg 
and His, as well as of the N-terminal amino group. In turn, hydrophilicity of the peptides is reduced, 
since net charge is reduced and thus, ion-pairing ions influence the hydrophobic character of a peptide 
resulting in increased hydrophobic interactions with the reversed-phase sorbent [87]. However, TFA in 
different concentrations (0.001–0.1% v/v) did not act as ion-pairing agent for the elution systems used 
by Chitta et al. and thus, can be substituted by formic acid in these systems. Although the SCIL phase 
possesses reversed-phase character, it was found that electrostatic interactions dominated at high 
organic and/or low pH modifier concentrations [87].  
3.1.2. Thin Layer Chromatography  
Ionic liquids were not only applied to RP HPLC, but also used for TLC and normal phase  
HPLC [94,95]. However, characterization of basic or amphoteric samples is challenging if using these 
methods. The problem is that acidic silanol groups of the stationary phase interact strongly with 
organic bases (Figure 11) resulting in (i) an increase in retention, and (ii) a broadening and/or tailing of 
sample peaks [96]. 
Figure 11. Schematic representation of a silica-based stationary phase interacting with an 
imidazolium-based IL, where -R represents alkyl substitutions (proposed by He et al.) 
(modified from [96]). 
  
It has already been reported that the use of IL additives may help to overcome these problems. Ionic 
liquids block silanol groups and in this way provide the desired separation of basic drugs as test 
analyte [97]. Similarly to RP HPLC, alkyl substituted imidazolium ILs were used for TLC and HPLC 
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as well. Baczek et al. investigated the effect of the percentage amount (0–10%) of the ILs as additives 
to the eluent on the separation of peptides by TLC. For approximately 50 peptides the Rf values 
increased with an increased concentration of 1,3-dimethylimidazolium methyl sulfate in a water/0%–5% 
acetonitrile/0.1% TFA mixture [98]. The influence on the retention of the peptides with an increasing 
IL concentration was weaker with increasing length of the amino acid sequences. In the study of 
Baczek et al., 1-ethyl-3-methylimidazolium tetrafluoroborate was applied. Upon addition of acetonitrile 
(1.5%) a retention coefficient with third-degree polynomial function was derived, however, a quadratic 
function was needed in case of the experiment without acetonitrile. This was explained by the 
interaction of the IL with the stationary phase [99]. 
Another method involved the addition of IL and matrix (α-cyano-4-hydroxycinnamic acid) to the 
separation mixture. This optimized the chromatographic method allowing for a direct coupling of the 
thin-layer chromatograms with imaging by MALDI mass spectrometry (see also section 3.2) [100]. 
3.2. Mass Spectrometry 
MALDI mass spectrometry is a widely used method for the characterization of biomolecules [101,102] 
as individual components from mixtures or even whole tissues [16]. The main characteristic of this 
method is the “soft” ionization in comparison to other methods, e.g., electrospray ionization [103]. 
For successful analytical results a suitable matrix is indispensable. Matrices absorb the energy of the 
laser and support ionization of the analyte. They are usually small acidic compounds that co-crystallize 
with analyte molecules and provide the access of protons [15,104]. Main problems of standard solid 
matrices are low homogeneity, formation of so called “hot spots” and/or adducts of the analyte with 
cations and anions. This results in low measurement reproducibility, decreased sensitivity, broadening 
or suppression of peaks [105]. Commonly used matrices for MALDI MS of peptides and proteins are 
α-cyano-4-hydroxycinnamic acid (CCA), sinapinic acid (SA), 2,5-dihydroxybenzoic acid (DHB), and 
indole acrylic acid. 
ILs as matrices for peptide analysis with MALDI mass spectrometry were first reported in 2004 by 
Mank et al. [106]. Different combinations of matrices were probed, but the CCA-butylamine (1:1) was 
described to be the best choice for MALDI MS of the peptides investigated. One of the reasons was 
that alkali adducts with the peptides were observed if the DHB-butylamine (1:1) matrix was applied, 
which was prepared in an ethanolic ionic liquid 1:1 (v/v) mixture. Herein, it was shown for the first 
time that this DHB-IL matrix can be used for a direct and easy screening of enzymatic reactions [106]. 
In the same year, another report of Zabet-Moghaddam et al. was published, where equimolar mixtures 
of SA, CCA, and DHB with organic bases, such as tributylamine, 1-methylimidazole or pyridine were 
used [105]. It was shown that ILs were not suitable as MALDI matrices without addition of classical 
matrices. The best results were achieved for the use of water immiscible ILs, e.g., [C4mim][NTf2] or 
[C4mim][PF6], with the addition of CCA. At the same time, peptides behaved differently in the  
IL-matrix compared to the IL-free medium [105]. This fact was also mentioned in later research  
works [103], stating that the homogeneity of the samples decreased in comparison to conventional 
matrices [105]. However, these first examples on the use of IL-mixtures with classical matrices for 
peptide analysis demonstrated an improved spot-to-spot reproducibility and better ionization 
efficiency. Since then, numerous reports appeared in the literature aiming to find out the best matrix 
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system for peptide analysis. Many different combinations of the basic part of an IL and the acidic part 
of the standard matrices were used [107]. From that time on, these mixtures are called “ionic liquid 
matrices (ILM)” [103]. Jones et al. also showed an enhanced sensitivity of the MALDI TOF method 
for peptide characterization if such ILM were used [103]. However, the first reports of the analysis of 
synthetic peptides with ILMs were described in 2006. A reduction of peptide adduct and matrix cluster 
formation, an improvement of the signal-to-noise ratio and an increase of the peak intensities was 
observed for the use of a CCA-pyridine ILM (2:1, v/v). Also, the detection limits were reduced using 
the described ratio [108]. In addition, an improvement in sample homogeneity was reported by  
Tholey et al. [109] who showed that the quantitative analysis of peptides was possible without the use 
of an internal standard. Additionally, a linear correlation between the peptide amount and the signal 
intensities was observed. Here, the samples were prepared with the ILM in a matrix(acid)-IL(base) 
ratio of 1:1. As bases, N,N-dimethylethylenediamine (DMED) and 3-(dimethylamino)-1-propylamine 
were used, and as matrix CCA and indole acrylic acid were applied. Both matrices were found to be 
suitable for peptide analysis. The addition of a matrix additive (1% H3PO4) to increase the detection 
limit and signal intensities was reported by the same research group [110]. Phosphopeptides were used 
as targets for the MALDI MS analysis described. 
A new way of sample preparation for high sensitivity quantitative analysis of peptides was proposed 
by Palmblad et al. [111]. A conductive hydrophobic TeflonTM tape was used as sample surface in the 
analysis in order to concentrate the analyte to microliter range and to achieve better ionization.  
Also, the successful attachment of cations (Cu2+ and K+) to target peptide angiotensin I in the ILM  
CCA/3-aminoquinoline/glycerol (1:4:6) in comparison to the standard dried droplet method and 
powder mixture sample preparation was reported by Hortal et al. shortly after [112]. In 2008, a further 
ILM was proposed as suitable matrix for peptide analysis with MALDI mass spectrometry, which was 
a mixture of CCA and aniline. This matrix was also structurally characterized. A similar or even 
improved signal-to-noise ratio was observed in comparison to the pure CCA matrix [113]. Other ILMs 
such as N,N-diisopropylethylammonium-CCA and N-isopropyl-N-methyl-l-butylammonium-CCA 
matrices were reported to be very suitable for the analysis of peptides and proteins in the molecular 
weight range from 1 kDa to 270 kDa. For example, these matrices showed much higher intensities of 
the analyte [114]. 
The efforts to use ILMs for the analysis of glycopeptides and glycans succeeded when using the 
matrix [1,1,3,3,-tetramethylguanidinium-2,4,6,-trihydroxyacetophenone] (GTHAP). The detection of 
glycopeptides containing large carbohydrate groups and small peptide chains was higher than in the 
solid matrix (2,4,6,-trihydroxyacetophenone). In addition, the degree of glycopeptide decomposition 
was suppressed if using GTHAP [115]. The avoidance of sugar fragmentation as well as the 
improvement of homogeneity and reproducibility of the spots were also important issues in the report 
of Gimenez et al., who investigated the effectiveness of different ILMs with SA and DHB on the 
ionization of intact glycoproteins with several degrees of glycosylation [116]. All ILMs preparation 
procedures used butylamine as organic base and were prepared either with or without an acid, e.g., 
0.1% of TFA or 1% of H3PO4. The authors demonstrated that the chemical composition of an ILM 
strongly influenced the analysis of their test substances. In addition, ionization efficiencies and spot 
homogeneity were best if using ILMs with higher amounts of the organic salt, i.e., the ILM containing 
3 M of butylamine and an equimolar amount of either DHB or SA was the optimal preparation 
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procedure. The results for the average molecular mass values also indicated that sugar fragmentation 
was prevented for either mixture, while the SA-ILM was best with respect to reliable analysis, 
sensitivity, sharpness of ion peaks and application of a wider range of laser intensities [116]. Finally, 
new reports by Fitzgerald and co-workers showed that ILMs are suitable for MS imaging, e.g., of 
onion skin, as well [117]. Here, 1-methylimidazolium-CCA and tripropylammonium-CCA were 
applied as matrices. Both were suggested to improve the detection limits to about 30- to 40-times in 
comparison to the standard matrix. Again, homogeneity and stability of the sample surface during the 
crystallization process was improved [117]. 
One further application of ILs in mass spectrometry other than the MALDI technique should be 
mentioned here as well, where ionic liquids were used for the identification of integral membrane 
proteins (IMPs) by microcolumn reversed phase liquid chromatography (μRPLC)-electrospray 
ionization tandem mass spectrometry (ESI-MS/MS) [118]. The authors here used 1% (v/v) 
[C4mim][BF4] in NH4(HCO3) buffer (pH 8.3) as the sample preparation buffer for IMPs analysis. 
Furthermore, compared to the commonly used methods (e.g., sodium dodecyl sulfate and methanol) a 
three times higher number of identified IMPs from rat brain was obtained, which was explained by the 
fact that [C4mim][BF4] may provide higher solubilizing ability for IMPs and good compatibility for 
tryptic digestion.  
3. Conclusions  
The application of ionic liquids in peptide chemistry is currently in the exciting phase of its 
development. The assembly of peptides by SPPS or in solution using ILs has been described, but 
primarily for shorter representatives. Therefore, these investigations are, in our opinion, in an early 
stage of development. Nevertheless researchers continue to find optimal more simple and 
straightforward conditions to carry out reactions involving amino acid derivatives and peptides. In 
general, synthesis and characterization of peptides using ionic liquids seems to have several positive 
effects, including the better solubility of solutes, the use of higher temperature, the possibility to 
reduce the concentrations of excessive agents, higher reaction yields, and higher resolution (analytics).  
It has been shown for synthetic processes that ILs are not just simple solvents, but may act as a 
functional part in a reaction process, e.g., by directly interacting with analytes. In addition, many 
reports concerning the characterization of peptides by mass spectrometry, in particular MALDI-TOF 
MS, and different types of chromatography were published in the last decade. On the other hand, 
methods such as peptide/protein structure determination by NMR spectroscopy or separation by 
capillary electrophoresis are not as popular in the literature, yet are starting to gradually emerge. The 
reason for this may be that a deeper understanding of the interactions of IL cations and anions with 
specific side chains and/or the peptidic backbone in dependence on the IL environment and the 
absence and/or presence of water is still missing. Thus, a closer examination of these interactions 
would support both, the design of suitable ILs for special applications concerning the generation of a 
peptide (primary amino acid sequence) and/or its conformation (three-dimensional structure) and the 
optimization of purification and characterization protocols. Future studies will therefore focus on 
intensive and systematic investigations in order to address the questions raised by the early examples 
summarized in the present report. 
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Epilogue 
This review focuses on recent application and progress of ILs in peptides synthesis. 
Although, the large number of different ILs with specific properties can be confusing and 
complicated, the review facilitates the decision for a specific IL in a distinct application. IL-
supported peptide synthesis as well as chemical and enzymatic peptide synthesis in ILs 
represent novel applications of ILs based on aspects such as a higher solubility of poorly 
soluble educts and an increased product yield compared to the use of common solvents. 
Furthermore, oxidative folding, native chemical ligation and radiolabelling of peptides in ILs 
were included in peptide chemistry. In addition, immobilized ILs can be used for purification 
using thin-layer chromatography, RP-HPLC or as additives in the mobile phase. For 
analytical purposes, the negligible vapour pressure of ILs enables their use as a suitable 
matrix for MALDI-MS. Although the use of ILs in peptide chemistry has just started, the 
ongoing research interest and new findings open up much broader applications within distinct 
research areas. Studies supporting these developments are described in parts II and III. 
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Preface 
After a comprehensive summary of the already published results comprising Ionic Liquids as 
alternative reaction media in peptide chemistry in the previous review, we intended to extend 
the application of ILs to oxidative folding and native chemical ligation of bioactive, cysteine-
containing peptides.234 The anticoagulant 66mer tridegin and a model peptide 
LYRAXCRANK (X = any amino acid) were subjected to NCL in different solvents including 
ILs.235,236 For oxidative folding several conotoxins such as CCAP-vil, -SIIIA, -PIIIA, -EVIA 
and-SVIE with up to three disulfide bridges were subjected to disulfide bond formation in 
ILs. Furthermore, different factors influencing the reaction outcome were analyzed, including 
the use of different ILs, different temperatures and varying water content, in order to increase 
our knowledge in this respect. A more detailed analysis employing -SIIIA as model peptide 
is described in part III. 
 
Ionic liquids as reaction media for oxidative folding and native chemical
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This paper represents the final report on the results obtained during a two-years funding period within the DFG
priority program 1191: Ionic liquids. The studies were focused on the interaction of ionic liquids with peptides in
two distinct reactions involving cysteine residues, namely oxidative folding and native chemical ligation (NCL).
Both reactions are generally performed in solution phase. With the exception of selected model compounds,
the bioactive peptides used herein are rather hydrophobic and long (N20 amino acids) representatives of their
respective class, e.g. conotoxins and enzyme inhibitors. Thus, ionic liquids were used as alternative media to cir-
cumvent solubility issues. We found that imidazolium-based ionic liquids, and more precisely [C2mim][OAc],
were most suitable for both reactions being superior to conventional aqueous buffer systems in several aspects,
including reaction yield and time, concentration of starting material and product as well as selectivity.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
The unique properties of ionic liquids (ILs) as a new class of solvents
have been discussed extensively in the last decade [1–3]. Among the
most interesting of these properties are the safety towards both, the
chemist and the environment, including non-flammability, negligible
vapor pressure and non-toxicity. Additionally, ILs are outstanding in
their chemical variability, providing the chemical community with
tools to tailor the solvent of their needs. However, the link between dis-
tinct changes in the IL composition and the applicability for a defined
reaction still needs to be investigated in more detail to exploit the full
potential of tailor-made solvents, co-solvents and additives.
Being rather restricted in the choice of solvent (primarily aqueous
buffer systems similar to the physiological environment), biochemists
have yet shown increasing interest in the application of ILs as solvents
and/or co-solvents for different classes of biomolecules. Recent reports
demonstrated the suitability of ILs as solvents and reaction media for
e.g. carbohydrates [4,5] and proteins [6,7], in particular enzymes
[3,8]. Ionic liquids seemed to be suitable to stabilize biological mac-
romolecules in solution, and thus, also attracted attention for other
applications such as those occurring in peptide chemistry, including
synthesis, purification/extraction, analytics and structure elucidation
[9]. The aim of our studieswas therefore to use ILs for selected reactions
employing peptides, with a focus on cysteine-rich bioactive representa-
tives of native origin. These peptides are medium-sized to long biomol-
ecules (9-mer to 66-mer) and contain two to six cysteine residues in
their sequence. There are two main reasons why the behavior of cyste-
ine residues in ionic liquids is of interest to us: First, cysteine residues
are required for native chemical ligation (NCL) of unprotected peptide
fragments (Fig. 1) [10,11], and second, they play an important role in
peptide structure formation due to the generation of disulfide bonds
(oxidative folding) [12]. Both reactions can be carried out successfully
in aqueous reaction media [11,12]. However, there are some drawbacks
and difficulties accompanying oxidative folding andNCLwhenperformed
in buffer systems.
Oxidation of cysteine residues, i.e. the formation of disulfide
bonds in peptides, is a major step in the synthesis of many biolog-
ically active, cysteine-containing peptides, such as cystine-knot
peptides/conopeptides, cardioactive peptides, peptide hormones and
others. Inmost cases, the oxidation step is carried out in aqueous buffer
solutions in the presence of redox active agents (e.g. oxidized and re-
duced glutathione) exploiting the self-folding capability of the peptide's
amino acid sequence rather than applying complex protecting group
strategies [12].
Native chemical ligation was first introduced by Kent and co-
workers in 1994 [10]. It provided an easy way to connect two unpro-
tected peptide fragments resulting in a native peptide bond at the liga-
tion site. However, as the method is based on a transthioesterification
(Fig. 1), there is an absolute requirement for a cysteine residue on the
N-terminus of the C-terminal fragment. In addition, the N-terminal seg-
ment should terminate as a thioester. Further investigation by Hackeng
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et al. showed that the reaction rate and outcome seriously depend on
the C-terminal amino acid of the N-terminal fragment [11]. Previous
investigations in our group had shown an improvement of cysteine
oxidation in distinct ILs [12,13]. Therefore, we decided to also use ILs
as alternativemedia forNCL. After first promising results on the applica-
tion of ILs in both reaction types, we started a more systematic investi-
gation on the parameters influencing the reaction process and outcome,
including IL cation and anion choice, temperature, water content and
peptide choice, which is still ongoing. The first results of these efforts
are summarized in this report.
2. Experimental
Peptide synthesis reagents and building blocks were purchased from
Orpegen Peptide Chemicals GmbH (Heidelberg, Germany) and Iris Bio-
tech GmbH (Marktredwitz, German), respectively. Ionic liquids were
either kindly provided by Dr. Annegret Stark (University of Leipzig,
Germany) or purchased from IoLiTec - Ionic Liquids Technologies GmbH
(Heilbronn, Germany).
2.1. Synthesis
Peptide synthesis was performed automatically according to a
standard Fmoc (N-(9-fluorenyl)-methoxycarbonyl) protocol, as earlier
described [12–14].
2.2. Purification and characterization
Peptide purification after synthesis was performed using a semi-
preparative HPLC instrument equipped with a C18 column (Knauer
Eurospher 100) and applying a gradient elution system with eluent A
being 0.1% TFA in water, and eluent B 0.1% TFA in acetonitrile/water
(90:10). The purity of the products before and after purification was
determined by analytical RP-HPLC with a gradient elution using the
aforementioned eluent A and 0.1% TFA in acetonitrile as eluent B. Peptide
identity was confirmed by MALDI-TOF mass spectrometry on a MALDI-
TOF/TOF Ultraflex I Bruker mass spectrometer or an autoflex II TOF/TOF
mass spectrometer. In both cases, α-cyano-4-hydroxycinnamic acid was
used as matrix.
2.3. Oxidative folding
Peptideswere subjected to oxidation in aqueous solutions as reported
elsewhere [12]. For oxidative folding in ILs, the linear peptide was
dissolved in a small volume of the corresponding IL (40–800 μl) at a con-
centration between 3 and 20 mM and left at room temperature with
gentle stirring. Work up was performed as previously described [9].
2.4. Native chemical ligation
NCL in buffer solutions was carried out according to literature
reports by Dawson et al. and Hackeng et al. [10,11]. The procedure
for native chemical ligation in ILs was carried out as reported in
Böhm et al. [14].
3. Results and discussion
3.1. Oxidative folding
As described in [12], the oxidation of various cysteine-rich peptides
in the ionic liquid [C2mim][OAc] revealed very promising results
(Fig. 2). Though [C2mim][OAc] already turned out best in a selection of
e.g. imidazolium-based ionic liquids with varying anions, our aim was
to investigate peptide oxidation in further ionic liquids which recently
showed great potential with regard to proteins and enzymes, respec-
tively [3,6,7]. All of the peptides we used are bioactive compounds
[12–14], and thus, beside the improvement of synthetic methods we
were interested in maintaining bioactivity after processing in ILs, too.
Nevertheless, in a two-years funding period work had to be structured
and, thus, model peptides were selected first to investigate the change
of different parameters for the respective reaction. These changes in-
clude the variation of IL cations and anions, water content, reaction tem-
perature and time, concentration of peptide and/or IL aswell as practical
issues such as technical performance.
As the first and most simple model peptide, CCAP-vil was chosen,
which is a cardioactive peptide first isolated from Conus villepinii [13].
This compound is not strictly a cysteine-rich peptide, since it contains
only one disulfide bond. However, due to the rather simple nature of
its oxidation process and the reportedly high yield for oxidation in aque-
ous systems, it proved a valuable tool to rapidly test a number of ILs with
respect to their general suitability for the approach [13]. Themost suitable
ionic liquid for the oxidation of CCAP-vil was [C2mim][OTs] (3%H2O, v/v),
with a yield of more than 90% although carried out at room temperature.
Furthermore, the reaction was carried out with increased water content
(3, 5, 7 and 10%) and at higher temperatures (40, 60 and 80 °C).Whereas
higher water concentrations turned out less favorable for our reaction,
the temperature increase accelerated the reaction (unpublished results).
The same effect was found for other peptides, e.g. μ-SIIIA, as well. The
availability of solutionNMRstructural information of CCAP-vil [13] allows
for molecular dynamics simulations in different media, which are cur-
rently undertaken to provide a more scientific explanation of the effects
observed in the experiments and to reveal insights into the molecular
basis of our observations of peptide-IL interactions.
The second model peptide used for oxidative folding in ILs was
the μ-conotoxin SIIIA [12]. This peptide, in contrast to CCAP-vil, con-
tains three disulfide bonds, and therefore has amuch higher potential to
form different isomers compared to CCAP-vil. However, it can still easily
be oxidized in buffer systems, yielding only one major compound
(Fig. 2).More detailed experimentswith this peptide showed, as already
seen before, that the most useful IL for this application was [C2mim]
[OAc], while [C4mim][OAc] still gave the desired reaction product, albeit
with a lower yield [12]. The other anions tested previously for folding of
μ-SIIIA, namely [OTs]−, [DEP]− and [N(CN)2]
−, gave no reaction product
at all [9,12]. With these findings in mind, further investigations were
focused on ILs with H-bonding abilities, such as the protic ILs ethylam-
monium formate (EAF) and methylammonium formate (MAF). Both
Fig. 1. Principle and mechanism of native chemical ligation [10].
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gave the desired product in relatively high yields (64% and 43%, respec-
tively,) [15] in contrast to other ILs (e.g. choline dihydrogenphosphate,
2 M solution), which did not result in the desired product. Therefore,
studies will be repeated and continued to obtain a complete picture of
whether and which ILs are applicable for peptide oxidation.
A more difficult peptide with respect to its self-folding ability in
aqueous systems is another μ-conotoxin, namely μ-PIIIA. Oxidation in
buffer resulted in a number of different completely and incompletely
oxidized isomers of the reduced precursor, some of which have been in-
vestigated inmore detail [16]. The occurrence of these isomers leads to a
significant reduction of the expected version possessing the so-called
“native fold” (as found in case of μ-SIIIA). Surprisingly, only one major
product is formed if the reaction is performed in [C2mim][OAc] [12].
Current experiments aim at the extraction of this product from the IL
reaction mixture in order to provide sufficient amount for structural
investigations as done for the buffer-oxidized isomers [16]. Simulta-
neously, first experiments have been performed with the even more
hydrophobic δ-conotoxINS EVIA and SVIE [12]. Unfortunately, these
peptides are very difficult to handle and thus, more efforts are required
to obtain their NMR solution structure from the products of the oxida-
tive folding approach in both media. In buffer, the desired disulfide-
bridged peptides are only obtained in very low yields (b10%), yet the
results with [C2mim][OAc] [12] were again promising for our future
studies with these conotoxins.
3.2. Native chemical ligation
First experiments with regard to native chemical ligation in ionic
liquids were performed using the anticoagulant peptide tridegin as
subject of analysis [14]. In contrast to the reaction in a buffer system,
where additives are required to succeed, the reaction in [C2mim][OAc]
proceeded smoothly even in the absence of any additive and at room
temperature. The yield of 45%was even higher than in buffer containing
thiophenol and benzylmercaptan (19%). Encouraged by these results,
we used the funding period to start with investigations concerning
NCL with model peptides. An approach focusing on the impact of the
C-terminal amino acid of the N-terminal ligation segment, as sug-
gested earlier by Hackeng et al. [11] was initiated with the sequence
LYRAXCRANK (X = any amino acid). The different LYRAX-peptide
thioesters and the C-terminal CRANK-sequence were synthesized on
the solid phase and subjected to ligation in ILs, primarily [C2mim]
[OAc]. First results with the peptide LYRAN as the N-terminal fragment
revealed that the ligation occursmuch faster than in buffer (Fig. 3). Fur-
ther studies are in progress with other amino acids (e.g. X = Gly, Leu,
Val, and Lys) to provide information for a more generally applicable
protocol.
4. Conclusions
4.1. Oxidative folding
From the findings on oxidative folding of peptides in ILs, different
conclusions can be drawn, the most important is that there are numer-
ous parameters influencing the quality and yield of the product [12–16].
First, the peptide itself, e.g. primary sequence, length, and net charge,
determines the success of the reaction performed in an IL. Second, the
IL itself has a great impact on the oxidation process, not only because
of the variability in cations and anions, but also due to aspects such as
water content. Indeed, the latterwas shown to have a detrimental effect
on the oxidation process in all cases tested that is in contrast to IL appli-
cations in protein research where in the majority of studies water was
highly essential to maintain folding and activity [3]. A temperature in-
crease, on the other hand, e.g. to 60 °C or even 80 °C seems to increase
reaction rate without damaging the dissolved molecules. This is consis-
tent with findings for proteins which are also thermo-stabilized in ILs.
From the current state of results we can conclude the following: i) The
high concentrations of a peptide, especially hydrophobic ones, that
can easily be dissolved in distinct ionic liquids, such as imidazolium-
based ILs, compared to aqueous systems show that ILs are generally use-
ful media for this type of reaction. Furthermore, despite a high peptide
concentration no dimer or multimer formation was observed so far.
This can be explained by the integration of individual molecules into
the IL network as earlier suggested for enzymes in ILs [9]. Moreover,
oligomerization (intermolecular reaction) is disfavored versus the in-
tramolecular disulfide formation due to proximity of the thiol functions
after prefolding of the linear sequence. Stability and aggregation issues
Fig. 2. General approach highlighting the selection process: moving from simple to more demanding model peptides with the aim to elucidate general aspects of IL–peptide-interaction.
TheHPLC profiles show crude products after oxidative folding in buffer, arrows indicate the proposed “native fold”, as shown below the profiles. (Z, pyroglutamic acid; O, hydroxyproline).
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were intensively studied for proteins in ILs, however, beside the high
thermal stability of the peptides in ILs, differences between peptides
and proteins with respect to the accepted water content seem to be
caused by differences in the respective interactions with the IL cations
and anions. Though similarities to proteins with respect to observed
trends of a correlation with the Hofmeister ion series exist [3], peptides
need to be discussed independently and need much more attention to
catch up with the knowledge available for proteins.
ii) Up to now, the selection of an IL for peptide reaction, in particular
oxidation, followedmore or less a “trial-and-error” approach. However,
it was found that the composition of the IL plays a major role with
respect to reaction outcome. Generally, ILs that are not liquid at room
temperature, but need the addition of water are not suitable for the
applications described herein, as water had a negative influence on
the reaction outcome. The tendency of the anion to accept hydrogen
bonds seems to be preferable for highly charged peptides, whereas
poorly charged representatives seem to require anions with a lower
tendency to hydrogen bonding. Nevertheless, further investigations
with e.g. negatively charged peptides are required to underpin this con-
clusion by extended andmore systematic studies. Earlier investigations
focused on imidazolium-based ILs, however, the herein presented first
positive results obtained for selected protic ILs are encouraging with
regard to further studies aiming at the definition of the requirements
for a tailor-made IL for a specific reaction involving peptides.
4.2. Native chemical ligation
The same as indicated above is true for the second type of reaction
studied within the two-years funding period. Preliminary results with
both the bioactive 66-mer peptide tridegin [14], and the 10-mer
model peptides again demonstrated the high potential of ionic liquids
as reaction media. Reaction rate was much higher compared to the
same reaction performed in the typical aqueous systems, and again,
the concentration of the respective peptide fragments can be increased
significantly due to a much better solubility in ILs compared to water-
based media. The transthioesterification (intermolecular reaction) of
two high concentrated reactants occur fast and smoothly suppressing
transformation of the thioester to the carboxylic acid and is favored be-
cause of the activated thioester and low water content. These first find-
ings for NCL allow to speculate that the same effects observed for
oxidative folding concerning water content and temperature can be
expected here, andwill be in the focus of our perspective investigations.
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Epilogue 
This publication summarizes the results from a two-year study and the outcome described in 
three publications. First, results regarding the NCL reaction applied to model peptide 
LYRAXCRANK obtained in ILs provide that a faster reaction might occur in the IL 
[C2mim][OAc] compared to the use of conventional buffer systems. Second, for oxidative 
folding carried out in ILs several parameters were investigated indicating major influence of 
the IL composition on product formation. Furthermore, high water content disfavoured, while 
an increase in temperature favoured product formation. Both, hydrophobic and hydrophilic 
conotoxins were dissolved in much higher concentrations in the respective IL compared to 
conventional oxidation in buffer without di- or oligomerization. This represents an advantage 
compared to common oxidation protocols using oxidizing agents, in particular for poorly 
soluble hydrophobic peptides, where high dilution is required to avoid dimer formation. 
Selected studies were completed meanwhile, which revealed further insight in the use of ILs 
in NCL (Kühl et al.)237 and oxidative folding (Heimer et al.). The latter publication is outlined in 
part III. 
  
4. Manuscripts  
67 
 
 
4.3 Application of room-temperature aprotic and protic 
Ionic Liquids for oxidative folding of cysteine-rich peptides 
 
Full Paper 
Authors 
Pascal Heimer, Alesia A. Tietze, Miriam Böhm, Ralf Giernoth, Andrea Kuchenbuch, Annegret 
Stark, Enrico Leipold, Stefan H. Heinemann, Christian Kandt, Diana Imhof  
 
ChemBioChem. 2014, 15, 18, 2754-65.  
doi: 10.1002/cbic.201402356.  
Copyright © 1999 - 2016 John Wiley & Sons, Inc. All Rights Reserved 
 
Preface 
The impact of IL composition (choice of cation and anion) in combination with several 
reaction parameters (educt concentration, temperature, water content) influences the product 
formation during oxidative folding of cysteine-rich peptides.234 This was investigated in order 
to expand the basic knowledge of this particular folding process carried out in suitable ILs. 
Herein, the conotoxin -SIIIA was used as a model peptide for the evaluation of reaction 
conditions in comparison with previously described results obtained in [C2mim][OAc].166 We 
intended to identify the most promising IL from a set of imidazolium-based, protic and aprotic 
ILs with respect to product formation. For the first time, bioactivity of -SIIIA oxidized in 
[C2mim][OAc] was measured in electrophysiological studies using NaV1.4-channel as the 
target protein. In addition, the effect of cation and anion of the ILs was investigated for the 
folding process of four conotoxins, namely -GI, -SIIIA, -PIIIA, -EVIA, containing two or 
three cysteine bridges. This work represents an extension of the previous studies, i.e. Tietze 
et al. (2012) and Böhm et al. (2014) described in parts I and II. 
DOI: 10.1002/cbic.201402356
Application of Room-Temperature Aprotic and Protic Ionic
Liquids for Oxidative Folding of Cysteine-Rich Peptides
Pascal Heimer,[a] Alesia A. Tietze,[b] Miriam Bçhm,[a] Ralf Giernoth,[c] Andrea Kuchenbuch,[c]
Annegret Stark,[d] Enrico Leipold,[e] Stefan H. Heinemann,[e] Christian Kandt,[f] and
Diana Imhof*[a]
Introduction
Room-temperature ionic liquids (RTILs) were designed as
“green solvents” to replace conventional volatile solvents with
the aim of reducing their possible impacts on the environ-
ment, including ozone depletion, photochemical smog, and
global climate change.[1,2] The potential of RTILs has been ex-
tensively exploited over the last decade in fields as diverse as
synthesis,[3] analytical chemistry,[4] electrochemistry,[5] catalysis/
biocatalysis,[6–10] and materials science,[11] at both laboratory
and industrial scales.[12,13] In addition, achievements for indus-
trial-scale production of “druggable” molecules are also highly
important and still the subject of ongoing research activities,
due to their potential for commercial applications in therapy
and diagnostics. As a consequence, bioactive natural products
have come more and more into the focus of applications of
ionic liquids for their synthetic preparation starting from rela-
tively inexpensive materials.
Recently we examined the use of selected RTILs for the
preparation of multiply disulfide-bridged peptides and oligo-
peptides.[4, 14–16] The aim of thoroughly investigating bioactivity,
mechanism of action, and therapeutic potential of such cys-
teine-rich peptides from snakes, scorpions, marine cone snails,
leeches, or plants is still hampered by their inefficient and par-
tially incorrect synthesis, accompanied by the formation of
rather large amounts of misfolded by-products. This leads to
limited availability, combined with insufficient quantities and
purities required for detailed investigations. Numerous strat-
egies, ranging from self-assembly to immobilization of folding
reagents and/or components on solid supports, demonstrate
the need to improve methods for oxidative refolding of disul-
fide-rich peptides and proteins.[17,18] The concept of “integrated
oxidative folding”, which combines the use of diselenide and
selectively (15N/13C)-labeled disulfide bridges, has been intro-
duced in order to achieve both improved folding yields and
simultaneous identification of correctly folded species by NMR
spectroscopy.[17,18] This approach, however, requires the incor-
poration of suitably protected selenocysteine units instead of
the naturally occurring cysteine residues.
The first objective of the current study was therefore to ex-
amine whether application of RTILs for reactions involving cys-
teine might lead to improvements in accessibility and yields of
naturally occurring Cys-rich peptides, on the basis that ILs
The oxidation of the conotoxin m-SIIIA in different ionic liquids
was investigated, and the results were compared with those
obtained in [C2mim][OAc] . Conversion of the reduced precur-
sor into the oxidized product was observed in the protic ILs
methyl- and ethylammonium formate (MAF and EAf, respec-
tively), whereas choline dihydrogenphosphate and Ammoeng
110 failed to yield folded peptide. However, the quality and
yield of the peptide obtained in MAF and EAF were lower than
in the case of the product from [C2mim][OAc]. Reaction condi-
tions (temperature, water content) also had an impact on pep-
tide conversion. A closer look at the activities of m-SIIIA ver-
sions derived from an up-scaled synthesis in [C2mim][OAc]
revealed a significant loss of the effect on ion channel NaV1.4
relative to the buffer-oxidized peptide, whereas digestion of
either m-SIIIA product by trypsin was unaffected. This was at-
tributed to adherence of ions from the IL to the peptide, be-
cause the disulfide connectivity is basically the same for the
differentially oxidized m-SIIIA versions.
[a] P. Heimer,+ M. Bçhm,+ Prof. Dr. D. Imhof
Department of Pharmaceutical Chemistry I
Pharmaceutical Institute, University of Bonn
Brhler Strasse 7, 53119 Bonn (Germany)
E-mail : dimhof@uni-bonn.de
[b] Dr. A. A. Tietze+
Technische Universitt Darmstadt
Clemens-Schçpf Institute of Organic and Biochemistry
Alarich-Weiss-Strasse 4, 64287 Darmstadt (Germany)
[c] Dr. R. Giernoth, A. Kuchenbuch
Department of Chemistry, University of Cologne
Greinstrasse 4, 50939 Kçln (Germany)
[d] Dr. A. Stark
Institute of Chemical Technology, University of Leipzig
Linnstrasse 3-4, 04103 Leipzig (Germany)
[e] Dr. E. Leipold, Prof. Dr. S. H. Heinemann
Department of Biophysics, Center for Molecular Biomedicine
Friedrich Schiller University Jena and Jena University Hospital
Hans-Knçll-Strasse 2, 07745 Jena (Germany)
[f] Dr. C. Kandt
Computational Structural Biology, Life Science Informatics B-IT
LIMES Center, Mulliken Center for Theoretical Chemistry, University of Bonn
Dahlmannstrasse 2, 53113 Bonn (Germany)
[+] These authors contributed equally to this work.
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201402356.
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 2754 – 2765 2754
CHEMBIOCHEM
FULL PAPERS
have been successfully applied to chemical and enzymatic
peptide syntheses, as well as fragment ligation.[4, 19] In this part
of the study, the focus was placed on the use of 1) imidazoli-
um-based RTILs differing in their anions (Scheme 1), and
2) conotoxin m-SIIIA as a model peptide, although others such
as a-GI, m-PIIIA, and d-EVIA were also included in the primary
experiment. The plan to use imidazolium-based ILs with differ-
ent anions was based on the idea that acetate as the anion
supports the formation of the native conotoxin fold.[14–16] It has
been postulated that, thanks to its small size and basic charac-
ter, it can participate in the disruption of hydrogen bonds
between polymer chains. This, in turn, led us to hypothesize a
similar mechanism with respect to the peptides investigated.
However, whether or not this could be verified by the applica-
tion of several other anions in combination with the 1-ethyl-3-
methylimidazolium cation was one specific aim of this study.
In addition, the set of ILs was extended to further represen-
tatives (Scheme 1) that have recently attracted attention in
peptide and protein research: namely Ammoeng 110, choline
dihydrogenphosphate, and the protic ILs (PILs) methylammoni-
um formate (MAF) and ethylammonium formate (EAF).[20–24]
The protic IL triethylammonium acetate (TEAA), for example,
was applied in a study of the denaturation of the proteolytic
enzyme a-chymotrypsin (a-CT) in the presence of urea. Attri
and co-workers described the attenuation of this process medi-
ated by the non-ionic chaotrope urea through TEAA.[22] In that
work, the authors sought to address the counteracting effects
of biocompatible ILs on urea-induced denaturation of biomole-
cules in comparison with their stabilizing effect on native pro-
tein folds and their function as refolding agents for a-CT. The
PILs MAF, EAF, and butylammonium formate (BAF), on the
other hand, were used in a study employing ultrafast transient
absorption experiments to determine the local polarities of
these PILs and their mixtures with water, with 12’-apo-b-caro-
tene-12’-carboxylic acid (12’CA) as the molecular probe.[23] Earli-
er experiments had suggested that the polarities of these ILs
are comparable to, or even higher than, that of methanol or, in
the case of MAF, even approaching that of water.[23–25] In addi-
tion, PILs were reported to be more polar than most imidazoli-
um-based ILs,[26,27] thus making them interesting candidates for
our study with respect to a direct comparison with the—so
far—best working imidazolium-based IL, [C2mim][OAc], for oxi-
dative folding of conopeptides.[14–16] However, it was speculat-
ed that further factors other than polarity, such as dipolarity
and hydrogen-bonding effects, could influence their features
and behavior in contact with a solute.
The study with the described selection of ILs, with m-SIIIA as
model, was further extended by the following aspects: firstly,
Scheme 1. Structures of the ionic liquids used to synthesize conotoxin m-SIIIA by the oxidative self-folding strategy, together with abbreviations.
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for the most promising ILs, reaction conditions (temperature,
water content, reaction time) were varied, and, secondly, elec-
trophysiological experiments were performed with m-SIIIA
products obtained from a large-scale synthesis in [C2mim]
[OAc]. Interestingly, the large-scale synthesis had a significant
effect on bioactivity, which was diminished relative to that of
the product obtained by conventional synthesis in buffer sys-
tems; this is discussed with regard to solute–solvent interac-
tions. In contrast, an enzymatic assay employing trypsin for
proteolytic degradation of differentially oxidized m-SIIIA ver-
sions revealed that the origin of the oxidized product, either
from an aqueous medium or from an IL, leaves both the acces-
sibility for enzymatic hydrolysis and the enzyme’s catalytic ac-
tivity virtually unaffected.
Results and Discussion
Effect of the anion of the ionic liquid
Oxidation of selected naturally occurring conopeptides[28–33]
(Figure S1 in the Supporting Information, Table 1) differing in
chain length (13–32 amino acids), cysteine content (four to six
residues), cysteine pattern, net charge, and physicochemical
properties were subjected to oxidative folding in the imidazoli-
um-based RTILs [C2mim][OAc], [C4mim][OAc], [C2mim][OTs] ,
[C2mim][DEP] , and [C2mim][N(CN)2] , and comparison was made
with the buffer systems described earlier.[29–35] All compounds
investigated were soluble in these ILs independent of their hy-
drophobicity. As a result, oxidation was carried out in rather
high concentrations (7–12 mm ; 1 mg of each precursor peptide
was used) relative to the previously used aqueous buffer sys-
tems (0.02–0.05 mm),[29–35] and in the absence of organic sol-
vents, as well as at room temperature (vs. 4 8C commonly used
for oxidation). Moreover, it was intended that the folding
should proceed without any auxiliary redox agent [e.g. , re-
duced and oxidized glutathione (GSH and GSSG, respectively)] ,
similarly to our initial studies.[14,15] With the exception of a-GI—
the simplest peptide in this study—the highest yield and quali-
ty of the peptide were obtained with [C2mim][OAc]. This con-
firmed our earlier findings, yet we were surprised by the fact
that no reaction occurred in the cases of the ILs with the
anions [OTs] , [DEP] , and [N(CN)2]
 with either peptide. In
contrast to other peptides, a-GI showed behavior in [C2mim]
[OAc] different from that found for the oxidation in aqueous
buffer. This peptide contains only four cysteine residues, so
only two disulfide bridges need to be formed upon oxidation.
This particular folding might indeed proceed more easily than
that of the other conotoxins, with three disulfide bridges and
lower water solubility, and production in the aqueous medium
is thus simple and unproblematic.
The set of peptides described here, together with the earlier
findings for other peptides,[15,16] led us to conclude that RTILs
possessing anions of relatively high hydrogen bond acceptor
strength and low degree of steric hindrance, such as ace-
tate,[36–38] support the folding of positively charged peptides
(Table 1, Figure S1). In this type of IL, the oxidation is selective,
resulting in higher yields than in conventionally used systems.
However, comparison of these results with the Kamlet–Taft
hydrogen bond acceptor strength (expressed as b values), as
determined by Lungwitz and Spange, shows that the yields of
the oxidative folding are independent of the b values, which
are 0.85, 0.64, and 0.99 for [C4mim][OAc], -[N(CN)2] , and -[DEP],
respectively.[36] Changing the cation from [C2mim]
+ to
[C4mim]
+ had no significant effect on solubility but decreased
the overall yield.
Further imidazolium-based ILs (Scheme 1) with anions de-
rived from amino acid derivatives (H-Xaa-OMe, with Xaa=Ala,
Leu, Val) were used in combination with m-SIIIA, the conotoxin
obtained in the highest quantity and quality in the initial ex-
periment, in order to evaluate their potential with regard to
peptide folding. Surprisingly, the oxidized version of m-SIIIA
was not formed in any of those ILs (Figure S2). A closer look at
the elution profiles also revealed different behavior of the pep-
tide in these media, with peak splitting and broadening being
observed. However, all of the major peaks displayed the same
molar mass—that is, the molar mass of the reduced peptide—
in MS analysis. It seems that in ILs with large anions (larger
than acetate) peptide oxidation is hampered; these ILs even
seem to stabilize the reduced form (i.e. , the linear peptide).
The peptide is thus probably not flexible enough to undergo
folding, due to strong contact and interaction with the IL
anions.
In an attempt to estimate the potential of the highly selec-
tive [C2mim][OAc] versus other imidazolium-based ILs for the
synthesis of conotoxins more precisely, the reaction was addi-
tionally performed in binary ionic liquid mixtures also contain-
ing [C2mim][DEP]. Here, the effect of a “non-folding” IL on the
efficiency of peptide conversion in a “folding” IL—that is,
[C2mim][OAc]—was monitored. The ILs ([C2mim][OAc] and
[C2mim][DEP]) were used in the following ratios: 1:3, 1:1, and
3:1 (v/v).
The results are shown in Figure 1: the higher the concentra-
tion of the [DEP] anion in the reaction mixture, the lower was
the yield. This behavior contrasts with results obtained in
Table 1. Peptides selected for this study and corresponding yields for
oxidation performed in different ionic liquids.
Oxidation yield [%]
Reaction medium a-GI m-SIIIA m-PIIIA d-EVIA
buffer system[a] 80[b] 50 16–18[b] <10[b]
[C2mim][OAc] 50 70 60 25
[C4mim][OAc] <5 n.d.
[c] 38 <5
[C2mim][OTs] n.p.
[d] n.p. n.p. n.p.
[C2mim][DEP] n.p. n.p. n.p. n.p.
[C2mim][N(CN)2] n.p. n.p. n.p. n.p.
[a] Buffer solution contained 0.1 mm Tris·-HCl (pH 8.7), 1 mm EDTA, 2 mm
GSH, 1 mm GSSG, and 30% isopropanol, except in the case of d-EVIA, in
which 40% isopropanol was used. [b] Final peptide concentrations for
redox-buffer systems were 0.05 mm (a-GI, m-SIIIA, m-PIIIA) and 0.02 mm
(d-EVIA). [c] The IL elutes with the same retention time as the oxidized
product. The yield could not be determined with sufficient certainty. n.d. :
not determined. [d] n.p. : no product was formed.
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aqueous buffer solutions, in which the deprotonation of the
cysteine thiol group is favored under more basic conditions
(pH>8.0), thus improving disulfide bridge formation.[30,31,34]
Studies with ILs not yet applied to oxidative folding of Cys-
rich peptides
In continuation of the initial experiments shown above, we fo-
cused our attention on studies employing ILs recently applied
to proteins: that is, Ammoeng 110,[20] choline dihydrogenphos-
phate (2m in water),[21] and selected protic ILs (MAF and
EAF)[22–25] (Figure 2). Moreover, [C2C2im][HCOO] was also includ-
ed, in order to cover two aspects: firstly the marginal variation
of the cation arising from addition of one methylene group at
position 3 of the imidazolium ring relative to [C2mim]
+ , and
secondly the use of the formate anion as occurring in the
protic ILs used in this study and displaying a basicity and struc-
tural make-up similar to those of acetate. In contrast with earli-
er findings with proteins,[20,21,39–41] neither use of Ammoeng 110
nor that of choline dihydrogenphosphate led to the desired
product. In the case of the latter medium, the fact that it
needs to be dissolved in water to provide a liquid medium for
synthetic application obviously was decisive for the negative
result obtained. Indeed, this is in agreement with our findings
that a water content of >3% (v/v, see below) in the IL nega-
tively influences the oxidation efficiency. Moreover, this IL is
slightly acidic, due to the acidity of the H2PO4
 anion.[21b] Am-
moeng 110, on the other hand, has often been used previously
in aqueous two-phase systems in connection with protein re-
search.[41] The majority of studies with proteins and ILs have
also applied mixtures with rather high concentrations of water
because many proteins lose their activity with decreasing
water content.[19,41]
Different results were obtained from the reactions per-
formed in the protic ILs MAF (6% water, v/v) and EAF (3%,
v/v). For both ILs the oxidized version of m-SIIIA (0.5 mg,
11.3 mm) was identified, as demonstrated in Figure 2A. In con-
trast with the reaction performed in [C2mim][OAc], which re-
vealed a major peak followed by a small broad and unresolved
peak (see also Figure 3, below),[14] yields could not be deter-
mined with any high degree of certainty when the protic ILs
were used (see next paragraph). The quality of the product
here was much lower than that of the product obtained in the
imidazolium-based IL (retention times differ in these ILs). Sur-
prisingly, the fractions isolated after elution at acetonitrile con-
centrations from 20 to 24% showed identical MS spectra (see,
e.g. , Figure 2B) indicating completely oxidized m-SIIIA. The dif-
ference in the profiles obtained for MAF and EAF is likely to be
due to the different water contents.
Finally, the use of [C2C2im][HCOO] was also not successful in
product formation (data not shown), similarly to what had
been found for the previously mentioned amino-acid-based
ILs. Therefore, the negative effect of the more highly alkylated
cation on peptide oxidation, as found for [C4mim]
+ in compari-
son with [C2mim]
+ , was confirmed.
The question of the cause of the differences between the
PILs and the imidazolium-based IL remains. It is likely that sev-
eral factors need to be taken into consideration, including the
size of the cation (alkyl ammonium vs. imidazolium), protona-
tion of peptide side chains triggered by the PIL cation, and the
basicity of the anion (formate vs. acetate). Also, an opposite
effect of these factors leading to partial compensation of each
other cannot be excluded. Here in particular, a probable posi-
tive effect of the smaller cation in the PILs might be negatively
Figure 1. Monitoring of oxidative folding of m-SIIIA in mixtures of [C2mim]
[OAc] and [C2mim][DEP] in different ratios: A) 1:3, B) 1:1, and C) 3:1 (v/v).
HPLC conditions were as follows: gradient 0–40% eluent B, with eluent A
being 0.1% TFA in water and eluent B being 0.1% TFA in acetonitrile; de-
tection was at 220 nm (*: oxidized m-SIIIA).
Figure 2. A) The protic ILs MAF and EAF were used for oxidization of linear
m-SIIIA over different time periods at 20 8C. The results shown (crude reac-
tion mixtures) are those obtained after 24 h and compared with the same
reaction in [C2mim][OAc] (bottom trace). RP-HPLC monitoring was per-
formed with the gradient 0–40% eluent B, with eluent A being 0.1% TFA in
water and eluent B being 0.1% TFA in acetonitrile; detection was at 220 nm.
B) Mass spectra of oxidized m-SIIIA (*) obtained from the reactions in MAF
(left) and in EAF (right). The mass spectrum of the peak of oxidized m-SIIIA
(**) from [C2mim][OAc] is identical to the examples shown (see also ref. [14]).
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influenced by the lower basicity of the formate anion relative
to acetate.
Variation of reaction conditions
To test the impact of water content (3–20%), reaction temper-
ature (20–80 8C), reaction time (0.5–24 h), and scale (15–20-fold
relative to preliminary experiments) on the yield and quality of
m-SIIIA, [C2mim][OAc], MAF, and EAF were screened. Table 2
summarizes the results of these tests at a peptide concentra-
tion of 11.3 mm (1 mg of peptide). The oxidized product was
formed in the majority of these experiments; however, as can
be seen in Figure 3, an increase in the water content led to
a reduction in product yield. Surprisingly, this was found both
for the imidazolium-based IL and for the protic ILs. When the
concentration of water was low (3%) the oxidized product
was formed already after 6 h, whereas at higher concentrations
(>5%) the reaction rate decreased and the product was not
efficiently formed after 6 h reaction time. In [C2mim][OAc] , the
finding of an improved stability of the peptide at higher tem-
peratures than on treatment in aqueous solutions correlates
well with observations for proteins, which were shown to
refold to their native conformations without denaturation after
heating to extreme temperatures (up to 110 8C).[10,42] Full con-
version of the linear peptide in [C2mim][OAc] at 80 8C could be
observed after just 3 h of reaction, unlike at lower tempera-
tures (Figures 3B and S3). In contrast, no positive effect of the
addition of water to the corresponding IL was observed for
peptide oxidation (Figure 3A).
Interestingly, this is different from what has been reported
for proteins,[10] because the activities of these biomolecules
depend to a certain individual degree on water in the operat-
ing system. This was explained by the fact that for an enzyme
the so-called “essential” water (in contrast with the “bulk” free
water), which is bound to the molecule in the form of several
single layers on the surface, is critical for its activity. This water
can be removed by hydrophilic ILs, whereas hydrophobic ILs
show only a marginal tendency to work in this way. In more
detail, in aqueous solution a protein’s functional groups are
surrounded by a hydration shell, composed of water molecules
attached to the charged groups on the protein surface; that is,
water is essential for protein stability and activity. The hydro-
phobicity and polarity of the protein’s environment (e.g. , sol-
vent) thus influence the stability and activity by changing the
protein hydration level.[44] A pure IL is characterized by a hydro-
gen-bond network that is disrupted and modified in the pres-
ence of water in the reaction mixture.[45] This indicates that the
solution’s composition and “structure” changes in aqueous IL
solutions.[46] Upon interaction of IL ions with the protein sur-
face, the protein can be stabilized in solution by a reduction in
the protein–water interfacial tension through the “salting-out”
effect, but with an increasing water concentration the hydra-
tion forces start to dominate, and the ions start to confer a
“salting-in” effect.
In comparison with earlier reports,[14,15] we noticed that an
increase in the batch size (15 mg of peptide, 11.3 mm) re-
quires an additional supply of air oxygen and careful stirring
for a successful reaction (i.e. , mass transfer limitations occur
otherwise). Further studies directed towards up-scaling of the
oxidation of reduced m-SIIIA (15–20 mg) in [C2mim][OAc] were
primarily focused on the impact on reaction rate, efficiency,
and yield.
Indeed, we observed a dramatic influence of these parame-
ters on the oxidative folding process and the product ob-
tained. The results acquired after 24 h reaction time are shown
in Figure 4 and revealed an influence of the ionic liquid ions
on the peptide’s elution behavior. Whereas the buffer-oxidized
version of m-SIIIA (1) eluted at 17.3% acetonitrile (0.1% TFA, v/
v), the buffer-oxidized IL-incubated peptide eluted at 22–24%
(peaks 2a and 2b).[14] However, the chromatogram of m-SIIIA
obtained from the scaled-up approach contained peaks at
16.5 min (i.e. , 16.5% of 0.1% TFA in acetonitrile; fraction 3),
17.6 min (fraction 4), 20.8 min (fraction 5), 22.9 min (fraction 6),
Table 2. Yields for the formation of oxidized m-SIIIA (11.3 mm) obtained
after 24 h reaction time. The reaction was generally monitored over a
time period from 0.5 to 24 h.
Oxidation yield [%]
Medium/conditions [C2mim][OAc] MAF
[a] EAF[a]
3% water[b] 70 n.d.[c] n.d.
5% water 60 n.d. 56 (4% water)
7% water 40 40 40
10% water 30 57 (12% water) 42
20% water n.d. 36 30
20 8C 70 43 64
40 8C 70 48 50
60 8C 90/60 (6 h) (69, 3 h)[d] (58, 1 h)[d]
80 8C 90 (6 h) (29, 1 h)[d] (38, 1 h)[d]
[a] The peaks (elution at 20–24% of acetonitrile with 0.1% TFA) contain-
ing completely oxidized m-SIIIA were used for the determination of these
reaction yields. [b] Reactions with different concentrations of water (v/v)
in the IL were all carried out at 20 8C. [c] n.d. : not determined. [d] Peptide
was degraded in this medium after the reaction time given.
Figure 3. Elution profiles for oxidative folding of m-SIIIA (11.3 mm) in [C2mim]
[OAc], depending on: A) water content after 24 h at room temperature, and
B) reaction time at 80 8C and with 3% water content (HPLC conditions as in
Figure 2).
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 2754 – 2765 2758
CHEMBIOCHEM
FULL PAPERS www.chembiochem.org
and 23.6 min (fraction 7), all showing the same molar mass
(2208.7 gmol1, [M+H]+ of oxidized peptide) in MS analysis
(Figure 4, inserts). It seemed that ionic liquid cations and
anions adhere to the peptide, leading to varying forms with re-
spect to ion composition and amount. It was supposed that
these ions are not covalently or strongly attached because
MALDI-TOF MS analysis did not reveal any of these composi-
tions (Figure 4B). Whether these variants represent different
m-SIIIA isomers or just one single isomer with different ion
compositions was thus investigated in more detail by MS/MS
analysis (see below).
The complete transformation of the reduced precursor into
the oxidized peptide was generally confirmed by mass spec-
trometry and Ellman’s test (Table S1). In addition, Raman spec-
troscopy (Figure S4) was used to verify the completion of the
folding process. In contrast with time-consuming and yet un-
suitable NMR analysis of the rather complex peptide, Raman
spectroscopy is a fast and convenient method to derive the re-
quired information in addition to MS and has previously been
successfully applied in the same respect.[14,15, 43]
Electrophysiological studies
In continuation of our previous studies on the subject,[14] we
measured the activities of different m-SIIIA fractions, produced
by various procedures, in blocking voltage-gated sodium chan-
nels NaV1.4 (Figure 5). In addition to the peptide oxidized in
a buffer system (Figure 5, fraction 1),[14] we tested the activity
of buffer-folded m-SIIIA after additional incubation (24 h) in
[C2mim][OAc] (Figure 5, fractions 2a and 2b). As mentioned
above, IL treatment changes the HPLC retention time of the
peptide. Moreover, we found an influence of this treatment on
the peptides’ ability to inhibit NaV1.4 channels. In contrast with
the blocking induced by 10 mm buffer-oxidized m-SIIIA (frac-
tion 1, ca. 84%), the IL-treated peptide of fraction 2, at a con-
Figure 4. A large amount of reduced m-SIIIA (15–20 mg) was oxidized in
[C2mim][OAc] (#: peak of IL) at 20 8C over 24 h. A) Beside the main peak (frac-
tion 4 several other peaks were observed, and the corresponding products
were isolated from the crude reaction mixture. B) Products corresponding to
individual peaks (fractions 3 and 5–7) were reinjected after separation of the
crude mixture (retention times are given), and C) subjected to MS analysis
with a MALDI-TOF mass spectrometer. An MS spectrum corresponding to
fraction 4 was published earlier.[14] HPLC conditions were as described in
Figure 2.
Figure 5. Blocking of sodium channel NaV1.4 by different versions of oxi-
dized m-SIIIA. A) NaV1.4 was heterologously expressed in HEK293 cells, and
current responses were recorded at test depolarizations to 0 mV before
(left, ctrl) and after (right) application of the indicated peptide fraction for
a period of 500 s. Fraction 1: buffer-oxidized peptide (10 mm) ; 2a and 2b :
buffer-oxidized and treated with [C2mim][OAc] (90 mm) ; 3–7: various frac-
tions purified after oxidation in [C2mim][OAc] (all 90 mm) obtained from the
experiment shown in Figure 4. B) Average activities of the indicated peptide
fractions in blocking NaV1.4 channels. Data are presented as meansSEM,
with the number of independent experiments indicated in parentheses.
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centration of 90 mm, showed only 11% (2a) and 10% (2b). A
similar reduction in activity was found for the fractions purified
from a large-scale oxidation in [C2mim][OAc]: fractions 3 (6%),
4 (10%), 5 (11%), and almost no detectable activity in 6 (3%)
and 7 (3%; 90 mm each, Figure 5).
In this respect, there was no difference between fractions
obtained from analytical or semipreparative RP-HPLC separa-
tion of the buffer-oxidized and [C2mim][OAc]-treated peptide
and the peptide oxidized in [C2mim][OAc].
The results found here contrast with what we had observed
for the small-scale-produced peptide and also with earlier
studies with an enzyme inhibitor, also synthesized in [C2mim]
[OAc].[14,16] It is generally recognized that the up-scaling of
a process can be accompanied by difficulties. The fact that
products with differing retention times but with the same
molar mass and similar activity were observed reveals a differ-
ent behavior and mechanism with regard to solute–IL interac-
tions for the up-scaling and purification process relative to that
described previously. Here, it is obvious that HPLC purification
was not sufficient to remove the noncovalently bound IL ions
from the peptide molecule. LC-ESI MS/MS analysis was used to
clarify the disulfide connectivity by application of a protocol of
partial reduction combined with carbamidomethylation (Sup-
porting Information). The disulfide bridges of the buffer-oxi-
dized peptide were first analyzed by this procedure and pre-
dominantly showed the suggested native folding: Cys3–Cys13,
Cys4–Cys19, Cys8–Cys20 (Table S2, Figures S8 and S9). Addi-
tionally, minor contamination with another isomer (i.e. , Cys3–
Cys8, Cys4–Cys13, Cys19–Cys20) was observed. Subsequently,
the same method was applied to investigate the connectivity
of the buffer-oxidized m-SIIIA incubated with [C2mim][OAc];
this gave the same results, clearly with no changes due to the
IL (Figures S10 and S11). Interestingly, the isomer correspond-
ing to the native fold was identified in fraction 6 of the IL-oxi-
dized m-SIIIA (Table S2, Figures S12–S14). In addition, fraction 5
also predominantly showed the same MS/MS fragmentation:
that is, the native fold but with hints of a minor portion of
non-native disulfide bridging (Table S2). In contrast, fractions 4
and 7 represent a disulfide connectivity different from that in
fractions 5 and 6. However, there was no single, dominant con-
nectivity found for these versions. Several different linkages
hinted at, for example, Cys4–Cys8, Cys3–Cys19, and Cys8–
Cys13 (data not shown). Nevertheless, the shift of the retention
times of fractions 5 and 6 relative to the buffer-oxidized m-SIIIA
is due to the adhesion of ions to the cyclic peptide. As a conse-
quence, the loss of bioactivity could be attributable to these
ions if the interactions of the most relevant amino acids of the
peptide with the ion channel are disturbed. To verify this hy-
pothesis, molecular dynamics simulations were performed (see
below).
Impact of IL ions on proteolytic degradation of m-SIIIA
To examine the influence of the oxidation procedure on the
quality and activity of m-SIIIA, we performed an enzymatic
assay with the peptide as competing substrate. The intention
was to compare different kinds of activity assays and, thus,
sensitivities of biological targets (enzyme vs. ion channel) to
the IL ions adhering to the peptide. Proteolytic degradation by
trypsin was examined in the presence of both oxidation prod-
ucts: the toxin obtained from aqueous buffer and the version
from the [C2mim][OAc] approach. Trypsin activity was moni-
tored with the aid of a chromogenic substrate (Na-benzoyl-dl-
arginine-4-nitroanilide hydrochloride, BAPNA) by measuring
the increase in absorption at 410 nm. m-SIIIA contains three
potential cleavage sites for trypsin (K11, R14, R18). In the pres-
ence of m-SIIIA, the peptide competes with the substrate
BAPNA for the active site of trypsin, thereby lowering the ab-
sorption increase and the “apparent” activity of trypsin. The
quantity of this effect was taken as a measure to assess the
cleavage of m-SIIIA by trypsin. For buffer-oxidized m-SIIIA, we
derived a concentration-response curve (IC50=6.461.60 mm,
Figure 6), and the maximum inhibition of BAPNA cleavage was
determined to be 68% (3%) of the value obtained in the
absence of m-SIIIA. Selected fractions of the IL-oxidized m-SIIIA
were then tested at a distinct concentration (from the stock
solutions used in electrophysiological experiments) and used
in the same way as the buffer-oxidized peptide.
With regard to the effect on BAPNA conversion these pep-
tide versions showed behavior similar to that of the buffer-oxi-
dized m-SIIIA, for which a reduction of 72% at the tested con-
centration was detected. The results for fractions 5 (78.5%),
6 (73.8%), and 7 (78.5%) differ slightly, but they were in
an acceptable range for the assay setup used (1.8–6.5% de-
viation; Figure 6). Nevertheless, in relation to what has been
observed in the electrophysiological experiment with a 70–
80% deviation of the results for the IL-oxidized peptide relative
to the buffer-oxidized m-SIIIA, the impact of the medium used
in the oxidation procedure on the peptide’s activity is not as
large for the enzyme as for the ion channel. This indicates
a much higher sensitivity of the latter and the corresponding
toxin–protein interaction than for the enzyme–substrate inter-
action, probably based on differences in binding area and
number of specific amino acid residues involved in the recog-
nition process on either side.
Figure 6. Proteolytic cleavage of substrate BAPNA in the presence of m-SIIIA
from different oxidation procedures. Buffer-oxidized m-SIIIA (*) ; IL-oxidized
m-SIIIA 5 (&), 6 (^), 7 (~).
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Hotspots of IL ions interacting with m-SIIIA
Using atomistic molecular dynamics simulation, we sampled
the m-SIIIA–[C2mim][OAc] interaction on a 100 ns timescale,
and for each residue we determined the average amount of
2.5  contacts to [C2mim]
+ (Figure 7A and C, Figure S15A
and C) and [OAc] (Figure 7B and D, Figure S15B and D). For
both folded (Figure 7) and unfolded m-SIIA (Figure S15) we
found that [C2mim]
+ interactions predominantly take place at
Asp15, whereas close contacts with the anion preferentially
occur at Lys11, Arg18, and Arg14. Together with the MS/MS
analysis of the disulfide connectivities of the different peptide
versions—that is, identification of the same isomers in differen-
tially oxidized m-SIIIA—this is a clear indication of IL ions being
responsible for activity loss, particularly if it is considered that
these basic residues are primarily responsible for interaction
with the ion channel pore.[32]
Conclusion
Despite the recent progress achieved in the development and
application of ILs for biocatalytic processes and for reactions
involving proteins in general, research into employment of ILs
in peptide chemistry is still in its infancy. Detailed understand-
ing of the molecular interactions between ionic liquids and
peptides or proteins can, however, only be provided through
greatly increased research activities in this field and the acquis-
ition of corresponding experimental data. Therefore, a selection
of ionic liquids has been used here to explore the impact of
the IL medium on the formation of oxidatively folded peptides,
in particular the conotoxin m-SIIIA. It has been shown that the
oxidized peptide was formed to a relevant extent in protic ILs,
whereas most imidazolium-
based ILs (differing in their
anions), as well as choline dihy-
drogenphosphate and Am-
moeng 110, failed to yield the
product. Nevertheless, in con-
trast with the results obtained
for the only efficiently function-
ing 1,3-dialkylimidazolium IL—
[C2mim][OAc]—the protic ILs
proved to give highly complex
product mixtures, thus making
them unsuitable as adequate
substitutes for established aque-
ous systems.
Another previously unob-
served aspect was seen upon in-
creasing the batch size. Instead
of the expected transfer of the
reaction outcome in terms of
quality and quantity for the
scaled-up approach in [C2mim]
[OAc], a rather unusual mixture
was obtained and analyzed. Iso-
lated materials with different
physico-chemical properties with
respect to the behavior in the
chromatographic separation pro-
cess, yet with identical molar
masses, displayed massive re-
ductions in biological activity rel-
ative to the toxin prepared in
the aqueous medium. This is a direct consequence of favorable
strong interactions between the peptide’s backbone and
amino acid side chains and ionic liquid cations and anions. The
experiment with the IL-incubated toxin, which was active
before the contact with the IL, the observations in LC-ESI MS/
MS analysis, and the molecular dynamics simulation strongly
support this idea. Although solutes generally interact with the
reaction medium—water in the case of biological materials, for
example—the findings of this study revealed a clear impact of
the IL on the biological recognition process. Therefore, the
contradictory findings relating to proteins in ILs described in
the literature might be the result of IL-dependent interactions
with the protein of interest disturbing the process to be ana-
lyzed. Fundamental research thus remains to be carried out to
clarify the effects observed and to allow full exploitation of the
potential of ILs for future applications in biological sciences.
Figure 7. Hotspots of [C2mim][OAc]–m-SIIIA interaction as determined by molecular dynamics simulations. For
each residue the average amount of close contacts to A), C) [C2mim]
+ , and B), D) [OAc] is shown quantitatively
and in the context of a m-SIIIA conformation closest to the simulation average structure. C), D) For clarity, the
course of the peptide backbone has been highlighted, with N and C marking the termini.
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Experimental Section
Chemicals : Fmoc-amino acids, coupling reagents (HBTU), and resin
were purchased from Orpegen Peptide Chemicals (Heidelberg, Ger-
many) or IRIS Biotech (Marktredwitz, Germany). Peptide synthesis
reagents (N-methylmorpholine, piperidine, trifluoroacetic acid) and
solvents (N,N-dimethylformamide, CH2Cl2) were of reagent grade,
solvents for chromatography (methanol, acetonitrile) were of ana-
lytical grade and were obtained from VWR International (Dresden,
Germany), and HPLC water was obtained from Fisher Scientific.
[C2mim][OAc] and [C4mim][OAc] were donated by BASF SE and
Sigma–Aldrich, respectively. [C2mim][N(CN)2] , [C2mim][DEP],
[C2mim][OTs], EAF, MAF, and Amoeng were obtained from IoLiTec,
Solvent Innovation, or Merck. Other ionic liquids were synthesized
as described below.
Synthesis of ionic liquids
1-Butyl-3-methylimidazolium bromide : 1-Bromobutane (1.2 equiv)
was heated to 70 8C, and N-methylimidazole (1.0 equiv) was added
dropwise. The solution was allowed to cool to room temperature,
diluted with CH2Cl2, and poured dropwise with intensive mechani-
cal stirring into cold ethyl acetate. The product separated immedi-
ately as a white precipitate. The solid was crushed to a powder
and washed twice with ethyl acetate (200 mL) by decantation. The
highly hygroscopic product was dried in vacuum to constant
weight and stored under ethyl acetate. Colorless crystalline solid,
25.2 g (115 mmol, 75%), 1H NMR (300 MHz, [D6]DMSO): d=9.42 (s,
1H), 7.89 (s, 1H), 7.78 (s, 1H), 4.17 (t, 3JH,H=7.2 Hz, 2H), 3.86 (s,
3H), 1.66–1.73 (m, 2H), 1.12–1.26 (m, 2H), 0.82 ppm (t, 3JH,H=
7.4 Hz, 3H); 13C NMR (75 MHz [D6]DMSO): d=137.0, 122.7, 124.0,
48.8, 36.2, 31.8, 19.2, 13.8 ppm.
1-Ethyl-3-methylimidazolium bromide : 1-Bromoethane (1.0 equiv)
was heated to 40 8C, and N-methylimidazole (1.0 equiv) was added
dropwise. The reaction mixture was stirred at 40 8C for 1 h. After-
wards the temperature was increased to 80 8C, and the mixture
was stirred for another hour. The solution was allowed to cool to
room temperature and poured dropwise with intensive mechanical
stirring into cold ethyl acetate. The product separated immediately
as a white precipitate. The solid was isolated and dissolved in
CH2Cl2. Activated charcoal and aluminium oxide were added, and
the solution was filtered off. The filtrate was treated with ethyl ace-
tate. After phase separation, the lower, yellow phase was isolated
and dried under reduced pressure at 50 8C. After cooling to room
temperature, the product crystallized slowly as a colorless solid.
Colorless crystalline solid, 55.8 g (294 mmol, 73%). 1H NMR
(300 MHz, [D6]DMSO): d=9.74 (s, 1H), 7.17–7.10 (m, 2H), 3.89 (q,
3JH,H=7.44 Hz, 2H), 3.58 (s, 3H), 1.06 ppm (t,
3JH,H=7.4 Hz, 3H);
13C NMR (75 MHz, [D6]DMSO): d=136.2, 123.4, 121.9, 44.0, 36.2,
35.7, 15.2 ppm.
1-Ethyl-3-methylimidazolium hydroxide ([C2mim][OH]): An aqueous
solution was prepared from 1-ethyl-3-methylimidazolium bromide
by use of anion exchange resin (Merck Ion exchanger III) and ultra-
pure water. Qualitative ion chromatography was used to check
whether all halide impurities had been removed.
General procedure for N-trifluoromethanesulfonyl amino acid
methyl esters : Triethylamine (2.0 equiv) was dissolved in abs.
CH2Cl2 under argon. The l-amino acid methyl ester hydrochloride
(1.0 equiv) was added to the solution, and the mixture was stirred
for 5 min at room temperature. The solution was cooled to 78 8C
(isopropanol/dry ice). Trifluoromethanesulfonic acid anhydride
(1.0 equiv) dissolved in CH2Cl2 was added. The mixture was allowed
to warm slowly to room temperature and stirred overnight. The so-
lution was treated with hydrochloric acid (9%), and the organic
layer was separated off. The organic layer was washed with brine
and concentrated to remove the solvents. The crude product was
purified by Kugelrohr distillation or by sublimation.
(S)-N-(Trifluoromethanesulfonyl)alanine methyl ester [N-Tf-
AlaOMe]: White crystalline solid, 1.85 g (7.84 mmol, 85%), Kugel-
rohr distillation at 120 8C and 0.01 mbar. M.p. : 63 8C; 1H NMR
(300 MHz, [D6]DMSO): d=10.28–10.14 (s, 1H), 4.22 (m, 1H), 3.73 (s,
3H), 1.38 ppm (d, 3JH,H=7.3 Hz, 3H);
13C NMR (75 MHz [D6]DMSO):
d=172.0, 119.8 (q, 1JC,F=321.3 Hz), 52.6, 53.0, 18.9 ppm; MS (ESI):
m/z calcd for C5H7NO4SF3 : 234.0 [M1]
 ; found: 233.8.
(S)-N-(Trifluoromethanesulfonyl)valine methyl ester [N-Tf-
ValOMe]: Colorless crystalline solid, 2.63 g (9.99 mmol, 65%),
Kugelrohr distillation at 120 8C and 0.01 mbar. 1H NMR (300 MHz,
[D6]DMSO):): d=10.06 (br s, 1H), 3.84 (m, 1H), 3.70 (s, 3H), 2.04–
2.15 (m, 1H), 0.91 (d,3JH,H=2.5 Hz, 3H), 0.89 ppm (d,
3JH,H=2.5 Hz,
3H); 13C NMR (75 MHz [D6]DMSO): d=171.1, 121.9 (q,
1JC,F=
321.81 Hz), 62.9, 53.7, 30.7, 19.1, 18.1 ppm; MS (ESI): m/z calcd for
C7H11NO4SF3
 : 262.23 [M1] ; found: 263.00.
(S)-N-(Trifluoromethanesulfonyl)leucine methyl ester [N-Tf-
LeuOMe]: Colorless crystalline solid, 4.51 g (16.3 mmol, 72%),
Kugelrohr distillation at 120 8C and 0.01 mbar. 1H NMR (300 MHz,
[D6]DMSO): d=10.13 (br s, 1H), 4.02–3.97 (m, 1H), 3.68 (s, 3H),
1.50–1.62 (m, 3H), 0.89 ppm (t, 3JH,H=6.4 Hz, 6H);
13C NMR (75 MHz
[D6]DMSO): d=171.5, 119.3 (q,
1JC,F=321.5 Hz), 55.1, 52.4, 40.3,
23.9, 22.52, 20.6 ppm; MS (ESI): m/z calcd for C8H13NO4SF3
 : 276.25
[M1] ; found: 275.9.
1-Butyl-3-methylimidazolium (S)-N-(trifluoromethanesulfonyl)a-
lanine methyl ester [C4mim][N-Tf-l-Ala-OMe]: The protonated
anion precursor (1.0 equiv) was dissolved in CH2Cl2 under argon.
Sodium hydride (60% in mineral oil, 1.7 equiv, effective dose
1.0 equiv) was added, and the solution was stirred until the evolu-
tion of gas had ceased. With continuous stirring, the desired ionic
liquid cation (1.0 equiv) was added as a solution (1m) of the bro-
mide salt in CH2Cl2. The solution was stirred for 24 h at ambient
temperature for grain growth by Oswald ripening. The solid was fil-
tered off, and the remaining solution was washed with small por-
tions of water until a test for halides with AgNO3 was negative.
The solvent was removed under reduced pressure, and the residue
was dried to constant weight under vacuum. Pale yellow liquid,
1.40 g (3.75 mmol, 88%). M.p. : <0 8C; 1H NMR (300 MHz
[D6]DMSO): d=cation: 9.42 (s, 1H), 7.87 (s, 1H), 7.79 (s, 1H), 4.20 (t,
3JH,H=7.3 Hz, 2H), 3.88 (s, 3H), 1.84–1.69 (m, 2H), 1.33–1.19 (m,
2H), 0.87 (t, 3JH,H=7.4 Hz, 2H), anion: 3.95–3.80 (m, 1H), 3.54 (s,
3H), 1.15 ppm (d, 3JH,H=7.3 Hz, 3H);
13C NMR (75 MHz [D6]DMSO):
d=anion: 176.0, 122.6 (q, 1JC,F=330 Hz), 54.3, 51.5, 22.1, cation:
137.3, 122.6, 124.2, 49.1, 36.2, 31.9, 19.3, 13.8 ppm.
General procedure for 1-ethyl-3-methylimidazolium (S)-N-tri-
fluoromethanesulfonyl amino acid methyl ester ionic liquids :
The (S)-N-trifluoromethanesulfonyl amino acid methyl ester
(1.0 equiv) was dissolved in ultrapure water. A solution of 1-ethyl-
3-methylimidazolium hydroxide (1.0 equiv) in ultrapure water was
added dropwise over a period of 1.5 h. The resulting mixture was
stirred at room temperature for 18 h. The water was removed
under reduced pressure to afford the desired product as a highly
viscous liquid.
1-Ethyl-3-methylimidazolium (S)-N-(trifluoromethanesulfonyl)a-
lanine methyl ester [C2mim][N-Tf-l-Ala-OMe]: Colorless liquid,
2.3 g (6.56 mmol, 77%). M.p. : <0 8C; 1H NMR (300 MHz [D6]DMSO):
d=cation: 9.31 (s, 1H), 7.80 (s, 1H), 7.71 (s, 1H), 4.20 (q, 3JH,H=
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7.3 Hz, 2H), 3.85 (s, 3H), 1.40 (t, 3JH,H=7.3 Hz, 3H), anion:< 3.89–
3.82 (m, 1H), 3.51 (s, 3H), 1.11 ppm (d, 3JH,H=6.9 Hz, 3H); MS (ESI):
m/z calcd for C6H11N2
+ : 111.1 [M1]+ ; found: 111.0; m/z calcd for
C5H7NO4SF3
 : 234.0 [M1] ; found: 233.9.
1-Ethyl-3-methylimidazolium (S)-N-(trifluoromethanesulfonyl)va-
line methyl ester [C2mim][N-Tf-l-Val-OMe]: Colorless liquid, 1.2 g
(3.33 mmol, 88%). M.p. : <0 C; 1H NMR (300 MHz [D6]DMSO): d=
cation: 9.22 (s, 1H), 7.78 (s, 1H), 7.70 (s, 1H), 4.19 (q, 3JH,H=7.3 Hz,
2H), 3.84 (s, 3H), 1.40 (t, 3JH,H=7.3 Hz, 3H), anion: 3.50 (s, 3H), 3.46
(d, 3JH,H=6.6 Hz, 1H), 1.72 (m, 1H), 0.78 ppm (t,
3JH,H=6.7 Hz, 6H);
MS (ESI): m/z calcd. for C6H11N2
+ : 111.1 [M1]+ ; found: 111.0; m/z
calcd for C7H11NO4SF3
 : 262.2 [M1] ; found: 262.9.
1-Ethyl-3-methylimidazolium (S)-N-(trifluoromethanesulfonyl)-
leucine methyl ester [C2mim][N-Tf-l-Leu-OMe]: Colorless liquid,
1.2 g (3.11 mmol, 76%). M.p. : <0 8C; 1H NMR (300 MHz [D6]DMSO):
d=cation: 9.36 (s, 1H), 7.78 (s, 1H), 7.69 (s, 1H), 4.20 (q, 3JH,H=
7.3 Hz, 2H), 3.85 (s, 3H), 1.40 (t, 3JH,H=7.3 Hz, 3H), anion: 3.77 (t,
3JH,H=7.1 Hz, 1H), 3.49 (s, 3H), 1.61 (m, 1H), 1.29 (t,
3JH,H=7.0 Hz,
2H), 0.81 ppm (t,3JH,H=7.0 Hz, 6H); MS (ESI): m/z calcd. for
C6H11N2
+ : 111.1 [M1]+ ; found: 111.0; m/z calcd for C8H13NO4SF3
 :
276.1 [M1] ; found: 275.9.
Synthesis and purification of peptides : Peptides were synthesized
automatically by a standard Fmoc [N-(9-fluorenyl)methoxycarbonyl]
protocol as described earlier[14, 32] with an EPS 221 peptide synthe-
sizer (Intavis Bioanalytical Instruments AG, Cologne, Germany). The
linear peptides (conotoxin sequences are represented in Figure S1)
were assembled by use of TentaGel R RAM resin with a loading ca-
pacity of 0.18 or 0.24 mmolg1. Cysteine side chains were protect-
ed with trityl groups. In general, coupling reactions were per-
formed with Fmoc-amino acids (5 equiv) activated with HBTU
(5 equiv) in the presence of N-methylmorpholine/DMF (1:1) for 5–
15 min (double couplings). Fmoc removal was effected by treating
the resin twice with piperidine in DMF (20%). All deprotection and
coupling steps were followed by intensive washings with DMF and
CH2Cl2, alternately. Peptide cleavage and deprotection was accom-
plished with reagent K (trifluoroacetic acid (TFA)/water/phenol/thi-
oanisole/ethanedithiol 82.5:5:5:5:2.5) for 4 h at room temperature.
The crude peptides were precipitated with diethyl ether, centri-
fuged, and washed several times with diethyl ether. The yields of
the crude peptides varied between 70–90% for the linear sequen-
ces. Peptides were purified by semipreparative reversed-phase C18
HPLC with the gradient elution system 0.1% TFA in water (eluent
A) and 0.1% TFA in acetonitrile/water (90:10) (eluent B).
Oxidation of peptides : Oxidative folding of peptides a-GI, m-SIIIA,
m-PIIIA, and d-EVIA in buffer with redox agents was performed by
the procedure described earlier.[14, 32] In ILs (preliminary experi-
ment), the linear peptide (1 mg) was dissolved in the correspond-
ing IL (40–120 mL) and left at room temperature with gentle stir-
ring. For experiments on the impact of water content in ILs, gradi-
ent grade water (VWR, Dresden, Germany) was added to the reac-
tion mixtures prior to the start of the reaction in final concentra-
tions of 3, 5, 7.5, 10, and 20%. For experiments on the impact of
elevated temperatures, the corresponding reaction mixture was
left in a thermomixer at 40, 60, and 80 8C. After an appropriate
time (0.5–24 h), the mixture was diluted 16-fold with acetonitrile/
water (1:4) and purified by RP-HPLC by the methods described in
Table S1.
Characterization of ionic liquids : The water content of each ionic
liquid was determined by a Karl Fischer titration (Metrohm 870 KF
Titrino plus).[47]
Molecular dynamics simulations : MD simulations were performed
with GROMACS version 4.0.3[48,49] and the GROMOS96 force field
with the 54a7 parameter set[50] by using Vienna PTM to model con-
otoxin’s post-translationally modified N and C termini.[51, 52] In all
simulations standard protonation states were assumed for titrata-
ble residues and all bond lengths to hydrogen were constrained
by LINCS[53] so that an integration time step of 2 fs could be
chosen. Systems were simulated at 300 K, maintained separately
for protein and ionic liquid by use of a velocity rescaling thermo-
stat[54] with a time constant (t) of 0.1 ps. Pressure coupling was
done with a Berendsen barostat[55] and use of a 1 bar reference
pressure, isotropic pressure coupling, and a time constant of 4 ps.
Electrostatic interactions were calculated by particle mesh Ewald
(PME) summation,[56,57] and twin range cutoffs of 1.0 and 1.4 nm
were applied for computing the van der Waals interactions.
[C2mim]
+ and [OAc] were parameterized by use of the automated
topology builder[58] and employment of a HF/STO-3G level of
theory to compute the partial charges, which were subsequently
scaled by a factor of 0.8 to model IL fluidity correctly.[59–62] By using
conformer 1 of the m-conotoxin SIIIA NMR structure as a starting
point,[30] two simulation systems were constructed. In the first
system, m-SIIIA was placed inside a cubic box with an edge length
of 5.14 nm and solvated with 485 [C2mim]
+ and 488 [OAc] mole-
cules. In the second system, m-SIIIA was converted into an extend-
ed conformation by using PyMol 1.4,[63] placed inside a cubic box
with an edge length of 9.21 nm, and solvated with 2490 [C2mim]
+
and 2492 [OAc] molecules. After steepest descent energy minimi-
zation, both systems were simulated for 100 ns.
Simulation analysis : To identify hotspots of IL–m-SIIIA interaction,
we computed the average number of IL contacts within a distance
of 2.5  or less for each m-SIIIA residue by use of the GroMACS tool
g mindist and QtiPlot for visualization. Additionally, the contact
frequencies were mapped color-coded onto m-SIIIA simulation con-
formations displaying the smallest root mean square displacement
from the simulation average structures. As in refs. [64]–[67], simula-
tion average structures were determined by using an iterative
scheme of calculating the average conformation and realigning
the trajectory to that average structure before computing a new
average structure. This procedure was repeated until the average
structure stopped changing.
Instrumentation for peptide analytics
Peptide purification : The crude peptides were purified by semipre-
parative reversed-phase HPLC with a Shimadzu LC-8A system
equipped with a C18 column (Knauer Eurospher 100, Berlin, Ger-
many). The gradient elution system was 0.1% TFA in water (eluent
A) and 0.1% TFA in acetonitrile/water (9:1; eluent B). The peptides
were eluted with a gradient of 0–50% eluent B in 120 min and
a flow rate of 10 mLmin1. The peaks were detected at 220 nm.
Collected fractions were combined, freeze-dried, and stored at
20 8C. Purities of the peptides were confirmed by analytical re-
versed-phase HPLC with a Shimadzu LC-10AT chromatograph (Duis-
burg, Germany) equipped with a Vydac 218TP54 column (C18,
5 mm particle size, 300  pore size, 4.625 mm). The peptides
were eluted with a gradient of 0–40% eluent B in 40 min. The flow
rate was 1 mLmin1, eluent A was 0.1% TFA in water, and eluent B
was 0.1% TFA in acetonitrile; detection was at 220 nm.
Amino acid analysis : The amino acid compositions of the peptides
were verified by amino acid analysis with a LC 3000 system from
Eppendorf-Biotronik (Hamburg, Germany). Hydrolysis was per-
formed with HCl (6n) in sealed tubes at 110 8C for 24 h. The analy-
ses obtained supported the expected quantitative results. Amino
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acid analysis in combination with HPLC (calibration curve) was
used for the determination of peptide concentrations in solution
prior to electrophysiological experiments.
Ellman’s test : The procedure used is based on the method de-
scribed by Ellman and co-workers and was described earlier.[32] In
brief, the measurements were carried out with a UV-1800 UV/Vis
spectrophotometer (Shimadzu, Duisburg, Germany). The reference
solution containing 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB,
19.8 mg) was prepared with Tris·HCl buffer (0.2m, 50 mL, pH 8).
Samples to be analyzed were prepared in DTNB/buffer solution
and measured relative to the reference solution in quartz cuvettes
of 1 cm pathlength.
Mass spectrometry : The molecular weights of crude and purified
peptides were confirmed by MALDI-TOF mass spectrometry with
an autoflex Bruker mass spectrometer (Bruker Daltonics, Bremen,
Germany) and use of either a-cyano-4-hydroxycinnamic acid or si-
napinic acid as matrices. The reflector mode was used for measure-
ments and Peptide Calibration Standard II for molar masses
<6000 gmol1.
Electrophysiological assay : HEK 293 cells (CAMR, Porton Down, Salis-
bury, UK) were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM, 45%) and Ham’s F12 Medium (45%), supplemented with
fetal calf serum (10%) in an incubator (5% CO2) at 37 8C. Cells were
co-transfected with a 3:1 ratio of the rat NaV1.4 expression plas-
mid[68] and a vector encoding the CD8 antigen[69] by use of the Ro-
tifect transfection kit (Roth, Karlsruhe, Germany). Dynabeads (Deut-
sche Dynal, Hamburg, Germany) were used for visual identification
of individual transfected cells. Na+ current was measured by apply-
ing the whole-cell configuration of the patch-clamp method to
HEK 293 cells 24–48 h after transfection. The patch pipettes con-
tained: NaCl (35 mm), CsF (105 mm), ethylene glycol bis(2-amino-
ethylether)tetraacetic acid (EGTA; 10 mm), HEPES (pH 7.4 with
CsOH, 10 mm). The bath solution contained: NaCl (150 mm), KCl
(2 mm), CaCl2 (1.5 mm), MgCl2 (1 mm), HEPES (pH 7.4 with NaOH,
10 mm). As patch-clamp amplifier an EPC-10 operated by Patch-
Master software (HEKA Elektronik, Lambrecht, Germany) was used.
Series resistance was corrected electronically up to 85%; record-
ings with series resistance greater than 5 MW were discarded. m-
SIIIA fractions were diluted in bath solution and stored at 20 8C
until use. Peptides were locally applied with a glass pipette as de-
scribed earlier.[70] Blocking of NaV1.4 currents by m-SIIIA fractions
was assayed with repetitive pulses to 0 mV from a holding poten-
tial of 120 mV. The repetition interval was 3 s, and m-SIIIA concen-
trations were 10 mm for the buffer-oxidized peptide and 90 mm for
IL-treated and IL-oxidized peptides. m-SIIIA-induced blocking of
NaV1.4 was determined by analyzing the inhibition of the peak cur-
rents after peptide application for 500 s. All experiments were per-
formed at room temperature (25 8C).
Enzymatic assay : The activity of trypsin (Merck) was measured
with Na-benzoyl-dl-arginine-4-nitroanilide hydrochloride as sub-
strate and use of a UV/Vis spectrophotometer (Thermo Fisher Mul-
tiskan GO). Substrate concentration was 0.214 mm in a buffer con-
taining Tris·HCl (pH 7.4, 40 mm), CaCl2 (20 mm), and DMSO (25%,
v/v).[71] Trypsin was dissolved in HCl (1 mm) at a concentration of
0.5 mgmL1. All m-SIIIA fractions were dissolved in the same buffer
as used in the electrophysiological assay (bath solution; see
above). For each measurement, substrate solution (100 mL) was
mixed with buffer and/or m-SIIIA solution (100 mL) on a microtiter
plate. The plate was then incubated for 5 min at 37 8C. Trypsin so-
lution (5 mL) was then added. After 10 s of shaking, the absorption
was measured at 410 nm for 10 min, with one data point taken
every 10 s. All measurements were performed at room temperature
(25 8C).
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Epilogue 
For the conotoxins tested, [C2mim][OAc] turned out to be the IL of choice regarding the 
quality and yield of the oxidation product. A water content of > 3-5 % (v/v) disfavoured 
product formation or completely prevented the oxidation reaction. Increase in temperature to 
60 or 80 °C increased the reaction speed and product yield, while for protic ILs the peptide 
was degraded after longer reaction time. Large scale production of -SIIIA in [C2mim][OAc] 
revealed several fully oxidized species. These peptide forms were analyzed with HPLC, LC-
ESI-MS/MS, and electrophysiological experiments revealing a lack in inhibitory activity at 
NaV1.4-channel. There are two hypotheses about why the conotoxin lost its biological activity 
when produced in an IL. On the one hand, the IL-oxidation could result in different isomers of 
non-native cysteine connectivity on the other hand the IL ions might adhere to the peptide 
even after purification compromising the interaction with the biological target. The natively 
folded cysteine bonding, i.e. C1-C4, C2-C5 and C3-C6, was identified in the IL-oxidized 
peptide using LC-ESI-MS/MS after partial reduction and alkylation, thus excluding the 
possibility of misfolding. Computational molecular dynamics simulations of the peptide NMR 
structure in an IL environment revealed that in particular acetate anions preferably associate 
with the side chains of basic residues which are responsible for the ion channel block, thus 
hampering the toxin-channel interaction. Surprisingly, the adherence of ions to the peptide 
did not affect proteolytic degradation by trypsin, indicating that the effect at a biological target 
(e.g. enzyme vs. ion channel) is depending on the sensitivity of a specific ligand-protein 
interaction. In addition, buffer-oxidized, bioactive -SIIIA stored in IL also resulted in a loss of 
bioactivity providing further evidence for the impairment by adhering IL ions. 
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Preface 
Identification of the binding site is essential to understand the mechanism of action of 
conotoxin binding to VGSCs.97 It is essential to improve our understanding of possible side 
effects of such toxins, but respective studies are rare. In this report, a combination of 
molecular modelling and electrophysiology has been used to identify the binding site of -
EVIA. This conotoxin was utilized herein to characterize the binding epitope for other voltage-
sensor toxins such as -SVIE and scorpion -toxins to support investigations on their 
selectivity for VGSCs. 
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Background: For a large number of conopeptides basic knowledge related to structure-activity relationships is un-
available although such information is indispensablewith respect to drug development and their use as drug leads.
Methods: A combined experimental and theoretical approach employing electrophysiology andmolecular model-
ing was applied for identifying the conopeptide δ-EVIA binding site at voltage-gated Na+ channels and to gain
insight into the toxin's mode of action.
Results: Conopeptide δ-EVIAwas synthesized and its structurewas re-determinedbyNMRspectroscopy formolec-
ular docking studies.Molecular docking andmolecular dynamics simulation studieswere performed involving the
domain IV voltage sensor in a resting conformation and part of the domain I S5 transmembrane segment. Molec-
ularmodelingwas stimulatedby functional studies,which demonstrated the importance of domains I and IV of the
neuronal NaV1.7 channel for toxin action.
Conclusions: δ-EVIA shares its binding epitope with other voltage-sensor toxins, such as the conotoxin δ-SVIE and
various scorpion α-toxins. In contrast to previous in silico toxin binding studies, we present here in silico binding
studies of a voltage-sensor toxin including the entire toxin binding site comprising the resting domain IV voltage
sensor and S5 of domain I.
General significance: The prototypical voltage-sensor toxin δ-EVIA is suited for the elucidation of its binding epi-
tope; in-depth analysis of its interaction with the channel target yields information on the mode of action and
might also help to unravel the mechanism of voltage-dependent channel gating and coupling of activation and
inactivation.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
The venoms of marine cone snails contain a spectrum of peptides
(conotoxins) that typically act on ion channels and receptors and thus
serve the snails for defense and prey capture [1–3]. Because of their
specific target interaction, some conotoxins are of medicinal value; for
example, the ω-conotoxin MVIIA from Conus magus (trade name:
Prialt®), which inhibits voltage-gated N-type Ca2+ channels in dorsal
root ganglia neurons, is used as a potent analgesic [4–7]. Given that
every cone snail species produces several hundreds of conopeptides, a
plethora of biologically interesting substances is yet to be discovered
[8,9]. A prerequisite for using such peptides for drug development, how-
ever, is a firm understanding of their structure and their molecular
mode of action.
Most conotoxins harbor two or more cysteine residues; disulfide
bridges stabilize their structure and determine their overall fold. Ac-
cordingly, conotoxins are classified into superfamilies according to
their signal sequences, whereas disulfide bond patterns determine the
cysteine framework [10]. Peptides of the M-superfamily that form
three disulfide bridges have attracted considerable attention because
they specifically inhibit voltage-gated ion channels. For example, μ-
conotoxins interact with voltage-gated Na+ (NaV) channels by occlud-
ing the pore via binding in the extracellularly accessible channel
vestibule [11]. This relatively simple interaction mechanism and the
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perspective to develop μ-conotoxins as drugs to suppress neuronal sig-
naling and therefore to be applied as analgesics has fueled research in
this direction [12].
Conotoxins of the O-superfamily also contain three disulfide bridges,
but they are much more diverse. Besides the already mentioned ω-
conotoxins, which target voltage-gated Ca2+ channels, this superfamily
comprises μO- and δ-conotoxins, both acting onNaV channels [13]. Their
mode of action, however, is very different from that of μ-conotoxins.
While μ-conotoxins are “pore blockers”, μO-conotoxins and δ-
conotoxins are so-called gating modifiers or voltage-sensor toxins, i.e.
they interfere with parts of the NaV channel proteins that are responsi-
ble for sensing changes in the transmembrane electric field (voltage
sensors) and to gate the channel open. Although the crystal structure
of the bacterial NaVAB channel [14] has been solved, high-resolution
structural data of mammalian NaV channels are still lacking and homol-
ogy considerations to NaVAB and voltage-gated K
+ channels and
numerous mutagenesis and functional studies have established the in-
sight that NaV channels consists of 4 homologous domains (I–IV), each
of whichwith 6 transmembrane segments (S1–S6); S1–S4 form voltage
sensors that move according to the electric field, while S5, S6 and the
connecting linker form the channel gate and the central Na+-selective
pore, respectively [15]. μO-conotoxins thus decrease NaV channel activ-
ity by interfering with the voltage sensor of domain II and the S5-pore
loop of domain III [13,16]. δ-Conotoxins, however, typically increase
NaV channel activity by interfering with rapid channel inactivation,
and mutations in the S3–S4 linker of domain IV have a strong impact
on this activity as demonstrated for δ-SVIE originating from Conus
striatus [17]. Regarding the functional modulation of NaV channels, δ-
conotoxins share similarities with scorpionα-toxins, most likely having
highly overlapping binding sites (NaV channel toxin site 6), even though
they show no sequence similarities [13,17].
Despite this intriguing activity, δ-conotoxins have attracted much
less attention than other conopeptides probably because of their high
hydrophobicity and limited availability. Besides synthetic δ-SVIE [17],
δ-EVIA from Conus ermineus [18] and δ-CnVID from Conus consors [19]
have been studied in more detail. In both of the latter cases, the toxin
showed a remarkable preference for neuronal NaV channels, while
those from skeletal muscle (NaV1.4) and the heart muscle (NaV1.5)
were largely unaffected by the toxins [18,19].
Given the advancement in peptide synthesis, novel structural data of
voltage-gated ion channels, and progress in in silico description of
peptide–protein interactions, we here aimed at providing insight into
the molecular mechanism by which δ-EVIA interacts with mammalian
NaV channels and which aspects of the channel protein may be respon-
sible for the toxin's subtype specificity.
δ-EVIA contains 32 amino acids with 4-hydroxyproline at position 6
and a C-terminal leucine amide. The six cysteines of the sequence are at
positions 3, 10, 20, 21, 25, and 29 (cysteine pattern C-C-CC-C-C corre-
sponding to the cysteine framework VI) with a connectivity as in repre-
sentatives of μ- and ω-conotoxins: C1–4, C2–5, and C3–6 [18,20]. The
structure of δ-EVIA was earlier reported and shown to be characterized
by a 1:1 cis/trans isomerismof the Leu12-Pro13 peptide bondwithin loop
2 (residues 11–19) of the disulfide-bridged sequence [21]. Both isomers
were separately analyzed (PDB ID: 1G1P and 1G1Z) and, in addition, the
exclusive occurrence of a trans leucyl-proline bond was demonstrated
for the P13A analog, which was also synthesized by the same group. In-
terestingly, the latter was found to be only two-times less active than
the parent peptide [21]. Another study reported on a peptidomimetic
cis Pro-amide bond loop-analog of δ-EVIA; the aforementioned cis/
trans peptide bond was exchanged using the pseudoproline approach
involving Cys(ΨMe,MePro)13 that resulted in an analog with a fixed cis
conformation of the respective bond in loop 2 [22].
Here we used a combined experimental and theoretical approach
employing electrophysiology and molecular modeling in order to iden-
tify the δ-EVIA binding site and to gain insight into itsmode of action. To
ascertain functional assays and modeling to be based on the same
material and information, δ-EVIA was synthesized and its structure
was re-determined by NMR spectroscopy. While functional evaluation
revealed the importance of domains I and IV of the neuronal NaV1.7
channel for toxin action, molecular docking and molecular dynamics
simulation studies involving the domain IV voltage sensor in a resting
conformation and part of the domain I S5 element revealed insight re-
garding how this voltage-sensor toxin specifically interferes with the
mobility of the domain IV voltage sensor and thus delays channel
inactivation.
2. Materials and methods
2.1. Peptide synthesis and chemical characterization
The linear peptide of δ-EVIA (sequence: DDCIKOYGFCSLPILKNGLCCS
GACVGVCADL-NH2; O = 4-hydroxyproline) was synthesized and puri-
fied as described earlier [23]. Oxidation was carried out using an already
established oxidative self-folding approach [11]. After the reaction was
completed, the solvent was evaporated by freeze-drying, and concentrat-
ed aliquotswere separated byRP-HPLC (see Supporting information). The
molecular weight of crude and purified peptide was confirmed by mass
spectrometry (see Supporting information).
Elucidation of the disulfide bonds of buffer-oxidized δ-EVIAwas per-
formed by LC-ESI MS/MS analysis. Therefore, an established protocol of
partial reduction combined with carbamidomethylation was applied
[24]. After sequencing of the linear, reduced peptide as control
(Supporting Fig. S3A), the buffer-oxidized peptide was analyzed and
the following connectivity was confirmed: C3–C21, C10–C25, C20–
C29, corresponding to the suggested fold reported earlier (Supporting
information, Supporting Fig. S3B, C) [21]. These findings confirm the
results obtained from NMR structural analysis.
2.2. NMR analysis and structure calculation
Solution NMR experiments were performed at 293 K on a Bruker
Avance III 600 MHz spectrometer. The peptide sample was dissolved
in 90% H2O/10% D2O using the freeze-dried solid compound prepared
in buffer solution. Data were acquired and processed with Topspin
(Bruker, Rheinstetten, Germany) and analyzedwith CCPN [25]. The pro-
ton resonance assignment was performed using a combination of 2D
[1H,1H]-TOCSY (80 ms spinlock time) and [1H,1H]-NOESY experiments.
Distance constraintswere extracted froma [1H,1H]-NOESY spectrumac-
quired with 120ms mixing time. Upper limit distance constraints were
calibrated according to their intensity in the NOESY spectrum. The three
disulfide bridges were used as additional restraints. Torsion angle con-
straints were obtained from proton chemical shift analysis using
DANGLE [26]. Structure calculations and refinements [27] were per-
formed with YASARA structure [28–31]. The 16% of structures with
the lowest energy were selected to represent the NMR ensemble
for trans-δ-EVIA and cis-δ-EVIA, respectively (Supporting Fig. S4).
Structures were refined in water at pH 4.
2.3. Homology modeling, molecular dynamics simulations and docking
studies
The YASARAmolecularmodeling programwas used to build homol-
ogy models of NaV1.7 and NaV1.4 channels and for molecular dynamics
simulations [29,30]. The voltage-sensor domain IV (VS-DIV) in the
resting-state conformation and the adjacent full domain I (DI) of the re-
spective voltage sensor were modeled independently. The resting-state
model of the voltage-sensor domain of the voltage-gated K+ channel
(KV1.2) created by Pathak et al. was used as a template for our
resting-state VS-DIV homology models [32]. For the homology model
of DI possible templates were identified by YASARA by running PSI-
BLAST iterations [33] on the basis of the amino acid sequence of
NaV1.4 to extract a position specific scoring matrix (PSSM) from
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UniRef90, followed by searching the Protein Data Bank (PDB) for a
match. The templates were ranked based on the alignment score and
the structural quality obtained from the PDBFinder2 database [34].
For the individual homology models of both domains, sequence
alignments of the respective channel domain against the template
structure were created with PSI-BLAST [33] against UniRef90. Multiple
models of VS-DIV and DI were built according to alternative alignments
of the target and template protein sequence. Side chains were added
with YASARA's implementation of SCWRL3 [35] and refined considering
electrostatic and knowledge-based packing iterations as well as solva-
tion effects. The model was subsequently subjected to a fully unre-
strained energy minimization with explicit solvent molecules by
simulated annealing employing the YASARA2 force field [36]. In ad-
dition, a hybrid model was built by combination of the best regions
of the individual models. The respective models were rated accord-
ing to a given quality Z-score and the best scoring model was used
for the final channel construct. Amore detailed description of YASARA's
homology modeling protocol can be found online (http://yasara.org/
homologymodeling.htm).
Structure refinements of the homology models were performed as
unrestrained all-atom molecular dynamics simulation for 10 ns in a
membrane environment (PEA) and explicit water using the PMEmeth-
od [37] to describe long-range electrostatics at a cut-off distance of 8 Å
and the YASARA2 [29] force field at physiological conditions (0.9%
NaCl, 298 K, pH 7.4 [31]). The Amber03 [38] force field was used for
the 50 ns structural refinements of the δ-EVIA–channel complex as
well as for the respective reference simulations of rNaV1.4 and
mNaV1.7 channelmodels. Dockingwas performed through 24 indepen-
dent runs using VINA [39] with default parameters. The setupwas done
with the YASARA molecular modeling program [30]. Analysis of hydro-
gen bonds was performed after energy minimization of the toxin–
protein complex after 50 ns membrane simulation in explicit water,
using the PME method [37] and a cut-off distance of 8 Å to describe
long-range electrostatics and the YASARA2 [29] force field (0.9% NaCl,
298 K, pH 7.4 [31]).
In order to qualitatively estimate the individual contribution of D4
S1–S2, D4 S3–S4 and D1 S5 to δ-EVIA binding, binding energies of δ-
EVIA to the channel model were calculated as the difference between
the potential energy (including solvation effects) of the complex and
the sum of the individual potential energies of the ligand-free receptor
and the free ligand.
In silicomutation analysis was performed after energyminimization
of the best scoring docking result. For eachmutation step, the side chain
orientation of the swapped residue was optimized [35] followed by an
energy minimization of the surrounding environment while the rest
of the protein was kept fixed. Binding energies of the mutated complex
were calculated using the VINA [39] scoring function aswell as calculat-
ing the difference between the potential energy (including solvation
effects) of the complex and the sum of the individual potential energies
of the ligand-free receptor and the free ligand.
Molecular graphics were created with YASARA [40] (www.yasara.
org) and POVRay (www.povray.org).
2.4. Generation of channel expression constructs
The wild-type channel constructs used in this study were the rat
skeletalmuscle channel NaV1.4 [41] (scn4a, P15390) and themouse pe-
ripheral nerve channel NaV1.7 (scn9a, Q62205); accession numbers
refer to the UniProt database. Chimeras between NaV1.4 and NaV1.7
were assembled by replacing nucleotides 1–1328 (7444), 1329–3120
(4744), 3121–3863 (4474), 3864–5520 (4447), 1–1328 and 3864–
5520 (7447) or 1329–3863 (4774) of scn4a with the homologous se-
quences of scn9a using a PCR-based strategy. The resulting channel chi-
meras contained either domain I (7444), domain II (4744), domain III
(4474), domain IV (4447), domains I and IV (7447), or domains II and
III of NaV1.7 in a NaV1.4 background. In addition, the following mutants
in the background of NaV1.4 with variations of the domain IV S3–S4
linker were generated: NaV1.4-L1424M:A1425F:S1427A:D1328E:
L1429M:Q1431E (here termed 4444-rs7), NaV1.4-L1424M:A1425F:
S1427A (here termed 4444-MFA), and NaV1.4-Q1431E (here termed
4444-QE). All mutant channel constructs were verified by DNA se-
quencing. Plasmid DNA was isolated from Escherichia coli using the
Pure-Yield plasmid purification kit (Promega GmbH, Mannheim,
Germany). Individual residues of the channel proteins are referenced
in 1-letter code.
2.5. Electrophysiological recordings
HEK 293 cells (CAMR, Porton Down, Salisbury, UK)weremaintained
in Dulbecco's Modified Eagle's Medium (DMEM, 45%) and Ham's F12
Medium (45%), supplemented with fetal calf serum (10%) in an incuba-
tor (5% CO2) at 37 °C. Cellswere co-transfectedwith a 3:1 ratio of awild-
type or chimeric channel expression plasmid and a vector encoding the
CD8 antigen using the Rotifect transfection kit (Roth, Karlsruhe,
Germany). Dynabeads (Deutsche Dynal, Hamburg,Germany) were
used for visual identification of individual transfected cells. Na+ current
was measured by applying the whole-cell configuration of the patch-
clampmethod to HEK 293 cells 24–48 h after transfection. The patch pi-
pettes contained (in mM): 35 NaCl, 105 CsF, 10 EGTA (ethylene glycol
bis(2-amino-ethylether)tetraacetic acid), 10 HEPES (pH 7.4 with
CsOH). The bath solution contained (in mM): 150 NaCl, 2 KCl, 1.5
CaCl2, 1 MgCl2, 10 HEPES (pH 7.4 with NaOH). As patch-clamp amplifier
an EPC-10 operated by PatchMaster software (HEKA Elektronik,
Lambrecht, Germany) was used. Series resistance was corrected elec-
tronically up to 80%. δ-EVIA aliquots were diluted in batch solution sup-
plemented with 2 mg/ml BSA and stored at−20 °C until use. δ-EVIA
was applied locally with a glass pipette as described earlier [42]. The ef-
fect of δ-EVIA onwild-type and chimeric channels was assayed with re-
petitive test pulses to−20 mV from a holding potential of−120 mV.
The repetition interval was 3 s and δ-EVIA concentration was always
150 μM. Removal of fast channel inactivation by δ-EVIA was evaluated
by analyzing the mean current level between 4.5 and 5 ms after start
of the depolarization (I5ms) relative to the peak current (Ipeak). The
ratio I5ms/Ipeak gives an estimate of the probability of the channels not
to be inactivated after 5 ms. Channel activation (I–V relationship) was
assayed by step depolarizations ranging from−80 to 60 mV in steps
of 10mV. Peak currents were fit according to a Hodgkin-Huxley formal-
ism according to [42, Eq. 1] yielding the half-maximal gate activation
voltage (Vm) and the corresponding slope factor (km). Steady-state inac-
tivation was measured for 500-ms time intervals at voltages between
−140 and−40 mV in steps of 10mV. The resulting remaining current,
measured at−20 mV, was described with a single Boltzmann function
yielding the half-maximal inactivation voltage (Vh) and the correspond-
ing slope factor (kh) [42, Eq. 2].
All experiments were performed at 20± 1 °C. All data are presented
as means ± SEM (n= number of independent experiments). P values
refer to two-sided Student's t-tests with unequal variances.
3. Results and discussion
3.1. Synthesis and NMR structure determination of δ-EVIA
The linear EVIA precursor was synthesized according to a standard
Fmoc-SPPS protocol [23] (Supporting Fig. S1A). Oxidative folding
(Supporting Fig. S1B) and the elucidation of disulfide bond connectivity
were assessed through MS/MS analysis and NMR spectroscopy. Al-
though the three-dimensional structure of δ-EVIA was reported earlier
[21], we here reproduced the structure (Fig. 1A–C) as a foundation for
the subsequent in silico binding studies. The overall fold of δ-EVIA
reflects the inhibitor cysteine knot (ICK, native fold) motif found in nu-
merous conopeptides of the O, P and I superfamilies and other toxic and
inhibitory peptides [21,43,44]. Compared to other δ-conotoxins, δ-EVIA
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shows an extended loop-2 region [21]. This loop is of low conformation-
al order.We also confirmed the coexistence of a cis- and trans-isomer of
δ-EVIA in a 1:1 ratio, whose structures were solved independently in
this study (Fig. 1B, C). The isomerism in δ-EVIA originates from a stable
or slowly exchanging cis and trans peptide bond conformation between
Leu12 and Pro13. The resonance assignments obtained are consistent
with the earlier reported analysis [17]. The resulting structures for the
δ-EVIA isomers have similar resolution as the previously reported struc-
tures (backbone r.m.s.d. δ-EVIA trans 1.62 Å and cis 1.91 Å compared to
the published structures 1G1P (trans) 1.59 Å and 1G1Z (cis) 2.31 Å). The
lowest energy structure for the δ-EVIA trans isomer deviates by 1.5 Å
from the lowest energy structure of PDB ID 1G1P (Supporting Fig. S4).
The lowest energy structure of cis-δ-EVIA deviates by 1.9 Å from that
of the cis-δ-EVIA isomer available as PDB ID 1G1Z. The observed devia-
tion for both isomers is mainly caused by the highly flexible loop 2 be-
tween residues Ser11 and Leu19. Overall, the herein reported
structures for the δ-EVIA isomers are consistent with the structures re-
ported earlier [17] andwere thus used for the computational studies de-
scribed below.
3.2. Functional properties of δ-EVIA
To infer about the biological activity of δ-EVIA, we assessed its effects
on the inactivation of recombinant muscular NaV1.4 and neuronal
NaV1.7 channels, expressed in HEK 293 cells. Consistent with a previous
reportwhere δ-EVIAwas shown to interact preferentiallywith neuronal
NaV channels [18], 150 μM of δ-EVIA substantially slowed down inacti-
vation of NaV1.7, while it was almost inactive on NaV1.4 (Fig. 1D, E).
This clear difference in sensitivity of NaV1.4 and NaV1.7 channels for
δ-EVIA provided the basis for a systematic localization of channel do-
mains that are important for δ-EVIA action. Thus, we constructed chi-
meric channels in which individual domains of NaV1.7 were inserted
into the background of the δ-EVIA insensitive channel NaV1.4. As dem-
onstrated in Fig. 2A, all domain chimeras gave rise to functional NaV
channels with fast inactivation characteristics as typical for NaV1.4 and
NaV1.7. Moreover, channel chimeras displayed only minor alterations
of their voltage dependence of activation (Supporting Fig. S12) and in-
activation (Supporting Fig. S13), suggesting that the rearrangement of
channel domains did not compromise normal channel function.
Functional assessment of such domain chimeras in voltage-clamp
experiments revealed that δ-EVIA slowed down inactivation of the chi-
mera that contains domain IV (4447) ofNaV1.7. This result is compatible
with previous findings that δ-conotoxins exert their action by interfer-
ing with the voltage sensor of domain IV, specifically the S3/S4 linker
[17], most likely because this voltage sensor is coupled to the intracellu-
lar inactivation gate [45–47]. Likewise, a chimera in which only the
domain IV S3–S4 linker of NaV1.7 was inserted in the background of
NaV1.4 (mutant 4444-rs7) exhibited a strong impact of δ-EVIA on chan-
nel inactivation, but neither chimera 4444-rs7 nor 4447 reached the δ-
EVIA sensitivity of wild type NaV1.7 (for statistics see Fig. 2B). However,
δ-EVIA also markedly slowed down inactivation of chimera 7444, while
the toxin had only a minor effect on channel inactivation when either
domain II (4744) or III (4474)were fromNaV1.7 (Fig. 2A, B). Interesting-
ly, δ-EVIA shares this domain-specificity with the structurally unrelated
scorpion α-toxins, which also interfere with fast NaV channel inactiva-
tion by interacting with domains I and IV [48,49]. Studies measuring
Fig. 1. Structure and activity of δ-EVIA. (A) δ-EVIA peptide sequence, including the location of disulfidebridges. (B, C) SolutionNMR structure of cis-δ-EVIA (B) and trans-δ-EVIA (C) given as
ensembles of 16 (cis) and 16 (trans) structures. Yellow indicates the position of cysteines. (D) Representative current traces obtained fromHEK 293 cells heterologously expressing either
NaV1.4 or NaV1.7 in response to a test voltage of−20mV before (black) and after (red) application of 150 μM δ-EVIA. The arrowmarks 5 ms after depolarization start, i.e. the time where
loss of fast channel inactivation by δ-EVIA was analyzed. Cartoons on top of the current traces illustrate the membrane topology of the wild types NaV1.4 (yellow) and NaV1.7 (blue).
(E) Mean of steady-state inactivation removal, expressed as I5ms/Ipeak, after application of 150 μM δ-EVIA;mean± SEM, n is given in parentheses; ***: P b 0.001. Electrophysiology studies
were performed with purified oxidized δ-EVIA containing a conformational equilibrium of cis and trans conformations of the proline imide bond.
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functional consequences of mixtures of scorpion α-toxins and δ-
conotoxins [17] suggest that their receptor sites overlap, thus anticipat-
ing similar interaction epitopes.
Although the δ-EVIA-mediated loss of inactivation observed for chi-
meras 7444 and 4447 did not reach the level of NaV1.7 wild type, our
data suggest that domains I and IV, but not domains II or III, possess
the major determinants for the specific action of δ-EVIA. This became
even more evident in constructs where domains I and IV were from
one, and domains II and III from the other channel type. As shown in
Fig. 2A and B, the full δ-EVIA effect, otherwise observed for NaV1.7 chan-
nels,was obtained for chimera 7447 (I5ms/Ipeak=0.48±0.07 for NaV1.7
vs. 0.6 ± 0.02 for 7447; P N 0.05), whereas the δ-EVIA sensitivity of chi-
mera 4774 rather resembled that of NaV1.4 (I5ms/Ipeak=0.06± 0.01 for
NaV1.4 vs. 0.15 ± 0.04 for 4774; P N 0.05). These results clearly demon-
strate that the interaction of δ-EVIA with NaV1.7 involves domains I and
IV of NaV1.7. They also show that the corresponding domains of NaV1.4
clearly diminish the effect of δ-EVIA; however, this is not an all-or-
nothing effect, thus anticipating that there might be only minor ener-
getic differences in the molecular interaction of the δ-conotoxin with
the corresponding receptor moieties of the channel proteins. These
data thus favor amodel inwhich the receptor site of δ-EVIA includes do-
mains I and IV, where the interactionwith the voltage sensor in domain
IVmediates the slowdown of channel inactivation,while the interaction
with domain I stabilizes the toxin–channel interaction.
According to the current traces shown in Fig. 2A, δ-EVIA not only af-
fects the time course of inactivation but also reduces the maximal in-
ward current in some cases. At a first glance this is unexpected
because removal of fast inactivation alone is expected to yield an in-
crease in peak current. We therefore measured the impact of δ-EVIA
on the voltage dependence of activation (Supporting Fig. S12) and inac-
tivation (Fig. 3A, Supporting Fig. S13) for all constructs. While only
minor effects on channel activation were noticed, δ-EVIA partially had
a strong left-shifting influence on the voltage dependence of inactiva-
tion. Since under standard conditions data were obtained from a hold-
ing potential of −120 mV, a left-shift of steady-state inactivation
towards holding voltage is expected to reduce the number of available
channels. As an operational data descriptor that includes the influence
of the toxin on both, half-maximal inactivation voltage (Vh) and the
voltage dependence of steady-state inactivation (kh), we present the
slope of steady-state inactivation between −140 and −120 mV in
Fig. 3B. The impact of δ-EVIA on this slope for the constructs investigat-
ed shows a similar pattern as that of inactivation loss at −20 mV
(Fig. 2B), indicating that the underlying molecular mechanisms are re-
lated or even identical.
Although we cannot provide unequivocal proof, the functional im-
pact of δ-EVIA on NaV channels via interaction with the domain IV volt-
age sensor shares considerable similarity with the interaction of
scorpion β-toxins [50] and μO-conotoxins [51] with domain II voltage
sensors. In both cases it seems that the toxin, once stabilized at the
channel surface (presumably via interaction with domains I or III, re-
spectively), can either retard the outwardmovement of the voltage sen-
sor or trap it in an activated position. For δ-EVIA, retardation of voltage-
sensor movement is expected to result in a slower time course of inac-
tivation,while voltage-sensor trappingwill promote closed-state inacti-
vation and, hence, is expected to diminish the number of available
channels and to reduce the peak current amplitude upon step depolar-
ization. One consequence of such a scenario is that toxin interaction
with the channels is strongly underestimated when the impact on the
time course of inactivation is considered only.
Fig. 2. Functional evaluation of NaV channel domain chimeras. (A) Representative current
traces obtained from HEK 293 cells heterologously expressing the indicated NaV chimeras
in response to a test voltage of −20 mV before (black) and after (red) application of
150 μM δ-EVIA. The cartoons on top of the current traces illustrate the domain structure
of the channel chimeras (yellow: NaV1.4, blue: NaV1.7). (B) Bar graph illustrating the
removal of fast inactivation of the indicated NaV1.4/1.7 chimeras by 150 μM δ-EVIA.
Dashed lines mark the ratios I5ms/Ipeak for wild-type channels NaV1.4 (yellow) and
NaV1.7 (blue). Data are mean ± SEM (n in parentheses); ***, P b 0.001, **, P b 0.01
tested against NaV1.4; #, P b 0.05, ##, P b 0.01, ###, P b 0.001 tested against NaV1.7.
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3.3. Structure-function relationship derived from theoretical binding
studies
3.3.1. Homology modeling
As mentioned earlier, the binding site of the scorpion α-toxin
strongly overlaps with that of δ-conotoxins [17]. Hence, we focused on
modeling the extracellular half of transmembrane segment S5 with
part of the subsequent S5-SS1 loop and the SS6-S6 loop of domain I,
as well as the voltage sensor of domain IV because these regions were
identified as the main binding sites for the much bigger scorpion α-
toxin LqhII [52]. The aim of the subsequent experiment was an in silico
evaluation of the interaction of δ-EVIA with this channel construct by
performing theoretical binding studies employing molecular docking
and molecular dynamics simulations.
Previous experiments with δ-SVIE suggest that the δ-conotoxins in-
teract with the DIV voltage sensor in its resting state, and strong depo-
larizations, i.e. activation of the voltage sensors, diminish the toxin effect
on channel inactivation [17]. Therefore, for in silico docking of δ-EVIA
with NaV channels, molecular models of the voltage sensors in the rest-
ing state are required. Although crystal structures of bacterial voltage-
gated Na+ channels (NaVRh PDB ID: 4DXW [53], NaVAB-Ile217Cys,
-wt PDB ID: 3RVY [14], 4EKW [54]) and voltage-gated K+ channels
(VGPCs) (KVAP PDB ID: 1ORQ [55]) are available in the RCSB database,
the structures of mammalian NaV channels, which are studied herein,
are not yet described. Furthermore, the channel structures reported
were crystallized in the open conformation and the conformation of
the voltage-sensor domain represents the activated conformation with
the S4 helix exposed to the external solution. Therefore, homology
models of rat NaV1.4 and mouse NaV1.7 and the respective chimeras
with the domain IV voltage sensor in the resting state had to be
established. Instead of homology modeling of the full NaV channels,
we independently built models for domain I and the resting state of
VS-DIV, which were subsequently aligned to the crystal structure of
NaVAB-Ile217Cys to bring both parts into the correct relative orientation
(Supporting Fig. S6).
In order to obtain a first NaV homology model (Fig. 4A), the respec-
tive domain parts of PDB ID 3rvy were replaced by the modeled parts
and then refined in a 10-ns all-atomMD simulation in a membrane en-
vironment (PEA, phosphatidylethanolamine). This refined NaV homolo-
gy model was then used to build the remaining channel models by
replacing the respective residues in order to maintain the backbone
conformation for all channel models.
Guided by the results of the electrophysiological experiments, we
constructed a set of four channel models representing NaV1.4, NaV1.7,
as well as the chimeras 7444 and 4447 (Fig. 2A). The previously reported
structure of KV1.2 VGPC in the closed conformation [32], which revealed
the voltage sensor in the resting state conformation, was used as a tem-
plate to homologymodel the resting state conformation of thedomain IV
voltage sensor of NaV1.4 and NaV1.7. Furthermore, the obtained homol-
ogy model was validated and aligned with the recently published cryo-
EM structure of the rabbit voltage-gated Ca2+ channel CaV1.1 (PDB
entry 3JBR) [56]. The relative orientation of VS-DIV S1–S4 and DI S5
and S6 is in good agreement in both structures (Supporting Fig. S15).
With the exception of the leading 9 residues in the DI S5-SS1 loop
(Supporting Fig. S5), this channel part had a very poor structural quality
andwas designated as highly uncertain by the homologymodeling soft-
ware and therefore was excluded from our channel models. The four
channel constructs were energy- minimized before they were used for
the docking experiments. Docking was locally restricted to the protein
area formerly highlighted as binding site for the scorpion α-toxin
LqhII [52]. The best-scored docking run was subjected to an additional
refinement step of 50 ns in amembrane environment (PEA); conforma-
tional stability during the entire simulation was verified (Supporting
Fig. S9). Only the lowest energy conformation of the cis isomer of δ-
EVIAwas used for docking because it was found that it exhibits a higher
bioactivity than the trans isomer [21].
Fig. 3. Impact of δ-EVIA on steady-state inactivation. (A) Mean inward Na+ current at
−20 mV measured after conditioning at various voltages for 500 ms before (black) and
after (red) application of 150 μM δ-EVIA for the indicated constructs. Data are
normalized to the values obtained at−120 mV (holding potential) of the control group.
(B) Bar graph illustrating the slope of the steady-state inactivation between−140 and
−120 mV of the indicated NaV1.4/1.7 chimeras after application of 150 μM δ-EVIA.
Dashed lines mark the ratios I5ms/Ipeak for wild-type channels NaV1.4 (yellow)
and NaV1.7 (blue). Data are mean ± SEM (n in parentheses); ***, P b 0.001, **, P b 0.01,
*, P b 0.05 tested against NaV1.4; #, P b 0.05, ##, P b 0.01, ###, P b 0.001 tested against
NaV1.7.
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3.3.2. In silico toxin binding studies
The docking results were scored according to the binding energy be-
tween the toxin and the channel construct (Supporting Table S2) and
revealed the highest toxin binding energy for the δ-EVIA–NaV1.7 com-
plex followed by the two δ-EVIA–NaV1.4 chimera complexes 4447 and
7444. The lowest toxin binding energy was observed for the δ-EVIA–
NaV1.4 complex. Although the absolute energy values are not straight-
forwardly interpreted and should only be seen as a qualitative measure,
the rank order of these interaction energies is in accord with the exper-
imental observations (Figs. 1–3), which anticipate that domains I and IV
of NaV1.7 make an additive contribution to the functional impact of δ-
EVIA in channel inactivation. Images of the corresponding docking re-
sults are displayed in Fig. 4 and Supporting Fig. S10.
In all channel models evaluated, δ-EVIA occupies the cleft formed by
the four transmembrane segments of the domain IV voltage-sensor do-
main. Together with the upper part of DI S5, they comprise the main δ-
EVIA binding site (also see Supporting Fig. S11A). A closer look at the δ-
EVIA–channel complexes indicates that the toxin adopts different orien-
tations upon binding to models of NaV1.7, NaV1.4 (Fig. 4B, C), 4447 and
7444 (Supporting Fig. S10). As shown in Fig. 4B for the δ-EVIA–NaV1.7
complex, the flexible loop of δ-EVIA comprising residues Ser11 to
Leu19 is located on top of the DIV S3–S4 loop, while the N-terminal
Asp1 is buried deeply in the cleft between S2 and S3 of the voltage-
sensor domain. In contrast, in the δ-EVIA–NaV1.4 complex (Fig. 4C)
this loop points upwards and is aligned almost in parallel to the DIV
S2 segment orienting the N terminus of δ-EVIA towards the upper end
of S1. A similar orientation of δ-EVIA was observed when the toxin
was bound to the 4447 channel model (Supporting Fig. S10A); the
toxin is rotated by approximately 60° directing the N-terminal Asp1 to-
wards S4. In the 7444 channel model, δ-EVIA adopts an almost identical
orientation as observed for the δ-EVIA–NaV1.7 complex (Supporting
Fig. S10B). However, theflexible loop of the toxin had slightlymoved to-
wards S3 compared to its orientation in the δ-EVIA–NaV1.7 complex.
Homology modeling of the channel constructs resulted in structures
with global conformations not differing significantly. Thus, we can ex-
clude differences in the starting conformations to be the reason for the
different toxin orientations obtained through docking simulations.
In order to estimate how different domain parts of the channel pro-
tein contribute to toxin binding, we calculated individual binding ener-
gies (average binding energies calculated from the last 5 ns of the 50-ns
refinement simulation, Supporting Fig. S9B) of δ-EVIA binding to DI S5,
DIV S1–S2 and DIV S3–S4. Again, the binding energies calculated by
VINA do not represent realistic values but will at least allow for a qual-
itative analysis of the docking results. As shown in Fig. 5A, all three
channel parts contribute to the toxin binding, but their individual con-
tribution differs among our four channel models. Interestingly, our
data further indicate that DI S5 in NaV1.4 is more weakly bound to δ-
EVIA compared to the other channel models.
We thus tried to identify potential key residues for toxin binding
through an in silico cumulative mutagenesis study (Fig. 5B, C;
Supporting Fig. S7A, B): residues that differ between the δ-EVIA-
insensitive NaV1.4 and δ-EVIA-sensitive NaV1.7 channel and that belong
to the δ-EVIA binding site were stepwisemutated towards the sensitive
channel and vice versa. The change in binding energy for δ-EVIA binding
was calculated for each mutation individually and is shown in Fig. 5B
and C (for change in binding energy including solvation effects (see
Supporting Fig. S7A, B). Four single residues originating from NaV1.7
in the background of NaV1.4 were identified, which stand out with
their positive impact on toxin binding over the other mutations
(Fig. 5C). These mutations were Q1372D in the DIV S1–S2 linker,
A1425F in the DIV S3–S4 linker and Q278H and V281F in the DI S5 seg-
ment. Most single mutations caused an increase in the δ-EVIA binding
energy with the exception of D1369G in the DIV S1–S2 linker region
and S1427A and D1428E in the DIV S3–S4 linker region, which caused
a decrease in the toxin binding energy. The in silicomutation study of
these residues (Fig. 5C) is consistent with the electrophysiological
experiments that identified the DIV S3–S4 linker as an important deter-
minant (see chimera 4444-rs7 in Figs. 2 and 3). Moreover, our NaV1.4-
EVIA structural model reveals that E1431 in the NaV1.4-Q1431Emutant
remains hydrogen bound to Tyr7 of the toxin, while this interaction is
not formed with the neutral Gln residue in the wild-type channel
(Fig. 4D). Similarly, the model supports the rationale that the increased
hydrophobicity in a NaV1.4-A1425F mutation leads to an increase in
toxin binding affinity by embedding the C-terminal Leu32 side chain
of the toxin (Fig. 4E, F). We thus also generated and assayed mutations
in the background of NaV1.4 channels that reconstitute only parts of the
DIV S3–S4 linker of NaV1.7. As documented in Supporting Fig. S14, mu-
tations 4444-Q1431E and 4444-MFA (the latter representing the
change A1425F) bothmake the channel more sensitive towards δ-EVIA.
Fig. 5B illustrates predictions for step-wise mutation of NaV1.7 to
NaV1.4, suggesting a somewhat different relevance of individual resi-
dues. The difference might be explained by the different toxin orienta-
tions observed at NaV1.4 versus NaV1.7, which in turn would cause
each single mutation step to have a different impact on the toxin bind-
ing affinity. A strong decrease in toxin affinity was found for mutations
located in DIV S2 (especially F1532D and W1536N), in the DIV S3–S4
linker (especially F1582A, A1584S and E1585D) and a single mutation
in DI S5 (H273Q). Interestingly, the residues W1536 in DI S2 as well as
F1582 and A1584 in DIV S3–S4 linker are conserved among the δ-
EVIA-sensitive NaV channel homologs (Supporting Fig. S11A) and pre-
sumably contribute to the subtype specificity of δ-EVIA.
In order to identify further key interaction sites, the best scoring
toxin–channel conformation from the docking runs was allowed to
equilibrate over a 50-nsmolecular dynamics simulation in a membrane
environment. The structures were fully equilibrated reaching a stable
conformation after about 30 ns according to the calculated r.m.s.d.
(with respect to the initial structure) over the entire simulation run
(Supporting Fig. S9A). Although toxin orientation differed upon binding
to the channel models, we realized that δ-EVIA binds to residues in DIV
S4 and DIV S3 in NaV1.7 and both toxin-sensitive chimeras (7444 and
4447) through salt bridge and/or hydrogen bond formation (Fig. 4B, C;
Supporting Fig. S10). In particular, at NaV1.7 the side chain of Asp2 of
δ-EVIA forms a salt bridge with the side chain of R1598 (Fig. 4B) in S4,
while the N-terminal amine group of δ-EVIA forms a hydrogen bond
to the protein backbone in S3 (M1581). Furthermore, Asp2 together
with Lys5 of the toxin spans a hydrogen bond network to Q265 in S5
of domain I. Two additional hydrogen bonds are formed between the
backbone of the toxin and the protein backbone of S5 (Fig. 4B).
In case of the 4447 chimera, the side chain of Lys5 of δ-EVIA forms a
salt bridge to the side chain of E1585 in the S3–S4 linker region and a
hydrogen bond to the protein backbone in S4 (T1595). Additionally, δ-
EVIA (Asp1) forms a single salt bridge to S5 (N275). Interestingly, in
the 7444 channel chimera, Asp1 and Asp2 form a salt bridge to R1441
(analogous to R1598 in NaV1.7; Supporting Fig. S10B, Supporting
Fig. S11B) and span a hydrogen bond network involving the side chains
of T1438 in S4, D1428 in the S3–S4 linker region and Y1379 in S2. How-
ever, no hydrogen bond or salt bridge to S5 was observed in this model.
In contrast, DIV S4 is not involved in toxin bindingwhen δ-EVIA binding
is modeled at the insensitive NaV1.4 channel. Moreover, toxin binding
involves mainly residues in S3 and S2 and only a single salt bridge
between δ-EVIA and S5 was observed (Asp2 — R277; Supporting
Fig. S10B). This particular toxin–channel interaction, especially to S4,
might explain the observed delayed inactivation of NaV1.7 channels
resulting from a hindered, thus slower outward movement of S4. The
datamoreover indicate that it seems to be sufficient to partly restore in-
teractions between the toxin and the S3–S4 linker region in order to re-
introduce a delayed channel inactivation by the toxin (Figs. 2 and 3,
Supporting Fig. S14).
A more detailed analysis of the trajectories generated by the 50-ns
refinement simulations of the best-scoring toxin–channel complexes
provides interesting insights into the δ-EVIA binding and supports the
idea of a toxin key interaction to S4 in order to efficiently slow down
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fast inactivation of voltage-gated Na+ channels. Therefore, we calculat-
ed average protein structures of the δ-EVIA–channel complex and used
average per-residue fluctuations relative to the starting structure
(expressed as root mean square fluctuations, r.m.s.f.) as a measure of
dynamic motion, which is often linked to intrinsic domain motion
[57–59]. As depicted in Supporting Fig. S8, the local per-residue
2060 D. Tietze et al. / Biochimica et Biophysica Acta 1860 (2016) 2053–2063
flexibility is reduced upon δ-EVIA binding relative to the reference
simulation with/without the toxin, especially in the linker region
connecting the transmembrane segments of the voltage-sensor domain
of NaV1.7 and the toxin-sensitive chimera 4447.
4. Conclusions
The solution NMR structure of the conopeptide δ-EVIA determined
herein is in good agreement with earlier reports [21] and was used for
the in silico binding studies. δ-EVIA slowed down the inactivation of
neuronal NaV1.7 channels, while the effect was marginal for the
NaV1.4 from the skeletal muscle. Domain chimeras between these two
NaV channel isoforms revealed that domains I and IV of NaV1.7 in-
creased the sensitivity of the resulting constructs to δ-EVIA in an addi-
tive manner, while exchange of domains II and III was without
noticeable functional consequences. Within domain IV, the linker be-
tween S3 and S4 is the most relevant structure for toxin action. Mecha-
nistically, the impact of δ-EVIA on the voltage sensor of domain IV can
be envisioned in two ways: interference with the voltage sensor in its
deactivated position slows down its activation and, hence, also the
time course of inactivation; interference in the activated position may
lead to voltage-sensor trapping with the consequence of facilitated
closed-state inactivation, which in effect will lead to a reduction of
peak current amplitude.
Based on the functional insights, homology channel models were
constructed, which contained the voltage sensor of domain IV in a rest-
ing conformation and the transmembrane segment S5 with part of do-
main I SS1. In a combination of in silico docking and molecular
dynamics simulations, the interaction of δ-EVIA with the respective
channel protein domains were assessed. The rank order to the estimat-
ed toxin binding energies were compatible with the experimental ob-
servation that domains I and IV of NaV1.7 support the functional
activity of δ-EVIA. In silico binding studies indicated that each trans-
membrane segment of the domain IV voltage sensor as well as S5 of do-
main I contribute to toxin binding. Although the orientation of the
conotoxin on the channel differed between different channel models,
the voltage-sensing S4 of domain IV remained its contact with the
toxin at the δ-EVIA-sensitive NaV channel constructs. The simulations
further indicate that the outermost voltage-sensing arginine residues
in DIV S4 take part in toxin binding. Recently, Chen and coworkers
also reported for the scorpionα-toxins AahII and LqhaIT that these argi-
nine residues directly interact with the toxin [60,61]. This observation is
compatible with the experimental finding that δ-conotoxins delay the
outwardmovement of S4, thus resulting in a slowing down of fast chan-
nel inactivation. However, detailed molecular dynamics simulations of
extendedmodels and various binding configurations are required to ob-
tain further insight into the sequence of individual molecular events
linked to voltage-sensor activation with and without δ-conotoxin
interference.
In summary, the conopeptide δ-EVIA from Conus ermineus exhibits a
preference for neuronal voltage-gated Na+ channels. In a domain-
swapping approach applied to neuronal NaV1.7 and muscular NaV1.4,
domains I and IV were identified as the major determinants for that
specificity. δ-EVIA therefore shares its binding epitope with other
voltage-sensor toxins, such as the conotoxin δ-SVIE and scorpion α-
toxins Lqh2, Lqh3, AahII, and LqhαIT [17,52,60,61]. In contrast to previ-
ous in silico toxin binding studies [60,61], we present here an in silico
binding study of a voltage-sensor toxin including the entire toxin
binding site comprising the resting domain IV voltage-sensor and S5
of domain I.
In particular because of its small size, the prototypical voltage-sensor
toxin δ-EVIA is suited for the elucidation of its binding epitope; in-depth
analysis of its interaction with the channel target yields valuable infor-
mation on themode of action andmight also help to unravel themech-
anism of voltage-dependent channel gating and coupling of activation
and inactivation. Future modeling attempts, however, will need to con-
sider the non-conserved extracellular S5–S6 linkers of domain I— an in-
tricate task because of their high structural flexibility.
Fig. 4.NaV channel homologymodels and δ-EVIA docking results. (A) Top view of the NaV1.7 channel model with docked δ-EVIA after 50 ns of refinement simulation. The voltage-sensor
domains of domains I through III were excluded from the refinement simulation. Channel domains are color-coded; the toxin is shown in green. (B, C) Energy-minimized final structural
models of cis-δ-EVIA docked to the binding sites of NaV1.7 (B, close-up of dashed circle of panel A) and NaV1.4 (C) after 50 ns refinement in a phospholipid environment in top (left) and
side view (right). Hydrogen bonds are indicated as yellow dashed lines. R1598, which is the outermost arginine residue in S4 of domain IV, is involved in δ-EVIA binding at NaV1.7, while
the corresponding R1441 in NaV1.4 is not. (D, E, F) Energy-minimized structures of the in silicomutagenesis study in the background of NaV1.4. (D) NaV1.4-Q1431E, (E) NaV1.4-A1425F,
(F) van der Waals surface representation of the hydrophobic region in the S3–S4 linker in NaV1.4-A1425F illustrating embedding of the C-terminal toxin residue Leu32 (surface colors:
gray, hydrophobic; red, acidic positively charged; cyan, polar uncharged).
Fig. 5. (A) Individual contributions of DI S5, DIV S1–S2, and DIV S3–S4 to δ-EVIA binding
calculated from the average binding energies through the last 5 ns of the refinement
simulation. Binding energies are given as normalized values with respect to the binding
energy of δ-EVIA to the DIV S3–S4 segment (set to one) for each channel construct. (B,
C) In silicomutagenesis study: mutation scan for δ-EVIA binding at NaV1.7 and NaV1.4.
For each mutation step, toxin binding energy was calculated individually and plotted as
an increase or decrease with respect to the binding energy calculated from the wild-
type channel.
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Epilogue 
In this manuscript the structure-activity relationships of -EVIA at different VGSCs were 
studied in order to understand the mode of action concerning channel specificity. Therefore, 
the NMR structure has been re-determined and the disulfide connectivity confirmed as the 
native one by using LC-ESI-MS/MS after partial reduction and derivatization. The NMR 
structure then has been used in molecular modelling studies to identify the binding site at 
VGSCs. Homology modelling, MD simulations and docking of the conotoxin was applied to 
the unaffected channel NaV1.4, to NaV1.7, where fast channel inactivation is observed, and to 
different chimeras of both channels. Considering as well the results from electrophysiological 
experiments using the same channels and channel chimeras the impact of each domain to 
the binding of -EVIA was identified, and domain I and IV determined to be essential for the 
specific interaction with the neuronal NaV1.7. 
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Preface 
The folding of disulfide-rich peptides seems to be highly sequence-dependent and thus, was 
investigated with various experimental and theoretical approaches.63,109 In this study the 
folding of a set of -conotoxins used as model peptides was in the focus of research. First, 
the folding was monitored experimentally in buffer solution employing redox-active agents. In 
general, folding behaviour of these conotoxins is examined starting from the reduced to 
oxidized peptide with the respective biological activity. Here, MD simulations using the 
existing NMR structures were conducted to observe the impact of a distinct disulfide bond on 
the stability of the native conformation compared to partially folded peptide by successive 
removal of distinct disulfide bonds. Furthermore, a visualistics approach rendering the 
structure into different layers was utilized for a more global view on the fluctuation of 
individual residues and their surface proximity throughout the simulation.  
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Computational study on µ-conotoxin conformations using 
molecular dynamics and computer visualization methods 
 Ajay Abisheck Paul George,[a] Pascal Heimer,[a] Raphael Menges,[b] Veda Thota,[a] Astrid Maaß,[c] Jan 
Hamaekers,[c] Martin Hofmann-Apitius,[d,e] Nils Lichtenberg,[b] Kai Lawonn,[b] Diana Imhof*[a] 
Abstract: The study of protein conformations using molecular 
dynamics (MD) simulations has been in place for decades. A major 
contribution to structural stability and native conformation of a 
protein is made by the primary sequence and disulfide bonds formed 
during the folding process. Here we studied the µ-conotoxins GIIIA, 
KIIIA, PIIIA, SIIIA, and SmIIIA as model peptides possessing three 
disulfide bonds. Their NMR structures were used for MD simulations 
in a novel approach. The simulation was conducted at a point 
between the folded native and the unfolded conformation by 
systematically breaking the disulfide bonds. The main objective was 
to monitor the cysteines regarding their behavior to support 
conformational stability and re-folding to the native conformation. An 
attempt was made to correlate the properties of the primary 
sequence with preferred folded conformations. In addition, a new 
visualization approach on a residue‘s location within a molecule was 
established that reveals novel insights into residue contribution to 
structural stability. 
1. Introduction 
Conotoxins are neuropeptides from the venom of marine cone 
snails, which interact with a wide range of biological targets (e.g. 
ion channels, transmembrane receptors, transporters) and 
hence are of pharmaceutical interest and of great potential as 
molecular probes to study specific subtypes of ion channels and 
receptors.[1] 
Conotoxins represent peptides of approximately 10-50 amino 
acid residues, classified according to their cysteine patterns and 
disulfide connectivity.[2,3] The typical CC-C-C-CC pattern defines 
the framework for conotoxins of the M-superfamily comprised by 
-, µ-, and M-conotoxins.[2,3] The family of the 27 currently 
known µ-conotoxins [4], selectively binds to the ion channel pore 
of voltage-gated sodium channels (VGSCs), thus blocking the 
influx of sodium ions into the cell. Therefore, these peptides also 
gained interest as useful tools for research studies in 
electrophysiology.[3,5]  The key determinant for their successful 
implementation, however, is an in-depth knowledge of the 
respective structure-activity relationships, which requires 
extraction of structural and biological data obtained from usually 
scarce quantities of material. The formation of multiple disulfide 
bonds in such peptides often hampers easy access by a 
synthetic approach. [3,5]  
µ-Conotoxins are known to primarily form the linkage C1-C4, 
C2-C5, and C3-C6, also referred to as the “native fold”.[6–8] The 
major question here is: Why do different primary amino acid 
sequences predominantly form a distinct fold out of fifteen 
possible disulfide isomers?[6] The molecular principles 
underlying this observation as well as the folding process remain 
elusive so far. In addition, prediction of the folding process is 
hampered due to a lack of adequate data. The subject however, 
is of a much greater importance than is generally recognized, 
since an accumulation of cysteines may also occur in distinct 
regions of larger peptides and proteins as can be exemplified by 
defensins,[9] resistin,[10] Kunitz serine protease inhibitors[11] and 
various growth factors.[10,12,13] In such cases information about 
the preferred disulfide connectivity based on the amino acid 
sequence might be important if neither X-ray data nor solution 
NMR structure analysis is available, which leads to the still 
unresolved problem of protein folding. 
In general, the protein folding problem is discussed to comprise 
three issues, i.e. (i) the thermodynamic code for a given primary 
sequence to fold, (ii) the possibility of predicting a protein’s 
native structure from its amino acid sequence, and (iii) the 
underlying kinetic process depending on the folding pathway. 
[14,15]
 Conotoxins represent a promising tool for the elucidation of 
folding processes because of their small to medium size and 
high disulfide bond content representing intermediates between 
peptides and proteins. Furthermore, they are natural peptides 
interacting with ion channels and receptors and as such 
interesting pharmacological tools.[2,3,5]  
Therefore, we studied the µ-conotoxins GIIIA, KIIIA, PIIIA, SIIIA 
and SmIIIA from a new perspective using molecular dynamics 
(MD) simulation and a novel visualization tool based on the 
NMR structures of these compounds. For comparison of 
experimental and theoretical data, we repeated the oxidation 
reaction for all µ-conotoxins as described earlier.[6] Reaction 
progress (self-folding) was monitored in a conventional buffer 
system containing redox agents. The individual sequences 
turned out to be distinguishable regarding reaction product yield 
and quality similar to what has been reported earlier.[7] With 
respect to the MD studies a rather unconventional novel 
approach was pursued by analyzing the reversed process, i.e. 
the unfolding of these peptides. More precisely, the behavior 
and stability of an individual peptide NMR structure was 
observed upon successive disulfide bond opening. Analyses 
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conducted on the resulting MD trajectories gave rise to 
inferences on characteristic factors contributing to 
conformational stability of the folded conopeptide, e.g. formation 
of helices. On the other hand, we introduced a novel 
visualization method based on a geometric approach. The 
premise of this approach is the extraction of information about a 
residue’s location with respect to the protein’s surface, thus 
rendering the analysis of the MD trajectories more visual and 
tangible. The results of this work firstly group the five µ-
conotoxins based on the stability of their disulfide-deficient 
versions and also contributes general guidelines before 
venturing into synthesis. 
2. Results and Discussion 
2.1. Oxidative self-folding of µ-conotoxins  
In order to provide experimental data for comparison, equal 
amounts of each µ-conotoxin studied herein (Table S1) were 
used for the oxidation reaction according to a protocol earlier 
described.[6] Under the conditions applied µ-SmIIIA and µ-PIIIA 
oxidation resulted in several peaks of fully oxidized product(s), 
i.e. identity of the individual fractions is different from the native 
fold (C1-C4, C2-C5, C3-C6).[6] In contrast, oxidation of all other 
peptides, e.g. µ-GIIIA, µ-KIIIA and µ-SIIIA, resulted in one major 
product as demonstrated earlier (Figure S1).[7,16,17] 
The formation of one main product for µ-GIIIA and µ-SIIIA can 
be explained by a rapid collapse into the favored “native” 
connectivity.[7] For µ-KIIIA such a rapid collapse results also in 
one main product, however, the connectivity C1-C5, C2-C4, C3-
C6 is preferred here, and the “native” fold is only present as a 
minor fraction.[18] Small differences in the elution profiles of 
buffer-oxidized µ-KIIIA (crude product), i.e. product formation, 
might result from differences in batch size and composition of 
the oxidation buffer compared to Khoo et al..[18] For instance, a 
2:1 ratio of reduced and oxidized glutathione compared to a 1:1 
ratio described by Khoo and coworkers[18] was used in our study.  
In case of µ-PIIIA and µ-SmIIIA, a different folding mechanism 
indicative of a slower re-arrangement results in the formation of 
several isomers.[7,19] This can be attributed to more diverse 
noncovalent interactions and electrostatic forces compared to µ-
GIIIA and µ-SIIIA. Here, it was suggested that the native isomer 
accumulates via re-shuffling of disulfide bonds during the folding 
process and is dependent on the thermodynamic stability of the 
isomer formed.[7,19] Although µ-SIIIA and µ-SmIIIA have a high 
sequence similarity (Table S1), the higher number of basic 
residues in µ-SmIIIA (six Arg) results in the formation of multiple 
isomers, while in µ-SIIIA (two Arg and one Lys) only one isomer 
is preferred.[7] µ-PIIIA forms multiple isomers for the same 
reason.[6] In contrast, the structure of µ-GIIIA tolerates a high 
number of basic residues and forms only one major product 
compared to µ-PIIIA and µ-SmIIIA.[7] Several aspects influencing 
the folding, such as the number of hydroxyproline residues, loop 
size between two linked cysteines or amidation of the C-
terminus are discussed controversially in the literature without a 
clear preference indicating the uniqueness of each sequence 
and respective biological activity.[7,8,20,21] 
 
2.2. Conformational analysis using molecular dynamics  
The solution NMR structures used herein were derived from the 
ConoServer database (Figure 1, Table S1).[4] Comparison, 
alignment and structural differences of the µ-conotoxin 
structures were discussed previously by Yao et al. and Tietze et 
al.. [6,22] All µ-conotoxins, except µ-KIIIA, align significantly better 
in the C-terminal part compared to the N-terminal revealing a 
conserved structure.[22] High similarity was shown for the 
backbone conformations between loop 2 and loop 3 regions of 
µ-KIIIA, µ-SIIIA, and µ-SmIIIA which have a higher selectivity for 
blocking NaV1.2 over NaV1.4 channels. On the other hand, µ-
GIIIA and µ-PIIIA which prefer NaV1.4 over NaV1.2 superimpose 
well in the region of the second loop between C2 and C5.[6] 
Besides contributing to the structural rigidity, the disulfide 
bridges cause cysteine residues to form a hydrophobic core, 
enveloped by other charged and hydrophilic residues (Figure 1). 
This hydrophobic effect plays a key role in the stability of the 
native fold.[21]  
Figure 1. Structure and surface representations of the investigated µ-
conotoxins. (A) The NMR structures of the five μ-conotoxins (GIIIA, KIIIA, PIIIA, 
SIIIA and SmIIIA) used in this study represented as cartoon. Secondary 
structure elements, α-helix (purple), 3-10 helix (blue), turn (cyan) and coil 
(white) were generated by STRIDE in VMD.[23]  The cysteine residues forming 
the disulfide bonds (yellow) are labeled. (B) Molecular surface was generated 
by SURF in VMD[23]  indicating the hydrophobic (white), basic (blue), acidic 
(red) and hydrophilic (green) regions. 
Regarding the simulation strategy it was decided to open the 
longest disulfide bridge first (biggest loop) as it would instantly 
introduce the highest level of flexibility into the peptide backbone. 
The intention for this opening strategy was to increase 
conformational entropy of the reduced version. In the case of µ-
KIIIA, the shortest disulfide bridge was opened first. This would 
serve as a means to gauge the effect of loop size in retaining a 
stable structure. The loops in between the three disulfide bonds 
differ in size (Table S2) and thus, need to be considered in the 
analysis process. 
It was observed during the simulations at room temperature that 
all natively folded structures showed good conformational 
stability based on the evaluation of root mean square deviation 
(RMSD) compared to NMR ensemble of each peptide with µ-
KIIIA possessing the lowest RMSD of 1.1 Å and µ-SmIIIA with 
the highest of 2.7 Å (Figure S2, Table S3). A test simulation of µ-
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PIIIA was done for 1 µs, and we considered that using 100 ns of 
the trajectory was a good representation of the simulation 
(Figure S3). RMSD of the backbone, root mean square of 
fluctuation (RMSF) of all atoms of each residue and the radius of 
gyration (Rg) of the whole protein were computed from each 
simulation for all of the five peptides (Figure S2, S4). 
The native structure of µ-GIIIA was observed to be held together 
by a combination of forces. Apart from the evident hydrophobic 
core formed by the cysteines, the presence of aspartic acid in its 
sequence gave rise to salt bridge formation observed between 
R1 and D12. As the C2-C5 disulfide bond was removed an 
increase in distance between the now unbound cysteines was 
observed. However, this did not affect the stability of the 
backbone proved by only a 0.3 Å increase in backbone RMSD 
between the native structure and the one with the C2-C5 
disulfide removed, but it could be observed that its RMSD 
progression is inconsistent in the simulation especially between 
30 ns and 50 ns. The peptide had excessive flexibility and 
adopted close to completely unfolded conformations during 
different intervals in the simulation (Figure S5). Importantly, the 
residues significant for bioactivity experienced none to very 
minimal increase in fluctuations (Table S4). Upon subsequent 
removal of the C3-C6 disulfide bridge, an obvious stretch in the 
overall shape of the peptide was observed. Interestingly, the 
cysteines forming the C3-C6 bridge moved much closer to each 
other than the C2-C5 cysteine residues in the two disulfide 
bridges opened structure. This is shown by the decrease in 
RMSD of the C2-C5 and C3-C6 removed peptide between 60-70 
ns (Figure S5). Rg of µ-GIIIA followed an almost identical pattern 
of progression to the RMSD, peaking between 40 and 55 ns 
before falling back towards its initial values, representing an 
unfolding-(re)folding event. The fluctuation of the residues K8, 
K11, R13, K16 and R19, which were reported to be responsible 
for binding,[3] did not show significant change in fluctuation 
compared to the structure with all disulfide bridges intact (Figure 
S2). With two disulfide bridges removed, R19 and K16 showed 
significant increase in fluctuations. It has been shown that K16 
has a low priority for biological activity. Moreover, the exchange 
of this residue increased binding affinity compared to the native 
toxin.[24] However, usually alanine residues confer higher 
hydrophobicity into the peptide backbone. Replacement of 
cysteine by serine would probably be a better choice regarding 
retaining the bioactivity. It is safe to state that if the C2-C5 
disulfide bond alone was removed the structure adopted a 
conformation still representing reasonable stability. 
µ-KIIIA has the lowest RMSD of 1.1 Å among the five peptides in 
their natively folded form. Removal of the C2-C4 disulfide bond 
thereby altering the C4 residue results in the loss of its helix and 
increases the RMSD by 0.7 Å. The remaining C1-C5 and C3-C6 
disulfide bonds, however, were sufficient to retain backbone 
stability of µ-KIIIA. The progression of RMSD and Rg for µ-KIIIA 
followed the same scheme as observed for µ-GIIIA, i.e. with the 
structure possessing two reduced disulfides revealing the largest 
variation in conformational flexibility. 
Although the average RMSD of native µ-PIIIA was a decent 2.3 
Å over the course of the simulation, the backbone was 
constantly subjected to changes as can be seen from the RMSD 
plot (Figure S2). The removal of the C2-C5 disulfide bond 
resulted in a lower fluctuating RMSD progression although it 
came at the expense of 1.5 Å increase in RMSD. The structure 
of µ-PIIIA with both the C2-C5 and C3-C6 disulfide bridges 
removed showed the largest extent of structural variation among 
the five conopeptides with an average RMSD of 4.9 Å (Figure 
S6). The peptide did not tend to refold within 100 ns simulation 
time. With one disulfide removed, none of its functionally 
significant residues showed pronounced increase in fluctuations, 
the highest of which was a 1.3 Å increase for R14 compared to 
the natively folded peptide. In contrast, almost all residues of µ-
SIIIA displayed marginally higher RMSF values for the one and 
two bond-removed structures in comparison to the native 
structure containing all three disulfide bonds.  
We focused on µ-GIIIA that forms a single, and µ-SmIIIA that 
forms multiple oxidation products during synthesis to illustrate 
this phenomenon described above (Figure S5). The overall 
RMSD between the native connectivity and the structure with 
one disulfide bond removed was observed to be the lowest in µ-
GIIIA (1.8 Å) and highest in µ-SmIIIA (2.7 Å) among the five 
peptides. Figure S4 shows average conformations for all three 
simulations of µ-GIIIA and µ-SmIIIA compared with their 
corresponding RMSD plots. An interesting observation from both 
peptides with opened disulfide bond was the formation of new 
secondary structure elements that were not present in the native 
state. In µ-SmIIIA with one opened disulfide bond, an α-helix 
was formed between residues R13 and H18 (Figure 2).  
Figure 2. Comparison of μ-SmIIIA native fold and the structure with one 
disulfide bond opened. (A) The structure of the native peptide (completely 
oxidized, three disulfide bonds) with 100 conformations of its basic residues 
(red) superimposed with three residues marked as important for binding 
activity.[3] The distribution of hydrogen bonds shows a sparse black area which 
indicates that the region surrounding it is relatively flexible. (B) The structure of 
the peptide containing one opened disulfide bond (C2-C5) showing (blue) its 
well-formed α-helix and the dense well-ordered hydrogen bonding illustrated 
as black cylinders. Higher rigidity, inducing improved structural stability of the 
peptide B with the C2-C5 disulfide bond removed in comparison to the fully 
oxidized peptide with all three disulfide bonds is apparent from the reference 
RMSF plot (C). Despite the rigidity of the backbone the orientations of the 
basic residues differs from the native structure. 
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The stability of this helix through the entire course of the 
simulation can be accounted for by a combination of hydrogen 
bond formation and the presence of the bonded C15 in the 
center of the helix. In comparison with the native fold, the 
structure with the C2-C5 bond opened appeared well ordered. 
The distribution of the hydrogen bonds around the helix can be 
seen in Figure 2. 
The µ-SmIIIA structure with two disulfide bonds reduced formed 
a less stable 3_10 helix between residues R16 and H18 
increasing the flexibility of the conformation. However, 
functionality of a conotoxin is dependent on a stable backbone 
structure coupled with the favorable orientation of basic side 
chain residues for binding to their target and not solely on the 
flexibility of a distinct part of the peptide.[3] In µ-SmIIIA, though 
the 3_10 helix formation reduced Rg of the peptide, the overall 
peptide structure drifted significantly from that of the native state, 
and the orientations adopted by the side chains of its basic 
residues varied largely when compared to either the native or 
the structure with one disulfide bond opened. Even with a single 
disulfide removed the functionally significant R7 showed a 
moderate increase in fluctuations (Table S4). 
Herewith it is demonstrated how the individual disulfide bridges 
and the residues that occur within the loops affect the 
conformational stability on the basis of observed fluctuations in 
the backbone and the side chain residues. In the following 
section a shift in perspective in the extraction of useful 
information from MD trajectories is introduced. Here we focus on 
global atomic movements within the molecule and how these 
contribute to observable surface level changes compared to 
local molecular fluctuations.  
 
2.3. Computation of residue surface proximity  
This study was performed with the aim to find a measure for 
each amino acid that gives us an impression of how close that 
particular residue is to the molecule’s surface. This measure 
was called “Residue Surface Proximity”. First, we computed an 
atom-layer extraction based on the solvent-accessible surface 
(SAS)[25] to assign each atom to a specific surface layer (Figure 
3, S7). The idea of layers was inspired by the work of Karampudi 
et al..[26] This method is able to assign atoms and their affiliated 
residues to a variation of layers. The different layers consist of 
the outermost surface layer, the intermediate layers, and a core 
layer. In general, an amino acid is assigned to the innermost 
layer that its atoms extend into. If an amino acid is found at the 
boundary of two layers, it is assigned to the inner layer, towards 
the core. Similar considerations were utilized in our approach 
(Figure 3). We adapted this approach according to the 
objectives, i.e. to make it feasible for the application to small 
proteins or peptides, such as µ-conotoxins. Our goal was to use 
the layer-membership of a residue as a hint for its surface 
proximity. The change of the layer-membership was used as a 
measure of stability, with respect to the surface proximity, 
throughout an MD simulation. In addition, a GPU implementation 
of an algorithm described by Zhang et al.[27] was used to extract 
the surface atoms. This algorithm identified all atoms that are 
part of the SAS of a given input molecule. Thus, we found the 
outer layer of the input data based on a selected probe radius 
(see also Methods) with respect to the SAS definition. All 
remaining atoms were classified as internal. The algorithm was 
then repeated using the atoms previously classified as internal 
layer as input, which yielded the next layer of atoms. The 
algorithm stopped once all atoms were part of a particular layer, 
e.g. after N iterations (Figure 3). 
Figure 3. Assembly of atoms in 2D space with their Van der Waals radius 
(gray) and a SAS probe (red, A). (B) Extending the atom radii by the probe 
radius yields the extended hull and the SAS (marked red). The outer atoms 
form the first SAS layer. (C) The outer atoms of the first layer are removed and 
the next layer of SAS is formed. (D) This process was repeated until the last 
layer was reached. (E) Each atom was assigned a value denoted as LA that 
was based on the iteration in which the atom has been assigned to the SAS. 
(F) Finally, an assignment of layers to each atom was obtained based on the 
definition of the SAS. 
The trajectories of the 100 ns MD were used as input to our 
layer extraction software. For the SAS definition a probe radius 
of 2.8 Å was used. This radius was chosen twice as high as the 
commonly used value of 1.4 Ǻ,[27,28] which approximates the size 
of a solvent water molecule. This decision is justified by layers to 
represent the surface proximity of each atom rather than the 
standard SAS. By increasing the probe radius this algorithm 
produces more layers, which gives a more fine-grained 
classification. Also, the spatial difference between two adjacent 
layers is lower as the total number of layers increases. For 1.4 Å, 
µ-GIIIA (Figure 4A) and µ-SmIIIA (Figure 5A) mostly contained 
three layers. In case of 2.8 Å, the number of layers increased to 
4 to 5. Furthermore, even higher probe radii were investigated 
up to values of 6 Ǻ, but the layer count did not increase much in 
these cases. Based on that finding, 2.8 Å was considered for the 
envisaged computation with an optimum ratio between layer 
count and SAS representation. The computations of the surface 
proximity for each amino acid were carried out by our software. 
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As demonstrated for µ-GIIIA, where the first disulfide bond (C3-
C15) is forming the innermost layer over the whole simulation 
time (Figure 4), only few layer changes indicate a rigid structure 
and low flexibility of residues. However, for µ-KIIIA the residues 
are stable within the respective layer (Figure S8). This is due to 
the short sequence resulting in a more compressed and rigid 
structure compared to the other peptides. The visualization of 
the different SAS layers for µ-PIIIA (Figure S8) shows C4 
moving to the surface after ~10 ns of simulation time and follows 
a series of shifts from the surface to the core during the 
simulation. Furthermore, it can be observed that the linked C16 
has an almost similar layer-membership pattern to that of C4.  
Figure 4. Visualization of the SAS layers at different time steps. (A) represents 
the layer heatmap for µ-GIIIA . Each column shows the atoms of one of the 
layers. (B) is the residue C10 captured at 10 ns. (C) is residue C10 captured at 
90 ns. (D) is residue C21 captured at 10 ns. (E) is residue C21 captured at 90 
ns. This figure proposes that C10 emerges from the center of the molecule 
towards the surface after ~10 ns. It can be observed that both residues (C10 
and C21) move to the core at the end of the simulation, which can also been 
seen directly from the heatmap plot. 
Although for µ-SIIIA layer changes can also be observed for the 
second (C4-C19) and third (C8-C20) disulfide bond, in contrast 
to µ-PIIIA the average is lower resulting in a more rigid structure 
again. Finally, µ-SmIIIA represents a more flexible structure 
because the first disulfide bridge (C3-C15) changes surface 
availability throughout the simulation (Figure 5). Here the 
innermost layer is formed by this cysteine bridge, because the 
two remaining ones (C4-C21, C10-C22) are connected to the 
cysteines at the end positions of the peptide and are therefore 
generally surface available. The cysteine residues from the 
disulfide bridge C10-C22 are able to change their layer 
independently. While C22 stays in an outer layer, the connected 
C10 is only in an outer layer for a short period of time from 40-48 
ns before going back to an inner layer (Figure 5).  
Figure 5. Layer heatmap shows LR of μ-SmIIIA over 100 ns simulation. (A) LR 
values for each amino acid are stacked along the y-axis and mapped to the 
color scale. Dark blue refers to the surface of the molecule, since the 
outermost layer is assigned the value zero. Higher layer values, mapped to 
yellow, depict the amino acids that mostly form the core of μ-SmIIIA. The plot 
reveals the distribution of residues among the layers. Some of the residues 
clearly change their layer membership throughout the simulation. (B) Snapshot 
of residue C15 (orange) taken at 20 ns indicating that this residue occupies 
the core region in the first 40 ns of the simulation. (C) After approximately 50 
ns C15 exhibits a tendency to stay at the surface. (D) The C10 residue stays 
in the core for the first 40 ns of the simulation. (E) Between approximately 40 
ns and 48 ns C10 shifts to the surface before going back into the core again 
after 50 ns. 
Interestingly, also non-cysteine residues such as serine (S19 for 
µ-SmIIIA, S10 for µ-PIIIA and µ-SIIIA) are able to occupy the 
core of the peptide. On the other hand, large basic residues (R) 
remain on the surface throughout the simulation and are thus 
always available for interaction with the ion channel. The 
obtained data represents a novel means of relating the surface 
availability of residues and stability of conotoxins.  
 
3. Conclusions 
While protein folding is considered frequently, the folding of 
smaller disulfide-rich peptides and oligopeptides is less well 
understood due to a much higher degree of flexibility and often a 
lower extent of structure-forming elements.[30] MD simulations 
have proved to assist experimental work in understanding and 
predicting the folding process.[31] Previous studies using the five 
µ-conotoxins investigated herein gave insights into the folding 
and binding modes adopted by these peptides.[6,18] Our work, 
however, aimed at determining how a particular disulfide bond 
contributes to the stability of the peptide. Consequently, this 
approach reviews the validity of the logic that the removal of a 
disulfide bridge, i.e. herein C2-C5, represents a reduction of the 
backbone stability when considering RMSD and RMSF values.  
With the C2-C5 disulfide bond removed, only µ-SmIIIA revealed 
a noticeable increase in the average fluctuations of its 
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functionally significant residues. In addition, the fact that 
secondary structural elements such as α-helices were formed in 
some peptides containing only two disulfide bonds suggests that 
in distinct cases (e.g. µ-GIIIA, µ-SmIIIA) greater structural 
stability of the backbone may be achieved if one disulfide bridge 
is removed. This helix-induced stability might strengthen the 
backbone and reduce the extent of overall fluctuations of the 
basic residues responsible for binding activity.[3] It can also occur 
that the nature of a given force field might influence 
conformation, e.g. induction of helix formation.[32] Therefore, the 
cause of retained or gained backbone stability must be always 
considered. The biological activity and selectivity of disulfide-
deficient mutants might differ from the native conformation as 
shown for µ-GIIIA recently.[33] 15 different disulfide isomers are 
possible for a peptide containing six cysteines and still three 
different isomers (ribbon, bead, and globular) might occur in 
case of four cysteines.[34] It has, however, not been mentioned in 
the report by Han et al., which isomer of the µ-GIIIA analogs has 
been tested because structural characterization of the respective 
products was not performed.[33] Apart from reports on µ-GIIIA 
regarding disulfide-deficient variants, another study by Khoo et 
al. provides insight into the removal of disulfide bridge C1-C9 in 
µ-KIIIA resulting in only a minimal change in biological activity 
against NaV1.2 and NaV1.4.[35] In contrast, there are no 
experimental data for disulfide-deficient species of µ-conotoxins 
PIIIA, SIIIA and SmIIIA available so far.  
With respect to drug design and synthesis the simplification to 
two disulfide bonds would be a clear benefit for disulfide-rich 
peptides and proteins. In this respect, we can conclude from our 
MD simulations that two disulfide bridges could be sufficient to 
maintain a stable backbone for the majority of the µ-conotoxins 
studied. However, it is important that the deficient structure is 
sufficiently supported by at least one pair of cross-linked 
disulfide bridges that span to almost either ends of the sequence. 
From the results obtained a rank order of the five peptides can 
be provided: µ-GIIIA and µ-KIIIA fall in the highly favorable 
category, µ-SIIIA falls in the moderately favorable, and µ-PIIIA 
and µ-SmIIIA fall into the least favorable group. We also 
conclude that the C3-C6 disulfide bridge plays the greatest role 
in retaining backbone stability.  
As expected, removal of two disulfide bridges led to increased 
backbone flexibility, the formation of a series of intermediate 
conformations and a less stable peptide. Increased fluctuations 
of basic side chain residues responsible for interactions with the 
sodium ion channels are in this case unlikely to stay in favorable 
orientations for binding. Furthermore, the formation of different 
disulfide isomers for µ-KIIIA, µ-PIIIA and µ-SmIIIA in the 
experimental self-folding approach indicates a difference in their 
folding behavior which cannot be explained unambiguously by 
simulations and disulfide removal.  
The second approach, the residue surface proximity, adds a 
new perspective on residue movements throughout an MD 
simulation and their influence on structural stability within a 
peptide. Our findings revealed the importance of considering the 
effects of global movements within the peptide that might not be 
apparent as fast thermal vibrations. It is decoupled of absolute 
spatial movements of the peptide because it only relies on the 
layered extraction of the SAS. A residue that changes its layer 
will very likely affect the layer-membership of other residues and 
reflects how different amino acids compete with each other. This 
represents an alternative method in addition to the interpretation 
of common magnitudes like RMSD, RMSF or Rg, which rely on 
euclidean space and consider groups of atoms individually. The 
work by Das et al. revealed more information about the 
counterplay of different residues,[36] since direction and 
amplitude of residue movements was derived from a principal 
component analysis (PCA). In our approach we also received 
directional and amplitude information. We deduce that the 
residue surface proximity is an intuitive perspective on MD 
simulations extracting complex trajectory data more easily. An 
attempt was made to draw a correlation between the results 
from the MD simulations and the visualization approach. The 
correlation between the layer delta ΔLR and RMSF values 
revealed interesting features comparing the individual residue 
flexibility and the invariability of their layer-membership. This can 
be exemplified with the fact that the majority of amino acids 
displaying higher flexibility are constantly found on the surface 
without significantly changing their position, e.g. residues K11, 
R13 and R19 in µ-GIIIA, K7, W8, R10, R14, in µ-KIIIA, K9, R14, 
O18, R20 in µ-PIIIA, K11, W12, R18 in µ-SIIIA, and R7, S11, 
R13, W14, R16, D17, H18, and R20 in µ-SmIIIA, ignoring the 
terminal amino acids. It is not surprising that these residues 
correlate with the ones important for biological activity. 
Interestingly, mainly cysteines and serine change their layer-
membership more frequently in the peptides. A reason for this 
might be that the aforementioned basic residues were held in 
distinct geometric positional range and the cysteine pattern 
holds the structure together and move to maintain the bioactive 
conformation. This approach might certainly serve as a tool to 
study molecular motion and surface properties from a 
perspective that is not achieved by the usual methods of MD 
trajectory analysis. The specific focus to global atomic 
movements within the molecule is a strong visual cue in 
determining components that contribute to overall stability. 
Experimental Section 
Chemical synthesis and purification of µ-conotoxins. Peptides were 
produced by automated solid phase peptide synthesis using a standard 
Fmoc (N-(9-fluorenyl) methoxycarbonyl)-protocol and an EPS 221 
peptide synthesizer (Intavis Bioanalytical Instruments AG, Cologne, 
Germany) as described earlier,[6] and purified by preparative reversed 
phase HPLC (Shimadzu LC-8A system, Duisburg, Germany). The 
gradient used was 0 - 50% eluent B in 120 min with 0.1% TFA in water 
(eluent A) and 0.1% TFA in acetonitrile/water (9:1) (eluent B) on a C18 
column (Knauer Eurosphere 100, Berlin, Germany) with the dimensions 
50 mm x 300 mm (5 mm particle size, 100 Å pore size). Reduced and 
oxidized peptides were analyzed on a LC-ESI micrOTOF-Q III mass 
spectrometer (Bruker Daltonics GmbH, Bremen, Germany) coupled with 
a Dionex Ultimate 3000 (Thermo Scientific, Dreieich, Germany) equipped 
with a EC100/2 Nucleoshell RP18 Gravity 2.7 µm column (Macherey-
Nagel, Düren, Germany). Analysis of the MS data was performed using 
Bruker Compass Data Analysis 4.1. LC conditions used were as follows: 
Eluent A was water with 0.1% acetic acid, while eluent B was acetonitrile 
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containing 0.1% acetic acid. A gradient of 0% – 60% of eluent B in 12 
min was used and detection was at 220 nm. 
Oxidation of reduced µ-conotoxin precursors. Oxidative folding of the 
linear µ-conotoxins GIIIA, KIIIA, PIIIA, SIIIA and SmIIIA in a buffer 
system containing redox agents was performed as described earlier.[6] 1 
mg of each µ-conotoxin was subjected to oxidation and fractions of the 
reaction mixture were monitored over time by RP HPLC using a 
Shimadzu LC-10AT system (Duisburg, Germany) equipped with a C18 
column (Vydac 218TP54, Worms, Germany, 4.6 mm x 25 mm, 5 mm 
particle size, 300 Å pore size) and the gradient 0 - 60% eluent B in 60 
min with 0.1% TFA in water (eluent A) and 0.1% TFA in acetonitrile 
(eluent B). Reaction control was performed over a time period of 24 h, 
oxidation was stopped by adding 1% TFA in water. Monitoring revealed 
that the oxidation reactions were completed within the first 60 min of 
reaction time. Fractions were collected for each peptide and subjected to 
LC-ESI mass spectrometry for confirmation of the molar mass 
corresponding to the oxidized products. 
Molecular dynamics (MD) simulations. Disulfide bonds were 
systematically removed to yield a partially folded, conformation as the 
starting structure for the simulation. Four out of five µ-conotoxins in this 
study possess the native disulfide connectivity (C1-C4, C2-C5, C3-C6), 
whereas µ-KIIIA adopts a C1-C5, C2-C4, C3-C6 as the stable 
conformation.[18] The following structures were used herein: PDB ID 
1TCG (µ-GIIIA),[16] PDB ID 2LXG (µ-KIIIA),[18] S00159 (µ-PIIIA),[6] BMRB 
20025 (µ-SIIIA),[22] and PDB ID 1Q2J (µ-SmIIIA).[37] Each peptide was 
subjected to three main production runs and on each run, pre-processing 
and equilibration was performed independently. First, the conformation 
with all three disulfide bonds was considered as the control simulation. In 
the second simulation, the link between C2-C5 (C2-C4 for µ-KIIIA) was 
removed leaving the two other cysteine bonds intact. In the third 
simulation, both the C2-C5 (C2-C4 for µ-KIIIA) as well as the C3-C6 
disulfide bonds were removed. All peptides underwent energy 
minimization and equilibration prior to being used as the starting structure 
of the simulation, as explained in detail below.  
GROMACS 5.0.5[38] was used for all the MD simulations in this study. An 
individual peptide was placed in the center of a cubic box of size 1 x 1 x 1 
nm. TIP3P[39] water model was used as the solvent to fill the box. 
Appropriate amounts of Cl- ions were added to balance the positive 
charge of the µ-conotoxins. Simulations were run using the 
AMBER99SB-ILDN[40] force field, which was chosen based on its better 
agreement with the NMR data and an accurate modeling of helical 
proteins in comparative studies.[43,44] In the process of preparing the 
peptide for the production MD simulation, energy minimization 
simulations were carried out in three steps. The first step steepest 
descents minimization with the whole protein held immobile in the solvent, 
followed by steepest descents with only the backbone frozen. The final 
step was 5000 steps of steepest descents with all restraints on the 
peptide removed. This 3-step minimization process with constraints 
enabled the solvent to soak into all parts of the peptide uniformly 
resulting in a well-minimized structure for the production MD. A thermal 
equilibration at 300 K using the modified Berendsen[43] thermostat and a 
constant pressure equilibration using the Parrinello-Rahman 
barostat[45,46] at 1 atm were carried out for 10ns each, prior to production 
MD. During both the temperature and pressure ensemble simulations, 
restraints on all bonds were applied using the LINCS[46] algorithm. The 
production MD was done for 100 ns with a 2 fs time step and data written 
to the logs and trajectory at every 5 ps. Periodic boundary conditions 
were applied to the system. Long range electrostatics were accounted by 
the particle mesh Ewald method.[47,48] 20000 frames were written to the 
trajectory during each simulation. The effect of periodic boundary 
conditions was adjusted by suppression of center of mass movement 
from the trajectory prior to analysis. Visualizations of conformations for 
the analysis and creation of images was performed using VMD.[23]  
Molecular surface visualization of global residue mobility. An in-
house software prototype was implemented to conduct the layer and 
residue surface proximity analysis. The prototype includes a GPU 
implementation of the surface atom extraction algorithm proposed by 
Zhang.[27] The algorithm was applied iteratively to compute several layers 
of atoms, which was inspired by the work of Karampudi and co-
workers.[26] With each layer comes an integer value LA per atom. LA was 
determined by the iteration in which an atom was assigned to a layer. 
Then, LA = 0 determined the outermost layer and the innermost layer was 
denoted by atoms with LA = N–1, where N is the number of iterations. For 
each residue we computed LR as the mean value of all of its atoms’ LA 
values. In this way we received a score for each residue that described 
its proximity to the SAS or the molecule’s core, respectively. LR is now 
defined as the Residue Surface Proximity. In order to incorporate the 
dynamics of a MD simulation, we further determined LR for each residue 
in each time step x of a simulation and compute ΔLR(x) = |LR(x) - LR(x-1)|. 
ΔLR(x) measures how much an amino acid’s surface proximity changes 
at time x with ΔLR representing the average change of surface proximity 
of a residue over the time span of a simulation. ΔLR can be interpreted as 
a hint for how stable a residue is in its surface proximity throughout a 
folding process or how much it competes with other residues. LR is 
indicative of how much a residue contributes to the surface or core of a 
molecule. Our software prototype can be used to visually analyze a 
residue’s surface proximity in further detail. 
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Epilogue 
In this report MD simulations of the -conotoxins GIIIA, KIIIA, PIIIA, SIIIIA and SmIIIA were 
performed to expose the structural stability of the folded and unfolded species with one and 
two disulfide bonds removed. As a result, the structures were assigned to classes according 
to their structural stability in disulfide-deficient variations. These were characterized with 
magnitudes such as RMSD, RMSF and radius of gyration and on the other hand with a layer 
approach revealing the positions of individual residues throughout the simulation (surface or 
core of the molecule). Although the disulfide bonds in the folded conotoxin can change their 
positions from the surface to the core of the molecule, they hold basic residues in a certain 
conformation on the surface. MD simulation of the peptides with one disulfide bond opened 
reveal stable structures and led to the assumption that these disulfide-deficient conotoxins 
maintain biological activity. This simplification would facilitate synthesis of these conotoxins 
to peptides with only four cysteine residues and also reduce the formation of possible 
isomers. A further reduction of the cysteine content would increase the flexibility of the 
structures resulting in less active compounds. Here, the combination of different theoretical 
approaches resulted in a promising tool for estimation of structural stability with respect to 
disulfide bridge removal prior to analog design and synthesis.  
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Preface 
Although synthesis and characterization of 15 disulfide isomers of a µ-conotoxin is an 
extensive task, a detailed structural analysis of isomers with three disulfide bonds is of high 
interest. Selective disulfide bond formation using a specific protecting group strategy is 
challenging because of possible disulfide rearrangement during product formation. In 
general, the obtained product has only been characterized with one or two methods to 
elucidate the structure and disulfide connectivity, however, not every method can be used for 
analysis because accurate and unequivocal results cannot be provided. Herein, all 15 
possible isomers of -conotoxin PIIIA have been synthesized and extensively analyzed. -
PIIIIA was used as model peptide because three different isomers could be isolated and 
characterized previously forming the basis for the present study.96 For structure elucidation 
several methods namely HPLC, NMR and MS/MS were applied and the respective results 
were analyzed to compare the suitability for the distinction of all isomers. Furthermore, all 
peptides have been tested for their ability to block the skeletal ion channel NaV1.4. To 
explain the mechanism of action a homology model was used to identify and characterize the 
toxin binding to the channel pore.   
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Conformational µ-PIIIA peptide isomers revisited: The impact of 
disulfide connectivity on structure and bioactivity  
P. Heimer,a A. A. Tietze,b E. Leipold,c D. Kaufmann,d C. A. Bäuml,a A. A. Paul George,a A. Maass,e J. 
Hamaekers,e A. Resemann,f F. J. Mayer,f D. Suckau,f O. Ohlenschläger,g S. H. Heinemann,c  D. 
Tietzed* and D. Imhofa* 
Peptides and proteins carrying a high number of cysteines can adopt various 3D structures depending on their disulfide 
connectivity. The unambiguous verification of such conformational isomers with more than two disulfide bonds is 
extremely challenging and experimental strategies for their unequivocal structural analysis are largely lacking. We 
synthesized the fifteen possible isomers of the 22mer conopeptide µ-PIIIA, applied 2D NMR spectroscopy and MS/MS for 
structure elucidation, and finally tested their activity to block the skeletal muscle voltage-gated sodium channel NaV1.4. 
The activity profile of µ-PIIIA isomers was correlated with results of molecular docking investigations. Our study provides 
intriguing insights in how the disulfide connectivity alters the global fold of the toxin and thus influences bioactivity. We 
also show that analysis procedures involving a comprehensive combination of conventional methods are required for the 
unambiguous assignment of disulfides in cysteine-rich peptides and proteins and that chemical standard compounds are a 
crucial need for the structural analysis of such molecules. 
Introduction 
There are fundamentally different reports regarding the 
concomitant occurrence of conformational isomers of proteins and 
peptides with multiple disulfide bonds irrespective of their origin, 
i.e. isolation from biological material, synthetic production, or 
recombinant expression.1–6 Peptide and protein toxins were 
suggested to be suitable candidates for studying this particular 
issue because many of them are known to possess highly structured 
three-dimensional arrangements.1–9 In addition, different disulfide 
bond patterns of the same primary amino acid sequence were 
shown to result in different biological activities.10–13 In this respect, 
it should be noted that the importance of identifying the individual 
disulfide connectivity is still underestimated, in particular in 
proteins harbouring more than four cysteine residues. At the same 
time it is commonly accepted that the elucidation of disulfide 
connectivity currently belongs to the major goals in proteomics and 
bioanalysis studies of peptide and protein therapeutics, such as 
monoclonal antibodies.14  
For conotoxins derived from the venoms of marine cone snails 
already in 1991 Olivera et al. suggested degenerate ways to obtain 
congruent conformations.15 In view of recent findings,11,13 this can 
be interpreted as different disulfide connectivity might result in 
congruent conformations despite conserved residues and cysteine 
arrangement. This raises the following questions: i) How probable is 
the occurrence of individual or all possible disulfide isomers? ii) 
Which conformational isomers of disulfide-rich peptides and 
proteins are formed in commonly used production strategies? iii) 
Are the existing analytical methods and techniques sufficient to 
unequivocally identify individual disulfide isomers? 
Irrespective of the research or development goals to be 
pursued, a detailed analytical characterization must be performed 
prior to research, clinical or commercial use. One of the main 
problems is chemical modifications of amino acids as a result of 
cellular posttranslational modification or of sample preparation and 
analysis processes causing product-related impurities such as 
undesired conformational disulfide isomers. We thus focused our 
attention on the 22mer conotoxin µ-PIIIA from Conus purpurascens 
containing six cysteine residues giving rise to three disulfide bonds, 
for which three differentially folded disulfide isomers were 
identified earlier in an oxidative self-folding approach.11  
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Here we describe the solid phase synthesis of the fifteen 
possible isomers using a targeted protecting group strategy for 
structural analysis and bioactivity testing (Scheme 1). We 
demonstrate that commonly used liquid chromatography methods 
are insufficient to identify distinct disulfide isomers while the 
disulfide connectivity of most - yet not all - isomers can be 
unambiguously assigned by applying a combination of MS/MS 
analysis and 2D NMR spectroscopy. All µ-PIIIA isomers were further 
analysed for their potency to block the skeletal muscle sodium 
channel NaV1.4. In addition, interactions between isomers and 
NaV1.4 channels were analysed on the molecular level by means of 
molecular docking simulations. 
 
Scheme 1 Outline of the work process: synthesis, data acquisition, 
and analysis. (a) Targeted folding of linear µ-PIIIA to fully oxidized 
disulfide isomers in three steps according to a cysteine-specific 
protecting group strategy. (b) Structure elucidation was 
accomplished by combining solution NMR and high-resolution 
tandem mass spectrometry. (c) Electrophysiological studies 
revealed the intensity of blocking activity of the individual µ-PIIIA 
isomers at the voltage-gated sodium channel NaV1.4. (d) 
Experimental results were correlated with results of molecular 
docking studies. 
Results and discussion 
Chemical analysis of synthetic µ-PIIIA disulfide isomers 
Synthesis of the µ-PIIIA disulfide isomers was performed according 
to Fmoc solid-phase peptide synthesis with regioselective disulfide 
bond formation using the protecting group strategy trityl (Trt), 
acetamidomethyl (Acm) and tert-butyl (tBu) for the respective pairs 
of cysteine residues (Supplementary Information, Table S1†).16,17 
Peptides were obtained in high purity and acceptable yield using RP 
HPLC (Supplementary Information, Fig. S1, Table S2†). Purified 
oxidized peptides (Fig. S1, Taďle SϮ†Ϳ ǁeƌe suďŵitted to stƌuĐtuƌal 
analysis (MS/MS, NMR) and electrophysiological studies. Additional 
liquid chromatography experiments were performed in order to 
address the issue of clear distinction between highly similar 
conformational isomers with respect to their physico-chemical 
properties (Fig. S2†). After complete assignment of the disulfide 
connectivity (see below) equal amounts of three PIIIA isomers 
sharing one disulfide bridge, e.g. isomers 3, 6, 9 (Cys21-Cys22), 
isomers 3, 4, 5 (Cys4-Cys5), and isomers 13, 14, 15 (Cys4-Cys22), 
respectively, were mixed and re-injected for RP HPLC analysis using 
two different columns (C4 and C18) and two different instruments. 
These elution profiles revealed either a single peak or multiple 
peaks, but in none of the cases base-line separation of all three 
isomers was obtained (Fig. S2†).  
Disulfide bond assignment of µ-PIIIA isomers by MS/MS analysis 
MS/MS sequencing based on the analysis of suitable sets of 
precursor and fragment ion masses for an individual peptide was 
then performed to establish the disulfide bond pattern in all 
isomers (Supplementary Information). The most commonly applied 
peptide fragmentation techniques rely on qTOF and TOF/TOF mass 
analysers employing collision-induced decay (CID), in-source-decay 
(ISD), and post-source decay (PSD).18–20 Our intention to apply LC-
ESI-qTOF-MS/MS and MALDI-TOF/TOF-MS/MS LID and MALDI 
MS/MS ISD in a direct comparative way, however, could not be 
realized due to incomplete fragmentation found in ESI MS/MS 
(Supplementary Information, Figures S3-S5, Tables S3, S4†). 
Enzymatic digestion was also not considered for µ-PIIIA isomers 
herein, because the cleavage sites result in unspecifically cleaved 
fragments.11 In addition, the µ-PIIIA sequence includes adjacent 
cysteine residues in two regions (C4/C5 and C21/C22) (Fig. 1a), 
which is a characteristic structural feature of several peptides and 
proteins,21–28 however, additionally complicates analysis due to 
contradicting results for disulfide assignment.29 Also, according to 
the applied synthetic strategy, a rearrangement of disulfide bonds 
might appear after cleavage of the tBu-protecting group and the 
following oxidation step in case of incomplete oxidation of the 
former Acm-protected Cys-pair.29–31 This earlier reported 
hypothesis29,30 is supported by the occurrence of several peaks in 
the crude peptide mixtures (Fig. S1†) and co-elution of these 
isomers (Fig. S2†) as aforementioned. It can be stated that for 
isomers 1, 7, 9, and 11 no contamination with scrambled isomers 
was observed (see MS/MS and NMR results below), which can be 
explained also by the different retention times of the intended 
version and the possible impurities (Tables S2 and S3†). However, at 
least one other remaining isomer has the same retention time of 
the anticipated peptide and, thus, cannot be excluded by HPLC only 
(Supplementary Information).  
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Figure 1 (a) Sequence of µ-PIIIA and (b) NMR structures of all 15 µ-PIIIA isomers. For each isomer with the indicated disulfide-bond pattern, 
the solution NMR structures are presented as ensembles of 20 structures with the lowest energy. *Structures 1 and 2 were reported by us 
previously;
 11
 structure 2 represents the so-called native µ-PIIIA isomer.33 #Structures predicted from MD simulation (see also Figure S6†). 
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To clarify the disulfide connectivity for each single isomer MS/MS 
analysis, subsequent NMR structure determination, and structure 
calculation for alternative isomers (Supplementary Information, 
Table S5†) were combined. MS/MS was performed with partially 
reduced and alkylated derivatives produced by an adapted earlier 
described protocol (Supplementary Information, Fig. 2, Figures S3-
S5, Tables S3, S4†).32 In the MALDI-MS/MS LID TOF/TOF spectra 
internal fragments (IF) for respective 2- and 4-
carbamidomethylated (CAM) species were taken into account, since 
distinct CAM IFs can only occur from a particular disulfide bridging 
in the oxidized peptide (Tables S3, S4†). Thus, it was possible to 
identify the same disulfide bonds in both the 2-CAM and 4-CAM 
species, which is indicative for successive bridge opening.  
Fig. 2 Partial reduction and mass spectrometry analysis workflow. a) 
Schematic representation of partial reduction of the oxidized peptide isomer 
using TCEP and subsequent carbamidomethylation (yellow star) performed 
with iodoacetamide for different time periods. b) HPLC-elution profile of 
isomer 8 after three minutes of partial reduction and alkylation. All samples 
were fractionated by liquid chromatography prior to further 
characterization. c) After freeze-drying of collected fractions, reduction was 
completed to remove the remaining disulfide connections prior to MS 
analysis. d) MALDI-MS spectra of fractions obtained from isomer 11 and 
schematic representation of the respective internal fragment (IF) obtained 
from MS/MS fragmentation for distinct masses. This indicates the level and 
position of carbamidomethylation within the peptide. The derivatization of 
the IF containing three cysteine residues is indicated by a molar mass of 
1440 (no CAM), 1497 (one CAM), 1554 (two CAM), or 1611 (three CAM). 
Thereby different combinations between 2- and 4-times 
carbamidomethylated peptide and IF are possible, depending on the present 
disulfide pattern. e) Selected MALDI-MS/MS-spectra obtained from fraction 
2 of isomer 5 with 2- and 4-times carbamidomethylated species after 
sequencing and manual evaluation including the obtained disulfide pattern 
(Table S3, Fig. S5†). 
As a consequence and based on the combination of the results from 
MS/MS analysis and the synthetic strategy, we subsequently 
determined the 3D structure of the anticipated isomer, while also 
considering two possible alternative disulfide patterns during 
structure determination (Supplementary Information, Table S5†). 
Structure analysis of µ-PIIIA isomers by 2D NMR 
Solution structures of 12 µ-PIIIA isomers were determined by 
standard 1H-based NMR spectroscopy (Fig. 1b). The sufficient 
spectral resolution of the 2D NMR spectra (TOCSY and 
NOESY/ROESY) at magnetic fields of either 14.1, 16.4 and/or 21.1 
Tesla allowed for an unambiguous resonance assignment of almost 
all isomers, except for 7, 12, and 13, where the resulting NOE 
spectra were not evaluable. In addition, the NMR spectra revealed 
at least one minor toxin conformation to be present in select 
isomer solutions (with the exception of 1, 2, 11, 14, and 15) as 
indicated by an additional set of cross peaks. Unfortunately, the 
NMR data did not allow for structure determination of these less 
abundant isomer conformations. The structures of 7, 12, and 13 
were modelled and the structural ensembles for these isomers 
were generated through a molecular dynamics simulation run (Fig. 
1b, S6†).  
For all structures a trans configuration of both hydroxyproline 
residues (Hyp8, Hyp18) was observed as dominant species and was 
ideŶtified ďǇ the oĐĐuƌƌeŶĐe of stƌoŶg Hɷ-Hαi-ϭ aŶd ŵediuŵ Hɷ-
Hβi-1 cross signals in case of Hyp8. Due to almost identical chemical 
shifts of Hɶ aŶd Hα of HǇpϭϴ aŶd Hα of LǇsϭϳ foƌ ŵost of the 
isoŵeƌs oŶlǇ the ŵediuŵ iŶteŶsitǇ Hɷ-Hβi-1 cross peak was 
observed, which indicates a trans configuration of Hyp18. No minor 
conformation comprising any of both Hyp residues in a cis 
configuration was observed, which is in contrast to the previous 
observations for µ-PIIIA.11,33   
The solution structure for each µ-PIIIA isomer was calculated 
using the respective NOE data (Fig. 1b, Supplementary Information, 
Tables S5-7†). The two alternative forms of disulfide connectivity 
(Table S5†Ϳ fƌoŵ the sǇŶthetiĐ stƌategǇ aŶd Poppe’s method34 for 
disulfide bond assignment were considered to test the unambiguity 
of the experimental NMR restraints for the structure calculations. In 
contrast to our previous studies of three µ-PIIIA isomers obtained 
from an oxidative self-folding approach,11 the solution structure of 
isomer 3 could be obtained herein due to higher purity of the 
sample yielding high-resolution NOE data for structure calculation.  
a
b
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The resulting structures fall into three categories with respect to 
their resolution, which is reflected by the overall deviation of the 
backbone coordinates of the structural ensemble (RMSD, root 
mean square deviation). The structures are highly dissimilar, 
ranging from a compact fold (isomers 2, 11, 14), an intermediate 
fold of compact and flexible parts (isomers 1, 8, 10) to very flexible, 
open structures as found for isomers 3-6, 9 and 15 (Fig. 1b). 
Nevertheless, all structures revealed similar backbone coordinates 
for the loop between Cys11 and Cys16 with an average backbone 
deviation of about 1.4 Å. 
The NMR structural ensembles of isomers 2,11 11, and 14 
exhibited the highest resolution (RMSD 1.22, 0.94, 0.90 Å), followed 
by isomers 1, 8, and 10 with a medium resolution (RMSD 1.46, 1.48, 
1.54 Å). Isomers 3-6, 9, and 15 generated only low-resolution 
structures (RMSD ranging from 1.99 to 2.77 Å, Fig. 1, Table S5†). 
The low resolution of the NMR ensembles obtained for isomers 3-6, 
and 9 are a direct consequence of their flexible N- and/or C-
terminal portions, i.e. if C4-C5 (isomers 3-5) and/or C21-C22 are 
connected (isomers 3, 6, 9). However, the remaining part of the 
molecule shows a low backbone deviation and thus is rigid (Fig. 1b, 
Table S5†). In contrast, the compact fold and the low global 
backbone deviation of isomers 2, 11, and 14 are indicative of a very 
rigid structure. Despite their rather compact fold, isomers 1, 8, and 
10 exhibit a much higher structural inhomogeneity than the rigid 
ones, probably due to their higher global flexibility. Apart from that, 
isomer 15 seems to stand out regarding its highly inhomogeneous 
backbone conformation (Fig. 1b), which might be caused by its 
unusual, ladder-like disulfide bond pattern connecting C4-C22, C5-
C21, and C11-C16.  
Calculations of the aforementioned alternative structures were 
performed considering two different disulfide linkages (Table S5†), 
which were also carried out for the earlier described isomers 1 and 
2.11 Reasonable alternative structures were obtained for isomers 1, 
2, 10, 14, and to a lesser extent also for isomers 4, 5, and 8 (Table 
S5†) applying the individual sets of experimental NMR restraints 
used to calculate the structures. However, according to MS/MS 
analysis we could confirm the intended disulfide connectivity in all 
of these isomers. 
 
Bioactivity of µ-PIIIA isomers at NaV1.4 ion channels  
The most likely biological function of µ-PIIIA is to act as a 
neurotoxin that blocks the permeation pathway of voltage- gated 
Na+ (NaV) channels. Previous reports have shown that µ-PIIIA has 
the highest potency to interfere with skeletal muscle channels 
(NaV1.4) although also being active on neuronal NaV channels and 
even select KV channels.
35 We therefore applied all isomers to HEK 
293 cells expressing human NaV1.4 channels and measured the 
impact of the toxin isomers on depolarization-elicited Na+ inward 
currents, expressed as the time course of current block and the 
maximal block after long toxin exposure (Fig. 3, Fig. S7†). Figure 3 
summarizes the inhibitory activity of the most active isomers 1, 2, 7, 
11, 12, 14, and 15. As demonstrated in Figure 3a, currents mediated 
by human NaV1.4 were inhibited by all isomers, albeit to different 
degrees. At a concentration of 10 µM, isomer 2, which has the 
native disulfide connectivity of µ-PIIIA, was most effective in 
inhibiting NaV1.4 channels, followed by isomers 15, 11, 14, 1, 7, and 
12. Analysis of the concentration dependence revealed that isomer 
c
Fig. 3 Disulfide isomers of µ-PIIIA differentially inhibit NaV1.4-mediated currents. a) Representative current traces of transiently expressed NaV1.4 channels 
evoked at a test potential of 20 mV before (black, ctrl) and after (red) application of 10 µM of the indicated µ-PIIIA isomers. b) Normalized peak current 
amplitudes obtained from repetitively evoked current responses were plotted as a function of time to follow the time course of current block mediated by 
various concentrations of µ-PIIIA isomers 2 and 15. Continuous lines are single exponential data fits used to characterize the onset of channel block. The 
arrowhead marks the start of µ-PIIIA application. The time axis was split to illustrate that channel block by isomer 15 saturates at about 50% suggesting that 
isomer 15 seals the channel pore only partially. In contrast, isomer 2-mediated channel inhibition saturates at about 95% with an IC50 of 105.3  29.9 nM. c) 
Steady-state block (bottom) as well as the associated single exponential time constant (top), describing the onset of channel block, for various 
concentrations of the indicated isomers. Lines connect data points for clarity. Symbols and color-coding of data obtained with isomers 2 and 15 are as in b). 
Numbers of individual experiments, n, are provided in parentheses.  
b
a
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2 blocked human NaV1.4 with an apparent IC50 of 105.3  29.9 nM, 
which is comparable to the value for the paralog rat NaV1.4 
channels (103.2  9.9 nM).11  
As observed for some µ-conotoxins, even at a saturating 
concentration of 100 µM a small current component of 7.2  2.2% 
remained, indicating that channel occupancy by isomer 2 does not 
completely eliminate Na+ conduction (Fig. 3a, b). The remaining 
isomers (15, 11, 14, 1, 7, 12) blocked NaV1.4 channels less potently 
than isomer 2. In addition, onset of block as estimated with single-
exponential functions was substantially slower than for isomer 2, 
thus precluding faithful assessment of channel block at lower 
concentrations than 10 µM and the associated IC50 values (Fig. 3c). 
Assessment of higher concentrations revealed that particularly 
isomers 15 and 7 are interesting: total current block at 10 and 
100 µM were virtually identical (15: 48.2  5.9% and 51.1  2.2%, 
respectively; 7: 32.3  4.3 and 35.1  4.6, respectively), while the 
time constant characterizing the kinetics of onset of block, block, 
roughly scaled linearly with the concentration (15: 10 µM: 160.0  
34.9 ms; 100 µM: 47.0  9.7 ms; 7: 10 µM: 853.0  195.0 ms; 100 
µM: 59.0  18.1 ms; Fig. 3c). This result indicates saturated 
association between isomers 15 and 7 and the channel, with 
imperfect (about 50% and 35%, respectively) occlusion of the Na+ 
permeation pathway. For isomers 11, 14, 1, and 12 saturation of 
channel block at 100 µM peptide concentration was not apparent 
(Fig. 3c).The channel block of isomers with even lower potency (3-6, 
8, 10, and 13) were analysed at 10 µM. As shown in Figure S7†, 
sample 13 was most active among this group, as it inhibited NaV1.4 
by 24.6  3.0% followed by samples 4 (21.7  3.5), 9 (17.7  1.7%), 
and 3 (17.6  3.6%). Isomer samples 6, 8, 5, and 10 reduced NaV1.4-
mediated currents by less than 15% (6: 12.6  1.3%, 8: 11.4  2.2%, 
5: 6.7  2.1%, 10: 1.0  3.0%), and thus were considered inactive 
under these conditions.  
 
In silico toxin binding studies  
Interactions of the µ-PIIIIA isomers with the NaV1.4 channel were 
further investigated employing a homology model which comprised 
the central pore module of the channel similar to the model 
developed earlier by us11 and others.36 We identified the recently 
published structure of the voltage-gated calcium channel CaV1.1 
(PDB ID 3jbr37) as a suitable template, allowing to model the large, 
pore-surrounding, extracellular loops that contain important 
interaction sites for µ-conotoxins, which were not yet included in 
available homology models (Supplementary Information, Fig. S8†). 
The recently solved structure of a eukaryotic voltage-gated Na+ 
channel (NaVPaS, pdb ID 5X0M
38) was not available, when this study 
was started. However, our homology model and the structure of 
the central pore module of NaVPaS are in good agreement, 
deviating by only 1.9 Å (Fig. S9b†).  
All 15 µ-PIIIA isomers (Fig. 1) were docked to the NaV1.4 
homology model using the HADDOCK easy web interface.39,40 The 
docking results were clustered according to the interface-ligand 
RMSDs and scored corresponding to the HADDOCK scoring function 
(Table S8†). The best scoring channel–toxin complex of the highest 
scoring cluster was subjected to further analysis. In all complexes 
evaluated, µ-PIIIA occupied the central pore interface. Viewing the 
complexes from the top revealed that the binding mode of the 
isomers is further distinguished mainly by the orientation of their 
arginine residues (Arg2, Arg12, Arg14, Arg20) and the positioning of 
their lysine residues (Lys9, Lys17) or Phe7 and Pyr1 with respect to 
the ĐhaŶŶel’s suƌfaĐe ;Fig. 4, Fig. S10†). We observed an 
inhomogeneous one-way orientation of the majority of the arginine 
residues in the direction of the pore loops connecting the 
transmembrane segments S5 with SS1 and SS2 with S6 of domains I 
and IV (Fig. S8†) in isomers 4, 10 (Fig. 4b, c), 5, 6, and 15 (Fig. S10e, 
g, c†). Among these four isomers, isomers 4, 5, and 10 showed a 
separate positioning of Arg2 together with Pyr1 offside the other 
arginine residues in the direction of the pore domains III and II (Fig. 
4b, c and Fig. S10e†). In contrast, all the remaining isomers (1-3, 7-
Fig. 4 a - c) Visualization of the best scoring µ-PIIIA–NaV1.4 complex 
conformations obtained from docking experiments. The four NaV1.4 
domains are indicated. Left panel – top view of the toxin-channel complex. 
The NaV1.4 channel surface (Van der Waals) is given in gray, the selectivity 
filter motif (DEKA) is highlighted in red. The toxin is shown in green with 
side chain atoms present (coloring scheme: carbon – cyan, nitrogen – blue, 
oxygen – red, sulfur – green). Middle and right panel – top and side view of 
the toxin-channel complex. The toxin is shown in surface representation 
(Van der Waals) and colored according to amino acid properties (coloring 
scheme: basic – blue, acidic – red, polar - cyan, non-polar – gray). The 
number of hydrogen bonds formed by the toxin with each channel domain 
(loops/SS1-SS2) is highlighted in purple distinguishing between hydrogen 
bonds formed with the TM bridging loops (S5-SS1, SS2-S6) and the pore 
helices (SS1-SS2). 
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9, 11-14) exhibit a rather uniform distribution of their basic Arg 
ƌesidues aĐƌoss the ĐhaŶŶel’s poƌe eŶtƌǇ ;Fig. 4, Fig. S10†).  
The docking results further suggest that the acidic residues in 
the S5-SS1 and SS2-S6 bridging pore loops serve as anchor points 
for the basic toxin residues allowing the toxin to span over the 
central pore. Moreover, the high number of acidic residues within 
these loop regions (Fig. S8†) might indicate a key role for toxin 
affinity. In addition to a versatile arginine orientation, an arginine 
residue protrudes more deeply into the pore and thus establishes 
additional interactions with the selectivity filter region such as 
observed for Arg20 of isomers 1 and 2 (Fig. 4a, Fig. S10a, viewing 
the complexes in side view†). However, such arginine orientation 
might be beneficial for an efficient pore block, but may not be 
critical as revealed by the bound conformation of 11, 14 and 15 (Fig. 
4b, Fig. S10l,d, c†). 
Interestingly, the docking result of the native isomer 2 is distinct 
from previous studies. Our model, however, confirms mutation 
analysis for native µ-PIIIA,35,41 since all basic residues are involved in 
hydrogen bonding being almost homogenously distributed among 
the channel surface and thus contributing to the effective pore 
block. This also supports the fact that PIIIA lacks a critical single 
residue for an all-or-none inhibition of the current flow. This could 
not be fully explained by previous models, in which the pore loops 
were not considered in the respective homology models.36,41–43 The 
bound conformation of 2 is also in agreement with the importance 
of distinct PIIIA residues, e.g. Arg14 and Arg2,35,41 even though 
Arg14 does not protrude into the channel pore (Fig. 4a). In our 
model, µ-PIIIA covered the pore slightly asymmetric, showing more 
hydrogen bonds to domain I and IV (8 in total, Fig. 4a) than to II and 
III (4 in total, Fig. 4a, Table S9†). Besides, Arg14, which is hydrogen-
bonded to the S5-SS1 loop of NaV1.4 domain II, might provide an 
important anchor to effectively occlude the pore being lost upon 
mutation. Our data also indicate that the pore loops are involved in 
toxin binding and should therefore be considered in future in silico 
binding studies.  
Experimental Section 
Materials and Methods 
Peptide synthesis. The amino acid sequence of µ-PIIIA was 
automatically assembled using Fluorenylmethyloxycarbonyl (Fmoc) 
chemistry and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
heǆafluoƌophosphate ;HBTUͿ, N-methylmorpholine/DMF (1:1) 
couplings on a Rink-amide resin (0.28 mmol/g). Protecting groups of 
amino acids other than cysteine were as follows: Boc-Pyr, Arg(Pbf), 
Hyp(tBu), Lys(Boc), Ser(tBu), Gln(Trt), and His(Trt). Synthesis of the 
linear peptide precursor was performed using Trt-, Acm- and tBu-
protected cysteine residues according to the intended disulfide 
connectivity (Table S1). The choice of the synthesis strategy was 
guided by the idea of combining isomers in which amino acid 
sequence including protecting groups is identical up to a distinct 
residue, and then the resin was split into respective parts to enable 
assembly of the remaining residues. Partially Acm- and tBu-
protected linear peptides were obtained in high purity after 
cleavage with TFA and a scavenger mixture (82.5% trifluoroacetic 
acid (TFA), 5% water, 5% phenol, 5% thioanisole, 2.5% 
ethanedithiol) for 3 h at room temperature. After MS 
characterization the purified linear semiprotected peptides were 
subjected to a stepwise oxidation protocol A - C (see below). For the 
formation of the first disulfide bridge (protocol A), the linear 
purified peptide was dissolved in a mixture of isopropanol/water 
(1:2) with a final peptide concentration of 0.05 mM and oxidation 
on air under basic conditions (pH 8.5 adjusted with 1 M NaOH). The 
reaction was monitored via HPLC and MS following iodoacetamide 
(IAA) derivatization until complete oxidation was confirmed. After 
lyophilization of the precursor, the crude powder was used without 
further purification for the next deprotection step of Acm groups 
followed by the oxidation step (protocol B). Therefore, a solution 
containing peptide (final concentration 0.05 mM) in a mixture of 
isopropanol/water/1 M HCl (80:12.5:7.5) was treated with iodine 
(final concentration 0.15 mM) in methanol at room temperature for 
3-52 h, i.e. until completed. The reaction was stopped using a 1-M 
solution of ascorbic acid in a 5-fold excess relative to iodine. 
Monitoring and confirmation of oxidation was performed with HPLC 
and MS, respectively. Following lyophilization of the crude reaction 
mixture, the final deprotection of the tBu-protecting groups was 
performed (protocol C). The crude material was dissolved in TFA 
corresponding to the amount of peptide (i.e. for 1 µmol of peptide 
1 mL TFA was used), and containing a scavenger cocktail consisting 
of diphenylsulfoxide/anisol/ trichloromethylsilane (1:10:15). The 
mixture was gently shaken for 3-5 h at room temperature and 
monitored via HPLC and MS. The individual peptide was then 
precipitated in cold diethyl ether, centrifuged and washed at least 
four times with diethyl ether prior to freeze-drying from 80% tert-
butanol/water. 
 
Peptide purification. The crude peptides were purified by 
semipreparative reversed-phase HPLC using a Shimadzu LC-8A 
system equipped with a C18 column (Knauer Eurospher 100). The 
gradient elution system was 0.1% TFA in water (eluent A) and 0.1% 
TFA in acetonitrile/water (9:1) (eluent B). The peptides were eluted 
with a gradient of 0-50% eluent B in 120 min and a flow rate of 10 
ml/min. The peaks were detected at 220 nm. Collected fractions 
were combined, freeze-dried and stored at -20 °C. 
 
Peptide chemical analysis. Peptide purity after separation was 
confirmed with a Shimadzu LC-10AT chromatograph equipped with 
a Vydac 218TP54 column (C18, 5 mm particle size, 300 Å pore size, 
4.6 x 25 mm) and a Vydac 208TP54 column (C8, 5 mm particle size, 
300 Å pore size, 4.6 x 25 mm). The peptides were eluted with a 
gradient of 10-40% eluent B in 30 min. The flow rate was 1 ml/min, 
eluent A was 0.1% TFA in water, and eluent B was 0.1% TFA in 
acetonitrile; detection was at 220 nm. The existence of linear 
semiprotected peptide carrying Acm and tBu protecting groups as 
well as each oxidation step after their removal was confirmed by 
MALDI-TOF mass spectrometry on an autoflex Bruker mass 
speĐtƌoŵeteƌ ;Bƌukeƌ DaltoŶiĐs GŵďH, BƌeŵeŶͿ usiŶg α-cyano-4-
hydroxycinnamic acid as matrix. The reflector mode was used for 
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measurements and Peptide Calibration Standard II for molar masses 
below 6.000 g/mol. Derivatization of the observed samples with 
iodoacetamide confirmed the absence of free thiol groups, i.e. the 
formation of the respective disulfide bridge (Figure S5). For co-
elution of different isomers the respective mixtures were measured 
using the aforementioned Shimadzu LC-10AT chromatograph 
equipped with a Vydac 218TP54 column (C18, 5 mm particle size, 
300 Å pore size, 4.6 x 25 mm) and a Waters 600 HPLC system 
equipped with a MultoHigh U C4 column (CS - Chromatographie 
Service GmbH, 2 µm particle size, 120 Å pore size, 4 x 100 mm,). 
Peptide isomers were eluted with a gradient of 5-50% eluent B in 20 
min. Flow rate and eluent system were identical to the method 
described above; detection was at 214 nm. 
Amino acid composition of the peptides was determined by amino 
acid analysis using a LC 3000 system (Eppendorf-Biotronik GmbH, 
Hamburg). Hydrolysis was performed with 6 N HCl in sealed tubes 
at 110 °C for 24 h. The obtained analyses supported the expected 
quantitative results. Amino acid analysis in combination with HPLC 
analysis (calibration curve) was used for the determination of 
peptide concentrations in solution prior to the further experiments 
to ensure equal concentrations in analysis and biological testing. 
 
MS/MS analysis of disulfide connectivity. The partial reduction and 
alkylation protocol was adapted from an earlier study.44 The pure 
peptide was dissolved in citrate buffer (0.05 M, pH 3.0) containing 
0.02 M tris(2-carboxyethyl)phosphine (TCEP). The final peptide 
concentration was approximately 100-ϯϬϬ μg/ŵl. The ŵiǆtuƌe ǁas 
then incubated at room temperature, and samples were taken at 
different times ranging from 0 s to 30 min. The samples were mixed 
with three equivalents of alkylation buffer (0.5 M Tris-acetate pH 
8.0, 2 mM EDTA and 1.1 M iodoacetamide) to stop the reaction and 
perform carbamidomethylation of the free thiol groups from partial 
reduction. The alkylation reaction was terminated by addition of 
one volume of 10% TFA after 5 min. Samples were stored on dry ice 
until further analysis with HPLC using the following gradient: 10% of 
eluent B for 15 min, then linear increase of eluent B up to 35% for 
another 25 min. Fractions were collected and further subjected to 
MS/MS sequencing. Linear and fully carbamidomethylated µ-PIIIA 
were subjected to sequencing on an ultrafleXtreme MALDI TOF/TOF 
mass spectrometer or an ultraflex III MALDI TOF/TOF mass 
spectrometer (Bruker Daltonics GmbH, Bremen, Germany) and 
were analyzed using flexAnalysis 3.4 and BioTools 3.2, respectively. 
For MS/MS analysis of the disulfide connectivity in the collected 
fractions from HPLC separations (Figure S2), the samples were 
measured in the oxidized and reduced form as follows. The 
peptides (10 - 100 µg in 10 - 50 µl water containing 0.1% TFA) were 
reduced by adding the appropriate volume of a 100 mM aqueous 
TCEP solution to a final concentration of 10 mM TCEP, and 
incubation was carried out for 1 h at 37 °C prior to further analysis 
by tandem mass spectrometry. 
A representative ESI-MS/MS spectrum of linear µ-PIIIA is shown in 
Figure S4 from an LC-ESI micrOTOF-Q III mass spectrometer (Bruker 
Daltonics GmbH, Bremen, Germany) coupled with a Dionex 
Ultimate 3000 (Thermo Scientific, Dreieich, Germany) equipped 
with a EC100/2 Nucleoshell RP18 Gravity 2.7 µm column 
(Macherey-Nagel, Düren, Germany). Analysis of the MS data was 
performed using Bruker Compass Data Analysis 4.1. LC conditions 
used were as follows: Eluent A was water with 0.1% acetic acid, 
while eluent B was acetonitrile containing 0.1% acetic acid. A 
gradient of 0% –60% of eluent B in 12 min was used and detection 
was at 220 nm. 
Since fragmentation of the linear peptide was insufficient even after 
optimization of MS/MS parameters (Figure S4), no further analysis 
of the disulfide connectivity of the different carbamidomethylated 
species was performed with this method. MS/MS analysis and 
sequencing was carried out using an ultrafleXtreme MALDI TOF/TOF 
mass spectrometer or an ultraflex III MALDI TOF/TOF mass 
spectrometer (both Bruker Daltonics GmbH, Bremen, Germany) 
(Table S3). Different techniques were applied for preparation and 
analysis of the samples. Samples were spotted on ground steel or 
AnchorChipTM taƌgets usiŶg satuƌated solutioŶ of HCCA ;α-cyano-4-
hydroxycinnamic acid) for ground steel and 0.7mg/ml for 
AnchorChipTM targets or sDHB (90:10 mixture of 2,5-
dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid) in 
50% acetonitrile/water containing 0.1% TFA as matrices. Initially, 
both ISD and LID TOF/TOF spectra were acquired. Since several 
samples contained both 2- and 4-times carbamidomethylated 
species, MS/MS LID measurements were performed in order to 
preselect the parent ion for fragmentation. Although ISD 
experiments generally revealed more fragments, especially 
regarding y- and c- ion series of the whole sequence, a greater 
amount of substance is required, pmol rather than fmol on target. 
Furthermore, ISD was not suitable for analysis of mixtures 
containing 2- and 4-carbamidomethylated species in one sample 
due to overlapping fragments resulting from both species. 
Peptide Calibration Standard II (Bruker Daltonics GmbH, Bremen, 
Germany) or ubiquitin (Sigma-Aldrich) were used for calibration of 
the respective MALDI spectra. In some cases further sample 
purification was necessary after complete reduction with TCEP. 
C18-concentration filters (ZipTip®) were used to remove TCEP from 
the reduced samples according to the annexed protocol from 
Millipore (Merck Millipore, Molsheim, Germany). Data processing 
and evaluation was performed using the software packages Bruker 
Compass Data Analysis 4.1, flexAnalysis 3.4, and BioTools 3.2. 
 
NMR experiments and structure analysis. NMR spectra were 
ƌeĐoƌded foƌ μ-PIIIA isomers in 90% H2O/10% D2O using the freeze-
dried solid compound at 293 K on Bruker Avance III spectrometers 
with proton frequencies of 600, 700 or 900 MHz equipped with 
cryogenic probes. In all NMR spectra, the 1H peak from water was 
used as a chemical shift reference by setting its frequency at 4.7 
ppm. All NMR data were processed and analyzed using TopSpin 2.1 
(Bruker) and CcpNMR Analysis45. The proton resonance assignment 
was performed by a combination of 2D [1H,1H]-DQF-COSY, [1H,1H]-
TOCSY, [1H,1H]-NOESY and [1H,13C]-HSQC spectra using water 
suppression. Distance constraints were extracted from [1H,1H]-
NOESY spectrum acquired with a mixing time of 120 ms and a 
recycle delay time of 1.5 s. Upper limit distance constraints were 
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calibrated according to their intensity in the NOESY spectrum and 
the intensity of geminal protons was used for peak intensity 
calibration. Torsion angle constraints were obtained from 1H and 
13C chemical shift analysis using DANGLE.46 Structure calculations 
and refinements were performed using the respective disulfide 
connectivity as additional restraints with YASARA structure.47–50 The 
20 structures with the lowest energy were selected to represent the 
NMR solution structures (Figure S7, Table S6 and S7). 
 
Electrophysiological experiments. Human SCN4A (encoding the 
NaVϭ.ϰ ĐhaŶŶel α suďuŶit, UŶiPƌot ID PϯϱϰϵϵͿ oŶ a plasŵid ǁith 
CMV promoter was transiently expressed in HEK 293 cells as shown 
previously.11 Co-transfection of a plasmid encoding the CD8 
antigen ensured visual detection of transfected cells with CD8-
specific Dynabeads (Deutsche Dynal, Hamburg, Germany). Currents 
were measured with the whole-cell patch clamp method 24-48 h 
after transfection.11 The patch pipettes contained (in mM): 35 
NaCl, 105 CsF, 10 EGTA (ethylene glycol bis(2-amino-
ethylether)tetraacetic acid), 10 HEPES (pH 7.4 with CsOH). The bath 
solution contained (in mM): 150 NaCl, 2 KCl, 1.5 CaCl2, 1 MgCl2, 10 
HEPES (pH 7.4 with NaOH). Holding potential was –120 mV, Na+ 
resistance was corrected electronically up to 80%. Peptides, diluted 
in the bath solution, were applied focally to cells under 
consideration with a fine-tipped glass capillary. Time course of peak 
current decrease after peptide application was described with 
single-exponential functions. 
 
Homology modelling, docking and simulation. The YASARA 
molecular modeling program was used to build the homology 
model of the pore module of the NaV1.4 channel and for molecular 
dynamics simulations.48,49 The crystal structure of CaV1.1 (PDB ID 
3jbr37) was used as template to model the NaV1.4 sodium channel 
which has an overall sequence identity of 21 %. Loop regions which 
could potentially be part of the toxin binding epitope were modeled 
or partly modeled with respect to their sequence conservation 
score (Figure S9)37 and according to the UniProt sequence 
alignment51 of NaV1.4 (UniProt ID P35499) and the template 
sequence (UniProt ID P07293, Figure S9). In order to correctly 
identify transmembrane segments and loop-regions, the crystal 
structure of the bacterial sodium channel NaVAB (PDB ID 3rvy
52) 
was structurally aligned with the template structure of CaV1.1. 
Structural alignments were achieved with the MUSTANG 
algorithm.53 If necessary, loops were extended by insertion of the 
ƌespeĐtiǀe ƌesidues iŶto the teŵplate loop seƋueŶĐe ďǇ Yasaƌa’s 
build loop command (Figure S9).54 In case loops had to be 
shortened, the respective residues were deleted and the resulting 
gap was closed. Remodeled loops were energy minimized in 
vacuum employing the NOVA49 force field while the rest of the 
protein was kept fixed using the LINCS method.55 The crude 
homology model was then energy minimized, refined through an 
unrestrained all-atom molecular dynamics simulation for 2 ns in a 
membrane environment (PEA) and explicit water, and energy 
minimized again prior to the docking studies using the Amber14 
force field.56,57  
The µ-PIIIA isomers were docked individually to the constructed 
homology model of the NaV1.4 channel. Therefore, as a preparatory 
step, we selected all the specific residues known to be located on 
the channel's surface and thus depicting the active, toxin-
interacting area as outlined in Figure 4. To perform the docking, the 
Easy Interface of the HADDOCK web service39,40 was used, which in 
turn requires the definition of active residues that are directly 
involved in the ligand interaction. The individual indices of the 
previously selected set of interacting residues were given as input. 
For the toxin itself, all 22 residues were designated to be involved in 
the interaction and thus set as active. 
For subsequent analyses, the best-scored HADDOCK cluster from 
each isomer's docking run was extracted, i.e. the one assigned to 
the lowest Z-score.  
To obtain a rough estimate of the µ-PIIIA binding affinity, the best 
scoring HADDOCK cluster was energy minimized employing the 
Yasara248 force field and re-sĐoƌed usiŶg VINA’s sĐoƌiŶg fuŶĐtioŶ 
employing the YASARA structure software package for set-up 
purposes keeping the ligand flexible and the receptor fully rigid. The 
individual Z-scores are listed in Table S8 together with the 
corresponding binding energies resulting from the VINA re-scorings. 
Structure predictions of isomers 12 and 13 were performed using 
the lowest energy structure of the alternative NMR structure 
calculation of isomer 1 (for 12) and 14 (for 13) as a starting point. 
The starting structure of isomer 7 was derived from the 
conformation of isomer 8, which had a similar disulfide bond 
pattern. The respective structures were then subjected to a 5 ns 
molecular dynamic simulation at 398 K followed by a 45 ns 
production run at 298 K, employing the Yasara2 force field. The 
structural ensembles were generated from 20 snapshot collected 
every 1 ns during the last 20 ns of the MD run.  
If not otherwise stated, energy minimizations and molecular 
dynamics simulations were performed in explicit water (TIP3P 
water model58) using the PME method59 to describe long-range 
electrostatics at a cut-off distance of 8 Å (for Yasara2 and Amber14 
force field) or 10.5 Å (for NOVA force field) at physiological 
conditions (0.9% NaCl, 298 K, pH 7.450). The energy minimization 
was achieved by a steepest descent minimization followed by a 
simulated annealing minimization until convergence (<0.05 
kJ/mol/200/steps). Charged amino acids were assigned according to 
the predicted pKa of the amino acid side chains by Ewald 
summation50 and were neutralized by adding counter ions (NaCl). 
Molecular graphics were created with YASARA60 
(www.yasara.org) and POVRay (www.povray.org). 
Conclusions 
In conclusion, we have described synthesis and in-depth analysis of 
the 15 possible µ-PIIIA isomers with 12 representing new molecules 
and three being reproduced from earlier studies.11 We show that a 
combination of all data obtained from HPLC, MS/MS fragmentation, 
and NMR analysis were required to unambiguously identify the 
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disulfide connectivity of each individual µ-PIIIA isomer. MALDI-
MS/MS sequencing facilitated the identification of the individual 
isomers after partial reduction and derivatisation. In this way, it 
could be demonstrated that the isomers 1-5, 7-11, and 13-15 did 
not contain any other peptide version with an alternative fold. The 
respective disulfide connectivity was also confirmed for 6 and 12, 
but these isomers revealed contaminations with scrambled variants 
in MS/MS analysis. The 3D structures of the µ-PIIIA isomers, 
represented by their respective NMR ensembles, strongly suggest 
that the global fold of the toxin is a direct consequence of the 
disulfide bond pattern. Surprisingly, the resulting structures are not 
only different in their global conformation but also in their 
backbone flexibilities. As one would expect, connecting the N- 
and/or C-terminal cysteines C4-C5 (3-5) and/or C21-C22 (3, 6, 9) 
resulted in flexible terminal regions. All other disulfide bond 
patterns resulted in a more compact fold, such as the native isomer 
2. Considering the block efficacy (Fig. 3, Fig. S7†) and the structure 
of each isomer (Fig. 1) it became evident that only a few disulfide 
combinations are compatible with an efficient inhibition of NaV1.4 
channels. The most active isomers 1, 2, 7, 11, 12, 13, 14, and 15 all 
contain at least one disulfide bond that connects the N- and C-
terminal sections of µ-PIIIA, thereby largely reducing the overall 
structural flexibility of these isomers. In contrast, most isomers with 
strongly reduced (3, 4, 9) or no activity (5, 6) comprise highly 
flexible N- or C-terminal portions due to a connection between 
consecutive cysteines. This suggests that structurally rigid µ-PIIIA 
isomers are generally more potent to inhibit NaV1.4 channels 
compared with isomers with more flexible structures. However, the 
almost inactive isomers 8 and 10 do not fit to this simplified 
interpretation because both contain a disulfide bond linking their N- 
and C-terminal parts. Interestingly, the NMR structural ensembles 
of both isomers showed a rather high structural inhomogeneity 
compared to the active isomers, which might serve as a possible 
explanation of their poor channel block. The docking results of both 
isomers revealed that Arg2 enforces the toxin to span over the pore 
(Fig. 4b, Fig. S10h†). Due to the local flexibility of the N-terminus, 
the resulting interaction of Arg2 with the flexible channel loop 
might be rather low, thus partly explaining the low bioactivity of 8 
and 10. Our data suggest that the channel selects for a toxin 
conformation indicated by the higher block rates of the more rigid 
toxin isomers. This clearly contradicts previous modeling data for μ-
PIIIA,36,41–43 which suggested multiple toxin conformations to bind 
to and block the central pore. This observation might be explained 
by the missing loop regions of their NaV1.4 models, which are 
indicated as being important to span the toxin over the central pore 
in our model. 
Thus far, systematic studies of the structural and functional 
impact of the disulfide bonding in all possible variants have been 
confined to peptides with two disulfide bridges only.10,13 This study 
on µ-conotoxin PIIIA was inspired by the existence of numerous 
natural peptides and proteins with important biological function or 
high therapeutic potential that possess at least three disulfide 
bonds and one pair of adjacent cysteines. Typical examples are 
defensins, hepcidin, insulin-like growth factor I, norrin, placental 
growth factor, resistin, sarcospan, vascular endothelial growth 
factor A, and Kunitz-type trypsin inhibitor SdPI.61 Our results for µ-
PIIIA isomers revealed the complexity of synthesis, chemical 
analysis, and structural characterization of such conformational 
isomers and the urgent need for standards for elucidating the 
disulfide connectivity and 3D structure of disulfide-rich peptides 
and proteins. 
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Epilogue 
The 15 possible -PIIIA isomers possessing each three disulfide bonds have been 
synthesized and characterized for the first time. Comparison of the analytical methods 
subjected revealed that HPLC and NMR alone are not sufficient to distinguish between all 
isomers indicating the need for better purification methods or alternative procedures. In 
contrast, MALDI-MS/MS was the only method to identify the respective disulfide connectivity, 
yet this was highly depending on the purity of the peptides after partial reduction and 
derivatization. In case of -PIIIA, LC-ESI-MS/MS was not suitable for full fragmentation of the 
linear peptide sequence contrary to the earlier described conotoxins -SIIIA and -EVIA. It 
was further found that the biological activity of the isomers seemed to correlate with the 
rigidity of the synthesized structure with the native connectivity as the most active one within 
a set of further active peptide isomers. More than 50% of the isomers investigated showed 
no significant block of the ion channel NaV1.4.  
This article improves the knowledge regarding -conotoxins by focusing on the impact of the 
disulfide bonds on structure elucidation and biological activity in contrast to the previous 
publication which concentrated on sequence dependence. Furthermore, a direct comparison 
of different analytical methods was carried out in order to answer the question if one method 
alone is sufficient to identify all 15 possible isomers of a -conotoxin. As a consequence of 
this study the urgent need for suitable standards of multiple disulfide-bridged peptides is 
derived. 
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5. Conclusions 
 
This work comprises two parts. The first chapter summarizes publications of parts I, II and III 
reporting the results from studies of the oxidative folding of cysteine-rich peptides in room-
temperature Ionic Liquids. The second chapter (parts III – VI) combines structure elucidation 
and analytical characterization with respective structure-activity relationship studies of 
selected conotoxins.  
 
5.1 Oxidative folding of cysteine-rich peptides in Ionic 
Liquids 
Ionic Liquids were established as novel solvents for various applications including peptide 
chemistry, e.g. in the synthesis and characterization of peptides.169 In this work oxidative 
folding of cysteine-containing conopeptides in Ionic Liquids was in the focus and was 
compared with conventional buffer oxidation using redox-active agents. Several features 
were identified, which influenced the product formation during the oxidation process. On the 
one hand, the primary sequence of the peptide including its length and net charge and, on 
the other hand, the RT-IL used for the oxidation had the largest influence on product 
formation depending on the hydrophilicity and hydrophobicity, respectively, of the peptide. 
For the conotoxins of interest, imidazolium-based RT-ILs showed best results. However, the 
anion had a large impact on the oxidation outcome. While acetate resulted in high oxidation 
yields, diethylphosphate, dicyanamide and tosylate did not lead to product formation for 
various conotoxins. The impact of IL ions on solvation of peptides and proteins have been 
described earlier.238 In addition, the water content of the respective RT-IL (>3% v/v) 
decreased oxidation efficacy of the applied peptides, while for proteins or enzymes higher 
concentrations of water are required to maintain the correct folding for bioactivity or catalytic 
function.169 Higher temperatures (60 – 80 °C) increased the oxidation rate and prevented the 
peptide from thermal decomposition resulting in a faster product formation compared to room 
temperature reactions. Although much higher peptide concentrations were applied for IL-
oxidation, the intramolecular formation of disulfide bonds was preferred in contrast to 
intermolecular formation of di- or oligomers due to the unique solvation effects of IL ions. The 
block of the ion channel NaV1.4 by IL-oxidized -conotoxin SIIIA could be demonstrated, 
however, the biological activity was drastically reduced. This effect was explained by IL ions 
attached to amino acid side chains responsible for the interaction between toxin and ion 
channel. This hypothesis was supported by MD simulations showing acetate ions interacting 
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with basic residues, e.g. Lys and Arg, of the sequence responsible for bioactivity. Attachment 
of IL ions to peptides influencing the structure was also reported by Lesch et al..239 Here, it 
was observed by a shift in the retention time after multiple purification steps in HPLC analysis 
indicating that the ions remained on the peptide. This shift was also observed for the peptide 
oxidized in buffer and stored in an IL, which also revealed a reduced bioactivity. Furthermore, 
formation of different disulfide-bridged isomers could be excluded after determination of the 
disulfide connectivity via LC-ESI-MS/MS, which is discussed in more detail in the chapter 
5.2. Therefore, the preparation of peptides and proteins in RT-ILs show significant limitations 
with respect to their biological function or target activity. However, although the inhibitory 
effect of the toxin -SIIIA on the ion channel was hindered by the attached IL ions, the 
peptide showed no limitations with respect to a tryptic digest using BAPNA as the 
chromogenic substrate. Here, access of the enzyme to the peptide was not hindered by the 
IL ions attached.  
Although ILs have high potential for several applications, their application for oxidative folding 
of conotoxins is limited because the product obtained has only decreased bioactivity 
compared to conventional, buffer-oxidized peptide even after several purification steps. A 
solution for this limitation would be an improved purification method to remove the attached 
ions and release of the fully bioactive compound. 
 
5.2 Analytical characterization and structure-activity 
relationships of conotoxins 
Detailed analytical characterizations in combination with structure elucidation are required to 
confirm the synthesized conotoxin structure and are essential for further SAR studies with 
the respective biological target. One important aspect is the analytical confirmation of the 
disulfide connectivity in the conotoxins of interest, and cysteine-containing peptides and 
proteins in general. Therefore, a partial reduction and derivatization protocol in combination 
with LC-ESI-MS/MS was applied to -SIIIA oxidized in buffer solution, oxidized in IL and 
buffer-oxidized peptide stored in IL to confirm the formation of the native disulfide 
connectivity. Partial reduction was performed with TCEP and alkylation of the thiol-function 
with IAA revealed the former disulfide bridging. In all cases the same disulfide crosslinking 
was observed for the tested peptides. In addition, small amounts of other isomers could be 
identified using this method. In addition, identification of the specific conotoxin binding sites 
were rarely investigated so far, because of their exhausting and time-consuming manner. 
However, such studies are pivotal for clarifying the respective target selectivity and 
preventing unwanted side effects resulting from unspecific binding to other targets.  
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The -conotoxin EVIA selectively inhibits the inactivation of neuronal Na+-channel NaV1.7 
without effecting muscular or cardiac muscular VGSCs (NaV1.4 and 1.5). This enhances 
terminal excitability of nerves and synaptic efficacy at the neuromuscular junction by 
increasing the duration of action potentials in myelinated axons and spinal neurons.240 
Although the structure was published previously by Volpon et al.210 the structure of the self-
synthesized -EVIA was confirmed by NMR studies. Determination of the disulfide 
connectivity was performed with the same protocol as previously described for -SIIIA using 
partial reduction and derivatization prior to sequencing via LC-ESI-MS/MS. The toxin binding 
site explaining the selectivity of the toxin was identified by a combination of theoretical 
molecular modelling and docking studies and experimental patch-clamp experiments using 
chimeras of sensitive NaV1.7 and insensitive NaV1.4. This combined approach identified 
domain I and IV as pivotal for the sensitivity of NaV1.7. In addition, the linker between 
segment 3 and 4 was identified as most important part for bioactivity within domain IV 
because of the interaction between inactivated voltage sensor and -EVIA decreasing speed 
of inactivation. These results improve the knowledge of voltage-dependent channel gating 
and the mechanism of activation and inactivation for respective isoforms. However, further 
research is required to fully understand the complete mechanisms of activation and 
inactivation of VGSCs. Here, the -conotoxins represent an interesting research tool for 
further investigations, but also to support studies of other voltage-sensor toxins obtained 
from scorpions, spiders or sea anemones.  
Although intensive studies of the past focused on -conotoxins, the reason for their high 
subtype specificity within VGSCs, which is conserved in a short sequence (15 - 25 AA), is not 
fully understood yet. Furthermore, the product formation during self-folding seems to be 
highly sequence-dependent resulting in one or more disulfide-bridged isomers.63,143 Besides 
the native conformation other isomers obtained for -KIIIA and -PIIIA revealed biological 
activity too, complicating the whole process of establishing reliable SARs. To study the 
impact of the amino acid sequence and formation of disulfide bonds on the formation of the 
folded peptide a combination of in silico and in vitro experiments was used. Therefore, five -
conotoxins (GIIIA, KIIIA, PIIIA, SIIIA and SmIIIA) were used as model peptides. The product 
formation during oxidation with redox-active agents described in previous studies was 
confirmed indicating two groups.63,91,116 One major product was observed for -GIIIA and -
SIIIA harbouring the native connectivity, whereas -PIIIA and -SmIIIA resulted in several 
fully oxidized isomers. For the remaining -KIIIA one major product with a non-native 
crosslinking (Cys1-Cys5, Cys2-Cys4, Cys3-Cys6) besides one minor product containing the 
native bridging were observed. The formation of different products can be explained with two 
existing folding mechanisms. On the one hand, a rapid collapse provokes fast formation of a 
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stable conformation, while on the other hand a slower re-arrangement results in the 
formation of different isomers for the individual conotoxins. Molecular dynamics simulations 
were utilized to receive an impression about this process. Starting from the respective NMR 
structures the removal of single disulfide bonds elucidated the conformational stability of the 
structures. Distance measurements of the free thiol functions for the one and two disulfide 
linked peptides in combination with RMSD and RMSF reveal the rigidity of the structure. 
From this research the contribution of the primary sequence to the final stability is 
ascertained. Furthermore, the rigidity of the disulfide-deficient species can be used to 
estimate their biological activity especially for the one bridge opened version. Here, the 
disulfide bond Cys2-Cys5 had no significant effect with respect to flexibility of the structure. 
The remaining two bridges (Cys1-Cys4, Cys3-Cys6) between the adjacent cysteines were 
sufficient to maintain the conformational stability. This implemented that this bond can be 
removed without significant or complete loss of biological activity. Although extensive 
research studies are missing to test all five conotoxins, the results obtained from previous 
studies with -KIIIA support our findings with respect to conformational stability and biological 
activity.241,242 Recent developments for disulfide-deficient species of -GIIIA revealed the 
influence of the individual disulfide bridges upon alanine mutation.243 After removing the 
Cys2-Cys5 connectivity biological activity on NaV1.4 was still observed. However, a reduced 
bioactivity (e.g. up to 50%) was observed for all mutations leaving open the impact of alanine 
substitutions on the rigidity of the structure. i.e. serine would probably represent a more 
suitable residue for future mutational studies. 
To clarify the impact of the residues on conformational stability of the conotoxins a 
visualization approach was applied in order to change the scope to more global residue 
movement observations. Therefore, residue surface proximity studies rendering the native 
structure in layers for the whole MD simulation time were performed. The layer membership 
of individual residues changes during simulation time influencing the adjacent residues. 
Here, the basic residues, essential for biological activity, maintain their position on the 
surface of the molecule. Instead the cysteine residues, responsible for structural stability, and 
also serine changes layer membership rather often. This opens a new perspective, revealing 
a paradox view on the commonly stable disulfide bonds moving frequently to stabilize the 
orientation of the basic residues on the surface of the molecule. Although such a layer 
approach was utilized for larger proteins before,244 the application to peptides reveals new 
insights into the movement of individual residues. Finally, the complex folding behaviour of 
disulfide-rich peptides holds great potential for future research to elucidate mechanisms of 
product (correctly folded) and by-product (misfolded) formation as well as simplification of the 
corresponding conotoxins to simpler synthetic versions. Research within the field of in silico 
studies help to understand and show complex processes, e.g. folding, docking and dynamic 
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simulations, to a broader scientific community. However, the results of such studies have to 
be verified with experimental data to ensure the correctness of the obtained data. 
After analyzing the influence of the primary sequence on the biological activity of -
conotoxins, the residues are kept constant to elucidate only the impact of a different disulfide 
crosslinking on the corresponding activity. In previous studies by Tietze et al., three isomers 
of -PIIIA were isolated from a self-folding approach and characterized.96 Besides the native-
bridged isomer another isomer harbouring the disulfide connectivity Cys1-Cys5, Cys2-Cys6, 
Cys3-Cys4, which was confirmed by 2D-NMR experiments, showed a higher biological 
activity on NaV1.4 compared to the native one. Therefore, -PIIIA was chosen as a model 
peptide to proceed with the further work in this direction.  
It could be shown that one method alone is not suitable for structure analysis of -PIIIA 
isomers, and, in turn, for venomics approaches because each method used has a unique 
output, i.e. confirmation of primary sequence, disulfide connectivity or 3D conformation 
lacking the combination of all aspects to distinguish between disulfide conformational 
isomers. In some cases, these limitations of the respective methods clearly depend on the 
primary sequence examined, which might result in ambiguous or even misleading 
information as was described for several examples, e.g. the disulfide connectivity of -
KIIIA.116 
The evaluation of all possible 15 -PIIIA isomers is even more time consuming compared to 
three isomers derived from an -conotoxin, because in the latter case all isoforms can 
possibly be baseline-separated in HPLC analysis. Thus, single forms can be isolated and 
characterized. This is indeed not the case for the disulfide-rich peptides containing three 
disulfide bonds, which was demonstrated in this work by co-elution of different isomers 
showing similar or even identical elution behaviour. In some cases the characterization of 
one single peak lead to ambiguous results due to contamination with other isomers. 
Nevertheless, for the first time 15 isomers of a 3-times disulfide-linked conotoxin were 
synthesized, chemically and structurally analyzed and tested for their activity at skeletal 
NaV1.4. Discrimination of the different isomers with MALDI-MS/MS was possible depending 
on the purity of the sample, whereas ESI-MS/MS was inefficient for the sequencing of -PIIIA 
because of low sequence coverage. It was shown that the potential of the available analytical 
methods (HPLC, NMR, MALDI-MS/MS and ESI-MS/MS) is limited and an individual method 
is not able to discriminate unequivocally between the 15 isomers. Thus, this study 
demonstrates the urgent need for suitable standards of peptides and proteins with multiple 
disulfide bonds to verify a disulfide connectivity obtained experimentally.  
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In the further process of SAR studies the obtained µ-PIIIA structures were clustered in three 
groups according to their structural flexibility. In docking studies the rigid isomers revealed a 
higher capacity of binding to NaV1.4 ion channel compared to the flexible structures. These 
results correlated well with the observations from the electrophysiological experiments, in 
which the rigid isomers Cys1-Cys5, Cys2-Cys3, Cys4-Cys6 and the native connectivity Cys1-
Cys4, Cys2-Cys5, Cys3-Cys6 were most active, while the most flexible isomers Cys1-Cys2, 
Cys3-Cys4, Cys5-Cys6 and Cys1-Cys3, Cys2-Cys6, Cys4-Cys5 were inactive. Furthermore, 
the resting time of the different structures on the channel pore also correlated with the 
experimentally determined time constants. These observations were attributed to the 
different orientations of the basic residues Arg2, Arg12, Arg14, Arg20, Lys9 and Lys17, as 
well as Phe7 and Pyr1 and their interaction with the surface of the channel and coverage of 
the pore region. Especially Arg14, which interacts with the selectivity filter motif, and Arg20, 
which protrudes the pore, were essential for high binding affinity. 
In conclusion, this thesis comprises studies covering multiple aspects of conotoxin research 
including synthesis, oxidation, structure elucidation, SAR studies and biological activity on 
VGSCs. In addition, the advantages and limitations of a set of analytical methods with 
respect to the determination of disulfide bridging of peptides was critically evaluated.  
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6. Abbreviations 
 
All Abbreviations of amino acids and their derivatives are according to the 
recommendation of the IUPAC-IUB Joint Commission on Biochemical Nomenclature 
(JCBN) and the Nomenclature Committee of IUB (NC-IUB).245 In general, L-
configuration of amino acids and amino acid derivatives was used. 
1D  one-dimensional  
2D  two-dimensional  
3D 
1,5-DAN  
three-dimensional  
1,5- diaminonaphthalene 
ACE 
BAPNA 
Boc 
BPTI 
[C2mim][OAc] 
CID 
Cys or C  
angiotensin-converting enzyme 
(N-benzoyl-DL-arginine-4-nitroanilide hydrochloride) 
tert-butyloxycarbonyl  
bovine pancreatic trypsin inhibitor 
1-ethyl-3-methylimidazolium acetate 
collision induced decay 
cysteine 
COSY 
CRISP 
DMSO  
correlated spectroscopy 
cysteine-rich secretory protein 
dimethyl sulfoxide  
DTT 
ESI 
FDA  
dithiothreitol 
electrospray ionization  
food and drug administration  
Fmoc 
GABA 
GLP-1 
GSH  
9-fluorenylmethyloxycarbonyl 
-Aminobutyric acid 
glucagon-like peptide-1 
glutathione reduced  
GSSG  glutathione oxidized  
HPLC  high performance liquid chromatography  
HSQC  heteronuclear single quantum coherence  
ICK  inhibitory cysteine knot  
IL  Ionic Liquid  
ISD in source decay 
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LC 
MALDI 
MS  
liquid chromatography 
matrix-assisted laser desorption ionization 
mass spectrometry  
MS/MS tandem mass spectrometry 
nAChR 
NCL 
NEM 
nicotinic acetylcholine receptor 
native chemical ligation 
N-ethylmaleimide  
NMR  nuclear magnetic resonance  
NOE  nuclear overhauser enhancement  
NOESY  nuclear overhauser and enhancement spectroscopy  
OS 
PDB 
PDI 
PG  
organic solvent  
protein data bank 
protein disulfide isomerases 
protecting group 
RMSD  root-mean-square-deviation  
ROE  rotating-frame overhauser enhancement  
ROESY  rotating-frame nuclear overhauser enhancement spectroscopy  
RP  reversed-phase  
RT-IL room-temperature Ionic Liquid  
SAR 
SPS 
SPPS  
structure-activity relationship 
solution-phase peptide synthesis  
solid-phase peptide synthesis 
TCEP 
TFA  
tris(2-carboxyethyl)phosphine 
trifluoro acetic acid  
TOCSY  total correlated spectroscopy  
TTX  tetrodotoxin  
VGSC  voltage-gated sodium channels  
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Supporting Figure 1. HPLC elution profiles of µ-conotoxins. Linear, reduced precursors of 
µ-conotoxins (A), and folded crude mixtures after 1 h (B) with the main product marked with 
an asterisk. Respective ESI mass spectra of the oxidized peptides are shown in (C).  
 
 
 Supporting Figure 2. Determination of peptide stability with RMSD (A), RMSF (B) and radius of gyration (C). All plots of the five -conotoxins 
are in alphabetic order: (a) GIIIA,bKIIIA, (c) PIIIA, (d) SIIIA, and (e) SmIIIA. In general, the peptide native fold is represented in black, the 
peptide with one bridge opened is shown in red, and the peptide with two open bonds is in green. Values are given in Table S3. 
1
4
3
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Supporting Figure 3. 1 µs test trajectory of native µ-PIIIA grouped into different clusters 
based on the RMSD values. 
 
 
 
  
  
1
4
5
 
Supporting Figure 4. Backbone stability of the five µ-conotoxins (black GIIIA, red KIIIA, green PIIIA, blue SIIIA, cyan SmIIIA) in the native 
state (A), with disulfide bridge C2 – C5 removed (B) and with two disulfide bridges C2 – C5, C3 – C6 removed (C). In the case of µ-KIIIA C2-C4 
and C3-C6 bonds were removed for the native peptide. 
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Supporting Figure 5. Backbone stability of -GIIIA and -SmIIIA. In general, the peptide 
native fold is represented in black, the peptide with one bridge opened is shown in red, and 
the peptide with two open bonds is in green. (A)-GIIIA average structures obtained and 
superimposed from 20 ns – 30 ns, 35 ns – 55 ns, and 65 ns – 70 ns. (B) RMSD for a 
simulation time of 100 ns of the respective peptide. In both cases, when compared with the 
native structure, the structure containing two disulfide bonds shows consistent structural 
stability. (C) -SmIIIA average structures obtained and superimposed from 15 ns – 25 ns, 45 
ns – 55 ns, and 85 ns – 95 ns. (D) RMSD for a simulation time of 100 ns of the respective 
peptide. In contrast to the native structure the appearance of helices in the structures after 
disulfide bonds removed is noteworthy resulting in comparable stability. Helix formation in 
µ-GIIIA occurs between residues D12 and Q18. In µ-SmIIIA helix formation is between the 
residues W14 and R20. 
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Supporting Figure 6. Representation of μ-PIIIA for native (black), one disulfide bridge (C2-
C5, red) and two disulfide bridges (C2-C5, C3-C6, green) removed (A). Backbone RMSD for 
the three peptides for 100 ns (B). 
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Supporting Figure 7. (A) Surface representation VDW and (B) Surface representation SAS 
(Solvent accessible surface) of the five -conotoxins.  
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Supporting Figure 8. The heatmaps show LR for the residues of μ-conotoxins KIIIA (A), 
PIIIA (B) and SIIIA (C) over a 100 ns simulation. LR values for each amino acid are stacked 
along the y-axis. LR is mapped to the color scale. Dark blue refers to the surface of the 
molecule, since the outermost layer is assigned the value zero. Higher layer values, mapped to 
yellow, depict the amino acids that mostly form the core of the respective conotoxin. The plot 
quickly reveals the distribution of residues among the layers. Some of the residues clearly 
change their surface proximity throughout the simulation. 
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Supporting Figure 9. Bar chart showing LR for the residues of all five μ-conotoxins GIIIA 
(A), KIIIA (B), PIIIA (C), SIIIA (D) and SmIIIA (E) for a 100 ns simulation. Larger bars 
show, that the corresponding residue changes its layer-membership frequently during the 
simulation. Thus, the plot quickly reveals the residues that compete with others, or these, that 
are stable with respect to their surface proximity. 
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Supporting Table 1. Comparison of sequence characteristics of the -conotoxins 
investigated in this study. Residues are highlighted according to their character: basic (blue), 
acidic (red), polar uncharged (green) and cysteine (yellow). (Z: pyroglutamate, O: 4-
hydroxyproline) *All peptides were used as amides. Native µ-SmIIIA occurs as C-terminal 
acid, however, is usually used as amide.[8,9] We used µ-SmIIIA as amide for reasons of 
comparison since both structures were found to be identical.[9] #In general IC50 values are 
given for expression in Xenopus oocytes with exception of SmIIIA, here only KD is available. 
 
  
μ-
Cono-
toxin 
Sequence Net Charge 
Structure Code (pdb)/ 
Structure Card[1] 
Bioactivity on 
NaV1.4#  
GIIIA -RDCCTOOKKCKDRQCKOQ-RCCA* +5 S00082 (1TCG)[2] 19 +/- 1 nM[3]  
KIIIA ---CCN----CSSKWCRDHSRCC-* +3 S00129 (2LXG)[4] 90 +/- 17 nM[5] 
PIIIA ZRLCCGFOKSCRSRQCKOH-RCC-* +6 S00159[6] 36 +/- 8 nM[3] 
SIIIA -ZNCCNG--GCSSKWCRDHARCC-* +2 S00125 (BMRB 20025)[7] 130 +/- 15 nM
[7]
 
SmIIIA -ZRCCNGRRGCSSRWCRDHSRCC-* +5 S00077 (1Q2J)[8] 0.22 +/- 1 nM[3] 
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Supporting Table 2. Comparison of disulfide loop length of the five µ-conotoxins. For the µ-
conotoxins GIIIA, PIIIA, SIIIA and SmIIIA, the values corresponding to disulfide loops 1, 2 
and 3 in the table is the number of residues present between the C1-C4, C2-C5 and C3-C6 
disulfide bridges respectively. For µ-KIIIA, the disulfide loops 1, 2 and 3 correspond to the 
number of residues occurring between the disulphide bridges C1-C5, C2-C4 and C3-C6. 
 
 
  
μ-Conotoxin Disulfide loop 1 Disulfide loop 2 Disulfide loop 3 
GIIIA 11 15 10 
KIIIA 15 6 11 
PIIIA 11 15 10 
SIIIA 9 14 11 
SmIIIA 11 16 11 
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Supporting Table 3. Assessment of stability using RMSD and radius of gyration for 100 ns 
MD simulation. 
µ-Conotoxin No. of Disulfide Bonds Backbone RMSD ( Å) Radius of Gyration ( Å) 
GIIIA 
3 1.8 7.6 
2 2.1 8.0 
1 2.8 8.2 
KIIIA 
3 1.1 6.7 
2 1.8 6.5 
1 2.5 7.1 
PIIIA 
3 2.3 8.0 
2 3.8 8.1 
1 4.9 8.5 
SIIIA 
3 2.6 7.0 
2 2.8 7.35 
1 5.7 8.5 
SmIIIA 
3 2.7 7.7 
2 2.9 7.6 
1 4.3 7.8 
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Supporting Table 4. Impact of the C2-C5 and C3-C6 disulfide bridge removal on the 
backbone and the functionally stable residues. Column 2 lists residues in each µ-conotoxin 
that are significant for binding activity as reported by Akondi et al..[15] Column 3 of the table 
shows the difference (within brackets) in residue fluctuation between the native bridged form 
and the C2-C5 disulfide removed form of the five µ-conotoxins. Column 4 reports the 
difference in residue fluctuation between the native bridged form and the C2-C5 and C3-C6 
disulfide removed conformations. The RMSF values are used as basis for determining 
increase or decrease of flexibility. A difference of close to 2 Ǻ between RMSF values is 
considered significant and is marked in bold. *In the case of µ-KIIIA the C2-C4 disulfide 
bridge is removed. **Besides the general statement for the conserved basic residue between 
C3 and C4 essential for biological activity of -conotoxins, no order of basic residues is 
described so far. 
 
  
µ-Conotoxin 
Functional basic 
residues in order of 
significance on 
biological activity on 
NaV1.4 
Comparison of flexibility 
on removal of the C2-C5* 
disulfide bridge (in Ǻ) 
Comparison of flexibility 
on removal of the C2-C5* 
and C3-C6 bridge 
disulfide bridge (in Ǻ) 
GIIIA R13 > R19 > R1, K8, K11, K16 > K9[10,11] 
R13 (0), R19 (0.5), R1 (0.7), 
K8(0.9), K11(0.1), K16 (0) 
K9 (0.1) 
R13 (0.5), R19 (2.6) ,R1 
(0.8), K8(0.7), K11(0.5), 
K16 (2.8), K9 (0) 
KIIIA H12 > R14 > K7 > 
R10[12,13] 
H12 (0.2), R14 (0.5), K7 
(0.4), R10 (0.3) 
H12 (0.8), R14 (0.9), K7 
(0.5), R10 (0.4) 
PIIIA R14 > K17 > R12, R20, 
R2, K9[14] 
R14 (1.3), K17 (0.7), R12 
(0), R20 (0.2), R2 (0.9), K9 
(1) 
R14 (1.4), K17 (0.2), R12 
(0.6), R20 (1.4), R2 (0.9), 
K9 (0.3) 
SIIIA R14 > K11, H16, R18** R14 (0.4), K11 (0.3), H16 (0.4), R18 (1.1) 
R14 (1.7), K11 (1.2), H16 
(1.9), R18 (2.8) 
SmIIIA R13 > R7, R8, R16, 
R20** 
R13 (1.4), R7 (1.6), R8 
(1.2), R16 (0.6), R20 (0.1) 
R13 (1.8), R7 (1.9), R8 
(2.2Å), R16 (0.6), R20 
(0.1) 
155 
 
Supporting References 
 
[1] Q. Kaas, R. Yu, A. H. Jin, S. Dutertre, D. J. Craik, Nucleic Acids Res. 2012, 40, 325–330. 
[2] K. Wakamatsu, D. Kohda, H. Hatanaka, J. M. Lancelin, Y. Ishida, M. Oya, H. Nakamura, F. 
Inagaki, K. Sato, Biochemistry 1992, 31, 12577–12584. 
[3] M. J. Wilson, D. Yoshikami, L. Azam, J. Gajewiak, B. M. Olivera, G. Bulaj, Proc. Natl. Acad. 
Sci. USA 2011, 108, 10302–10307. 
[4] K. K. Khoo, K. Gupta, B. R. Green, M. M. Zhang, M. Watkins, B. M. Olivera, P. Balaram, D. 
Yoshikami, G. Bulaj, R. S. Norton, Biochemistry 2012, 51, 9826–9835. 
[5] M. M. Zhang, B. R. Green, P. Catlin, B. Fiedler, L. Azam, A. Chadwick, H. Terlau, J. R. 
McArthur, R. J. French, J. Gulyas, et al., J. Biol. Chem. 2007, 282, 30699–30706. 
[6] A. A. Tietze, D. Tietze, O. Ohlenschläger, E. Leipold, F. Ullrich, T. Kühl, A. Mischo, G. 
Buntkowsky, M. Görlach, S. H. Heinemann, D. Imhof, Angew. Chem. Int. Ed. 2012, 51, 4058–
4061. 
[7] S. Yao, M. M. Zhang, D. Yoshikami, L. Azam, B. M. Olivera, G. Bulaj, R. S. Norton, 
Biochemistry 2008, 47, 10940–10949. 
[8] D. W. Keizer, P. J. West, E. F. Lee, D. Yoshikami, B. M. Olivera, G. Bulaj, R. S. Norton, J. 
Biol. Chem. 2003, 278, 46805–46813. 
[9] E. Fuller, B. R. Green, P. Catlin, O. Buczek, J. S. Nielsen, B. M. Olivera, G. Bulaj, Febs J. 
2005, 272, 1727–1738. 
[10] G. Choudhary, M. P. Aliste, D. P. Tieleman, R. J. French, S. C. Dudley  Jr., Channels 2007, 1, 
344–352. 
[11] K. Sato, Y. Ishida, K. Wakamatsu, R. KJato, H. Honda, Y. Ohizumi, H. Nakamura, M. Ohya, 
J.-M. Lancelin, D. Kohda, et al., J. Biol. Chem. 1991, 266, 16989–16991. 
[12] J. R. McArthur, G. Singh, D. McMaster, R. Winkfein, D. P. Tieleman, R. J. French, Mol. 
Pharmacol. 2011, 80, 573–84. 
[13] S. Mahdavi, S. Kuyucak, Toxins 2014, 6, 3454–3470. 
[14] J. R. McArthur, G. Singh, M. L. O’Mara, D. McMaster, V. Ostroumov, D. P. Tieleman, R. J. 
French, Mol. Pharmacol. 2011, 80, 219–227. 
[15] K. B. Akondi, M. Muttenthaler, Q. Kaas, D. J. Craik, R. J. Lewis, P. F. Alewood, Chem. Rev. 
2014, 114, 5815–5847. 
 
156 
 
Supplementary Information 
 
Conformational µ-PIIIA peptide isomers revisited: The 
impact of disulfide connectivity on structure and bioactivity  
 
Pascal Heimer,[a] Alesia A. Tietze,[b] Enrico Leipold,[c] Desiree Kaufmann,[d] Charlotte A. 
Bäuml,[a] Ajay A. Paul George,[a] Astrid Maass,[e] Jan Hamaekers,[e] Anja Resemann,[f] Franz 
J. Mayer,[f] Detlev Suckau,[f] Oliver Ohlenschläger,[g] Stefan H. Heinemann,[c]  Daniel Tietze[d]*
 
and Diana Imhof[a]* 
 
  
157 
 
Supporting Information  
Supporting Text 
Synthesis Notes. The combination of the standard acetamidomethyl (Acm), tert-butyl (tBu) 
and trityl (Trt) cysteine protecting groups was used for the synthesis of µ-PIIIA isomers 
(Figure S2, Table S1).1–3 Partially Cys-protected linear precursors were produced and 
subjected to stepwise oxidation in the following order regarding side chain deprotection: (1) 
oxidation of formerly Trt-protected Cys-pair, (2) deprotection and oxidation of the Acm-
protected Cys-pair, and (3) deprotection and oxidation of the tBu-protected Cys-pair. 
Reaction control was carried out after each oxidation step to monitor the different behavior of 
the isomers during folding. Under the conditions applied, several isomers (1-3, 6, 14, 15) 
were produced as main products in higher yields compared to other peptides (7, 8, 10, 12, 
13), which contained side products (Figure S2, Table S2). In addition, for isomers 4, 5, 9, and 
10, two main products were obtained. These findings were rather unexpected with respect to 
the chemical synthesis strategy applied because critical aspects such as high temperature 
loss of the Acm group4 were considered in advance and, furthermore, an already established 
protecting group strategy was used.1 However, obvious side reactions take place at the final 
deprotection and oxidation step, where in some cases two completely oxidized species with 
different retention times were observed. This can only be explained by disulfide scrambling 
during oxidation with diphenylsulfoxide and trimethylsilylchloride, described by Szabo et al.3 
In this report, scrambling between the former Acm- and tBu-protected cysteines of the α-
conotoxin GI occurred during the synthesis process. However, this is in contrast to other 
protocols in which such a scrambling was not observed.5,6 
 
HPLC co-elution of isomer mixtures. In order to understand our previous findings obtained 
from an oxidative self-folding approach7, co-elution of different mixtures of isomers was 
performed (Figure S6). In general, equal amounts of three isomers in each case were mixed 
together and directly injected in the respective HPLC system equipped with either a C4 or a 
C18 column. In case of the RP18 column separations, only for one mixture (isomers 1, 2, 3) 
three peaks were detectable in the elution profile, yet not baseline separated (Figure S6a). 
Further mixtures of relevant isomers sharing a distinct disulfide bond such as 1, 3, and 15 
(C11-C16) or 3, 6, and 9 (C21-C22) (Figure S6b, c, e, f) resulted in two peaks. One 
exception was the mixture of isomers 3, 4, and 5 sharing bridge C4-C5 (Figure S6d), where 
only one peak was observed. In our opinion, this could be the reason why previous NMR 
experiments with isomer 3 failed due to contamination with other isomers that were obviously 
not present or as dominant for isomers 1 and 2 in the former study.7 Since the 
measurements using the C18 column revealed no significant difference in the retention times 
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of the isomer compared to those performed on a C8 column, the co-elution experiment was 
not carried out using C8 material. Instead, another HPLC instrument equipped with a C4 
column was chosen (Figure S6 g-l). However, observations were similar compared to the 
results obtained with the C18 column. One exception was the mixture of isomers 1, 2, and 3, 
where only two peaks were identified instead of three as found on the C18 column. These 
findings clearly indicate that resolution of µ-PIIIA isomers is not possible with the 
chromatographic methods commonly used to separate peptides and small proteins. 
Consequently, co-elution does not provide sufficient proof of identity for disulfide-rich 
peptides and proteins from biological, synthetic or recombinantly expressed material if not 
demonstrated for the respective standard molecules in suitable mixtures. 
 
NMR structure determination. For some µ-PIIIA isomers (with the exception of 1, β, 9, 11, 
14, 15) we observed an additional set of NMR cross peaks due to an intermediate or high 
backbone deviation. With respect to the MS/MS data, which did not indicate any major 
impurities resulting from alternative isomers (except for 6 and 1β), the additional NMR 
signals probably resulted from other toxin conformations being in slow exchange with the 
major conformation. Similar observations were reported for the three possible α-GI isomers 
possessing two disulfide bonds, yielding a very rigid backbone conformation for the natively 
folded isomer and flexible conformations for the non-native versions.8 The same was recently 
published for α-conotoxin Pu1.2,9 in which the C1-C2, C3-C4 isomer ensemble displayed the 
highest RMSD value and the lowest structural definition. 
Distance constraints derived from NOE data do not necessarily lead to a unique structure 
thus being compatible with multiple disulfide bond patterns.10 Even inter-cysteine NOEs, 
which are typically recognized as indicative for unique disulfide connectivity can lead to 
biased results for closely packed disulfide networks. Poppe and coworkers found that the 
disulfide pattern is underdetermined for approximately 30% of all NMR structures deposited 
in the PDB database.10 In order to test the NMR restraints with respect to the ambiguity of 
predicting the disulfide pattern, two alternative structure calculations based on the individual 
sets of NMR restraints were performed for all 15 isomers. These calculations revealed 
plausible alternative structures for isomers 1, β, 10, and 14, and to a lesser extent also for 4, 
5, and 8 (Table S5). This clearly indicates the importance of an unambiguous assignment of 
the disulfide bond patterns by additional methods, such as the aforementioned MS/MS 
analysis. 
However, re-evaluation of the results from the self-folding approach described earlier for 
isomers 1-γ7 revealed contamination with one or more isomers. This was supported by 
comparing our previous 2D TOCSY NMR spectra with the data obtained herein confirming 
that the former isomer β also contained 1 and vice versa. In addition, the former isomer γ 
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contained significant amounts of other isomers, most likely isomers 4 and 6, thus 
rationalizing the poor quality of the NOE data at that time.7 
Electrophysiological experiments. Human SCN4A (encoding the NaV1.4 channel α 
subunit, UniProt ID P35499) on a plasmid with CMV promoter was transiently expressed in 
HEK 293 cells as shown previously.11 Co-transfection of a plasmid encoding the CD8 antigen 
ensured visual detection of transfected cells with CD8-specific Dynabeads (Deutsche Dynal, 
Hamburg, Germany). Currents were measured with the whole-cell patch clamp method 24-
48 h after transfection.11 The patch pipettes contained (in mM): 35 NaCl, 105 CsF, 10 EGTA 
(ethylene glycol bis(2-amino-ethylether)tetraacetic acid), 10 HEPES (pH 7.4 with CsOH). The 
bath solution contained (in mM): 150 NaCl, 2 KCl, 1.5 CaCl2, 1 MgCl2, 10 HEPES (pH 7.4 
with NaOH). Holding potential was –120 mV, Na+ currents were elicited with depolarizing 
steps to 20 mV. Series resistance was corrected electronically up to 80%. Peptides, diluted 
in the bath solution, were applied focally to cells under consideration with a fine-tipped glass 
capillary. Time course of peak current decrease after peptide application was described with 
single-exponential functions.  
 
Homology modeling. High-affinity µ-conotoxin binding to the pore requires optimal 
positioning of the residues that contribute to the toxin receptor. However, the orientation of 
key residues responsible for high affinity toxin binding mainly depends on the global fold of 
the toxin. In case of cysteine rich toxins such as µ-PIIIA, the disulfide bond patter most likely 
determines the global fold. Therefore, the question arises how do individual disulfide bonds 
contribute determine the global fold of the toxin and how does this affect the orientation of 
key residues. To answer these questions, we aimed at using the aforementioned NMR 
structures and a homology model of NaV1.4 for molecular docking studies.  
Although crystal structures of voltage-gated Na+ channels (NaVRh PDB ID: 4DXW12, NaVAB-
Ile217Cys, -wt PDB ID: 3RVY13, 4EKW14) are available in the RCSB database, including the 
recently solved structure of an eukaryotic Nav channel (NaVPaS, pdb ID 5X0M)15 the 
structure of the mammalian NaV1.4 channel is not yet described. Therefore, we built an 
extended pore model including essential parts of the loop structures that connect the 
transmembrane segments S5 and S6 (see also Figure S9) of each pore domain with the 
pore helices SS1 and SS2 and the selectivity filter. So far, the recently determined crystal 
structure of a voltage-gated Ca2+ channel (PDB ID 3jbr)16, which also exhibits extended loop 
structures compared to NaV1.4 (Figure S9) being partly similar in length and sequence 
(sequence identity 21 %) according to the conservation score (Figure S9), was identified as 
the only available template for the anticipated loop modeling approach at that time. The 
structure of NaVPaS was not available, when this study was started, but is in good agreement 
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with our modelled structure (r.m.s.d. 1.9 Å, Figure S10). However, loops connecting S5 and 
SS1 of domain I and domain III were only partly modeled due to their much smaller size 
(domain I) or their poor sequence similarity (domain III, see Figure S9). The remaining loops 
were either correct in length or were modified by inserting or deleting the respective residues 
accordingly (Figure S9). Furthermore, due to the high structural similarity of the pore 
modules of CaV1.1 and NaVAB (PDB ID 3rvy, r.m.s.d. 1.56 Å, sequence identity 26.2 %) 
comprising transmembrane segments S5 and S6 and pore helices SS1 and SS2 of each 
pore domain, CaV1.1 was also considered as a suitable template for the pore module of 
NaV1.4. In order to retain the template structure as much as possible, the template sequence 
was only changed according to the target sequence for those regions that are essential for 
toxin binding (Figure S9). The crude homology model was then re-aligned with the pore 
module of the crystal structure of NaVAB re-adjusting backbone coordinates and side chain 
orientations accordingly and followed by a 2-ns refinement simulation in a membrane 
environment. 
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Supporting Table 1. Protecting group strategy used for the preparation of µ-PIIIA isomers. 
Isomer Connectivity Trt* Acm* tBu* 
1** C4-C21, C5-C22, C11-C16 C4-C21 C5-C22 C11-C16 
2** C4-C16, C5-C21, C11-C22 C4-C16 C11-C22 C5-C21 
3** C4-C5, C11-C16, C21-C22 C4-C5 C11-C16 C21-C22 
4 C4-C5, C11-C21, C16-C22 C4-C5 C11-C21 C16-C22 
5 C4-C5, C11-C22, C16-C21 C4-C5 C11-C22 C16-C21 
6 C4-C11, C5-C16, C21-C22 C21-C22 C5-C16 C4-C11 
7 C4-C11, C5-C21, C16-C22 C4-C11 C5-C21 C16-C22 
8 C4-C11, C5-C22, C16-C21 C16-C21 C5-C22 C4-C11 
9 C4-C16, C5-C11, C21-C22 C21-C22 C4-C16 C5-C11 
10 C4-C16, C5-C22, C11-C21 C11-C21 C5-C22 C4-C16 
11 C4-C21, C5-C11, C16-C22 C5-C11 C4-C21 C16-C22 
12 C4-C21, C5-C16, C11-C22 C5-C16 C11-C22 C4-C21 
13 C4-C22, C5-C11, C16-C21 C4-C22 C16-C21 C5-C11 
14 C4-C22, C5-C16, C11-C21 C4-C22 C11-C21 C5-C16 
15 C4-C22, C5-C21, C11-C16 C4-C22 C5-C21 C11-C16 
*Protecting group used for the given cysteine pair. 
**These isomers have been described previously7. 
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Supporting Table 2. Analytical characterization of µ-PIIIA isomers produced in this study. 
Isomer 
tR (C18) 
[min] 
tR (C8) 
[min] 
MW (calc.) 
[mono] 
MW (found) 
[M+H]+ 
NMR  
(MHz) 
1 16.4 17.7 2603.1 2604.2 600 
2 16.2 17.1 2603.1 2604.2 600 
3 17.6 18.8 2603.1 2604.2 700 
4  18.5 19.6 2603.1 2604.1 700 
5 17.5 18.7 2603.1 2604.1 600 
6 17.4 18.3 2603.1 2604.1 700 
7 
1: 16.9* 
2: 18.1 
1: 17.0 
2: 18.4 
2603.1 2604.1 700 
8 17.4 18.5 2603.1 2604.2 700 
9 
1: 16.1*  
2: 19.6 
1: 17.1 
2: 20.6 
2603.1 2604.1 700 
10 17.4  18.6 2603.1 2604.3 600 
11 15.6 16.8 2603.1 2604.2 900 
12 17.4  18.5 2603.1 2604.1 700 
13 19.9 20.9 2603.1 2604.2 700 
14 16.3  17.5 2603.1 2604.1 700 
15 16.4 17.3 2603.1 2604.0 900 
tR, retention time; MW, molecular weight; calc., calculated. 
*Isomers occurring as two or more peaks in HPLC analysis were separately analyzed, 
and the respective fraction used for NMR structure determination is marked. 
  
Supporting Table 3. Results from MALDI MS/MS sequencing of partially reduced and alkylated μ-PIIIA species of the respective isomers as 
derived from internal fragments and BioTools analysis (Bruker). The carbamidomethylated species were analyzed to obtain the corresponding 
results. The disulfide connectivity obtained in MS/MS, which correlates to the envisaged synthesis product, is marked in bold. Isomers, in which the 
expected bridging is not correlating with the MS data are marked in italics. Retention times (first column) are given relative to the 6x 
carbamidomethylated version. The unmodified (0 CAM) and 6x carbamidomethylated versions cannot be used for structure elucidation and are 
therefore marked with “-“.  
Isomer 1 (C4-C21, C5-C22, C11-C16) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
-0.5 2724.2 2 1497 ZRLC*CGFOKSCRSRQCKOHRC*C-NH2 C4–C21 
2838.3 4 1554 ZRLCC*GFOKSC*RSRQC*KOHRCC*-NH2 C4–C21 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
2.0  2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
2724.2 2 1440 + 1497 ZRLC’C*GFOKSCRSRQCKOHRC’C*-NH2 C5–C22 and C4–C21 
Disulfide connectivity with highest score: C4–C21, C5–C22, C11–C16 
Isomer 2 (C4-C16, C5-C21, C11-C22) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
0.5 2724.2 2 1497 ZRLC*CGFOKSCRSRQC*KOHRCC-NH2 C4–C16 
2838.3 4 1497 + 1554 ZRLC*CGFOKSC*RSRQC*KOHRCC*-NH2 C5–C21 
1.4 2724.2 2 1440 + 1497 ZRL(CC)*GFOKSCRSRQCKOHR(CC)*-NH2 C4–C22 and C5–C21 
1
6
3
 
  
2838.3 4 1497 ZRLC*C*GFOKSCRSRQCKOHRC*C*-NH2 C4-C5, C4-C22, C5-C22 
2.4 2724.2 2 1440 ZRLC*C*GFOKSCRSRQCKOHRCC-NH2 C4-C5, C4-C22, C5-C22 
2.8 2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C16, C5–C21, C11–C22 
Isomer 2 (C4-C16, C5-C21, C11-C22) from oxidative self-folding approach in buffer7 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
-1.0 2724.2 2 1497 ZRLCC*GFOKSCRSRQCKOHRC*C-NH2 C5–C21 
2838.2 4 1554 ZRLC*C*GFOKSCRSRQC*KOHRC*C-NH2 C11–C22 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
0.2 2724.2 2 1497 ZRLC*CGFOKSCRSRQC*KOHRCC-NH2 C4–C16 
2838.2 4 1554 ZRLC*C*GFOKSCRSRQC*KOHRC*C-NH2 C11–C22 
1.1 2724.2 2 1440 + 1497 ZRL(CC)*GFOKSCRSRQCKOHR(CC)*-NH2 C5–C22 and C5–C21 
2838.5 4 1497 + 1611 ZRLCCGFOKSC*RSRQC*KOHRC*C*-NH2 C5-C22 
2.8  2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C16, C5–C21, C11–C22, minor C4–C21, C5–C22, C11–C16 
Isomer 3 (C4-C5, C11-C16, C21-C22) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1.4 2724.2 2 1440 ZRLC*C*GFOKSCRSRQCKOHRCC-NH2 C4–C5 
1
6
4
 
  
2838.3 4 1497 ZRLC*C*GFOKSCRSRQCKOHRC*C*-NH2 C11–C16 
3.1 2724.2 2 1554 ZRLCCGFOKSC*RSRQC*KOHRCC-NH2 C11–C16 
2838.3 4 1611 ZRLCCGFOKSC*RSRQC*KOHRC*C*-NH2 C4–C5 
4.1  2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C5, C11–C16, C21–C22 
Isomer 4 (C4-C5, C11-C21, C16-C22) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
0.3 2724.4 2 1440 ZRLC*C*GFOKSCRSRQCKOHRCC-NH2 C4–C5 
2838.5 4 1497 ZRLC*C*GFOKSCRSRQC*KOHRCC*-NH2 C11–C21 
2.7 2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
3.5 2724.4 2 1497 ZRLCCGFOKSC*RSRQC*KOHRCC-NH2 C16–C22 
2838.5 4 1611 ZRLCCGFOKSC*RSRQC*KOHRC*C*-NH2 C4–C5 
Disulfide connectivity with highest score: C4–C5, C11–C21, C16–C22 
Isomer 5 (C4-C5, C11-C22, C16-C21) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1.4 2724.2 2 1497 ZRLCCGFOKSC*RSRQCKOHRCC*-NH2 C11–C22 
3.1 2724.2 2 1554 ZRLCCGFOKSCRSRQC*KOHRC*C-NH2 C16–C21 
1
6
5
 
  
2838.3 4 1611 ZRLCCGFOKSC*RSRQC*KOHRC*C*-NH2 C4–C5 
4.1 2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
2724.2 2 1440 ZRLC*C*GFOKSCRSRQCKOHRCC-NH2 C4–C5 
2838.3 4 1497 ZRLC*C*GFOKSC*RSRQCKOHRCC*-NH2 C16–C21 
Disulfide connectivity with highest score: C4–C5, C11–C22, C16–C21 
Isomer 6 (C4-C11, C5-C16, C21-C22) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
3.1 2724.4 2 1554 + 1497 ZRLCCGFOKSC’RSRQC’KOHRC*C*-NH2 C11–C16 and C21–C22 
2838.4 4 1611 +1554 ZRLCCGFOKSC*RSRQC*KOHRC*C*-NH2 
ZRLCC*GFOKSCRSRQC*KOHRC*C*-NH2 
C4–C5 and C4–C11 
3.4 2724.4 2 1497 ZRLCC*GFOKSCRSRQC*KOHRCC-NH2 C5–C16 
2838.4 4 1611 +1554 ZRLCCGFOKSC*RSRQC*KOHRC*C*-NH2 
ZRLCC*GFOKSCRSRQC*KOHRC*C*-NH2 
C4–C5 and C4–C11 
4.2 2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C11, C5–C16, C21–C22, minor C4–C5, C11–C16, C21–C22 
Isomer 7 (C4-C11, C5-C21, C16-C22) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1.3 2724.2 2 1497 ZRLCCGFOKSC’RSRQC’KOHRC*C*-NH2 C5–C21 
1
6
6
 
  
2838.2 4 1611 +1554 ZRLC*CGFOKSC*RSRQC*KOHRC*C-NH2 
ZRLCC*GFOKSCRSRQC*KOHRC*C*-NH2 
C5-C22 and C4–C11  
2.7 2724.2 2 1497 ZRLCC*GFOKSCRSRQCKOHRC*C-NH2 C5–C21 
2838.2 4 1497 +1554 ZRLC*C*GFOKSC*RSRQCKOHRCC*-NH2 
ZRLCC*GFOKSCRSRQC*KOHRC*C*-NH2 
C16–C21 and C4–C11 
3.7 2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C11, C5–C21, C16–C22, minor C4–C11, C5–C22, C16–C21 
Isomer 8 (C4-C11, C5-C22, C16-C21) 
tR[a] 
(min) 
 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1.4 2724.2 2 1440 ZRLCC*GFOKSCRSRQCKOHRCC*-NH2 C5–C22 
2838.3 4 1497 ZRLC*C*GFOKSC*RSRQCKOHRCC*-NH2 C16–C21 
3.1 2724.2 2 1497 + 1554 ZRLC’CGFOKSC’RSRQC*KOHRC*C-NH2 C4–C11 and C16–C21 
2838.3 4 1611 ZRLC*CGFOKSC*RSRQC*KOHRC*C-NH2 C5–C22 
4.0 2724.2 2 1497 ZRLC*CGFOKSC*RSRQCKOHRCC-NH2 C4–C11 
2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C11, C5–C22, C16–C21 
Isomer 9 (C4-C16, C5-C11, C21-C22)  
Retention 
time[a] 
(min) 
Mass 
found 
(m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
Fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1
6
7
 
  
1.4 2724.2 2 1440 ZRLCC*GFOKSCRSRQCKOHRCC*-NH2 C5–C11 
2838.3 4 1554 ZRLC*C*GFOKSC*RSRQCKOHRCC*-NH2 C4–C16 
3.1 2724.2 2 1497  ZRLC’CGFOKSC’RSRQC*KOHRC*C-NH2 C4–C16 
2838.3 4 1554 ZRLC*CGFOKSC*RSRQC*KOHRC*C-NH2 C21–C22 
4.0 2724.2 2 1497 ZRLC*CGFOKSC*RSRQCKOHRCC-NH2 C21–C22 
2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4-C16, C5-C11, C21-C22 
Isomer 10 (C4-C16, C5-C22, C11-C21) 
tR[a] 
(min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
0.7 2724.4 2 1497 + 1440 ZRLC*CGFOKSCRSRQC*KOHRCC-NH2 
ZRLCC*GFOKSCRSRQCKOHRCC*-NH2 
C4–C16 and C5–C22 
2838.4 4 1497 +1611 ZRLC*C*GFOKSCRSRQC*KOHRCC*-NH2 
ZRLC*CGFOKSC*RSRQC*KOHRC*C-NH2 
C11–C21 and C5–C22 
2.9 2724.4 2 1497 + 1554 ZRLC*CGFOKSCRSRQC*KOHRCC-NH2 
ZRLCCGFOKSC*RSRQCKOHRC*C-NH2 
C4–C16 and C11–C21 
2838.5 4 1611 + 1554 ZRLC*CGFOKSC*RSRQC*KOHRC*C-NH2 
ZRLCC*GFOKSC*RSRQCKOHRC*C*-NH2 
C5–C22 and C4–C16 
3.6  2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C16, C5–C22, C11–C21 
Isomer 11 (C4-C21, C5-C11, C16-C22) 
tR[a] 
(min) 
MW  
found 
No. of CAM-
modified 
Internal 
fragment 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
1
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(m/z) residues (0-6) found[b] (m/z) 
-1.0 2724.3 2 1497 ZRLCC*GFOKSC*RSRQCKOHRCC-NH2 C5–C11 
2838.4 4 1554 ZRLC*C*GFOKSC*RSRQCKOHRC*C-NH2 C16–C22 
-0.2 2724.3 2 1497 ZRLC*CGFOKSCRSRQCKOHRC*C-NH2 C4–C21 
2838.4 4 1554 ZRLC*C*GFOKSC*RSRQCKOHRC*C-NH2 C16–C22 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
2.2 2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C21, C5–C11, C16–C22 
Isomer 12 (C4-C21, C5-C16, C11-C22)  
tR[a] 
(min) 
MW  
found 
(m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1.2 2724.3 2 1440 ZRLC*CGFOKSCRSRQCKOHRCC*-NH2 C16–C22 
2838.4 4 1497 ZRLC*C*GFOKSCRSRQC*KOHRCC*-NH2 C4–C21 
2.8 2610.1 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
3.1 2724.3 2 1497 ZRLCC*GFOKSCRSRQC*KOHRCC-NH2 C4–C21 
2838.4 4 1611 ZRLCC*GFOKSC*RSRQC*KOHRC*C-NH2 C16–C22 
Disulfide connectivity with highest score: C4–C21, C5–C16, C11–C22 
Isomer 13 (C4-C22, C5-C11, C16-C21)  
tR[a] 
 (min) 
MW  
found (m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
1
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0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1.1 2724.3 2 1440 ZRLC*CGFOKSCRSRQCKOHRCC*-NH2 C4–C22 
2838.4 4 1497 ZRLC*C*GFOKSC*RSRQCKOHRCC*-NH2 C16–C21 
2.7 2724.2 2 1554 ZRLCCGFOKSCRSRQC*KOHRC*C-NH2 C16–C21 
2838.3 4 1611 ZRLCC*GFOKSC*RSRQC*KOHRC*C-NH2 C4–C22 
3.6  2610.1 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C22, C5–C11, C16–C21 
Isomer 14 (C4-C22, C5-C16, C11-C21) 
tR[a] 
(min) 
MW  
found 
(m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
1.3 2724.2 2 1440 ZRLC*CGFOKSCRSRQCKOHRCC*-NH2 C4–C22 
2838.3 4 1497 ZRLC*C*GFOKSCRSRQC*KOHRCC*-NH2 C11–C21 
3.0 2724.2 2 1497 + 1554 ZRLCC*GFOKSC’RSRQC*KOHRC’C-NH2 C5–C16 and C11–C21 
2838.3 4 1611 ZRLCC*GFOKSC*RSRQC*KOHRC*C-NH2 C4–C22 
3.9  2610.1 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
2724.2 2 1497 ZRLCC*GFOKSCRSRQC*KOHRCC-NH2 C5–C16 
Disulfide connectivity with highest score: C4–C22, C5–C16, C11–C21 
Isomer 15 (C4-C22, C5-C21, C11-C16) 
tR[a] 
(min) 
MW  
found 
(m/z) 
No. of CAM-
modified 
residues (0-6) 
Internal 
fragment 
found[b] (m/z) 
Sequence (*carbamidomethylation, CAM) Disulfide connectivity 
1
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0 2952.0 6 1611 ZRLC*C*GFOKSC*RSRQC*KOHRC*C*-NH2 - 
0.7 2724.2 2 1497 ZRLCC*GFOKSCRSRQCKOHRC*C-NH2 C5–C21 
2838.3 4 1554 ZRLC*C*GFOKSCRSRQCKOHRC*C*-NH2 C11–C16 
1.6 2724.2 2 1440 + 1497 ZRLC*C’GFOKSCRSRQCKOHRC’C*-NH2 C4–C22 and C5–C21 
2838.3 4 1497 ZRLC*C*GFOKSCRSRQCKOHRC*C*-NH2 C11–C16 
3.2  2610.2 0 1440 ZRLCCGFOKSCRSRQCKOHRCC-NH2 - 
Disulfide connectivity with highest score: C4–C22, C5–C21, C11–C16 
[a] HPLC chromatogram, 10% eluent B for 15 min, then linear increase of eluent B up to 35% for another 25 min with A) 0.1% TFA in water and B) 0.1% TFA in 
acetonitrile. Retention time is given in minutes relative to the 6x-carbamidomethylated peptide version. 
[b] “Internal fragment found” is the fragment observed after MS/MS analysis for spectra containing the partial sequence SCRSRQCKOHRC with respective 
carbamidomethylated positions. 
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Supporting Table 4. Internal fragments for 2- and 4-times carbamidomethylated (CAM) µ-PIIIA species with distinct disulfide bond pattern. The 
positions of the CAM modification indicate the disulfide linkage directly for 2-CAM, while in the case of 4-CAM the non-carbamidomethylated 
positions are connected. 
Internal fragment  
(2-CAM) 
2724 
Resulting possible 
disulfide bond 
Internal fragment  
(4-CAM) 
2838 
Resulting possible 
disulfide bond 
1440 C4-C5 1497 C11,C16,C21,C22 
C4-C22 C5,C11,C16,C21 
C5-C22 C4,C11,C16,C21 
1497 C4-C11 1554 C5,C16,C21,C22 
C4-C16 C5,C11,C21,C22 
C4-C21 C5,C11,C16,C22 
C5-C11 C4,C16,C21,C22 
C5-C16 C4,C11,C21,C22 
C5-C21 C4,C11,C16,C22 
C11-C22 C4,C5,C16,C21 
C16-C22 C4,C5,C11,C21 
C21-C22 C4,C5,C11,C16 
1554 C11-C16  1611  C4,C5,C21,C22 
C11-C21 C4,C5,C16,C22 
C16-C21 C4,C5,C11,C22 
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 Supporting Table 5. Overview of NMR calculations including alternative calculations for isomers possible from disulfide scrambling. 
No. Connectivity 
1st  
bond 
2nd 
bond 
3rd 
bond 
Isomer 
found 
Alternative 
isomers 
NMR structure 
calculation 
(rmsd) for 
intended isomer 
Structure 
calculation for 
alternative 
isomer 
Structure 
calculation for 
alternative  
isomer 
1* 
C4-C21, C5-C22, 
C11-C16 
C4-C21 C5-C22 
C11-
C16 1 11, 12 *1.46 
12: 1.56 
(0.75, 4-22) 
11: 1.1  
(0.65, 4-22) 
2* 
C4-C16, C5-C21, 
C11-C22 
C4-C16 
C11-
C22 
C5-C21 2 9, 10 *1.22 9: 1.2  (0.72, 4-22) 
10: 0.94  
(0.65, 4-22) 
3* 
C4-C5, C11-C16, 
C21-C22 
C4-C5 
C11-
C16 
C21-
C22 3 4, 5 1.9 4: 3.5** 5: 3.9** 
4 
C4-C5, C11-C21, 
C16-C22 
C4-C5 
C11-
C21 
C16-
C22 4 3, 5 2.4 
3: 3.2  
(0.7, 8-20) 
5: 3.6  
(1.0, 8-22) 
5 
C4-C5, C11-C22, 
C16-C21 
C4-C5 
C11-
C22 
C16-
C21 5 3, 4 2.3 
3: 4.8  
(1.2, 7-18) 
4: 3.4  
(1.3 8-17) 
6 
C4-C11, C5-C16, 
C21-C22 
C21-
C22 
C5-C16 C4-C11 6 3, 9 2.7 (1.2, 1-18) 3: 3.4  (1.9, 1-18) 
9: 3.5  
(1.9, 1-18) 
7 
C4-C11, C5-C21, 
C16-C22 
C4-C11 C5-C21 
C16-
C22 - 6, 8 - - - 
8  
C4-C11, C5-C22, 
C16-C21 
C16-
C21 
C5-C22 C4-C11 8 5, 13 1.5 (1.1, 4-22) 
5: 4.4  
(2.8, 4-22; 1.2, 
10-22) 
13: 2.6  
(2.0, 4-22; 1.7, 4-
18) 
9 
C4-C16, C5-C11, 
C21-C22 
C21-
C22 
C4-C16 C5-C11 9 3, 6 2.2 (1.3, 1-18) 3: 3.5 6: 3.1  (2.4, 1-18) 
10  C4-C16, C5-C22, 
C11-C21 
C11-
C21 
C5-C22 C4-C16 10 4, 14 1.5 (1.05, 4-22) 
4: 2.2  
(1.7, 4-22; 1.2, 
4-18) 
14: 2.2  
(1.5, 4-22; 1.2, 4-
18) 1
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11  C4-C21, C5-C11, 
C16-C22 
C5-C11 C4-C21 
C16-
C22 11 9, 13 0.9 9: 3.4** 13: 4.1** 
12 
C4-C21, C5-C16, 
C11-C22 
C5-C16 
C11-
C22 
C4-C21 
- 6, 14 - - - 
13  
C4-C22, C5-C11, 
C16-C21 
C4-C22 
C16-
C21 
C5-C11 
- 14, 15 - - - 
14 
C4-C22, C5-C16, 
C11-C21 
C4-C22 
C11-
C21 
C5-C16 14 13, 15 0.9 13: 1.5 15: 2.0  (1.5, 4-22) 
15 
C4-C22, C5-C21, 
C11-C16 
C4-C22 C5-C21 
C11-
C16 15 13, 14 2.2 (1.5, 4-22) 13: 4.7** 14: 4.7** 
*These isomers have been described previously and were confirmed herein.7 **No convergence.  
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Supporting Table 6. Energy and structural statistics of the NMR ensembles of the μ-PIIIA isomers (lowest energy structures). 
NMR distance & dihedral constraints   (20 structures) 
Isomer 1* 2* 3 4 5 6 8 9 10 11 14 15  
Distance 
constraints 137 218 204 204 212 192 190 161 209 185 214 237  
Dihedral angle 
restraints 30 42 30 36 36 36 36 36 35 36 36 36  
Structure statistics 
 
Violations Mean (s.d.) in kJ/mol            
Total restraint 
violation energy   13.659 3.213 2.129 3.921 3.198 -9187 9.950 6.019 8.171 9.636  
Distance 
restraints   13.603 3.138 1.961 3.710 3.123 2.584 9.894 5.959 5.293 9.532  
Dihedral angle 
restraints 0.068 0.087 0.056 0.076 0.168 0.211 0.075 0.098 0.055 0.060 2.879 0.104  
Total Force field 
energy (Yasara) -233 -223 -9978 -9267 -9754 -8756 -9551 -9190 -10208 -9075 -7386 -10182  
Internal solute 
energy   -2599 -2819 -2789 -1420 -2876 -1884 -2707 -2901 -1608 -2799  
Electrostatic solv. 
energy   -7498 -6484 -7009 -7470 -6763 -7413 -7679 -6241 -5873 -7456  
Van der Waals 
solv. energy   118 36 44  134 89 107 177 66 95 73  
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Mean global 
r.m.s.d. (Å)              
Backbone global 
(residues 1-22) 
1.46 
(±0.44) 
1.22 
(±0.42) 
1.99 
(±0.65) 
2.46 
(±0.76) 
2.32  
(±0.77) 
2.77 
(±1.24) 
1.48 
(±0.33) 
2.12 
(±0.54) 
1.54 
(±0.23) 
0.94 
(±0.40) 
0.90 
(±0.35) 
2.21 
(±0.78)  
Heavy atoms 
(residues 1-22) 
2.65 
(±0.57) 
2.31 
(±0.46) 
2.39 
(±0.52) 
2.85 
(±0.70) 
2.76 
(±0.59) 
3.09 
(±1.17) 
2.12 
(±0.34) 
2.49 
(±0.55) 
2.23 
(±0.31) 
1.49 
(±0.31) 
1.74 
(±0.32) 
2.70 
(±0.68)  
Backbone rigid 
(residues) 
0.84 
(4-22) 
(±0.24) 
0.61 
(4-22) 
(±0.22) 
0.58 
(6-19) 
(±0.16) 
1.61 
(4-22) 
(±0.34) 
1.84 
(4-22) 
(±0.64) 
1.24 
(1-18) 
(±0.50) 
1.12 
(4-22) 
(±0.26) 
1.12 
(1-18) 
(±0.41) 
0.82 
(3-17) 
(±0.21) 
0.76 
(4-22) 
(±0.31) 
0.58 
(4-22) 
(±0.13) 
1.48 
(4-22) 
(±0.33) 
 
Heavy atoms 
rigid (residues) 
1.88 
(4-22) 
(±0.42) 
1.61 
(4-22) 
(±0.34) 
1.16 
(6-19) 
(±0.22) 
2.02 
(4-22) 
(±0.29) 
2.03 
(4-22) 
(±0.50) 
1.86 
(1-18) 
(±0.52) 
1.80 
(4-22) 
(±0.31) 
1.67 
(1-18) 
(±0.44) 
1.57 
(3-17) 
(±0.40) 
1.45 
(4-22) 
(±0.33) 
1.27 
(4-22) 
(±0.16) 
1.94 
(4-22) 
(±0.32) 
 
*Data obtained from CYANA according to Tietze et al.7. 
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Supporting Table 7. NMR resonance assignments for structural isomers of μ-PIIIA for the 
respective isomers: proton chemical shifts (ppm) in H2O/D2O (9:1). The isomers 1 and 2 have 
been described previously in Tietze et al.7. 
Isomer 3  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu - 4.21 1.88, 2.38 2.27, 2.26 - - - 
2     Arg 8.31 4.17 1.68, 1.62 1.52, 1.51 3.06 - - 
3     Leu 8.33 4.25 1.49 1.49 0.70, 0.76 - - 
4     Cys 8.61 4.15 3.26, 3.56 - - - - 
5     Cys 7.93 4.88 2.59, 3.00 - - - - 
6     Gly 8.5 3.75, 3.58 - - - - - 
7     Phe 8.09 4.74 2.99, 2.78 - 7.13 - 7.2 
8     Hyp - 4.44 1.92, 2.20 4.46 3.57, 3.76 - - 
9     Lys 8.53 4.16 1.67, 1.74 1.38, 1.36 1.58 2.88 - 
10   Ser 8.14 4.27 3.74, 3.72 - - - - 
11   Cys 8.32 4.59 2.99, 3.07 - - - - 
12   Arg 8.63 4.31 1.60, 1.85 1.49 3.07 7.05 - 
13   Ser 7.78 4.37 3.89, 3.78 - - - - 
14   Arg 8.3 4.02 1.75 1.52 3.08 7.07 - 
15   Gln 8.1 4.17 1.85, 1.96 2.21 - - - 
16   Cys 7.97 4.46 2.96, 3.08 - - - - 
17   Lys 8.06 4.45 1.58, 1.66 1.30, 1.34 1.54 2.84 7.42 
18   Hyp - 4.39 1.83, 2.17 4.45 3.64, 3.73 - - 
19   His 8.67 4.53 3.09 - - - - 
20   Arg 8.36 4.18 1.60, 1.65 1.46 3.04 7.06 - 
21   Cys 8.16 4.81 3.48, 3.28 - - - - 
22   Cys 8.67 3.82 3.19 - - - - 
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Isomer 4  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.77 4.21 2.38 - - - - 
2     Arg 8.26 4.19 1.60, 1.66 1.51 3.07 - - 
3     Leu 8.33 4.25 1.48, 1.64 - 0.72 - - 
4     Cys 8.61 4.15 3.55, 3.27 - - - - 
5     Cys 7.94 4.91 3.31, 2.59 - - - - 
6     Gly 8.5 3.76, 3.75 - - - - - 
7     Phe 8.1 4.75 2.99, 2.77 - - - - 
8     Hyp - 4.45 1.92, 2.20 4.46 3.76, 3.57 - - 
9     Lys 8.53 4.14 1.74, 1.67 1.36, 1.39 1.58 2.89 - 
10   Ser 8.15 4.28 3.74, 3.71 - - - - 
11   Cys 8.31 4.6 3.06, 2.99 - - - - 
12   Arg 8.62 4.31 1.60, 1.84 1.48 3.06 7.06 - 
13   Ser 7.79 4.36 3.78, 3.89 - - - - 
14   Arg 8.29 4.02 - - 3.07 - - 
15   Gln 8.1 4.17 1.96, 1.85 2.21 - 7.06 - 
16   Cys 7.97 4.46 2.94, 3.08 - - - - 
17   Lys 8.08 4.45 1.58, 1.66 1.33, 1.32 1.54 2.84 - 
18   Hyp - 4.39 2.18, 1.83 4.45 3.72, 3.64 - - 
19   His 8.63 4.52 3.07 - - - - 
20   Arg 8.33 4.18 1.66, 1.75 1.49 3.07 - - 
21   Cys 8.16 - 3.28, 3.48 - - - - 
22   Cys 8.68 3.81 - - - - - 
 
Isomer 5  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.76 4.22 2.39, 1.88 2.27 - - - 
2     Arg 8.33 4.2 1.74, 1.65 1.51 3.06 - - 
3     Leu 8.33 4.24 1.50 - 0.70, 0.76 - - 
4     Cys 8.61 4.16 3.27 - - - - 
5     Cys 7.91 4.89 3.30, 2.60 - - - - 
6     Gly 8.5 3.75 - - - - - 
7     Phe 8.09 4.74 2.99, 2.77 - 7.13 - - 
8     Hyp - 4.45 1.92, 2.20 4.45 3.58, 3.76 - - 
9     Lys 8.53 4.15 1.74, 1.66 1.39, 1.38 1.58 2.88 - 
10   Ser 8.15 4.27 3.72, 3.73 - - - - 
11   Cys 8.31 4.59 2.99, 3.07 - - - - 
12   Arg 8.62 4.31 1.59, 1.85 1.50, 1.49 3.06, 2.98 - - 
13   Ser 7.78 4.37 3.89, 3.78 - - - - 
14   Arg 8.3 4.02 1.75 1.52 3.07 - - 
15   Gln 8.1 4.17 1.96, 1.85 2.21 - - - 
16   Cys 7.97 4.46 3.08, 2.96 - - - - 
17   Lys 8.06 4.45 1.66, 1.58 1.33.1.32 1.53 2.84 - 
18   Hyp - 4.39 1.83, 2.17 4.45 3.64, 3.72 - - 
19   His 8.67 4.53 3.09 - - - - 
20   Arg 8.36 4.2 1.66, 1.60 1.46 3.04 - - 
21   Cys 8.15 4.81 3.28, 3.48 - - - - 
22   Cys 8.67 3.81 3.21 - - - - 
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Isomer 6  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.77 4.23 - - - - - 
2     Arg 8.32 4.19 1.59, 1.66 1.50, 1.51 - - - 
3     Leu 8.33 4.27 1.53 1.45 0.74 - - 
4     Cys 8.61 4.16 3.57, 3.28 - - - - 
5     Cys 7.93 4.89 2.59 - - - - 
6     Gly 8.5 3.76 - - - - - 
7     Phe 8.09 4.74 2.78, 3.00 - 7.14 - - 
8     Hyp - 4.46 2.21, 1.92 4.46 3.59, 3.76 - - 
9     Lys 8.53 4.16 1.67, 1.75 1.40 1.58 - 7.42 
10   Ser 8.15 4.28 3.72, 3.75 - - - - 
11   Cys 8.32 4.59 3.08, 2.99 - - - - 
12   Arg 8.63 4.31 1.85, 1.60 1.51 3.07 - - 
13   Ser 7.79 4.37 3.90, 3.79 - - - - 
14   Arg 8.3 4.03 1.76 1.53 3.08 - - 
15   Gln 8.1 4.18 1.95, 1.86 2.22 - - - 
16   Cys 7.98 4.47 2.96, 3.08 - - - - 
17   Lys 8.07 4.46 1.59, 1.67 1.33 1.55 - - 
18   Hyp - 4.4 2.18, 1.84 4.46 3.65, 3.73 - - 
19   His 8.65 4.53 3.08 - - - - 
20   Arg 8.34 4.19 1.71, 1.61 1.5 - - - 
21   Cys 8.16 4.82 3.48, 3.29 - - - - 
22   Cys 8.67 3.82 3.22 - - - - 
 
Isomer 8  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.77 4.23 2.27, 2.38 1.87 - - - 
2     Arg 8.33 4.17 1.64, 1.74 1.47 - - - 
3     Leu 8.34 4.25 1.40, 1.53 - 0.72 - - 
4     Cys 8.61 4.15 3.26, 3.55 - - - - 
5     Cys 7.9 4.88 3.28, 2.59 - - - - 
6     Gly 8.5 3.75 - - - - - 
7     Phe 8.09 4.74 2.77, 2.99 - 7.13 - - 
8     Hyp - 4.45 1.93, 2.20 4.46 3.58, 3.76 - - 
9     Lys 8.53 4.15 1.66, 1.74 1.36 1.57 2.88 - 
10   Ser 8.15 4.26 3.71, 3.73 - - - - 
11   Cys 8.31 4.59 2.98, 3.07 - - - - 
12   Arg 8.62 4.31 1.84, 1.59 1.47 3.07 - - 
13   Ser 7.78 4.37 3.78, 3.89 - - - - 
14   Arg 8.3 4.02 1.75 1.52 3.07 - - 
15   Gln 8.1 4.17 1.96, 1.85 2.21 - - - 
16   Cys 7.97 4.46 2.95, 3.08 - - - - 
17   Lys 8.06 4.45 1.66, 1.58 1.33, 1.29 1.53 2.84 - 
18   Hyp - 4.4 2.16, 1.83 4.45 3.72, 3.64 - - 
19   His 8.67 4.53 3.09 - - - - 
20   Arg 8.36 4.18 1.66, 1.59 1.45 3.08 - - 
21   Cys 8.16 4.82 3.47, 3.28 - - - - 
22   Cys 8.67 3.81 3.2 - - - - 
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Isomer 9  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu - 4.24 2.38, 1.88 2.28 - - - 
2     Arg 8.33 4.17 1.68, 1.62 1.47, 1.45 3.05 - - 
3     Leu 8.32 4.26 1.49 - 0.73 - - 
4     Cys 8.61 4.14 3.54, 3.26 - - - - 
5     Cys 7.93 4.88 2.61 - - - - 
6     Gly 8.5 3.75 - - - - - 
7     Phe 8.09 4.74 2.99, 2.77 - 7.13 - - 
8     Hyp - 4.44 1.92, 2.20 4.45 3.58, 3.75 - - 
9     Lys 8.53 4.15 1.74, 1.66 1.34, 1.39 1.58 2.88 - 
10   Ser 8.15 4.27 3.74, 3.71 - - - - 
11   Cys 8.32 4.59 3.07, 2.98 - - - - 
12   Arg 8.62 4.31 1.84, 1.60 1.49 3.06 - - 
13   Ser 7.78 4.36 3.89, 3.78 - - - - 
14   Arg 8.3 4.02 1.75 1.53 3.07 - - 
15   Gln 8.1 4.17 1.85, 1.96 2.21 - - - 
16   Cys 7.97 4.46 2.95, 3.08 - - - - 
17   Lys 8.07 4.45 1.66, 1.58 1.34, 1.3 1.54 2.84 - 
18   Hyp - 4.39 2.17, 1.83 4.45 3.73, 3.64 - - 
19   His 8.66 4.52 3.07 - 7.16 - - 
20   Arg 8.35 4.18 1.66, 1.59 1.47 3.05 - - 
21   Cys 8.16 4.81 3.48 - - - - 
22   Cys 8.67 3.81 - - - - - 
 
Isomer 10  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.77 4.23 2.38, 1.86 2.27 - - - 
2     Arg 8.33 4.18 1.74, 1.64 1.51 - - - 
3     Leu 8.32 4.25 1.46, 1.47 - 0.77, 0.70 - - 
4     Cys 8.61 4.15 3.54, 3.26 - - - - 
5     Cys 7.93 4.88 3.00, 2.91 - - - - 
6     Gly 8.5 3.75 - - - - - 
7     Phe 8.09 4.73 2.77, 2.99 - 7.18 - - 
8     Hyp - 4.45 1.92, 2.20 4.46 3.57, 3.76 - - 
9     Lys 8.53 4.15 1.74, 1.66 1.35, 1.40 1.57 2.87 - 
10   Ser 8.15 4.27 3.73 - - - - 
11   Cys 8.32 4.59 3.07, 2.99 - - - - 
12   Arg 8.63 4.31 1.85, 1.59 1.49 3.06 - - 
13   Ser 7.78 4.37 3.89, 3.78 - - - - 
14   Arg 8.3 4.02 1.75, 1.76 1.51, 1.53 3.07 - - 
15   Gln 8.1 4.17 1.85, 1.96 2.21 - - - 
16   Cys 7.97 4.46 2.96, 3.08 - - - - 
17   Lys 8.07 4.45 1.66, 1.58 1.33, 1.3 1.52 2.84 - 
18   Hyp - 4.4 2.16, 1.83 4.45 3.72, 3.64 - - 
19   His 8.67 4.53 3.08 - - - - 
20   Arg 8.36 4.18 1.66, 1.59 1.47, 1.48 3.07 - - 
21   Cys 8.16 4.82 3.48, 3.28 - - - - 
22   Cys 8.67 3.81 - - - - - 
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Isomer 11  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.80 4.3 2.46 2.35 - - - 
2     Arg 8.35 4.22 1.74, 1.70 1.53 3.12 - - 
3     Leu 8.3 4.35 1.60, 1.53 - 0.78, 0.84 - - 
4     Cys 8.44 4.6 3.02, 3.13 - - - - 
5     Cys 8.28 4.65 3.05, 3.17 - - - - 
6     Gly 8.39 3.79, 3.71 - - - - - 
7     Phe - 4.83 2.93, 3.17 - - - 7.27 
8     Hyp - 4.41 2.03, 2.28 4.57 3.83, 3.80 - - 
9     Lys 8.42 4 1.81 1.37 1.61 2.91 - 
10   Ser 7.89 4.42 3.87, 3.80 - - - - 
11   Cys 8.13 4.66 3.19, 3.10 - - - - 
12   Arg 8.31 4.29 1.75, 1.74 - 1.53- - - 
13   Ser 7.98 4.42 3.79, 3.84 - - - - 
14   Arg 8.21 4.31 1.71, 1.84 1.58 3.13 - - 
15   Gln 8.29 4.46 1.91, 2.04 2, 27 - - - 
16   Cys 8.69 4.59 - - - - - 
17   Lys 8.38 4.46 1.77, 1.75 1.4 1.50 - - 
18   Hyp - 4.29 1.99, 2.27 4.53 3.69, 3.68 - - 
19   His 8.39 4.64 3.05, 3.17 - 7.14 - 8.55- 
20   Arg 8.44 4.0 1.8 1.6 3.13 -  
21   Cys 8.51 4.78 3.08, 3.01 - - - - 
22   Cys 8.74 4.75 3.21, 3.06 - - - - 
 
Isomer 13 
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu - 4.21 1.88, 2.38 2.27, 2.26 - - - 
2     Arg 8.31 4.17 1.68, 1.62 1.52, 1.51 3.06 - - 
3     Leu 8.33 4.25 1.49 1.49 0.70, 0.76 - - 
4     Cys 8.61 4.15 3.26, 3.56 - - - - 
5     Cys 7.93 4.88 2.59, 3.00 - - - - 
6     Gly 8.5 3.75, 3.58 - - - - - 
7     Phe 8.09 4.74 2.99, 2.78 - 7.13 - 7.2 
8     Hyp - 4.44 1.92, 2.20 4.46 3.57, 3.76 - - 
9     Lys 8.53 4.16 1.67, 1.74 1.38, 1.36 1.58 2.88 - 
10   Ser 8.14 4.27 3.74, 3.72 - - - - 
11   Cys 8.32 4.59 2.99, 3.07 - - - - 
12   Arg 8.63 4.31 1.60, 1.85 1.49 3.07 7.05 - 
13   Ser 7.78 4.37 3.89, 3.78 - - - - 
14   Arg 8.3 4.02 1.75 1.52 3.08 7.07 - 
15   Gln 8.1 4.17 1.85, 1.96 2.21 - - - 
16   Cys 7.97 4.46 2.96, 3.08 - - - - 
17   Lys 8.06 4.45 1.58, 1.66 1.30, 1.34 1.54 2.84 7.42 
18   Hyp - 4.39 1.83, 2.17 4.45 3.64, 3.73 - - 
19   His 8.67 4.53 3.09, 3.09 - - - - 
20   Arg 8.36 4.18 1.60, 1.65 1.46 3.04 7.06 - 
21   Cys 8.16 4.81 3.48, 3.28 - - - - 
22   Cys 8.67 3.82 3.19 - - - - 
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Isomer 14  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.77 4.22 1.89, 2.40 2.27 - - - 
2     Arg 8.31 4.17 1.68, 1.62 1.51, 1.50 3.06 - - 
3     Leu 8.33 4.25 1.48 1.49 0.71, 0.77 - - 
4     Cys 8.61 4.15 3.54, 3.26 - - - - 
5     Cys 7.98 4.9 3.39, 2.68 - - - - 
6     Gly 8.5 3.76 - - - - - 
7     Phe 8.09 4.74 2.99, 2.78 - 7.13 - - 
8     Hyp - 4.44 2.20, 1.92 4.46 3.76, 3.58- - - 
9     Lys 8.53 4.16 1.67, 1.74 1.35, 1.39 1.58 2.89 - 
10   Ser 8.13 4.27 3.74, 3.72 - - - - 
11   Cys 8.32 4.59 2.99, 3.07 - - - - 
12   Arg 8.62 4.31 1.60, 1.85 1.49 3.06, 3.07 - - 
13   Ser 7.78 4.37 3.89, 3.78 - - - - 
14   Arg 8.3 4.02 1.75 1.52 3.08 7.07 - 
15   Gln 8.1 4.17 1.96, 1.86 2.21 - - - 
16   Cys 7.97 4.46 2.96, 3.08 - - - - 
17   Lys 8.06 4.45 1.58, 1.66 1.34, 1.30 1.53, 1.54 2.84 - 
18   Hyp - 4.39 2.17, 1.83 4.45 3.64, 3.72 - - 
19   His 8.67 4.53 3.09 - - - - 
20   Arg 8.36 4.18 1.60, 1.65 1.46 3.04 - - 
21   Cys 8.16 4.82 3.28, 3.48 - - - - 
22   Cys 8.67 3.81 3.2 - - - - 
 
Isomer 15  
 NH Hα Hȕ HȖ Hį Hİ Hζ 
1     Glu 7.78 4.24 - - - - - 
2     Arg 8.32 4.19 1.71, 1.64 1.52, 1.48 3.06 7.08 - 
3     Leu 8.38 4.28 1.45, 1.48 1.55 0.72, 0.78 - - 
4     Cys 8.42 4.53 3.14 - - - - 
5     Cys 8.29 4.59 3.12, 3.17 - - - - 
6     Gly 8.13 3.68, 3.78 - - - - - 
7     Phe 7.99 4.73 2.98, 2.79 - 7.13 - - 
8     Hyp - 4.47 2.22, 1.93 4.47 3.73, 3.60 - - 
9     Lys 8.49 4.13 1.68, 1.74 1.35, 1.38 1.57 2.87 7.42 
10   Ser 8.09 4.26 3.72, 3.76 - - - - 
11   Cys 8.23 4.58 3.08, 2.97 - - - - 
12   Arg 8.63 4.35 1.87, 1.59 1.49, 1.52 3.07, 3.08 7.06 - 
13   Ser 7.76 4.41 3.78, 3.91 - - - - 
14   Arg 8.33 4.05 1.76, 1.78 1.54 3.08 7.1 - 
15   Gln 8.1 4.22 1.84, 1.97 2.21 - - - 
16   Cys 7.94 4.44 2.92, 3.04 - - - - 
17   Lys 8.2 4.42 1.64 1.26, 1.32 1.57 2.82 - 
18   Hyp - 4.41 1.84, 2.17 4.47 3.73, 3.63 - - 
19   His 8.53 4.55 3.06, 3.10 - - - - 
20   Arg 8.44 4.2 1.74, 1.65 1.51 3.09, 3.06 7.06 - 
21   Cys 8.52 4.66 3.10, 3.15 - - - - 
22   Cys 8.22 4.53 3.25, 3.14 - - - - 
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Supporting Table 8. Summary of the HADDOCK docking runs. For each isomer docking the 
three best-scoring clusters are outlined. Docking results are ranked according to their Z-scores.  
Isomer 
Z-score HADDOCK 
score 
Cluster 
size 
RMSD from 
the overall 
lowest-energy 
structure [Å] 
Buried surface 
area [Å2] 
Vina score 
binding 
energy 
[kcal/mol] 
1  -1.2 174.1 ± 6 25 3.2 ± 0.0 3114.0 ± 168 12.2 
 
-1.2 175.3 ± 17 19 0.7 ± 0.5 2888.9 ± 212  
 
-0.9 181.9 ± 4 60 2.8 ± 0.1 2909.7 ± 72  
2  -1.4 162.9 ± 20 41 1.3 ± 0.8 2877.3 ± 134 10.4 
 
-0.9 182.3 ± 5 18 2.5 ± 0.1 2961.9 ± 146  
 
-0.8 183.6 ± 13 26 2.2 ± 0.2 2817.6 ± 121  
3  -1.6 127.2 ± 11 45 1.2 ± 0.7 3349.9 ± 140 7.9 
 
-1.5 129.7 ± 2 92 3.7 ± 0.1 3435.1 ± 51  
 
-0.8 151.2 ± 24 9 3.1 ± 0.0 3185.7 ± 201  
4  -2.1 139.5 ± 5 89 1.4 ± 0.9 3239.6 ± 43 10.7 
 
-0.9 181.0 ± 3 20 3.5 ± 0.3 3078.0 ± 98  
 
-0.3 202.0 ± 5 33 3.3 ± 0.1 2906.4 ± 142  
5  -0.9 158.8 ± 3 41 3.2 ± 0.0 3237.1 ± 51 11.1 
 
-0.6 168.9 ± 11 55 3.1 ± 0.2 3038.7 ± 97  
 
-0.6 169.6 ± 35 54 0.9 ± 0.6 3040.3 ± 44  
6 -1.8 132.2 ± 8 42 0.5 ± 0.3 3360.5 ± 98 11.5 
 
-1.0 156.1 ± 16 19 3.0 ± 0.1 3120.9 ± 124  
 
-0.8 163.2 ± 11 19 2.9 ± 0.0 3254.4 ± 35  
7 -1.2 171.8 ± 7 38 0.7 ± 0.5 2913.6 ± 123 10.8 
-1.0 177.3 ± 10 40 2.5 ± 0.0 3028.1 ± 123  
-0.6 187.5 ± 7 18 2.5 ± 0.1 3056.5 ± 164  
8  -1.4 151.5 ± 8 14 2.6 ± 0.1 3083.6 ± 141 12.2 
 
-1.0 162.9 ± 16 14 0.8 ± 0.5 3004.7 ± 138  
 
-0.4 180.4 ± 8 58 2.4 ± 0.0 3120.0 ± 59  
9  -1.3 162.1 ± 20 19 1.2 ± 0.8 3262.9 ± 243 11.0 
 
-0.9 169.3 ± 7 28 2.3 ± 0.2 3168.8 ± 80  
 
-0.9 170.1 ± 23 40 3.0 ± 0.1 2912.1 ± 270  
10  -1.6 142.2 ± 28 25 0.9 ± 0.7 3134.1 ± 52 11.4 
 
-0.9 165.1 ± 4 10 2.3 ± 0.1 3022.5 ± 110  
 
-0.8 169.6 ± 18 28 2.2 ± 0.1 3057.6 ± 79  
11  -2.2 131.2 ± 21 28 0.5 ± 0.3 3019.3 ± 99 12.1 
 
-0.8 164.1 ± 14 24 3.0 ± 0.0 3123.3 ± 62  
 
-0.4 174.4 ± 14 30 2.2 ± 0.1 2967.6 ± 34  
12  -1.9 123.5 ± 11 82 0.8 ± 0.5 3220.7 ± 55 11.1 
-0.7 169.6 ± 11 37 2.4 ± 0.0 3021.8 ± 110  
-0.7 171.4 ± 14 21 2.8 ± 0.1 2903.0 ± 155  
13  -1.0 193.0 ± 19 22 2.8 ± 0.0 2913.5 ± 108 10.2 
-0.7 201.4 ± 29 78 1.1 ± 0.9 2858.1 ± 161  
-0.6 204.5 ± 4 21 2.1 ± 0.0 2891.9 ± 44  
14  -1.8 181.0 ± 12 89 0.7 ± 0.5 2830.2 ± 41 10.8 
 
0 211.4 ± 6 45 2.5 ± 0.0 2713.1 ± 98  
 
0 211.7 ± 21 34 2.0 ± 0.2 2679.1 ± 126  
15  -1.5 162.2 ± 21 65 1.2 ± 0.7 2966.4 ± 186 9.9 
 
-1.3 168.1 ± 12 28 2.0 ± 0.1 3096.8 ± 29  
 
-0.9 179.5 ± 13 9 3.4 ± 0.1 3146.3 ± 147  
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Supporting Table 9. H-bond analysis of the best scoring µ-PIIIA-channel complex 
  domain 
Isomer total number 
of H-bonds 
I 
loops/SS1-
SS2 
II 
loops/SS1-
SS2 
III 
loops/SS1-
SS2 
IV 
loops/SS1-
SS2 
1  19 3/4 0/4 3/1 2/2 
2  12 1/1 2/1 0/1 4/2 
3  17 2/4 0/4 2/1 2/2 
4  23 6/3 1/1 4/1 6/2 
5  17 4/2 2/3 0/3 1/2 
6  21 0/4 1/7 2/3 2/2 
7  17 2/3 1/4 0/3 1/1 
8  26 3/7 1/4 0/2 3/6 
9  23 1/5 4/3 5/2 1/2 
10  21 3/4 1/2 2/1 5/4 
11  19 0/3 4/4 2/4 0/2 
12  22 1/3 4/5 2/3 1/3 
13  20 2/7 1/2 2/3 0/3 
14  17 2/3 1/1 0/3 3/4 
15  18 4/1 0/3 1/1 5/3 
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Supporting Figure 1. HPLC profiles of crude (left), and purified (center) µ-PIIIA isomers as well 
as corresponding MALDI-TOF mass spectra (right). Peak marked with an asterisks (*) is the 
fraction used for NMR structure analysis.  
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Supporting Figure 2. Co-elution profiles of different mixtures of µ-PIIIA isomers on a C18 
column: a) isomers 1, 2, and 3 (originally isolated from an oxidative self-folding approach 
described earlier7), b) isomers 1, 3, and 15 sharing disulfide bridge C11–C16, c) isomers 3, 6, 
and 9 with common disulfide bond C21–C22, d) isomers 3, 4, and 5 with disulfide bond C4–C5, 
e) isomers 2, 7, and 15 sharing C5–C21, and f) isomers 13, 14, and 15 with common disulfide 
bond C4–C22. g-l) Co-elution profiles for the same mixtures g-l) separated on a C4 column. 
 
g
  
h
  
i  
k l 
j 
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Supporting Figure 3. a) HPLC elution profiles for partial reduction of µ-PIIIA isomer 3 after 
addition of TCEP and vigorously shaking for 10 sec. b) HPLC of reaction mixture 1 minute after 
addition of TCEP with respective masses found in each fraction (ESI-MS analysis).  
  
a  b  
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Supporting Figure 4. Sequence analysis of linear µ-PIIIA by LC-ESI-MS/MS indicating that the 
full-length peptide could not be analyzed due to insufficient fragmentation and low sequence 
coverage. “+” indicates the charge of the observed fragment ion. 
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Supporting Figure 5. a) MALDI-MS/MS sequencing of a 2-times carbamidomethlyated species 
of isomer 5 after fragmentation obtained with LID TOF/TOF. Cysteine residues 16 and 21 were 
carbamidomethylated. b) MALDI MS/MS LID TOF/TOF sequencing of the corresponding 4-times 
carbamidomethlyated species. Cysteine residues 11, 16, 21 and 22 were carbamidomethylated 
a  
b 
c  
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indicating the disulfide pattern of isomer 5 (C4-C5, C11-C22, C16-C21). c) MALDI ISD-MS/MS 
spectra obtained from 6-times carbamidomethylated peptide. Although the sequence coverage 
is higher compared to fragmentation with MS/MS LID TOF/TOF, no preselection of the precursor 
ion is possible which is essential for discrimination between different carbamidomethylated 
species present in one fraction. In this case c- and y-ions are formed in contrast to b- and y-ions 
by MS/MS LID TOF/TOF.  
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Supporting Figure 6. Structure predictions for µ-PIIIA isomers 7, 12 and 13. a) Development of 
the backbone r.m.s.d. during molecular dynamic simulations for the three isomers, indicating 
structural equilibration after ~ 30 ns of simulation. b) structural ensembles (20 structures) 
generated from the last 20 ns of the simulation (mean r.m.s.d, backbone global: 7 0.61 Å, 12 
0.72 Å, 13 0.41 Å)  
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Supporting Figure 7. Block of NaV1.4-mediated currents by disulfide isomers of µ-PIIIA. a) 
Representative current traces of transiently expressed NaV1.4 channels evoked at a test 
potential of 20 mV before (black, ctrl) and after (red) application of 10 µM of the indicated µ-
PIIIA isomers. b) Steady-state block of NaV1.4-mediated currents by 10 µM of the indicated µ-
PIIIA isomers (bottom) and the associated single exponential time constant, τblock, describing the 
onset of block (top). Dark gray indicates isomers already shown in Figure 3. Numbers of 
individual experiments, n, are provided in parentheses. 
b 
a  
  
 
1
9
4
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Supporting Figure 8. Alignment of the pore modules of the channel template CaV1.1 (PDB ID 
3jbr16, uniprot ID P07293) and the target sequence of NaV1.4 (uniprot ID P35499) of all four 
domains. Conservation of the aligned residues is indicated in the histogram below the sequence 
and given as a numerical index reflecting the conservation of physico-chemical properties in the 
alignment employing the AMAS method17: identities score highest and the next most conserved 
group contain substitutions to amino acids lying in the same physico-chemical class. 
Regions from the template structure that were part of the final homology model are indicated by 
secondary structure elements, schematically outlined above (transmembrane segments – black 
box, loops - straight black line) the aligned amino acid sequences. Homology-modeled regions 
within the template structures are color-coded. Sequence alignments were created with Clustal 
Omega18–20 on www.uniprot.org. The alignment figure was created with JALVIEW 2.821. 
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Supporting Figure 9. a) Homology model of NaV1.4, selectivity filter residues are shown in stick 
representation (coloring scheme: carbon – cyan, nitrogen – blue, oxygen – red, calcium – 
yellow), subunits are indicated with roman letters. b) superimposed structures of the NaV1.4 
homology model (yellow) with the recently published structure of the eukaryotic NaVPaS channel 
(blue, cyan; pdb ID 5X0M)15 which show a structural deviation (r.m.s.d.) of 1.9 Å.  
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Supporting Figure 10. a – l) Visualization of the best-scoring µ-PIIIA–NaV1.4 complex 
conformations obtained from docking experiments. The four NaV1.4 domains are indicated. Left 
panel – topview of the toxin-channel complex. The NaV1.4 channel surface (Van der Waals) is 
given in gray, the selectivity filter motif (DEKA) is highlighted in red. The toxin is shown in green 
with side chain atoms present (coloring scheme: carbon – cyan, nitrogen – blue, oxygen – red, 
sulfur – green). Middle and right panel – top and side view of the toxin-channel complex. The 
toxin is shown in surface representation (Van der Waals) and colored according to amino acid 
properties (coloring scheme: basic – blue, acidic – red, polar - cyan, non-polar – gray). The 
number of hydrogen bonds formed by the toxin with each channel domain (loops/SS1-SS2) is 
highlighted in purple distinguishing between hydrogen bonds formed with the TM bridging loops 
(S5-SS1, SS2-S6) and the pore helices (SS1-SS2).  
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